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The extracellular matrix receptor integrin ανβ6 is known to potentiate breast cancer (BrCa) 
cell invasion, metastasis and tumour-trophic growth factor receptor crosstalk during 
tumourigenesis. Monoclonal antibody blockade of ανβ6 diminishes invasion in vitro and 
arrests BrCa tumour growth and metastasis in vivo. Aberrant integrin activation status has 
been implicated in progression to metastatic disease in BrCa; with differential 
internalisation and endocytic trafficking kinetics reported for active versus inactive integrin 
species in malignant disease. Despite its emerging potential for targeted therapy, little is 
known regarding regulation of integrin ανβ6–mediated activation and signalling during 
progression to an invasive, metastatic state. It is hypothesised that the aetiopathological 
significance of integrin ανβ6 during neoplastic transformation and malignant progression in 
BrCa is dependent specifically upon its activation status and associated conformation, 
since this active state will permit establishment of known integrin–mediated oncogenic 
signalling underpinning acquisition of a malignant phenotype, including activation of 
invasion and metastasis. 
 
results  
Canonical integrin activation studies using divalent cations and cognate ligand stimulation 
indicated antibodies 6.2E5 and 6.2G2 recognise activation-associated epitopes, which are 
also ligand-induced binding sites (LIBS) in live-labelled cells by FCM and IMF. However, 
their utility to discriminate the active fraction distinct from the total or inactive fractions of 
ανβ6 by IHC in primary BrCa samples could not be robustly established.  Evaluation of the 
6.2E5 and 6.2G2 epitopes in the MCF10 isogenic model revealed that relative surface 
abundance of these active epitopes determined by FCM was not significantly altered; but 
their subcellular redistribution upon neoplastic transformation and malignant progression 
was observed by IMF, implicating derailed internalisation and trafficking of active ανβ6 
during breast tumourigenesis and metastatic disease progression. Proteomic interrogation 
and network analysis of the 2D-enriched adhesion assays identified 7 novel putative 
molecular regulators of a ligand-engaged, activated ανβ6–mediated adhesion environment 
(DMBT-1, MARCKS, MXRA5, SEPT6, SEPT9, MYH9, MYH10) in the BT-20 TNBC cell line. 
Functional validation of these candidate mediators of the “β6 adhesome” by siRNA 
strategies was not achieved due to inconsistent stable knockdown. Phosphoproteomic 
definition of LAP ligand-engaged, active ανβ6–mediated signalling (“β6 kinome”) during 
receptor-ligand internalisation revealed EGFR-dependency for downstream ERK1/2 signal 
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activation in BT-20 and SUM159, but not MDA-MB-468 TNBC cells. Kinase substrate 
enrichment analysis (KSEA) identified 5 novel putative mediators of downstream ανβ6 
signalling (COT, MAPKAPK2, PDPK1, Nuak1, TBK1) and implicated Akt1 isoform-specific 
activation downstream of ανβ6–LAP internalisation. Following LAP-induced ανβ6 activation 
and internalisation, EGFR underwent phosphorylation at multiple known activation sites, 
including a residue (Thr693) critical for EGFR receptor internalisation; suggesting integrin 
ανβ6–EGFR reciprocity during respective receptor activation and internalisation.   
 
conclusion 
The active conformer of integrin ανβ6 may be studied using antibodies 6.2E5 and 6.2G2 in 
live-labelled cells by FCM and IMF. Subcellular redistribution of activation-associated 
epitopes during BrCa progression implicates derailed internalisation and intracellular 
trafficking kinetics of active ανβ6 during tumourigenesis, while protein expression studies 
identified 7 putative molecular regulators of ligand-engaged, active ανβ6–mediated 
adhesion. Integrin ανβ6-mediated signalling during internalisation revealed an ανβ6–EGFR-
Akt1 signalling axis during breast tumourigenesis and disease progression, while further 
understanding of integrin biology and growth factor receptor crosstalk may provide 
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investigating the role of  integrin ανβ6 activation 




1. introduction  
 
breast cancer and the integrin ανβ6 :    an overview 
 
Breast cancer (BrCa) is the most prevalent of all female cancers worldwide, 
accounting for 1.7 million new cancer diagnoses and constituting 12% of all 
cancers diagnosed globally in 2012 (CDC 2016). It is the most common of all 
cancers in the United Kingdom (UK) with 53 252 women and 344 men diagnosed 
with invasive BrCa, collectively accounting for 15% of all cancer cases, in the UK in 
2013 (CR-UK 2016).  
 
 
Although female BrCa incidence remains highest in the Western world where the 
lifetime risk is estimated to be 1 in 8, epidemiological studies highlight the 
increasing incidence of female BrCa in both the developing and developed worlds 
(Jemal et al 2011, WHO 2014, CDC 2016). Given the existing and projected global 
healthcare burden attributable to BrCa, the need to refine BrCa prevention and 







 Metastatic disease remains the most significant cause of BrCa-associated morbidity 
and mortality, remaining incurable, but treatable (Duffy et al 2008, Veiseh et al 
2011, Dawson et al 2013). Worldwide, approximately 90% of BrCa-associated 
deaths are attributed to metastatic disease dissemination (Cummings et al 2014, 




Activation of tumour cell invasion and metastasis is a cardinal cancer hallmark, 
signifying disease progression from a potentially curable, localised benign lesion 
to malignant, potentially fatal cancer (Van't Veer and Weigelt 2003, Hanahan and 
Weinberg 2011). Malignant transformation is underpinned by the derailment of 
cell adhesion repertoires to facilitate tumour cell invasion and metastatic 
dissemination. Thus, inhibiting acquisition of a pro-invasive, or restitution of a non-
invasive cell adhesion repertoire, are emerging strategies for the clinical 
management of disseminated disease (Desgrosellier and Cheresh 2010, Bendas 
and Borsig 2012, Zhong and Rescorla 2012).  
 
 
Previous research has established the role of the integrin superfamily of cell-
surface adhesion receptors during cell migration and invasion under both 
physiological and pathological conditions (Hood and Cheresh 2002, Wehrle-Haller 
and Imhof 2003, Sahai 2005, Harburger and Calderwood 2009, Desgrosellier and 
Cheresh 2010, Buchheit et al 2012). Notably, the poor-prognostic and tumour-
trophic effects of integrin ανβ6 observed in multiple cancers, including BrCa, have 
been demonstrated both in vitro and in vivo (Thomas et al 2001b, Thomas et al 
2006, Ramsay et al 2007, Yang et al 2012, Allen et al 2014, Moore et al 2014).  
 
 
Recent investigations have demonstrated integrin ανβ6 expression is associated 
with risk of progression to invasive disease in ductal carcinoma in situ (DCIS) (Allen 
et al 2014). Furthermore, therapeutic blockade of integrin ανβ6 has been shown to 
reduce breast 4T-1 tumour cell growth and metastasis in vivo (Eberlein et al 2013) 
and potentiate trastuzumab efficacy in human epidermal growth factor-2 (HER2)-
driven BrCa (Moore et al 2014). Given its established potential as a therapeutic 
target, the mechanisms by which integrin ανβ6 regulates invasive cellular processes 
and mediates cross-talk with other growth factor receptors (GFRs) to drive BrCa 
progression warrants further investigation to expedite its use to augment existing, 






 1.1  breast cancer  
 
1.1.1  an overview  
 
The term breast cancer (BrCa) collectively describes neoplasms arising from 
epithelial cells lining the mammary ducts and lobules, termed ductal carcinoma or 
lobular carcinoma respectively (Figure 1.1). BrCa is a markedly heterogeneous 
disease in terms of its histopathological features, clinical outcomes and therapeutic 
response. Since it cannot be defined as a single, discrete clinicopathological entity, 
BrCa has been classified into several more homogeneous morphological and 
molecular subtypes facilitating patient stratification to inform appropriate 
therapeutic management of disease (Crum et al 2003, Lakhani et al 2012, Bateman 
and Shaw 2013, Cummings et al 2014, Lakhtakia and Chinoy 2014, Vuong et al 
2014, Makki 2015).  
 
 
Currently, 25 histological breast pathologies are recognised by the World Health 
Organisation (WHO) which encompass not only malignant, invasive cancers of the 
breast, but also: pre-cursor lesions, benign lesions and neoplasms of 
fibroepithelial, myoepithelial and mesenchymal origin arising in the breast 
(Lakhani et al 2012, Sinn and Kreipe 2013).  
 
 
Approximately 95% of BrCa are classified as adenocarcinomas upon diagnosis 
(Makki 2015). Advances in molecular medicine have permitted genetic 
interrogation of BrCa subtypes (Perou et al 2000), facilitating refinement of 
traditional histological classification to include molecular subtyping (Vuong et al 
2014). These molecular approaches to BrCa more accurately reflect its complexity 
and marked histological and genetic heterogeneity, facilitating selection of the 
most suitable treatment regimen (Crum et al 2003, Stevens and Lowe 2005, Hsiao 
et al 2010, NICE 2011, Lakhani et al 2012, Viale 2012, Bateman and Shaw 2013, 
Cummings et al 2014).  
 
 
However, in accordance with National Institute for Health and Care Excellence 
guidelines (NICE 2009a, NICE 2009b, NICE 2011), the current approach to 
molecular diagnostics informing treatment regimens for BrCa patients in the UK 
remains rooted in the evaluation of tumour oestrogen (ER), progesterone (PR) and 







Figure 1.1  
Basic breast anatomy (A) and multi-step model of the origins of: (B) ductal (DCIS) and (C) lobular carcinoma in situ (LCIS)  
 
(1.1A) The adult female breast parenchyma comprises 12 – 20 distinct lobes each feeding into a system of tributary lactiferous ducts opening into the nipple. Clusters of 
blind-ended terminal ductules and a drainage duct system form the mammary lobule. Both mammary ducts and lobules are encompassed by adipose (fatty) tissue 
containing supportive fibrocollagenous septa attached to the fascia covering the pectoralis muscle.  Columnar or cuboidal epithelium lines each duct (luminal epithelial 
cells). Myoepithelial cells form a discontinuous circumferential cuff around the luminal epithelial cells. Epithelia of the ducts (intra- and extralobular) and terminal ductucles 
may undergo neoplastic change. Cancers arising from the ducts are ductal carcinomas (1.1B), whilst those originating in the terminal ductules are lobular carcinomas (C) 





 1.1.2         BrCa risk factors 
 
1.1.2.1      environment and lifestyle  
 
Around 75% of BrCa risk is associated with environmental and lifestyle factors, with 
age showing the strongest association with BrCa incidence (Jemal et al 2011, CR-
UK 2014, WHO 2014). On average, 80% of BrCa diagnoses in the UK between 
2009 and 2011 were amongst women aged over 50, and as such, age is 
recognised as a key BrCa risk factor (CR-UK 2014).  
 
 
Lifestyle is also known to influence BrCa risk. Approximately 27% of BrCa cases in 
the UK are linked to lifestyle choices that are believed to affect sex-hormone 
exposure. These include reproductive factors such as young age of first menarche, 
low or nil parity, older age of first parity and older age of menopause. Hormone-
based interventions including oral contraceptives and hormone-replacement 
therapy also confer a risk of developing BrCa. Due to limited evidence, tobacco 
smoking is thought to be a probable cause of BrCa, possibly via increasing sex 
hormone levels, with which BrCa is associated. Alcohol intake is also recognised as 
a BrCa risk factor, with 6% of BrCa cases in the UK linked to alcohol consumption. 
However, alcohol is not deemed a BrCa risk factor in BRCA1/2 mutation carriers 
(CR-UK 2014, CR-UK 2016).  
 
 
Curiously, some preventable risk factors associated with lifestyle actually confer a 
protective benefit in early adulthood.  The World Cancer Research Fund/American 
Institute for Cancer Research (WCRF/AICR) classified obesity as a cause of post-
menopausal BrCa, but was deemed a protective factor in pre-menopausal BrCa 
(Lauby-Secretan et al 2016, WCRF 2017). In the UK, approximately 9% of female 
BrCa are linked to excess body weight (Parkin and Boyd 2011).  
 
 
Furthermore, lack of physical activity has been associated with BrCa risk. Wu et al’s 
(2013) meta-analysis showed that BrCa risk decreased by 5% for every 2 hours per 
week increment in recreational activity (both moderate and vigorous). Indeed, 
inadequate physical activity (less than 150 minutes moderate physical activity per 









1.1.2.2     family history  
 
Family history and genetics are linked to approximately 25% of BrCa cases. Risk of 
developing BrCa doubles in women with one first-degree relative with BrCa 
compared to women with no first-degree relatives affected by BrCa. However, to 
put this risk in perspective, 87% of women diagnosed with BrCa have no first-
degree relatives with the disease (CR-UK 2016). It is estimated that between 5 – 
10% of all breast cancers bear a hereditary component typically presenting with an 
early age of onset and associated with over-representation of bilateral BrCa, 





1.1.2.3       BRCA1 and BRCA2 genes  
 
The most well-known genetic mutations associated with BrCa occur in the BRCA1 
and BRCA2 tumour suppressor genes, accounting for 25 – 28% of family risk. 
Germline BRCA1/2 mutations confer a high risk of ovarian and breast cancers, 
exhibiting high but incomplete penetrance. However, BRCA1 and BRCA2 
mutations are relatively rare, respectively affecting 0.11% and 0.12% of the general 
population. These mutations are associated with approximately 2% of total BrCa 
cases but account for 15 – 20% of cases with a family history of BrCa amongst first-
degree relatives. Risk of developing BrCa amongst BRCA1/2 mutation carriers may 
be modulated by other known BrCa risk factors including family history and 





1.1.2.4 other genetic factors  
 
Several autosomal dominant hereditary syndromes are associated with a high 
lifetime BrCa risk, including Li-Fraumeni and PTEN multiple hamartoma syndromes 
caused by mutations in tumour protein p53 (TP53) and phosphatase and tensin 
homologue (PTEN) genes respectively. Mutations in CHEK2, ATM, BRIP1 or PALB2 
genes reportedly confer an immediate BrCa risk to BRCA1/2 mutation carriers but 
incidence amongst the general population is rare (CR-UK 2014, Larsen et al 2014, 






Goncalves et al (2014) reviewed literature reporting emerging genomic data 
generated by massively parallel DNA and RNA sequencing strategies on large 
BrCa genome cohorts. The authors concluded that this volume of data would not 
only increase our collective understanding of the genetic and epigenetic natural 
history of breast cancer, but also present novel challenges to established 
hypotheses regarding breast tumourigenesis.  
 
 
For example, the emerging importance of epigenetic dysregulation in BrCa was 
highlighted. Notably, perturbed DNA hypermethylation of promoter CpG islands 
incurring stable epigenetic transcriptional silencing of tumour suppressor genes 
(such as the von Hippel-Lindau (VHL) gene) has been implicated in carcinogenesis 
(Tsai and Baylin 2011). Indeed, hypermethylation of CpG islands in the MutL 
Homologue 1 (MLH1) gene promoter region is known to underpin sporadic 




Goncalves et al (2014) urged that the combination of DNA- and RNA-based 
sequencing studies to unpick BrCa (epi-)genomes, should be augmented with 
mass-spectrometric characterisation of BrCa proteomes to characterise post-
translational modifications (PTMs) occurring at the protein level, for a complete 
picture of genetic, epigenetic and proteomic factors driving breast tumourigenesis 
and metastatic disease progression. The authors believed that this holistic 
approach would expedite translation of genomic understanding of BrCa into 
demonstrably improved patient outcomes; something that Gonclaves et al felt was 
hitherto lacking in BrCa research. 
 
 
Subsequently, Cutts et al (2015) developed the Breast Cancer Campaign Tissue 
Bank Bioinformatics portal (BCCTBbp), which seeks to achieve such an integrative, 
holistic “-omics” approach to translational BrCa research. The BCCTBbp online 
bioinformatics resource permits integration of genomic, methylomic, 
transcriptomic, microRNA and proteomic data mined from 146 literature-reported 
BrCa datasets. The aim of the portal is to augment existing BrCa knowledge and 
expedite the clinical utility of existing and emerging BrCa research to improve 







 Furthermore, the developers hoped that the existence of such an exhaustive 
online repository of integrated BrCa research would refine design and 
implementation of future studies; eliminating unnecessary repetition of 
experiments where validated data already exists. Thus, the pool of scientific 
knowledge regarding BrCa could be more rapidly augmented through more 
efficient use of limited research resources to address the most pressing gaps in 





1.1.3         BrCa pathology 
 
1.1.3.1      BrCa natural history  
 
Current understanding of BrCa natural history is founded in histopathological 
evidence that breast tumourigenesis is a prolonged, multi-step process 
characterised by sequential histological states, from benign hyperplastic lesions 
(atypical hyperplasia) through pre-invasive localised neoplastic disease (carcinoma 
in situ), culminating in malignant, invasive BrCa (Figure 1.2) (Arpino et al 2005, 
Hsiao et al 2010, Bertos and Park 2011, Viale 2012, Bateman and Shaw 2013, 
Lakhtakia and Chinoy 2014, WHO 2014, Dai et al 2016).  
 
 
According to this model, in situ disease is considered an obligatory prelude to 
invasive, metastatic disease (Arpino et al 2005). Historically it was believed this 
multi-step model of breast carcinogenesis was driven by a gradual accumulation of 
genetic mutations underlying observed histological changes, that would 
eventually spawn cellular variants with invasive, metastatic potential responsible 
for disease progression and dissemination (Schmidt 2002, Crum et al 2003, 





























































An example of the multi-step model of breast tumourigenesis represented by the 
development of atypical ductal hyperplasia, through DCIS culminating in invasive BrCa  
  
Cells comprising the mammary lobules or ducts may undergo hyperplastic and proliferative changes 
to acquire a neoplastic phenotype. Progression from in situ to metastatic, disseminated disease is 
determined by acquisition of invasive potential. A localised tumour remaining bounded by its 
encompassing basement membrane is deemed to be in situ carcinoma due to the absence of invasion 
beyond its normal anatomical boundary. However, once the basement membrane delineating the 
epithelial-stromal interface is breached, the tumour has progressed to invasive disease with the 
potential for metastatic dissemination (Crum et al 2003, Schedin and Elias 2004, Bertos and Park 






1.1.3.2      diagnostics and molecular pathology: 
informing patient management strategies  
Traditional histopathological grading and tumour-node-metastases (TNM) staging 
of tumours are well-established classification systems for BrCa diagnostics and 
prognostics, prevailing in clinical practice today (Bertos and Park 2011, Viale 2012, 
Sinn and Kreipe 2013, Lakhtakia and Chinoy 2014).  
 
 
In accordance with National Institute of Health and Care Excellence (NICE) quality 
standards (NICE 2011) and clinical guidelines (NICE 2009a, NICE 2009b), grading 
and staging of histological features to define morphological BrCa subtype is 
augmented by ancilliary investigations characterising: tumour oestrogen receptor 
(ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 
(HER2) status for patient stratification and prognostication, to inform patient 
management by a multidisciplinary team (MDT) of healthcare professionals 
overseeing the patient care pathway (Crum et al 2003, Stevens and Lowe 2005, 




1.1.3.3      receptor status in BrCa  
Ancillary immunohistochemical (IHC) and/or fluorescence in situ hybridisation 
(FISH) investigations to establish therapeutically targetable hormone receptor 
(ER/PR) and HER2 status are respectively vital for patient prognostication and 
therapeutic stratification (Bertos and Park 2011, Viale 2012, Subbiah and Gonzalez-
Angulo 2014, Dai et al 2016) and requisite within the UK in accordance with NICE 
guidance (NICE 2009a, NICE 2009b, NICE 2011).  
 
 
Tumour receptor status provides valuable predictive information to determine 
patient eligibility for established targeted therapies. Approximately 70% of 
sporadic BrCa cases exhibit ER-positivity and 50% are PR-positive whilst in around 
15% of cases, HER2 is overexpressed (Hsiao et al 2010, Bertos and Park 2011). 
Breast tumours that do not express any of these molecular targets are classified as 







 In TNBC, the lack of well-defined molecular targets for biological or hormone 
intervention strategies limit treatment options to standard chemotherapeutics 
and/or surgery. TNBC tumours are aggressive and associated with poor prognosis 
if disease progression occurs following chemotherapy (Rodler et al 2010, Andre 





1.1.3.4      intrinsic subtypes in BrCa  
Perou et al’s (2000) landmark paper revolutionised understanding of the molecular 
pathology underlying BrCa subtypes. This heralded a new age in BrCa 
classification and molecular taxonomy based on intrinsic gene expression profiles 
which are continually updated, augmented and refined in accordance with the 
latest research (Schnitt 2010, Dieci et al 2014).  
 
 
Recent advances in high-throughput technologies permitting molecular and 
proteomic dissection of BrCa subtypes in large-scale comparative studies have 
spawned novel molecular classification systems based upon tumour-derived gene-
expression profiles. These have provided invaluable insights into the diverse 
natural history of BrCa and varied therapeutic response through identification of 
genetic and post-translational drivers inducting and sustaining tumour formation, 
subsequently driving disease progression and therapeutic resistance. Currently, 5 
molecular subtypes are widely recognised (Table 1.1) (Perou et al 2000, Sorlie 
2009, Hsiao et al 2010, Schnitt 2010, Bertos and Park 2011, Polyak 2011, Eroles et 








Molecular subtype IHC signature Treatment modality 
Luminal A HER2-; ER+ &/ PR+ 
Tamoxifen 
Endocrine therapy 
Luminal B HER2+; ER+ &/ PR+ 
Trastuzumab 
Tamoxifen 
Basal-like HER2-; ER-; PR-; HER1+; CK5/6+ Neoadjuvant therapy 
HER-2(+)/ER(-) HER2+; ER- & PR- Neoadjuvant therapy 
Normal breast-like all markers - 
no targeted molecular  
therapeutics available 
 
Table 1.1  
Overview of the five, established intrinsic molecular BrCa subtypes and their respective 
immunohistochemical (IHC) profiles 
Breast tumours may be broadly classified into 5 subtypes based upon expression of oestrogen 
receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 1 (HER1 / EGFR), 
human epidermal growth factor receptor 2 (HER2) and cytokeratins (CK) 5/6. Molecular stratification of 
tumour type is used to inform choice of appropriate therapeutic intervention. Table adapted from 





1.1.3.5     disease  progression  in  BrCa:     
          from  in  situ  to  invasive  disease 
It is reported that approximately 20% of all mammography-detected cases in the 
U.S of BrCa are pre-invasive ductal carcinoma in situ (Ernster et al 2002); around 5 
100 cases of DCIS are diagnosed in the UK every year (CR-UK 2016). However, 
robustly defined predictive markers of progression to invasive disease remain 
elusive; their discovery compounded by the phenotypic heterogeneity exhibited 
by both in situ and invasive breast tumours in terms of clinicopathological features 
(such as histological grade), ER/PR/HER-2 expression and epidermal growth factor 
receptor (EGFR) status.  
 
 
Greater understanding of the molecular, genetic and microenvironmental drivers 
mediating progression from in situ to invasive disease is critical for the 
identification of novel therapeutic targets to combat metastatic dissemination and 
alleviate its associated morbidity and mortality (Hu et al 2008, Chaffer and 






 In their DNA microarray analysis of primary breast tumours resected from 117 
young BrCa patients (under 55 years of age at diagnosis), van 't Veer et al (2002) 
were the first to characterise a poor prognosis BrCa gene expression signature 
that was strongly predictive of short interval to distant metastasis that allowed for 
patient-tailored treatment regimens. The authors concluded that BrCa prognosis 
may be determined from gene expression profiling of the primary tumour. 
Logically, amongst the 70 prognostic classifier genes refined by van’t Veer from 
231 original reporter genes to determine risk of metastasis, were genes associated 
with rapid progression to metastatic disease; chiefly those known to govern 
invasion, matrix degradation, angiogenesis, cell motility and survival signalling. 
 
 
Van’t Veer et al’s (2003) poor prognosis BrCa gene signature was found to 
effectively identify high-risk patients who would benefit from adjuvant therapy and 
also significantly reduce the number of patients subjected to unnecessary 
treatment. The authors proposed that using such patient-therapy-centric gene 
expression signatures offered a powerful genomic approach to refine use of 




Activation of invasion and metastasis has long been deemed a seminal cancer 
hallmark, heralding disease progression to disseminated disease (Hanahan and 
Weinberg 2000, Chaffer and Weinberg 2011, Hanahan and Weinberg 2011). Van't 
Veer and Weigelt (2003) discussed the concept of a “roadmap to metastasis”, 
whereby cancer cell metastatic potential is intrinsically determined early in 
tumourigenesis. Furthermore, the authors proposed that BrCa cells acquire a gene 
signature early in tumour development that is predictive of metastatic site.  
 
 
Veer and Weigelt’s (2003) review of gene expression profile studies highlighted 
that although a poor prognosis gene signature may be a common feature within 
the primary tumour, subpopulations of cells within the tumour display tissue-
trophic gene expression profiles predictive of metastatic site. For example, the 
expression of osteolytic pathway genes: interleukin-11 (IL-11), chemokine 
receptor-4 (CXCR-4), matrix metalloprotease-1 (MMP-1) and connective tissue 







 In their review of emerging BrCa molecular research contextualised within 
Hanahan and Weinberg’s cancer hallmark definitions, Dai et al (2016) argued that 
BrCa subtypes expressing basal, stem cell or epithelial-to-mesenchymal transition 
(EMT) markers represent tumours bearing the requisite properties for activating 
invasion and metastasis. Furthermore, the authors argued that these pre-
metastatic markers are more likely to be enriched in TNBC and require urgent 




Li et al (2015) reported CpG-island hypermethylation profiles of 7 genes (BRCA1: 
BReast CAncer 1, DAPK1: Death Associated Protein Kinase 1, MSH2: MutS 
Homolgue 2, CDKN2A: Cyclin Dependent Kinase iNhibitor 2a, PGR: ProGesterone 
Receptor, PRKCDBP: Protein Kinase C Delta Binding Protein, RANKL: Receptor 
Activator of Nuclear factor Kappa-Β Ligand) showing a profound impact on patient 
outcomes. Analysing a multi-institutional cohort of 123 BrCa patient primary tissue 
samples, Li and colleagues (2015) compared gene methylation signatures of a 56-
gene cancer-specific biomarker microarray in BrCa patients with metastatic cancer 
or metastatic relapse within 5-years post-operatively, against BrCa patients 
showing no disease progression.  From these analyses, the authors identified a 7-
gene panel (BRCA1, DAPK1, MSH2, CDKN2A, PGR, PRKCDBP, RANKL) deemed 
highly prognostic of BrCa progression and metastatic relapse.  This study 
highlights the emerging significance of epigenetic factors, including promoter 
hypermethylation, during breast tumourigenesis and disease progression.  
 
 
Furthermore, Lesurf et al (2016) compared the mRNA, microRNA (miRNA) and 
DNA copy-number profiles of a primary human BrCa cohort comprising 59 in situ 
lesions (DCIS) with a cohort of 85 invasive BrCa tumours (IDC). The authors 
deduced that some molecular features associated with metastatic disease 
progression in BrCa were unique to intrinsic subtypes; a similar conclusion to that 
drawn by Dai et al (2016) in their meta-analysis. The lack of universal marker(s) 
identified as predictors of disease progression in the Lesurf study lead the authors 
to conclude that each BrCa intrinsic subtype is likely to follow its own distinct 
evolutionary course of disease progression.  
 
 
Interestingly, Lesurf et al (2016) also noted that Gene Ontology (GO) analyses of 
their dataset revealed prominent molecular traits distinguishing DCIS from IDC are 





 adhesion, extracellular matrix (ECM)-cell receptor interactions and collagen fibril 
organisation; highlighting the emerging significance of the tumour 
microenvironment as purveyor of a metastatic niche.  
 
 
Given the significance of the integrin superfamily in these processes, together with 
the established association of integrin ανβ6 overexpression in transformed adult 
tissues, it is interesting to postulate the possible role of integrin ανβ6 as a driver of 
tumour microenvironment establishment and regulation (Gumbiner 1996, Felding-
Habermann et al 2001, Chen et al 2003, Felding-Habermann 2003, Srichai and 





1.1.3.6      the tumour microenvironment in BrCa 
In addition to the intrinsic tumourigenic traits of incipient BrCa cells during 
invasion, the influence of the tumour microenvironment has emerged as an 
important concept in establishing communication networks driving metastatic 
disease progression (Calvo and Sahai 2011, Place et al 2011, Schedin and Keely 
2011, Angelucci et al 2012, Bezdenezhnykh et al 2014). Indeed, Maller et al (2010) 
reviewed the role of the extracellular matrix (ECM) in driving mammary gland 
morphogenesis, maintenance of ductal epithelium architecture and its pro-invasive 
remodelling during carcinogenesis.  Hu et al (2008) implicate the intricate interplay 
between tumour-trophic fibroblasts, tumour-suppressive myoepithelial and breast 
luminal epithelial cells potentiating transition from in situ to invasive BrCa. 
Ingthorsson et al (2010) highlight the importance of proliferative regulation by 
breast endothelial cells within the mammary microenvironment of both normal 
and malignant breast epithelia.  
 
 
Heterotypic crosstalk amongst cell adhesion receptors and TGF-β-mediated 
signalling pathways has been identified as critical for breast tissue homeostasis 
and its derailment is associated with breast tumourigenesis. The pleiotropic 
cytokine TGF-β1 performs both tumour suppressive and tumour-trophic roles in 
the mammary microenvironment (Hu et al 2008, Desgrosellier and Cheresh 2010, 
Munger and Sheppard 2011, Bendas and Borsig 2012, Hale et al 2012). It is 
believed that the combination of epithelial-to-mesenchymal transition (EMT) and 





 tumourigenesis and disease progression drives the conversion of TGF-β1 from a 
tumour suppressor to a tumour promoter (Tang et al 2003, Taylor et al 2013, 
Bezdenezhnykh et al 2014, Zarzynska 2014, Zhang et al 2014).  
 
 
Given the role of integrin adhesion receptors as key mediators of mechanosignal 
transduction between cells and their encompassing ECM, together with the 
reciprocity of integrin-TGF-β1 signalling, integrin-mediated regulation of invasion 
in BrCa remains a logical and active area of cancer research (White and Muller 
2007, Van Aarsen et al 2008, Desgrosellier and Cheresh 2010, Margadant and 
Sonnenberg 2010, Allen et al 2011, Munger and Sheppard 2011, Aoudjit and 
Vuori 2012, Bendas and Borsig 2012, Allen et al 2014, Moore et al 2014, Truong et 










 1.2  the integrin superfamily of adhesion receptors  
 
1.2.1  an overview  
 
The integrin superfamily of ubiquitously expressed, cell-surface type I 
transmembrane glycoproteins, mediate both intercellular adhesions and 
interactions between the cell and its encompassing ECM (Figure 1.3). They form 
obligate heterodimers comprising a large alpha (α) subunit (~120 – 170 kDa) non-
covalently associated with a smaller beta (β) subunit (~90 – 100 kDa) (Danen 2013).  
There are 18 genes encoding the α subunit species and 8 genes encoding the β 
subunit species, giving rise to the 24 integrin heterodimer species known to exist 
in humans. The integrins are subclassified according to their heterodimeric 
constitution, which determines cognate ECM-ligand specificity and tissue 




In both health and disease, many aspects of cell physiology and fate are 
determined by integrin signalling, including; cell survival, proliferation, 
differentiation, adhesion, polarity, migration (Shimaoka and Springer 2003, 
Campbell and Humphries 2011, Munger and Sheppard 2011) and senescence 
(Rapisarda et al 2017). Integrins are capable of modulating many aspects of cell 
behaviour including cell migration and invasion via physical adhesions established 
by binding ECM-derived cognate ligands and through bidirectional signal 
transduction (Bouvard et al, 2013; Harburger & Calderwood, 2009; Hood & 





1.2.2  integrin structure and regulatory motifs  
 
Integrin receptors are typified by a large extracellular domain with short 
transmembrane and cytoplasmic domains, devoid of any inherent kinase activity. 
Owing to their lack of intrinsic enzymatic activity, the integrin receptor superfamily 
relies upon interactions with other intracellular mediators to induct downstream 
signalling and exert their functional effects. Integrin binding of adaptor proteins 
requisite for functional outputs is determined by defined amino acid sequences 
forming regulatory motifs within the cytoplasmic tail domains of the α- and β-
integrin subunits (Hynes 2002, Brakebusch and Fassler 2003, Campbell and 












































Figure 1.3  
The integrin heterodimeric cellular adhesion receptor and its regulatory motifs  
 
Schematic overview of the structure of an integrin receptor, illustrating intracellular regulatory motifs 
residing within the integrin cytoplasmic tail domains including the evolutionary conserved, calcium-
binding repeat I-EGF (epidermal growth factor) domains within the β-subunit and PTB-binding NPxY 
and NxxY motifs (intersected by a serine-threonine-rich (--TST--) sequence) requisite for adaptor 
protein recruitment, cytoskeletal association, integrin signalling and functional output. The conserved 
α-subunit GFFKR and β-subunit HDRK motifs enable subunit association and stabilisation in an 
inactive integrin receptor conformation. Extracellular motifs residing within the head βI-domain 
include the divalent metal cation binding sites comprising: a metal ion-dependent adhesion site 
(MIDAS), adjacent to MIDAS (ADMIDAS) and a synergistic metal ion-binding site (syMBS) formerly 
ascribed as ligand-associated metal ion-binding site (LIMBS) that act in concert to modulate cognate 







With short cytoplasmic tails (typically less than 75 amino acids in length), notable 
sequence homology is shared amongst the β-subunit cytoplasmic domains 
(cytodomains). Conversely, the α-integrin cytoplasmic tails are markedly divergent, 
save for a conserved GFFKR motif proximal to the transmembrane region that is 
requisite for association with the β tail domain and salt bridge formation (Hughes 
et al 1996). 
 
 
Integrin β cytodomain homology is most highly conserved within 3 defined 
regions (cytodomains-1, -2 and -3). Using point mutation studies in the avian 
integrin β1-subunit, Reszka et al (1992) first identified these 3 regulatory amino 
acid clusters (cyto-1: 764-774; cyto-2:785-788; cyto-3: 797-800) that determine 
integrin β1 localisation within focal adhesions (FAs) and heterodimer affinity and 
specificity. The authors found that membrane-proximal cyto-2 (an NPxY) motif 
supported structural conformation and integrin β1 localisation within FAs; whilst 
membrane-distal cyto-3 (an NxxY motif) was thought to negatively regulate 
integrin function.   
 
 
The role of these innate regulatory motifs autonomously governing integrin 
function is now an established concept. Takagi et al (1997) demonstrated the 
functional significance of disulphide-linked βI-domain sequences determining 
integrin ligand specificity. The authors found that integrin ανβ1 ligand specificity 
could be manipulated by replacing the integrin β1 CTSEQNC (187 – 193) βI-
domain sequence with the corresponding CYDMKTTC integrin β3 sequence.  
 
 
This ανβ1-β3-integrin β1 mutant variant engaged the integrin ανβ3 cognate ligands 
fibrinogen, von Willebrand Factor and vitronectin; ligands that integrin ανβ1 does 
not recognise. Reciprocal experiments manipulating integrin ανβ3 by replacing the 
CYDMKTTC β3 sequence with the β1 CTSEQNC sequence generated an ανβ3-β1-
integrin β3 mutant incapable of binding integrin ανβ3 cognate ligands. Takagi et al 
(1997) therefore concluded that these 2 disulphide βI domain sequences defined 
a novel regulatory site within β integrin species critical for ligand specificity.        
 
 
The β3 integrin cytoplasmic tail domain is frequently used as the template 
sequence for mapping integrin-binding partner interactions (Legate and Fassler 





 mediates binding to: skelemin (Reddy et al 1998), the Src-family kinase Fyn (Reddy 
et al 2008), FAK and paxillin (Schaller et al 1995). For inactive integrins, this β-
integrin cytoplasmic tail HDRK sequence binds to the α-integrin tail via formation 
of a salt bridge between the aspartate (D) residue in HDRK and the arginine (R) of 
the α-integrin cytodomain GFFKR motif; an interaction that is critical for 
stabilisation of the integrin heterodimer in the inactive conformation (Hughes et al 
1996, Legate and Fassler 2009).  
 
 
The membrane-proximal NPxY and membrane-distal NxxY motifs (flanking a 
Ser/Thr-rich (TST) intervening sequence) contained within the β-subunit 
cytoplasmic domain bind cytoskeletal and intracellular signalling proteins bearing 
a phosphotyrosine-binding (PTB)-domain. Some adaptor proteins bind specifically 
to a defined integrin species, however many binding partners are more 
promiscuous and associate with several different integrin cytoplasmic tails; this is 
particularly true of adaptor moieties binding the NPxY motif, whilst NxxY-binding 




Alongside regulatory motifs governing integrin-protein interactions, several sites 
mediating association of the integrin receptor with divalent metal-cation species 
are known. These metal-ion binding motifs modulate integrin conformation and 
ligand affinity. A metal-ion-dependent adhesion site (MIDAS) residing in the α-
subunit β-propellor region has been described. In non-αI integrins, a βI domain 
metal-ion cluster comprising an interlinked linear array of a central MIDAS flanked 
by the adjacent to MIDAS (ADMIDAS) and synergistic metal ion-binding site 
(SyMBS), formerly attributed as ligand-associated metal ion-binding site (LIMBS), is 
reported (Zhang and Chen 2012).  
 
 
Association of calcium (Ca2+), magnesium (Mg2+) or manganese (Mn2+) ions within 
these metal-ion motifs regulates integrin function in terms of conformation, ligand 
affinity and engagement. The ADMIDAS motif has been assigned a negative 
regulatory role whilst SyMBS is deemed a positive regulator of integrin function 
(Chen et al 2003), with cation occupation of the SyMBS critical for integrin 
activation (Valdramidou et al 2008, Zhu et al 2008). In addition to the motif site, the 
species of cation occupying these motifs is also known to modulate integrin 







During biogenesis and assembly in the endoplasmic reticulum, Ca2+ is requisite for 
subunit folding, mediating an inhibitory effect to prevent aberrant activation of 
nascent integrin receptors en route to the plasma lemma (Tiwari et al 2011).  
Displacement of inhibitory ions with Mg2+ or Mn2+ ions permits cognate ligand 
engagement; MIDAS occupation by Mg2+ or Mn2+ has been found requisite for 
ligand binding, permitting integrin activation and induction of downstream 
signalling (Dransfield et al 1992, Day et al 2002, Shimaoka et al 2002, Craig et al 
2004, Pesho et al 2006, Campbell and Humphries 2011, Tiwari et al 2011, Zhang 




1.2.3  integrin activation and signalling  
 
Integrin function is allosterically regulated, whereby receptor conformation 
critically mediates cognate ligand affinity and downstream signalling events. The 
integrins are believed to exist in a continuum of conformational states relating to 
ligand affinity and receptor activation status (Figure 1.4) (Shimaoka et al 2002, 
Shattil et al 2010, Campbell and Humphries 2011, Kim et al 2011b).  
 
 
Given their lack of intrinsic enzymatic activity, integrin β-subunit recruitment of 
multidomain adaptor proteins via their cytoplasmic domain regulatory motifs 
(NPxY; NxxY), is critical for integrin-mediated structural and signalling functions 
inducted upon integrin receptor activation; either by intracellular (“inside-out” 
signalling) or extracellular (“outside-in” signalling) mechanisms of activation 










Figure 1.4  
Integrins exist in a continuum of activation states (inactive [non-signalling], primed [inside-
out signalling] or active [outside-in signalling]) whereby the adopted conformation 
determines ligand affinity and focal adhesion assembly 
 
The integrins are classified as single-pass Type I transmembrane glycoproteins that form non-
covalently associated obligate heterodimers comprising an alpha (α) and beta (β) subunit. These 
subunits are encoded by 18α- and 8β-integrin genes, giving rise to the 24 known integrin α/β 
receptor combinations. They are classified into subfamilies based upon their ligand specificity and 
tissue restriction. Activation and modulation of integrin “outside-in” signalling is influenced by growth 
factors in addition to the composition and tensile properties of the ECM. These signalling events 
determine a number of cell properties including survival, proliferation, differentiation, migration, 
polarity and adhesion. Integrin outside-in signalling determines cytoskeletal actin dynamics, including 
focal adhesion assembly, critical for tumour cell migration and invasion. Inside-out signalling requires 
recruitment of intracellular integrin activators, such as kindlins or talin, that bind to the cytoplasmic tail 
of the β-subunit inducing a conformational change increasing integrin affinity for extracellular ligands. 
Abbreviations: FAK – focal adhesion kinase; IPP – ILK/PINCH/parvin complex; ILK – integrin-linked 
kinase; PINCH – particularly interesting Cys-His-rich protein; PIPKIγ – 






 Integrins in their bent, inactive (non-signalling) conformation may be primed by 
intracellular regulators of activation (talin, kindlins) to adopt a conformation more 
receptive to ligand engagement (“inside-out” signalling) (Calderwood et al 2013); 
or upon exposure to extracellular activating moieties such as divalent cations or 
cognate ligand, adopt the active signalling-replete conformation (“outside-in” 
signalling) (Smith et al 1994, Day et al 2002, Chen et al 2003, Tiwari et al 2011, 
Zhang and Chen 2012). In both instances, integrin function is critically dependent 
upon multi-domain adaptor protein recruitment and assembly (Humphries 1996, 
Humphries 2002, Ziegler et al 2008, Harburger and Calderwood 2009, Legate and 




These adaptor proteins (requisite for integrin-mediated phenotypic outputs) may 
be broadly classified into 3 function-based categories: i) adaptors with a 
predominantly structural function coupling integrins to the cytoskeleton (talin, 
tensin and filamin mediating F-actin binding); ii) scaffolding adaptors bearing 
binding sites to facilitate recruitment of additional proteins to nascent and 
maturing focal adhesions (FAs); and iii) adaptor proteins with intrinsic catalytic 
activity (FAK, ILK) requisite for adhesion-mediated signal-transduction following 
adhesion complex formation (Legate and Fassler 2009). 
 
 
Formation of integrin-mediated adhesion complexes is a multi-step process, 
driven by sequential mechanical and biochemical events. Collectively, advances in 
super-resolution microscopy, photo-activated localisation microscopy (PALM) and 
stochastic optical reconstruction microscopy (STORM), have permitted dissection 
and spatiotemporal characterisation of the dynamic nature of integrin-mediated 
adhesion complexes; distinguishing nascent from mature complexes and 
revealing the influence of mechanical force, as well as ligand specificity, on 
adhesion complex formation (Changede and Sheetz 2017).  
 
 
It has been shown that upon receptor activation following ECM ligand 
engagement, integrins cluster to form nascent adhesions roughly 100 nm (±20 
nm) in size, comprising approximately 50 integrins associated with talin (-1 or -2), 
FAK and paxillin (Changede et al 2015). Ye et al (2014) demonstrated that a novel 
lateral interaction between integrin transmembrane domains promoted integrin 
αIIbβ3 activation and clustering. Subsequent maturation of nascent integrin 





 polymerisation at the cytoplasmic interface of the cluster to permit cell spreading 
(Iskratsch et al 2013). 
 
 
Several mechanisms regulating the spatiotemporal recruitment of adaptor 
proteins to the β-integrin cytoplasmic tail have been proposed, including: lipid-
binding to the PTB domain of adaptor proteins or the direct phosphorylation of 
residues within the β–integrin cytodomain (Legate and Fassler 2009). The 
hierarchical binding of adaptor proteins modulates integrin receptor clustering 
and organisation at the plasma lemma, governing complete receptor activation 
and downstream signalling (Changede and Sheetz 2017).  
 
 
The guanine nucleotide exchanger cytohesin-1 has been proposed as a proximal 
regulator of intracellular integrin activation (Liddington and Ginsberg 2002). Nagel 
et al (1998) reported that cytohesin-1 bound the integrin-β2 cytoplasmic domain to 
regulate integrin β2–mediated adhesion in response to phosphatidylinositol 3-
kinase (PI 3-kinase) activation in Jurkat cells. Although cytohesin-1 is deemed 
integrin β2–specific, other more general intracellular regulators of integrin 
activation have been described, including talin.    
 
 
The homodimeric scaffold protein talin is known to play a critical role in integrin 
activation via breakage of the salt bridge formed between α and β integrin 
subunits when in the inactive conformation. This causes the α-β integrin 
heterodimer cytoplasmic tails to separate, permitting spatially favourable binding 
of adaptor proteins such as α-actininin, filamin and kindlins (Garcia-Alvarez et al 
2003, Montanez et al 2008, Ziegler et al 2008, Critchley 2009, Bouaouina et al 
2012, Atherton et al 2015).  
 
 
Furthermore, as a structural adaptor, talin interacts with the actin cytoskeleton both 
directly, and indirectly via vinculin. Talin has also been shown to increase integrin 
clustering and promote inside-out integrin activation. Talin cooperatively binds the 
integrin β-subunit and PIP2 (via its FERM domain), promoting integrin clustering 
and activation by preventing β-integrin cytoplasmic domain interaction with its α-








 Kindlins (-1, -2 and -3) show sequence homology with the talin FERM domain and 
demonstrably bind the integrin β-subunit cytoplasmic domain. All three kindlins 
have been implicated in integrin activation with studies revealing that kindlin 
binding to the β-integrin cytoplasmic tail is requisite but not sufficient for integrin 
activation (Calderwood et al 2013). Kindlin-2 has been shown to bind the β 
integrin subunit at its membrane-distal NxxY motif and was found requisite to 
target integrin-linked kinase (ILK) to adhesion complexes (Montanez et al 2008). 
 
 
In addition to recruitment and binding of adaptor proteins to mediate integrin 
activation and downstream signalling, integrins themselves have shown the ability 
to be phosphorylated at serine residues by protein kinase C (PKC). Freed et al 
(1989) demonstrated that β5 integrin phosphorylation was increased in human 
fibroblasts and osteosarcoma cells treated with phorbol esters (potent PKC 
activators). Using PKCε-/- cells, Stawowy et al (2005) later identified that the PKCε 
isoform mediated β1-integrin phosphorylation at Thr788 and Thr789 residues 
residing within the serine/threonine rich intervening sequence between 
membrane-proximal and membrane-distal NxxY motifs.  
 
 
Akt and PDK1 are also thought to be mediators of direct integrin β-subunit 
phosphorylation. Both Akt and PDK1 have been shown to phosphorylate integrin 
β3 at Thr779 in vitro to modulate Shc binding, with Akt activation correlating with 
β3-integrin Thr779 phosphorylation in vivo (Kirk et al 2000). Curiously, using 
selective-inhibitor studies in primary human platelets, Lerea et al (1999) 
demonstrated that β3-integrin subunit Thr779 may also be an ERK2 substrate. 
Later, Ahmed et al (2002a) reported a direct interaction between integrin ανβ6 and 
ERK2. Thus, direct phosphorylation of integrin cytoplasmic tail domains, in 
addition to canonical adaptor protein recruitment, remain areas of active research 
to further refine our understanding of integrin receptor activation, clustering and 
downstream signalling driving phenotypic changes.    
 
 
In addition to molecular regulators instigating integrin activation, negative 
regulators of integrin activation (or rather, regulators of integrin deactivation) have 
also been described (Pouwels et al 2012). Notably, from an RNAi screen, Rantala et 
al (2011) identified SHANK Associated RH Domain Interactor (SHARPIN) as a 
putative molecular inhibitor of β1-integrin activation. The authors found that siRNA-
mediated gene silencing of SHARPIN promoted integrin β1 activation in human 





 β1 activity was increased in keratinocytes, leucocytes and fibrobalsts isolated from 
SHARPIN deficient mice but re-expression of SHARPIN rescued phenotype. Rantala 
and colleagues (2011) also demonstrated that SHARPIN binds a conserved region 
of integrin α-subunits, inhibiting recruitment of talin and kindlins to the β-subunit 
cytoplasmic domain thus preventing integrin receptor activation.  
 
 
A Disintegrin And Metalloprotease domain (ADAM)-23, a member of the ADAM 
family of type I transmembrane glycoproteins, was reported to specifically interact 
(via its disintegrin domain) with the integrin ανβ3 (Cal et al 2000). Later, Verbisck et 
al (2009) demonstrated that ADAM23 negatively regulated integrin ανβ3 activation. 
The authors showed that loss of ADAM23 expression (using shRNA) in MDA-MB-
435 BrCa cells promoted integrin ανβ3 activation (as discerned by flow cytometry 
using the active conformer specific anti-integrin ανβ3 monoclonal antibody AP5 in 
comparison with the conformation state-independent antibody LM609 to 
recognise total integrin ανβ3).  
 
 
Furthermore, shRNA-induced loss of ADAM23 promoted a four-fold increase in 
MDA-MB-435 cell migration on the integrin ανβ3 cognate ligand vitronectin. 
Evaluation of ADAM23 promoter methylation status in human primary breast 
tumour samples revealed ADAM23 silencing by promoter hypermethylation was 
associated with disease progression (development of distal metastases) and worse 
patient outcomes (shorter 5-year disease-specific survival). These findings lead 
Verbisck and colleagues (2009) to conclude that ADAM23 negatively regulated 
integrin ανβ3 activation and that promoter hypermethylation-associated loss of 
ADAM23 expression in human BrCa is a prometastatic risk associated with worse 
disease outcome; highlighting the significance of aberrant regulation of integrin 
activation driving disease progression in BrCa.  
 
 
Therefore, in addition to positive intracellular molecular regulators, it is critical to 
acknowledge emerging evidence pointing to the existence of counteracting 
negative regulators of integrin activation requisite to fine-tune the delicate balance 
of integrin receptor activation, priming and deactivation to maintain a healthy 
state. Given the critical link between integrin conformation/receptor activation 
status and downstream signalling capacity, cell adhesion research continues to 
investigate intra- and extracellular regulators of integrin activation and inactivation. 
Aberrant integrin activation or impaired conformation is implicated in chronic solid 





 Marshall 2016) including pulmonary (Munger et al 1999) and renal fibrosis (Hahm 
et al 2007); and coagulation disorders typified by Glanzmann thrombasthaenia 
(Nurden 2006).  
 
 
Altered integrin cellular adhesion repertoires are of emerging significance within 
cancer research (Desgrosellier and Cheresh 2010). Acquisition of an invasive 
phenotype enabled by perturbed integrin expression and activation leading to a 
loss of epithelial polarity and gain of motility has been hypothesised (Guo and 
Giancotti 2004, Mosesson et al 2008), and is now an established, active area of 
cancer research, notably in BrCa (Aoudjit and Vuori 2001, Felding-Habermann et 
al 2001, Arjonen et al 2012, Vazquez Rodriguez et al 2017).  
 
 
Therefore, the ability to restore integrin function and activation status to that of a 
healthy state with targeted therapeutics, would alleviate the burden of chronic 
disease, or progression to metastatic disease dissemination in cancer, mediated 
by integrin conformation defects or aberrant integrin signalling. However, this 
requires refining our understanding of integrin activation and signalling 
modalities; thus ongoing research to robustly characterise mechanisms of integrin 








1.2.4     integrins and cancer 
 
Previous studies have demonstrated integrin overexpression frequently occurs in a 
variety of cancers, including BrCa. Their regulatory role modulating cellular 
adhesion and survival signals during migration and invasion to facilitate tumour 
progression continues to be investigated in the hope of identifying novel 
therapeutic targets (Aoudjit and Vuori 2001, Jin and Varner 2004, White and 
Muller 2007, Desgrosellier and Cheresh 2010, Allen et al 2011, Taherian et al 
2011, Aoudjit and Vuori 2012, Allen et al 2014). An emerging concept is the 
significance of the active, signalling-replete integrin subpopulation during cancer 
progression (Aoudjit and Vuori 2001, Felding-Habermann et al 2001, Taherian et 
al 2011, Eberlein et al 2013, Lee et al 2013, Li et al 2013). 
 
 
1.2.4.1    integrin activation status in cancer 
Felding-Habermann et al (2001) demonstrated in vitro and in vivo that integrin ανβ3 
in its active but not its inactive state, enabled tumour cell-thrombocyte interactions 
to circumvent anoikis facilitating establishment of a metatstatic phenotype in the 
MDA-MB-435 BrCa cell line. It was concluded that anomalous integrin activation 
may induct an adverse course of BrCa.  
 
 
Lee et al (2013) demonstrated that β1 integrin was constitutively active in prostate 
cancer cell lines with known high metastatic potential in comparison with those of 
low metatstatic potential. Furthermore, in vivo antibody-blockade of constitutively 
active β1 integrin demonstrably inhibited prostate cancer metastasis and was 
associated with reduced phosphorylation of integrin β1 downstream effectors focal 
adhesion kinase (FAK) and Akt. The authors found increased β1 integrin activation 
correlated with metastatic potential in vivo, further implicating the significance of 
aberrant integrin activation states during tumour progression.  
 
 
Arjonen et al (2012) demonstrated that distinct trafficking kinetics of the active and 
inactive β1 integrin conformers modulate cell surface availability of these two 
receptor pools in the MDA-MB-231 BrCa cell line. Although both β1 conformations 
undergo clathrin- and dynamin-dependent endocytosis, the net rate of 
internalisation was higher for active β1 compared to inactive β1, however the 
inactive β1 is more rapidly recycled back to the plasma membrane via a short, 





 routes, integrin activation status has been implicated in spatial restriction of the 
active integrin pool to localise and direct integrin-mediated functions. 
Dozynkiewicz et al (2012) reported Rab25 was seen to spatially restrict recycling of 
active, ligand-engaged integrin α5β1 conformers to the tips of invasive protusions 
in ovarian cancer cells migrating through a 3D-matrix. 
 
 
Collectively, these findings would suggest recognition of integrin activation status 
by the endocytic machinery to modulate internalisation rates and intracellular 
trafficking routes as determined by integrin conformation. The mechanisms by 
which this may occur are as yet undefined and warrant further investigation. 
However, Bouvard et al (2013) acknowledge the link between integrin activation 
status and endocytic regulation remains open to debate, with current evidence 
suggesting endocytosis of active integrins may be restricted to fibroblasts and 
cancer cells. Thus, integrin receptor endocytic trafficking during tumourigenesis 




1.2.4.2      intracellular trafficking of integrins 
In addition to integrin activation status, derailed endocytic receptor trafficking is an 
emerging cancer hallmark with postulated roles in both tumourigenesis and 
disease progression (Mosesson et al 2008). Rainero et al (2013) comprehensively 
reviewed current research concepts that indicate integrin internalisation, 
intracellular trafficking and recycling routes determine cancer cell migration and 
invasion. Broadly, these phenomena cooperate to control the spatial restriction of 
integrin receptors used by migrating (and invading) cells during physiological 
conditions but undergo marked derailment during tumourigenesis.  
 
 
Interactions between integrin adhesion receptors and receptor tyrosine kinases 
(RTKs) that synergistically modulate internalisation kinetics and trafficking routes of 
both receptor classes is of growing research interest given the potential 
implications for combination targeted therapies. Muller et al (2009) reported the 
importance of p53 mutations perturbing both integrin and RTK recycling to 
potentiate invasion and metastasis during disease progression. Interestingly, it has 
been observed that the Rab-GTPase components of vesicle trafficking pathways 
exhibit both tumour suppressor and oncogenic functions in human cancers. It is 





 events themselves. Thus, research seeking to define the mechanisms by which the 
aforementioned phenomena occur is ongoing. It is hoped that this will highlight 
novel targets for therapeutic intervention to combat the activation of invasion and 
metastasis associated with cancer progression (Dozynkiewicz et al 2012, Rainero et 
al 2012, Rainero et al 2013).  
 
 
Active endo-exocytic cycling of fibronectin (Fn)-binding integrin receptors was first 
reported by Bretscher (1989). Subsequent studies have demonstrated that 
integrins may undergo endo-exocytic cycling via both “short-loop” and “long-
loop” trafficking pathways after internalisation into early endosomes (EEs) such that 
the total cell surface pool of integrin receptors may be routed through the 
endosomal machinery once every 30 minutes (Roberts et al 2001, Rainero et al 
2013). Short-loop recycling is characterised by rapid redelivery of EE receptor 
cargo to the plasma membrane.  
 
 
Conversely, long-loop trafficking pathways are characterised by slower recycling 
kinetics with delivery of EE cargo to the perinuclear recycling complex (PNRC) for 
endosomal sorting for either degradation or recycling to the plasma membrane. 
Spatial redistribution of integrin receptors as determined by endocytic 
internalisation and intracellular trafficking is now known to be critical for 
maintenance of cell polarity and control of cell motility through predominantly 
retrograde movement (from cell front to cell rear) of integrin bulk translocation 
(Caswell and Norman 2006).  
 
 
Integrins may endocytose via many of the established internalisation routes 
including macropinocytosis, caveolin-dependent pathways, clathrin-dependent 
pathways or via clathrin-independent carriers. The internalisation kinetics and 
routes of all 24-integrin species are not yet fully characterised or understood. 
Studies of integrin α5β1 suggest that specific integrin heterodimers are not 
restricted to a single-entry route. The integrin α5β1 has been shown to undergo 
both clathrin-dependent and clathrin-independent internalisation routes 
highlighting the complexity of endocytic integrin regulation (Teckchandani et al 









 1.2.4.3     integrin-RTK crosstalk during trafficking 
Intracellular trafficking and signalling by integrins has been shown to dictate 
internalisation and recycling of other endocytic cargoes, such as RTKs, in an 
integrin-heterodimer-specific manner. This phenomenon emerged during integrin 
blockade studies, notably during evaluation of the cyclic pentapeptide Cilengitide 
(cyclo-RGDfNmeV) as an anti-angiogenic therapeutic to abrogate integrin ανβ3 and 
ανβ5 function. It was found that when integrin ανβ3 was able to engage cognate 
ligand(s), recycling of the RTK vascular endothelial growth factor receptor 2 
(VEGFR2) was slow but compensated for by rapid VEGFR2 degradation upon 
VEGF engagement (Reynolds et al 2009, Millard et al 2011).  
 
 
However, integrin ανβ3 functional blockade induced rapid recycling of VEGFR2 via 
a Rab4-dependent short loop, which circumvented VEGFR2 degradation, leading 
to an increase in the available cell-surface pool of VEGFR2. As a functional 
consequence of this, tumour vascularisation was promoted due to upregulation of 
VEGF-mediated endothelial cell migration and angiogenic sprouting. 
Furthermore, the proangiogenic effects of Cilengitide were seen to be dose-
dependent (Reynolds et al 2009). 
 
 
In addition to modulating RTK trafficking, integrin functional blockade has been 
shown to induce compensatory “integrin switching”. During integrin ανβ3 blockade 
experiments using Cilengitide, a compensatory upregulation of other integrin 
species was reported. Caswell et al (2008) defined a Rab-coupling protein (RCP)-
driven integrin α5β1 compensatory switch inducted upon integrin ανβ3 abrogation 
leading to formation of an integrin α5β1–RCP complex. The α5β1–RCP complex 
recruits epidermal growth factor receptor (EGFR), an event that potentiated 
increased EGFR recycling and signalling to drive invasive cell migration.  
 
 
The phenomena of compensatory integrin switching and perturbation of RTK-
integrin synergy post integrin functional blockade has important ramifications for 
the development and future applications of integrin-targeted therapies. Hence, 
further characterisation of the complexities of integrin internalisation, trafficking 
and recycling remains paramount in order to expedite the translation of integrin-







 1.2.4.4     integrin-targeted therapeutics 
Given the established role of integrins in both health and disease, considerable 
efforts have been undertaken to develop targeted therapeutics to abrogate 
aberrant function or harness the power of tissue-restricted integrin expression to 
refine specificity of drug delivery (Millard et al 2011, Jiang et al 2013, Raab-
Westphal et al 2017). A range of therapeutic moieties have been synthesised 
including monoclonal antibody therapies, small molecule inhibitors and peptide-
based therapeutics (summarised in Figure 1.5).  
 
 
Interestingly, integrin antagonist therapies in use or successfully reaching late-
stage clinical trials are directed against the ligand-binding site or the ligand itself 
(Hamidi et al 2016, Ley et al 2016). Best typifying the state of integrin therapeutics 
are those targeting the human platelet integrin αIIbβ3 for thrombotic disorders 
(Raab-Westphal et al 2017). Abciximab (ReoPro, clone 7E3), a Fab’ fragment 
chimeric mouse-human monoclonal antibody targeting the human platelet 
integrin αIIbβ3 (but with specificity for ανβ3 and αMβ2) was the first integrin 
antagonist therapy clinically approved in 1994 for perioperative use in 
percutaneous coronary intervention by the US Food and Drug Administration. Its 
mechanism of action is direct competitive inhibition of the αIIbβ3 ligand-binding 
site, thus preventing platelet aggregation (Tam et al 1998).    
 
 
Also targeting the platelet integrin αIIbβ3 are the synthetic cyclic heptapeptide 
Eptifibatide and the non-peptide small molecule inhibitor Tirofiban, both of which 
are also competitive inhibitors of fibrinogen ligand binding to ablate thrombosis 
formation. Apticide (Tc-99m-P280) was developed as a non-therapeutic imaging 
peptide that binds integrin αIIbβ3 to permit diagnostic imaging of deep vein 
thromboses (Millard et al 2011). Collectively, the integrin αIIbβ3 therapeutics 
exemplify the potential utility of clinical integrin targeting; their failure to gain 
widespread clinical application proving demonstrative of the complexities and 
pitfalls in translating novel molecular-based therapies into routine medical 
practice.   
 
 
The integrin ανβ6 has also been targeted as a potential point for cancer therapy 
intervention strategies using monoclonal antibodies (264RAD, Oncology iMED 
AstraZeneca UK and STX-100, Biogen Idec); or for tumour PET-imaging using 






Antibody STX-100 was in a phase 2 clinical trial for nephropathy and idiopathic 
pulmonary fibrosis, which completed in May 2017 (ClinicalTrials.gov Identifier 
NCT01371305) but results are pending publication. The PET-imaging agent is 
currently in phase 1 clinical trials for idiopathic pulmonary fibrosis 
(ClinicalTrials.gov Identifier NCT03069989) (Raab-Westphal et al 2017). It will be 
interesting to evaluate the efficacy of these integrin ανβ6 targeted agents when trial 
results are published.  
 
 
Pre-clinical data for the antibody 264RAD is promising, as a stand-alone, but more 
interestingly, as a component of combination therapy regimens in BrCa (Moore et 
al 2014) and pancreatic ductal adenocarcinoma (PDAC) (in-house data pending 
publication). Its application in conjunction with trastuzumab therapy was seen to 
have an augmentative effect, potentiating the efficacy of HER-2 targeting with 
trastuzumab in HER-2 positive BrCa in vitro and in vivo by a mechanism not yet 
defined but apparently mediated by Akt2 (Moore et al 2014). Thus, the potential 
utility of co-targeting relevant integrin receptor species in tandem with existing, 








Figure 1.5  
Integrin receptor classes, their ligand-specificities and targeted therapies  
Figure prepared for publication in press (Raab-Westphal et al 2017). See figure legend overleaf.  
Figure 1.5  
Integrin receptor classes, their ligand-specificities and targeted therapies  
 
Schematic overview of the integrin receptor classes, heterodimer subunit associations and 
their ligand specificities together with targeted therapies reaching clinical trials published to 
date. Marketed therapeutic agents currently available in clinic are underlined (abciximab, 
epitifibatide, lifitegrast, natalizumab, tirofiban, Tm-99m-P280, vedolizumab). Agents 
reaching the market but withdrawn are indicated with a dashed underline (efalizumab). 
Cancer therapeutics are written in purple script (abituzumab, cilengitide, efatucizumab, 
intetumumab, MK-0429, P5, STX-100, volociximab). Subunit-specific or heterodimer 
targeting is indicated. Figure prepared for publication in press (Raab-Westphal et al 2017) 








1.2.5     the integrin ανβ6 
Expression of the epithelial-restricted integrin ανβ6 is low to absent in health, but is 
upregulated during embryogenesis, tissue morphogenesis (development), 
trauma, chronic inflammation and wound-healing (Khan and Marshall 2016). 
Integrin ανβ6 frequently localises at the invasive front of neoplastic cells implicating 
its involvement during cellular invasion and metastasis. Tumoural expression of 
integrin ανβ6 is a poor prognostic indicator in a variety of cancers, including BrCa 
(Nystrom et al 2006, Thomas et al 2006, Van Aarsen et al 2008, Margadant and 




Although the αν subunit may heterodimerise with β1, β3, β5, β6 or β8 integrins, β6 
dimerisation is restricted to the αν subunit.  Our current mapping of integrin β6–
subunit structure is inferred from other RGD-binding β integrins (Humphries 2002, 
Humphries et al 2003, Luo et al 2007, Zhu et al 2008, Campbell and Humphries 
2011). The integrin ανβ6 binds cognate ligands in the ECM bearing an RGD 
tripeptide motif. A metal ion-dependent adhesion site (MIDAS) provides a site for 
divalent cation binding, which potentiates ligand-engagement (Hynes 2002, 
Humphries et al 2003, Craig et al 2004, San Sebastian et al 2006, Bouaouina et al 




Integrin structure as defined by X-ray crystallography has not yet been explicitly 
elicited for the β6 subunit. However, research published by Dr Timothy Springer’s 
lab (Springer Lab, Department of Biological Chemistry and Molecular 
Pharmacology, Harvard Medical School, Boston MA, USA) has revealed important 
insights into integrin β6 structure and regulatory functional motifs. Dong et al 
(2014) defined the molecular mechanism establishing integrin ανβ6 high specificity 
for the RGD tripeptide motif residing in the prodomains of latent transforming 
growth factor (TGF)-β1 and TGF-β3.  
 
 
Using a combination of crystallographic structural analysis, point mutation studies 
and peptide affinity measurements, Dong and colleagues demonstrated that 
integrin ανβ6 binds TGF-β1 and TGF-β3 with high affinity via an RGDLXXL/I motif 
within the TGF-β1/3 prodomains; with the LXXL/I amphipathic α-helix binding in a 





 distinct βI-domain loops (named “specificity-determining loops” (SDLs): SDL-1 (β1-




To define the basis of the unparalleled high affinity of integrin ανβ6 for pro-TGF-β 
(and its derived peptides), Dong and colleagues (2014) elucidated the structure of 
the integrin ανβ6 headpiece. The authors mapped 3 proximally arranged metal 
ion-binding sites in the βI domain: SyMBS, MIDAS and ADMIDAS (as had been 
determined previously for other βI domain-bearing integrin species). In the 
absence of ligand, the integrin ανβ6 headpiece adopts a closed conformation. In 
the presence of ligand (pro-TGF-β), it was found that the aspartate residue of RGD 
coordinated the MIDAS-metal ion inducing headpiece opening in the presence of 
both Mg2+ or Ca2+. Interestingly, the authors attributed the high affinity and 
selectivity of integrin ανβ6 for pro-TGF-β to the interaction between the β6 
hydrophobic pocket and TGF-β LXXL/I amphipathic α-helix motif; conferring 1000-
fold selectivity for pro-TGF-β over the RGD motif present in Fn, and 1000-fold 
selectivity over integrin ανβ3 for pro-TGF-β engagement. 
 
 
Integrin receptors typically possess a large extracellular domain for ligand 
engagement comprising multiple modular domains, a short single-spanning 
transmembrane domain of around 25 – 29 amino acid residues and a short, 
unstructured cytoplasmic tail devoid of any intrinsic enzymatic activity. Thus, 
integrin signalling is entirely dependent on the recruitment of adaptor proteins 
(Danen 2013). Several well-defined regulatory motifs have been identified in the β 
integrin C-terminus that bind many integrin-binding proteins such as talin and the 
kindlins. These include a membrane proximal NPxY and membrane distal NxxY 
motifs on the β integrin tail, which are classic phosphotyrosine-binding (PTB) 
domains (Legate and Fassler 2009).  
 
 
Several integrin ανβ6 direct-binding partners have been reported. Using a cDNA 
library screen, Ramsay et al (2007) identified HS1-Associated Protein X-1 (HAX-1) 
as a novel β6-integrin binding partner and successfully confirmed this by 
coimmunoprecipitation of HAX-1 and the β6–subunit. A direct physical association 
between ERK2 and the β6 subunit has also been described (Ahmed et al 2002a) 
and the Four and a Half LIM protein 2 (FHL2) was shown to associate with the cyto-







In addition, the β6 tail domain bears a unique 11 amino acid sequence 
(EKQKVDLSTDC) requisite for integrin ανβ6-dependent invasive processes via 
direct association with psoriasin (S100A7) in OSCC cell lines (Morgan et al 2011). 
Indeed, transfection of these 11 amino acid residues into the C-terminus of the 
integrin β3 subunit was previously found to promote MMP-2 or MMP-9-mediated 
ανβ3–dependent invasion in OSCC cells (Morgan et al 2004), demonstrative of the 




Experimental studies have demonstrated that integrin ανβ6 imparts a pro-invasive 
and more aggressive phenotype in oral squamous carcinoma (OSCC) (Table 1.2) 
(Thomas et al 2001b, Nystrom et al 2006, Thomas et al 2006) and BrCa (Allen et al 
2014, Moore et al 2014). Furthermore, functional blockade of integrin ανβ6 has 
been shown to reduce ανβ6–mediated proliferation, survival and tumour 
progression in several cancer models, highlighting its potential utility as a 
therapeutic target.  
 
 
Both Van Aarsen et al (2008) and Eberlein et al (2013) demonstrated in vivo 
inhibition of tumour progression via functional antibody-blockade of integrin ανβ6 
using antibodies 6.3G9 and 264RAD respectively. Mechanistically, abrogation of 
integrin ανβ6 activity was seen to modulate TGF-β1 activity in xenografts of Detroit 
562 human pharyngeal cancer cell lines in both studies. Eberlein and colleagues 
(2013) demonstrated similar abrogation of integrin ανβ6–protumourigenic activity 
on orthotopic 4T-1 murine breast tumour growth in vivo.   
 
 
Later, Eberlein et al (2015) determined that non-small cell lung carcinoma (NSCLC) 
cells expressing E-cadherin, EpCAM and integrin ανβ6 were able to activate normal 
human dermal fibroblasts via integrin ανβ6-dependent TGF-β1 signalling to modify 
gene expression and therapeutic response. The mechanism of activation was 
abrogated using 264RAD to ablate integrin ανβ6 function. The authors concluded 
that although tumour cell initiated fibroblast activation is integrin ανβ6 dependent, 
once co-opted fibroblasts acquired an active phenotype, sustenance of TGF-β1 
signalling was mediated by other TGF-β pathway regulators to maintain an 
activation loop. Therefore, the role of tumour cell integrin ανβ6–dependent 
signalling (both autocrine and paracrine) during stromal modification in cancer 







Tumour-trophic function Comment Cell type 
TGF-β activation Binds & activates latent TGF-β1 Keratinocytes 
Invasion & migration 
Promotes migration over known adhesion substrates 
LAP, Fn & Vn. 




Proliferation & survival Upregulation is protective against anoikis via activation of Akt-dependent survival signals OSCC 
Table 1.2  
Summary of tumour-trophic properties of integrin ανβ6 expression demonstrated in 
keratinocytes and oral squamous cell carcinoma (OSCC) cells  
Table content adapted from Thomas et al (2006), Thomas et al (2002) and Thomas et al (2001a). 
Integrin ανβ6 expression has been implicated in tumour progression. Its tumour-trophic functions have 
been summarised here.  Abbreviations: Fn – fibronectin; MMP – matrix metalloproteinase; OSCC – oral 
squamous cell carcinoma; TGF-β1 – transforming growth factor-β; Vn – vitronectin. 
 
 
In a large BrCa patient cohort, Moore et al (2014) correlated integrin ανβ6 
overexpression with poor survival and increased distal metastases, demonstrative 
of the clinical significance of integrin ανβ6. Furthermore, using in vivo BrCa models 
the authors demonstrated that integrin ανβ6 blockade reduced tumour growth and 
metastasis. Of particular interest, is their finding that ανβ6 functional abrogation 
potentiated trastuzumab efficacy in an in vivo model of HER2-driven BrCa. This 
infers integrin ανβ6 cooperates with HER2 to modulate HER2 signalling capacity 
and oncogenic effects, concordant with previous hypotheses that integrins may 
modulate RTK endocytic fate to drive disease progression (Caswell et al 2008, 
Muller et al 2009, Rainero et al 2013). 
 
 
Since Ramsay et al (2007) demonstrated HAX-1-dependent endocytosis of integrin 
ανβ6 was requisite for ανβ6-mediated invasive processes in OSCC, it is possible that 
the oncogenic effects of ανβ6 in BrCa may also be driven by endo-exocytic kinetics. 
However, little is currently known regarding regulation of integrin ανβ6 
internalisation and intracellular trafficking. Several protein-binding partners have 
been implicated in integrin ανβ6 endocytic regulation including HAX-1 and 
psoriasin (Morgan et al 2011).  
 
 
It is known that integrin ανβ6 is one of the cell surface receptors to which the foot 
and mouth disease virus (FMDV) binds to mediate infection of bovine epithelia. 
Using this mechanism as a model to study integrin ανβ6 internalisation and 





 clathrin-dependent endocytosis to mediate FMDV infection, a process that 
required endosomal acidification.  
 
 
In addition to integrin-GFR synergistic interactions, integrin crosstalk with other 
adhesion receptors has also been identified as a regulatory checkpoint during 
integrin endo-exocytic cycling. Notably, Src-mediated phosphorylation of the 
proteoglycan ECM-receptor syndecan-4 was found to be a critical switch 
governing the balance between endo-exocytic cycling of integrins ανβ3 and α5β1. 
Upon syndecan-4 phosphorylation by Src, integrin ανβ3 recycling was promoted at 
the expense of integrin α5β1, leading to accumulation of integrin ανβ3 at the 
plasma membrane facilitating adhesion complex stabilisation.  
 
 
In the absence of Src-mediated syndecan-4 phosphorylation, α5β1 recycling to the 
plasma membrane was upregulated to promote focal adhesion turnover. Tight 
control of this integrin ανβ3/α5β1 switching phenomenon was deemed essential for 
efficient cell migration (Morgan et al 2013). Since integrin ανβ6 has been shown to 
co-localise with syndecan-4 (unpublished data), it is possible that integrin ανβ6 
endo-exocytic cycling kinetics may also be subject to regulation by 
phosphorylation of associated adhesion receptors to elicit similar integrin 
switching phenomena.  
 
 
The pro-tumourigenic phenotypic effects imparted by integrin receptor switching 
were investigated by Janes and Watt (2004). Since integrin ανβ5 expression is 
downregulated whilst integrin ανβ6 is upregulated during transformation from 
healthy stratified squamous epithelia to squamous cell carcinoma (SCC), the 
authors sought to characterise the functional effects of this alteration in integrin 
receptor profile. Based on their findings, Janes and Watt (2004) proposed that 
integrin ανβ6 expression conferred a survival advantage over integrin ανβ5 
expression by promoting Akt-dependent survival signals, enabling circumvention 
of anoikis. However, a mechanism was not elucidated to account for the integrin 
ανβ6-dependent nature of Akt signalling observed.  
 
 
The protumourigenic effects of integrin ανβ6–associated Akt-dependent survival 
signalling is concordant with the findings of Moore et al (2014) that functional 





 induced a significant downregulation in Akt2 expression in vivo in human HER-2-
driven BrCa xenograft models. Collectively, these data would suggest functional 
outputs downstream of integrin ανβ6 are likely to be Akt dependent. Further 
characterisation of this phenomenon is warranted in light of integrin- ανβ6 targeted 
therapies currently in development.  
 
 
The integrin ανβ6 is now of emerging significance as predictive of progression to 
invasive disease within the context of DCIS. Using immunohistochemical 
assessment of archival FFPE samples from a historical cohort of 532 ductal 
carcinoma in situ (DCIS) patients, Allen et al (2014), demonstrated that integrin 
ανβ6 expression was significantly (p<0.006) predictive of progression from in situ to 
invasive disease.  
 
 
In addition, Allen and colleagues (2014) established that myoepithelial cell integrin 
ανβ6 positivity occurred with greater frequency in DCIS with associated invasion 
compared to pure DCIS with no evidence of microinvasion or invasion. 
Furthermore, their analysis of 52 case-control DCIS samples with accompanying 
long-term clinical follow-up data acquired from the UK, Australia and New Zealand 
ductal carcinoma in situ (UK/ANZ-DCIS) Trial (Cuzick et al 2011) revealed that 
integrin ανβ6 expression is a significant predictor (p<0.02) of invasive progression 
and disease recurrence. 
 
 
In adjunctive functional investigations to elucidate a putative mechanism by which 
myoepithelial integrin ανβ6 expression may determine invasive risk in DCIS, Allen 
et al (2014) established that myoepithelial cells expressing integrin ανβ6 promoted 
tumour cell invasion in vitro in the MCF-7, MDA-MB-231 and T47D breast cancer 
cell lines when treated with conditioned media from an immortalised 
myoepithelial cell line transduced to constitutively and stably overexpress the 
integrin β6 subunit (β6-1089) compared to cells treated with conditioned media 
from non-transfected β6 cDNA–null 1089 myoepithelial cells (N-1089).  
 
 
Furthermore, myoepithelial integrin ανβ6 expression was reported to promote 
breast tumour growth in vivo when the mammary fat pads of female C.B-17 SCID 
mice were injected with MDA-MB-231 mixed with β6-1089, compared to those co-
injected with MDA-MB-231 and N-1089 cells. Based on MMP-9 gelatin 





 IHC coincidental immunopositivity for both integrin ανβ6 and MMP-9 in clinical 
FFPE sections of DCIS with invasion), Allen et al (2014) concluded that 
myoepithelial integrin ανβ6 expression conferred a tumourigenic growth 
advantage. The authors proposed that integrin ανβ6–mediated MMP-9 
upregulation and TGF-β1 activation established a pro-invasive tumour niche 
facilitating disease progression.  
 
 
This study highlights the aetiopathological significance of integrin ανβ6 as a 
participant moiety in a regulatory hub modulating MMP-9 and TGF-β1 activity 
working in concert to generate and establish a pro-invasive tumour 
microenvironment. Indeed, integrin ανβ6 acting in concert with other MMP 
moieties has been implicated as a significant pro-invasive factor in other 
malignancies, not only BrCa.  
 
 
For example, Thomas et al (2002) demonstrated that upregulation of integrin ανβ6 
promoted MMP-3 activation and potentiated OSCC migration and invasion on 
fibronectin (Fn). Furthermore, Impola et al (2004) proposed MMP-7, MMP-9 and 
MMP-12 as prognostic markers (concomitant with integrin ανβ6 overexpression) at 
the invasive fronts of oral verrucous and OSCC cells. Al-Hazmi et al (2007) 
characterised a positive feedback loop governing MMP-2/MMP-9 activation in the 
VB6 OSCC cell line engineered to overexpress integrin ανβ6, whereby cell 
migration on Fn was enhanced by MMP-2/-9 activity which subsequently enhanced 
cell motility and MMP secretion.  
 
 
Collectively, these studies reveal the putative significance of integrin ανβ6 as a 
regulatory node coordinating TGF-β1 and MMP activity, modulating ECM 
remodelling and protease-driven invasive processes in cancer. If integrin ανβ6 
receptor activation status could be demonstrated within the context of these 
findings, it may be possible to define the spatiotemporal role of integrin ανβ6 













Specific discrimination between inactive (non-signalling) and active (signalling 
replete) integrin ανβ6 receptor pools would permit unequivocal determination of 
the sequential significance of integrin ανβ6 activation to elucidate its pathological 
role as an initiator, a driver or a responsive sequela in the invasive niche.  
 
 
Collectively, there is a resounding evidence base to justify research seeking to 
further define the role of the integrin ανβ6 and its activation status during breast 
tumourigenesis and disease progression. It is hoped that this research will provide 
novel insights into mechanisms regulating integrin ανβ6 activation and downstream 
signalling pathways; in the hope that predictive biomarkers and/or potential 
regulatory nodes suitable for targeted therapy may be identified to improve 








 1.3 scope and purpose of study  
 
Given its established pro-invasive and poor-prognostic association during 
tumourigenesis, further characterisation of the mechanisms by which integrin ανβ6 
mediates invasion and metastatic dissemination in BrCa is warranted. Indeed, 
therapeutic exploitation of integrin ανβ6 functional blockade using monoclonal 
antibodies in both stand-alone and combination treatment modalities for BrCa, is 
already a realistic prospect (Moore et al 2014).  
 
 
There is a groundswell of evidence to support the hypotheses that both integrin 
activation status and intracellular trafficking kinetics potentiate disease progression 
in several in vivo cancer models (Arjonen et al 2012, Eberlein et al 2013), including 
BrCa (Felding-Habermann et al 2001, Moore et al 2014). Thus, targeting aberrant 
activation and/or derailed internalisation and intra-cellular trafficking kinetics may 
prove viable and effective aspects of integrin ανβ6 adhesion receptor biology ripe 
for therapeutic exploitation and intervention. However, to facilitate investigations 
dissecting the relevance of integrin activation status in BrCa, a robust means by 
which the active, signalling-replete conformer of the integrin ανβ6 may be 
distinguished from the inactive, non-signalling subpopulation must first be devised 
and validated.  
 
 
Furthermore, it must be acknowledged that the mechanisms by which the 
downstream phenotypic effects of integrin ανβ6 are elicited both pre- and post-
receptor functional abrogation, remain unknown. This impeding dearth of existing 
experimental evidence to define signalling events and network integration 
mediated by the integrin ανβ6 assuredly merits exploration of both the integrin 
ανβ6 adhesome and kinome to identify novel molecular regulators of the integrin 
ανβ6 adhesive and signalling functions respectively.  
 
 
Therefore, dissecting the regulatory mechanisms governing key facets of integrin 
ανβ6 functional biology including; ανβ6-mediated adhesive processes, putative 
ανβ6-RTK cross-talk, ECM ligand-induced ανβ6-activation and ensuing 
internalisation, in tandem with their associated downstream signalling motifs, is 







 1.4 hypothesis, aims and objectives  
1.4.1  hypothesis 
 
The aetiopathological significance of the cellular adhesion receptor integrin ανβ6 
during neoplastic transformation and malignant progression in BrCa is dependent 
specifically upon its activation status and associated conformation, since this active 
state will permit establishment of known integrin–mediated oncogenic signalling 
that underpins acquisition of a malignant phenotype, including activation of 
invasion and metastasis. It is hypothesised that the pool of activated, signalling 
replete integrin ανβ6 receptors are both conformationally and functionally distinct 
from the inactive, non-signalling receptor pool, with the active conformers 
specifically mediating integrin ανβ6–derived phenotypic changes during oncogenic 
transformation of the breast and progression to disseminated disease.  
 
 
1.4.2  aims and objectives 
 




i) establish a means by which the active subpopulation of integrin ανβ6 may be 
distinguished using monoclonal antibodies to permit further investigations into 
activation status  
 
 
ii) once validated, employ monoclonal antibodies to evaluate the relevance of 
the active fraction of integrin ανβ6 during BrCa carcinogenesis using an vitro 




iii) develop, optimise and use a label-free proteomics strategy to identify novel 
molecular regulators modulating ligand engaged integrin ανβ6-mediated 
adhesions in a 2D-environment to define the integrin ανβ6 adhesome  
 
 
iv) develop and apply a phosphoproteomic strategy to dissect integrin ανβ6-
mediated downstream signalling events inducted upon cognate ECM ligand-
engagement and subsequent receptor-ligand internalisation facilitating 



















2.1 cell culture 
 
 
All cell lines were obtained from in-house stocks (Centre for Tumour Biology, Barts 
Cancer Institute, QMUL, London) and authenticated at a commercial facility by 
short tandem repeat (STR) profile analysis at 16 loci (PowerPlex® 16 HS 16 Loci 
Service, (LGC©Standards 2011)). Cell lines were cultured in the absence of 
antibiotics and antimycotics at 37°C in a humidified atmosphere with 8% CO2 and 
passaged subconfluent (60 – 90%) to retain the exponential growth phase. Whilst 
in culture, cell morphology was reviewed routinely by phase contrast microscopy 
(OLYMPUS IMT-2, Olympus Corp.) for rudimentary evaluation of phenotypic 
stability and cell condition.  
 
 
Young et al (2010) acknowledge the critical requirement for routine Mycoplasma 
spp. screening in cell culture, since infection is known to modify cellular 
physiology, eliciting deleterious effects on experiment validity. Therefore, all cell 
lines were regularly tested for Mycoplasma spp. infection by nested polymerase 
chain reaction (PCR) to ensure experimental procedures were performed on cells 
free from occult infection by Mycoplasma species (Dobrovolny and Bess 2011). 
 
 
Derivation of cell lines used in this study together with their respective specific 
culture requirements are summarised in Tables 2.1 – 2.3. Details of tissue culture 
reagents and media supplements are given in Table 2.4. 
chapter II: 
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Cell line Aetiology & Derivation Culture Conditions Comment/Experimental Applications 
A375puro 
Tumourigenic human melanoma cell line derived from a metastatic 
malignant melanoma (MM) isolated from a 54-year old female engineered 
to express the puromycin resistance gene. Karyotype: hypotriploid 
(Kogelberg et al 2008, ATCC 2012a, Man et al 2013, Pisano et al 2013, Prat 
et al 2013).  
Adherent growth 
DMEM/10% FBS/L-glutamine 
Used as negative control cell line for integrin ανβ6 
expression. 
A375β6 
Derived from the A375 parent cell line and engineered to constitutively 
overexpress the integrin β6 subunit. A375 cells were infected with pBabe 
retroviruses encoding puromycin resistance or additional cDNA for human 
integrin β6 subunit. Cells were selected in 1.25 μg ml-1 puromycin with 
subsequent sorting by magnetic beads using the integrin ανβ6 specific 
antibody clone 10D5 (MAB2077Z, Merck Millipore) (Hausner et al 2007, 
Kogelberg et al 2008).  
Adherent growth 
DMEM/10% FBS/ 
2 mM L-glutamine 
 
Used as positive control cell line for integrin ανβ6 
expression. Expression of integrin ανβ6 in this cell line is 
known to drift. Monthly assessment of integrin ανβ6 
expression levels by flow cytometry should be 
undertaken for cells in continuous passage. Re-selection 
in puromycin or magnetic bead sorting using antibody 
clone 10D5 (Merck Millipore) may be undertaken as 
required (Hausner et al 2007, Kogelberg et al 2008). 
DX3puro 
Human melanoma cell line derived from a metastatic malignant melanoma 
engineered to express the puromycin resistance gene. Endogenously 
expresses several integrins but not the β6 subunit (Hausner et al 2007). 
Adherent growth 
DMEM/10% FBS/ 
2 mM L-glutamine 
Used as negative control cell line for integrin ανβ6 
expression. 
DX3β6puro 
Derived from the DX3 parent cell line (Albino et al 1981) and engineered to 
constitutively overexpress the integrin β6 subunit. DX3 cells were infected 
with pBabe retroviruses encoding puromycin resistance or additional cDNA 
for human integrin β6 subunit. Cells were selected in 1.25 μg ml-1 puromycin 
with subsequent sorting by magnetic beads using the integrin β6 specific 





Used as positive control cell line for integrin ανβ6 
expression. Expression of integrin ανβ6 in this cell line is 
known to drift. Monthly assessment of integrin ανβ6 
expression levels by flow cytometry should be 
undertaken for cells in continuous passage. Re-selection 
in puromycin or magnetic bead sorting using antibody 
clone 10D5 (Merck Millipore) may be undertaken as 
required (Hausner et al 2007, CRT 2013) 
VB6 
Generated by retroviral transfection of the ανβ5 expressing human V3 cell 
line with β6 integrin subunit cDNA yielding constitutive high expression of 
the β6 integrin heterodimer. The V3 cell line being originally engineered 
from the αv integrin subunit negative H357 oral squamous cell carcinoma 
cell line transfected with αv integrin subunit DNA (Thomas et al 2001a, 
Nystrom et al 2006) 
Adherent growth 
KGM: α-MEM/10% FBS/ 
2mM L-glutamine 
insulin [10 μg ml-1] 
EGF [20 ng ml-1] 
HC [500 μg ml-1] 
CT [100 ng ml-1] 
Used as positive control cell line and functional model of 
integrin ανβ6 overexpression.  
Table 2.1: Malignant melanoma (MM) and oral squamous cell carcinoma (OSCC) cell lines employed in this study as integrin ανβ6 positive and negative control cell lines.  
These cell lines were previously engineered and established in-house for use as matched pair biological models of integrin ανβ6 overexpression and negative correlates. Information on cell 
line aetiology and derivation is provided and referenced in table text. Abbreviations: α-MEM – Minimum Essential Medium alpha modifications; American ATCC – American Type Culture 
Collection; CRT – Cancer Research Technology© Ltd; DMEM – Dulbecco’s Modified Eagle Medium; FBS – foetal bovine serum; KGM – keratinocyte growth medium  
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Table 2.2: The MCF-10 isogenic series of human breast cancer cell lines employed in this study.  
Information compiled from references provided in text. Abbreviations: CT – cholera toxin; DCIS – ductal carcinoma in situ; DMEM – Dulbecco’s Modified Eagle Medium; EGF – epidermal 
growth factor; FBS – foetal bovine serum; HC – hydrocortisone; HS – horse serum; IDC – invasive ductal carcinoma; MCF – Michigan Cancer Foundation; RP MI 1640 – Roswell Park Memorial 
Institute 1640 medium; SCID – severe combined immunodeficiency.     
 
Cell line Aetiology Culture Conditions Comment 
MCF-10A 
Non-tumourigenic human breast cell line originating from spontaneous 
immortalization of non-malignant fibrocystic mammary epithelium isolated in 
August 1984 during reduction mammoplasty from a 36 year old Caucasian, 
parous premenopausal female with no family history of breast malignancy. The 
cell line was derived from the adherent sub-population of cells in culture in 
standard calcium levels (1.05 mM) (Soule et al 1990, Dawson et al 1996, ATCC 
2012b). 
Receptor status: Triple negative (ER- / PR- /ERBB2/HER2-) 
Subtype: Basal B  
Adherent growth. 
DMEM/Ham’s F12 (1:1)/5% HS/ 
2mM L-glutamine 
insulin [10 μg ml-1] 
EGF [20 ng ml-1] 
HC [500 μg ml-1] 
CT [100 ng ml-1] 
The MCF-10 sublines were derived by extended culture in low 
calcium (0.03 – 0.06 mM) with passage of floating cells (MCF-10F), 
or by trypsin-Versene passage of adherent cells (MCF-10A) cultured 
in customary calcium levels (1.05 mM). MCF-10 was deemed by 
Soule et al (1990) to possess traits of normal breast epithelium 
based upon the criteria: i) absence of tumourigenicity in nude mice; 
ii) growth in culture controlled by requisite growth factors and 
hormones; iii) confluent cultures exhibit dome formation; iv) 
absence of anchorage-independent growth and v) 3-dimensional 






Transformed variant derived by transfection of the MCF-10A cell line with a 
plasmid vector (pHo6T1) containing the T24 Ha-ras oncogene and 
aminoglycoside phosphotransferase gene conferring resistance to geneticin 
enabling antibiotic selection (Basolo et al 1991, Dawson et al 1996, Heppner et 
al 2000). 
Adherent growth. 
DMEM/Ham’s F12 (1:1)/5% HS/ 
insulin/2mM L-
glutamine/EGF/HC/CT 
(concentrations as above) 
Example of proliferative breast disease that is tumourigenic but not 
metastatic (neoplastic but non-malignant) (Tang et al 2003, Kadota 
et al 2010). 
MCF-10AT1K.cl2 
(-K.cl2) 
Clone isolated from cells derived from an enzymatically dissociated xenograft of 
MCF-10AT1 cells (derived from a 100-day first transplant generation lesion) that 
produced carcinoma in vivo in nude/beige mice. The derived clone, MCF-
10AT1K.cl2 generates premalignant lesions capable of neoplastic progression 
(Tang et al 2003). 
Adherent growth 
DMEM/Ham’s F12 (1:1)/5% HS/ 
insulin/2mM L-
glutamine/EGF/HC/CT 
(concentrations as above) 
Example of proliferative breast disease that is neoplastic and may 




Cloned from the cell culture of a xenograft generated by injection of 
premalignant MCF-10A cells into SCID mice that resulted in tumour growth 
(Heppner et al 2000, Miller et al 2000, Barnabas and Cohen 2013) 
Adherent growth 
DMEM/Ham’s F12 (1:1)/5% 
HS/2mM L-glutamine 
Recapitulate DCIS-like comedo lesions spontaneously progressing 
to IDC as xenografts in SCID mice. 
MCF-10A.CA1h 
(-CA1h) 
Derived by serial trocar passage of MCF-10AT1K.cl2 xenografts in nude/beige 
mice generating the MCF-10ACA1 lines giving rise to tumours directly upon 
transplantation. Organoids extracted from a trocar passage tumour were 
xenografted into nude/beige mice. The CA1h subclone was then isolated from 
the resulting tumour and cloned in agarose (Strickland et al 2000, Santner et al 
2001, Tang et al 2003) 
Adherent growth 
DMEM/Ham’s F12 (1:1)/5% 
HS/2mM L-glutamine 




Derived by serial trocar passage of MCF-10AT1K.cl2 xenografts in nude/beige 
mice generating the MCF-10ACA1 lines giving rise to tumours directly upon 
transplantation. The CA1a subclone was isolated by in vitro selection, along with 
other variants (CA1b, CA1c, CA1d) (Strickland et al 2000, Santner et al 2001, 
Tang et al 2003). 
Adherent growth 
DMEM/Ham’s F12 (1:1)/5% 
HS/2mM L-glutamine 
Tumourigenic, malignant. Form poorly differentiated carcinomas 
upon xenografting and metastasise to lungs upon tail vein injection. 
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Figure 2.1: Schematic overview of the derivation of the MCF-10A series of human BrCa cell lines comprising the MCF10 isogenic model of BrCa progression.  
The MCF-10A series provides a basic model of breast tumourigenesis representing the transformation of benign, non-malignant breast epithelium (MCF-10A) through neoplastic 
transformation following an oncogenic event (MCF-10AT) and acquisition of invasive potential (-Kcl.2 & -DCIS.com) culminating in malignant, invasive variants (MCF-10ACA1) forming well-
differentiated (-CA1h) and poorly-differentiated (-CA1a) tumours upon xenografting in nude/beige mice. Details of transformation and selection processes for generation of clones are 
provided in Table 2.2.   
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Table 2.3: Additional human breast cancer cell lines employed in this study. Information compiled from references as provided in text. Abbreviations: α-MEM – Minimum essential medium alpha 
modification; BRAF – V-Raf Murine Sarcoma Viral Oncogene Homolog B; BRCA1 – Breast Cancer 1, Early Onset; CDKN2A – cyclin-dependent kinase inhibitor 2A; DMEM – Dulbecco’s Modified Eagle Medium; EGFR 
– epidermal growth factor receptor; FBS – foetal bovine serum; G6PD – glucose-6-phosphate dehydrogenase; HRAS – Harvey Rat Sarcoma Viral Oncogene Homologue; IDC – invasive ductal carcinoma; KRAS – 
Kirsten Rat Sarcoma Viral Oncogene Homologue; L-Gln – L-glutamine; PIK3CA – phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha; PTEN – phosphatase and tensin homologue; RB1 – 
retinoblastoma protein; RPMI 1640 – Roswell Park Memorial Institute 1640 medium; SMAD4 – Mothers against decapentaplegic homolog 4; TGFαR – transforming growth factor-α receptor; TP53 – tumour protein 
53; WT – wild type. Receptor and mutational status details compiled from (Hollestelle et al 2007, Kenny et al 2007, Kao et al 2009, Chavez et al 2010). 
Cell line Aetiology Culture Conditions Receptor Status Comment 
BT-20 
Tumourigenic breast adenocarcinoma cell 
line derived from cells isolated upon 
dissection of a primary IDC tumour 
resected from a 74 year old Caucasian 
female. (Lasfargues and Ozzello 1958, 
ATCC 2013a). 
Adherent growth.  
α-MEM/15% FBS/2mM L-Gln  
Triple negative 
(ER- / PR- / ERBB2/HER2-) 
 
Subtype: Basal A 
ανβ6 status: endogenous overexpression 
Mutational status: PIK3CA, TP53 
EGFR amplification  
Cells express WNT3 & WNT7B oncogenes. Although 
negative for ER, express an exon 5-deleted ER mRNA 
Express WT BRCA1 
SUM159 
Cell line first isolated and described by 
Forozan et al (1999) from a primary 
anaplastic breast carcinoma from a 
patient who had not received 
chemotherapy prior to sampling.  
Adherent growth. 
Ham’s F12/10% FBS/2mM  L-Gln 
Triple negative 
(ER- / PR- / ERBB2/HER2-) 
Subtype: Basal B / claudin low 
ανβ6 status: endogenous overexpression 
Mutational status: TP53, PIK3CA, HRAS 
Cells express WT BRCA1 
BT-474 
Tumourigenic BC cell line derived from a 
solid, invasive ductal carcinoma isolated 
from a Caucasian female aged 60 years 
(Lasfargues et al 1978, ATCC 2013b). 
Adherent, patchy growth. Form 
compact islands of multilayered 
colonies, rarely reaches 
confluence. 
RPMI 1640/10% FBS/ 
insulin (10 μg ml-1)/2mM L-Gln 
Triple positive 
(ER+ / PR+/ ERBB2/HER2+) 
Subtype: Luminal 
ανβ6 status: endogenous overexpression 
Mutational status: PIK3CA 
Cells exhibit Her2 amplification 
 
MDA-MB-231 
Tumourigenic breast adenocarcinoma cell 
line derived from a metastatic site by 
pleural effusion from a 51 year old 
Caucasian female (ATCC 2012c). 
Adherent growth. 
DMEM/10% FBS/2mM L-Gln 
Triple negative 
(ER- / PR- / ERBB2/HER2-) 
 
Subtype: Basal B 
ανβ6 status: negative 
Mutational status: BRAF, CDKN2A, KRAS, TP53 
Cells express WNT7B oncogene, EGFR and TGFαR 
Express WT BRCA1 & PIK3CA  
MDA-MB-468 
Tumourigenic breast adenocarcinoma cell 
line isolated from a metatstatic by pleural 
effusion in 1977 from a 51 year old Black 
female (ATCC 2012d).  
Adherent growth. 
DMEM/10% FBS/2mM L-Gln 
Triple negative 
(ER- / PR- / ERBB2/HER2-) 
 
Subtype: Basal A 
Cells express EGFR and TGFαR. EGFR amplification is 
reported; present at 1 x 106 per cell. Tissue donor 
heterozygous for G6PD alleles but cell line consistently 
exhibits G6PD A phenotype only. 
ανβ6 status: endogenous expression 
Mutational status: PTEN, RB1, SMAD4, TP53 
Express WT BRCA1 
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Table 2.4: Standard tissue culture reagents and growth media supplements.  
Information compiled from supplier product details.   
Culture 




concn Cell Line / Experimental Application (s) 
adenine - A2786 Sigma Aldrich© - 18 mM VB6 / supplement for KGM 
α-MEM minimum essential medium, alpha-modification 22571-020 Invitrogen™ - - base media for VB6  & BT-20  
CT cholera toxin (Vibrio cholerae) 227035 Calbiochem - 100 ng ml-1 supplement for KGM (VB6) & MCF-10A media (MCF-10A, -AT & Kcl.2) 
DMEM Dulbecco’s minimum essential medium  D6429 Sigma Aldrich
© - - 
base media for DX3puro/β6, A375puro/β6, MDA-MB-231, MDA-MB-
468 & BT-20 
prepared 1:1 with Ham’s F12 as base media for entire MCF-10A series  
EDTA ethylenediaminetetraacetic acid E6758 Sigma Aldrich
© 0.5 M pH8 stock 20 mM wash step to remove residual cations during activation experiements 
EGF epidermal growth factor E9644 Sigma Aldrich© - 20 ng  ml-1 supplement for KGM (VB6) & MCF-10A media (MCF-10A, -AT & Kcl.2) 
charcoal 
stripped FBS 
foetal bovine serum  
(charcoal stripped) 12676029 Gibco
®Invitrogen™ - - supplement for all complete culture media  
FBS foetal bovine serum 10500-064 Gibco®Invitrogen™ - - supplement for all complete culture media  
L-Glu L-glutamine  Sigma Aldrich© 200 mM 2 mM supplement for all complete culture media 
Ham’s F12 - N6658 Sigma Aldrich©   prepared 1:1 with DMEM as base media for entire MCF-10A series 
HC hydrocortisone H4001 Sigma Aldrich©   supplement for KGM (VB6) & MCF-10A media (MCF-10A, -AT & Kcl.2) 
HEPES 4-(2-hydroxyethyl)piperazine-1-ethanesulphonic acid H3375 Sigma Aldrich
© 1 M 20 mM  25 mM  
zwitterionic  organic buffer to maintain physiological pH even in 
variable %CO2. Used at 20 mM in low serum media & 25 mM in 
DMEM5 
Insulin - I1882 Sigma Aldrich©  20 μg  ml-1 supplement for KGM (VB6), BT-474 media & MCF-10A media (MCF-10A, -AT & Kcl.2) 
PBS- phosphate buffered saline without CaCl2 & MgCl2 
D8537 Sigma Aldrich© - - standard TC washing procedures  cation-free washes (activation experiments) 
PBS+ phosphate buffered saline with CaCl2 & MgCl2 
D8662 Sigma Aldrich© - - ligand preparation for coating culture dishes 
RPMI-1640 Roswell Park Memorial Institue-1640 medium R8758 Sigma Aldrich
© - - base media for BT-474 
Trypsin Trypsin-EDTA L11-004 PAA Laboratories  
0.5 mg ml-1 
trypsin 
0.22 mg ml-1 
EDTA 
serine protease (trypsin) used to cleave proteins mediating cellular 
attachments supplemented with the chelating agent EDTA to facilitate 
dissociation of calcium-dependent intercellular adhesions when 
passaging adherent cell lines. 
chapter II: 
materials & methods 
 52 
  
2.2  antibodies and reagents 
 
 
A panel of integrin ανβ6-specific antibodies (see Table 2.5) was used to screen cell 
lines by flow cytometry and confocal immunofluorescence microscopy in order to 
characterise expression levels and subcellular distribution of integrin ανβ6 




Summaries of additional primary, secondary and isotype-matched control 
antibodies used to date for flow cytometry (FCM), immunofluorescence 
microscopy (IMF) and Western blotting (WB) procedures are also provided in 
Tables 2.6 - 2.9. Details of ligands used in activation studies, functional assays and 
immunoprecipitation experiments are provided in Table 2.10. A list of kinase 
inhibitors for functional validation of putative regulators of integrin ανβ6 activation-
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Raised by immunisation of ανβ6 knockout mice with WT murine 
keratinocytes. Recognises human and murine integrin ανβ6, may 
recognize the receptor in other species but has not been evaluated. 
Antibody is specific for the intact ανβ6 heterodimer & is ligand 




Mouse Merck Millipore 
MAB2077Z 






Epitope maps to the extracellular region of the heterodimer (no 
further details supplied). Generated by retroviral transfection of 
mouse fibroblasts with human β6 subunit cDNA (3T3b6.19) resulting 
in expression of a mouse/human ανβ6 chimaera. Recognises the 
mature, fully glycosylated integrin ανβ6 heterodimer only. 
Mono- 
IgG2a 





No datasheet available. Recognises all maturation states of integrin 
ανβ6 including immature non-, partially- and fully mature-
glycosylated forms.  
Mono- 
IgG1 






No datasheet available. Generated and first described by Weinreb et 
al (2004). Information regarding recognised epitope to be 
ascertained by communication with BioGen Idec and competitive 
binding assays. Protein A only, no dialysis. Data within this thesis 
demonstrates that 6.2E5 recognises an activation-associated epitope 
and ligand-induced binding site; is not ligand-mimetic and does not 
induce activation upon binding. 
Mono- 
IgG1 







No datasheet available. Generated and first described by Weinreb et 
al (2004). As above for 6.2E5. 
Protein A only, dialysed.  
Mono- 
IgG1 
Mouse Biogen Idec 
PW6782-






Table 2.5: Panel of anti-integrin ανβ6 unconjugated primary antibodies employed in this study to identify subpopulations of integrin ανβ6 by maturation state and 
activation status. Use of antibodies for applications not indicated by the supplier are denoted¶. Other applications of these antibodies not utilised to date are also 
indicated¢. Information compiled from manufacturer datasheets. Where datasheets were irretrievable from online resources or unavailable from in-house records, 
information was taken from reagent/aliquot labels. Abbreviations:  CDR3 – complemenarity-determining region; CR-UK – Cancer Research UK; FB – functional blockade; 
FCM – flow cytometry; IMF – immunofluorescence; IP – immunoprecipitation; WB – Western (immuno-) blotting; WT – wild type. ★NB: Antibodies 620W7 (CR-UK), 6.2E5 & 
6.2G2 (both Biogen Idec Ltd) were kind gifts and are not currently commercially available. Antibody 53A2 was obtained from existing stocks of the antibody first generated 
in-house in collaboration with CR-UK. It is acknowledged that antibody 53A2 is now commercially available (AbCam® ab97588).   
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Recognises endogenous total integrin α5 protein. 
Immunogen was a synthetic peptide corresponding to 
residues surrounding Ser458 of human integrin α5 protein. 
Poly- 
IgG Rabbit CST #4705S 150 1 WB 
α5 P1D6 Recognises human integrin α5 subunit. Immunogen and antibody derivation details are not given.  
Mono- 
IgG3 
Mouse MM MAB1956Z Azide free - 10 FCM 
αν L230 
Anti-integrin αv (CD51) antibody recognises the following αv-
bearing heterodimers: αvβ1; αvβ3 ; αvβ5; αvβ6. Human 
endothelial cells were used as the immunogen. 
Mono- 
IgG1 
Mouse in-house - - 10 FCM 
β1 P4C10 Recognises the integrin β1 (CD29) subunit. Cognate epitope is not trypsin sensitive.  
Mono- 
IgG2a 
Mouse in-house - - 10 FCM 
β1 EP1041Y 
Recognises the integrin β1 (CD29) subunit. Antibody raised 
against a synthetic peptide corresponding to a residue 
proximal to the C-terminus of human integrin β1.  
Mono- 
IgG1 




Epitope maps to the C-terminus of the β6-integrin subunit of 
human origin. Recognises the β6-integrin subunit of rat, 
mouse & human origin. 
Poly- 
IgG Goat SCBT sc-6632 97 0.2 WB 
β6 CSβ6 
Antibody raised by immunising –knockout mice with 
recombinant secreted human integrin ανβ6. Does not 
recognise αν-subunit or other αν integrins. It is not known 




Mouse Calbio MAB2076Z - 5 IHC 
β8 - 
Antibody raised against a synthetic peptide mapping to the 
C-terminal amino acids 611-660 of the human integrin 
subunit β8.  
Poly- 
IgG Rabbit AbCam ab80673 - 5 WB 
ανβ3 LM609 
Antibody generated against a purified adhesion receptor 








ανβ5 P1F6 Antibody raised against UCLA-P3 cells derived from a human lung adenocarcinoma. 
Mono- 
IgG1 
Mouse MM MAB1961 - 10 FCM 
ανβ6(ανβ8) 264RAD 
A recombinant human antibody generated in a Xenomouse 
bearing the integrin ανβ6 recognition sequence 
VETGRADYHFYAMDV on its CDR3. Also recognises the 







gifted - 10 FB 
Table 2.6: Additional anti-integrin antibodies employed to date in this study. Applications of these antibodies are indicated. Clone numbers are provided for monoclonal 
antibodies. Product numbers are given for polyclonal antibodies. Information compiled from manufacturer datasheets or in-house records. Where datasheets were 
irretrievable from online resources or unavailable from in-house records, information was taken from reagent/aliquot labels.  Abbreviations:  AZ – Astra Zeneca UK; Calbio – 
Calbiochem; CST – Cell Signalling Technology; MM – Merck Millipore; SCBT – Santa Cruz BioTechnology. 
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Antibody recognises endogenous total Akt1, Akt2 & 
Akt3. Antibodies were raised against a synthetic 
peptide mapping to the carboxy-terminal sequence 
of murine Akt & purified by protein A & peptide 
affinity chromatography. Reactivity with with human 
Akt confirmed in QC testing. No cross-reaction with 
related kinases reported. 
Poly- 
IgG Rabbit CST 9272S 60 1 WB 
pAkt  
(pSer473) D9E 
Antibodies produced following immunisation of 
rabbits with a synthetic phosphopeptide mapping to 
residues flanking Ser473 of human Akt. Recognises 
endogenous Akt phosphorylated at the C-terminus 
Ser473 residue. 
Mono- 
IgG Rabbit CST 4060S 60 2 WB 
Akt1  D7510 
Antibodies raised against a synthetic peptide 
mapping to a sequence flanking Leu110 of human 
Akt 1. Does not cross-react with Akt2 or Akt3. 
Mono- 
IgG Rabbit CST 2938S 60 2 WB 
pAkt1 (pSer473) D7F10 
Antibodies produced by immunising host species 
with a synthetic phosphopeptide mapping to residues 
flanking Ser473. 
Mono- 
IgG Rabbit CST 9018S 60 1 WB 
BAK D4E4 
Antibodies raised against a KLH-conjugated synthetic 
peptide corresponding to amino acids 23 – 38 of the 
N-terminus of human BAK. 
Mono- 
IgG Rabbit CST 12105S 25 5 WB 
biotin - 
Antibody generated in rabbits by multiple 
immunisations with biotin conjugated to KLH in 
Freund’s adjuvant. 
Poly- 
IgG Rabbit AbCam ab1227 80 10 FCM 
calnexin - Antibodies raised against a synthetic peptide relating to a sequence in the Ala51 region of human calnexin. 
Poly- 
IgG Rabbit CST 2433BC 90 2 WB 
Table 2.7 (part i): Additional unconjugated primary antibodies employed in this study.  
Applications of these antibodies are indicated. For monoclonal antibodies, clone numbers are given. Product numbers are provided for polyclonal antibodies. Information 
compiled from manufacturer datasheets. Where datasheets were irretrievable from online resources or unavailable from in-house records, information was taken from 
reagent/aliquot labels. Abbreviations:  BDT – BD Transduction Laboratories; CST – Cell Signalling Technology; Hsc-70 – heat shock cognate protein; KLH – keyhole limpet 
























Amino acids 4 – 171 of rat clathrin heavy chain were 
used as the immunogen. Antibody QC testing 
confirmed specificity for human clathrin heavy chain. 
Mono- 
IgG1 





(MAP3K8 / Tpl2) - 
Antibodies raised against a recombinant fragment 
mapping to a region within amino acids 223-467 of 
human COT (MAP3K8/Tpl2). 
Poly- 






Antibodies raised against a synthetic peptide of a 
proprietary sequence derived from a region of human 
MAP3K8 flanking the Thr290 phosphorylation site. 
Poly- 
IgG Rabbit AbCam ab195706 60 1 WB 
pCOT 
(pSer400) - 
A mixture of synthetic phosphorylated peptides 
mapping to residues flanking Ser400 of human, 
mouse & rat Tpl2 (COT/MAP3K8) were as used as the 
immunogen. Human species reactivity predicted 
based upon 100% sequence homology. 
Poly- 
IgG Rabbit CST 4491S 60 / 62 1 WB 
pEGFR 
(pTyr1068)  
A synthetic phosphopeptide mapping to residues 
surrounding Tyr1068 of the human EGF receptor was 
used to immunise animals; the resulting antibodies 
were purified by protein A and peptide affinity 
chromatography 
Poly- 




Antibodies were raised in animals immunised with a 
synthetic phosphopeptide mapping to residues 
flanking Tyr1086 of the human EGF receptor; and 
purified by protein A and peptide affinity 
chromatography 
Poly- 
IgG Rabbit CST 2220S 175 2 WB 
ERK1/2   
Antibodies produced following immunisation of 
rabbits with a synthetic peptide corresponding a 
sequence located in the C-terminus of rat p44 MAP 
kinase (Erk1) & purified by protein A and peptide 
affinity chromatography. 
Poly- 
IgG Rabbit CST 9102L 42 / 44 1 WB 

























Antibodies raised against a synthetic peptide 
mapping to residues encompassing Thr202/Tyr204 of 
human p44 MAP kinase (Erk1/2). Phospho-p44/42 
MAPK (Erk1/2) (Thr202/Tyr204) 
Poly 
IgG Rabbit CST 9101L 42 / 44 2 WB 
pFAK 
(pTyr397) (Y397) 
Recognises endogenous FAK when phosphorylated 
at Tyr397.  Antibodies raised against a synthetic 
phosphopeptide mapping to residues encompassing 
Tyr397 of human FAK. Antibody may cross-react with 
other tyrosine-phosphorylated RTKs. 
Poly- 
IgG Rabbit CST 3283S 125 2 WB 
human IgG (Fc’) ABM121 
Epitope maps to the Fc’ fragment of human IgG. 
Antibody generated using the immunogen human 
IgG-Fc purified by high affinity chromatography. 
Mono- 
IgG1 
Mouse AbCam ab113636 - 10 FCM IMF 
Hsc-70 B-6 Epitope maps between amino acids 580-601 of the C-terminus of Hsc-70 of human origin.  
Mono- 
IgG2a 
Mouse SCBT sc-7298 70 0.2 WB 
MAPKAPK2 
(MAPK2 / MK2) - 
Antibodies raised against a synthetic peptide 
mapping to the C-terminus region of human 
MAPKAPK-2. Detects endogenous MAPKAPK-2 does 
not cross react with MAPKAPK-3 or -5. 
Poly- 






A synthetic phosphopeptide corresponding to 
residues flanking Thr334 of human MAPKAPK-2 was 
used as the immunogen.  
Mono- 
IgG Rabbit CST 3007S 49   
Nuak1 
(ARK5) - 
A synthetic peptide corresponding to the sequence 
of human ARK5 (Nuak1) was used as the immunogen. 
Poly- 
IgG Rabbit CST 4458S 78  WB 
paxillin H-114 
Recognises α, β & γ paxillin isoforms. Epitope maps to 
amino acids 155 – 268 residing within an internal 
region of human paxillin. 
Poly- 
IgG Rabbit SCBT sc5574 68 10 IMF 
PDPK1 
(PDK1) - 
Antibodies were raised against a synthetic peptide 
mapping to residues encompassing the C-terminus of 
human PDK1. 
Poly- 
IgG Rabbit CST 3062S 58 - 68  WB 
pPDPK1 
(pSer241) - 
A synthetic phosphopeptide mappingto residues 
flanking Ser241 of human PDK1 was used as the 
immunogen. 
Poly- 
IgG Rabbit CST 3062S 58 - 68  WB 
























Amino acid residues 142 – 263 of mouse-derived 
Smad2 were used as the immunogen. Cross-reaction 
with Smad3 is predicted based on sequence 
homology of the immunogen.  
Mono 
IgG1 κ 
Mouse BDT 610843 58 0.2 WB 
pSmad3 
(pSer423/425) C25A9 
Antibody raised against a synthetic phosphopeptide 
mapping to residues encompassing Ser423/425 of 
Smad3. Antibody recognises endogenous Smad3 
when phosphorylated at Ser423/425. No cross-
reaction with other Smad family members. 
Mono- 
IgG Rabbit CST 9520S 52 1 WB 
talin C-20 Recognises talin-1 & -2 of human origin. Epitope is mapped to the C-terminus of human talin-2. 
Poly- 
IgG Goat SCBT sc-7534 230 0.2 WB 
TBK1 
(NAK) - 
Antibodies were raised against a synthetic peptide 
mapping to residues proximal to the C-terminus of 
human TBK1/NAK. 
Poly- 
IgG Rabbit CST 3013S 84  WB 
pTBK1 
(pSer172) EPR2867(2) 
Recombinant rabbit monoclonal antibody raised 
against a synthetic peptide mapping to residues 
encompassing Ser172 of human NAK. 
Mono- 
IgG Rabbit AbCam ab109272 84  
IP 
WB 






A synthetic peptide derived from a region between 
residues 1 – 100 of human beta tubulin was used as 
the immunogen. 
Poly- 
IgG Goat AbCam ab21057 50 1 WB 
pTyr PY20 
Antibody detects phosphotyrosine (pTyr) and pTyr-




Mouse AbCam ab10321 multiple 2 WB IMF 
vinculin hVIN-1 
Antibodies raised against the full length, native 




Mouse AbCam ab11194 116 0.2 WB 
Table 2.7 (part iv): Additional unconjugated primary antibodies employed in this study. Applications of these antibodies are indicated. For monoclonal antibodies, clone 
numbers are given. Product numbers are provided for polyclonal antibodies. Information compiled from manufacturer datasheets. Where datasheets were irretrievable from 
online resources or unavailable from in-house records, information was taken from reagent/aliquot labels. Abbreviations:  BDT – BD Transduction Laboratories; CST – Cell 
Signalling Technology; Hsc-70 – heat shock cognate protein; KLH – keyhole limpet haemocyanin; MAPK – mitogen-activated protein kinase; MW – molecular weight; p – 
phospho-; SCBT – Santa Cruz Biotechnology; TfRC – transferrin receptor complex; Tyr – tyrosine. 
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Invitrogen 31154 11600 
10 FB 
Mouse IgG 1 Ci4 
Mono- 
IgG1 
Mouse Merck Millipore MABC002 500 
5 FCM 
IMF 








Rabbit IgG N/A 
Poly- 









goat serum N/A 
Poly- 
IgG Goat Vector Labs 
PK-6101 




Table 2.8: Negative control antibodies employed in this study.  
Applications of these antibodies are indicated. For monoclonal primary antibodies, isotype-matched monoclonal antibodies were employed. Polyclonal immunoglobulins 
served as the negative control where available. Normal goat serum used at a dilution of 1:50 (no concentration given on vial) for blocking non-specific protein interactions 
during IMF staining procedures. Goat serum was used as all secondary antibodies employed for IMF staining are raised in goat. 
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(μg ml-1) Application 
anti-goat IgG (H+L) Donkey AlexaFluor®680 A21084 Invitrogen™ 2000 0.2 WB (LI-COR) 
anti-mouse IgG (H+L) Goat AlexaFluor®488 A11029 Invitrogen™ 2000 16 FCM IMF 
anti-mouse IgG (H+L) Donkey AlexaFluor®680 A10038 Invitrogen™ 2000 0.2 WB (LI-COR) 
anti-mouse IgG (H+L) Donkey AlexaFluor®790 A11371 Invitrogen™ 2000 0.2 WB (LI-COR) 
anti-rabbit IgG (H+L) Goat AlexaFluor®488 A11034 Invitrogen™ 2000 16 FCM IMF 
anti-rabbit IgG (H+L) Donkey AlexaFluor®647 A31573 Invitrogen™ 2000 16 IMF 
anti-rabbit IgG (H+L) Donkey AlexaFluor®680 A10043 Invitrogen™ 2000 0.2 WB (LI-COR) 
anti-rabbit IgG (H+L) Donkey AlexaFluor®790 A11374 Invitrogen™ 2000 0.2 WB (LI-COR) 
anti-rat IgG (H+L) Goat AlexaFluor®488 A11006 Invitrogen™ 2000 16 FCM IMF 
anti-rat IgG (H+L) Goat AlexaFluor®546 A11081 Invitrogen™ 2000 16 FCM IMF 
anti-rat IgG (H+L) Donkey AlexaFluor®594 A21209 Invitrogen™ 2000 16 IMF 
anti-goat 
immunoglobulins Rabbit HRP P0160 Dako 1300 0.2 WB (ECL) 
anti-mouse 
immunoglobulins Rabbit HRP P0260 Dako 1300 0.2 WB (ECL) 
anti-rabbit 
immunoglobulins Donkey HRP NA9340V G E Healthcare 1000 0.2 WB (ECL) 
Table 2.9: Conjugated secondary antibodies employed in this study. 
Applications of these antibodies are indicated. Abbreviations: FCM – flow cytometry; HRP – horseradish peroxidase; IMF – immunofluorescence; WB – Western 










Ligand Cognate Receptor(s) Tag Species of origin Supplier Cat No. Supplied conc
n Working concn Application 
A20FMDV2 ανβ6 biotin synthetic peptide in-house (DiCara et al 2007) - 2 mM 100 nM 
FCM 
LSA 
BioTJ-Ran - biotin synthetic peptide in-house (as above) - 2 mM 100 nM FCM LSA 




EGF EGFR - human recombinant Sigma Aldrich E9644 
1 mg 
(lyophilised) 50 ng ml
-1 LSA 
Fn α5β1 / ανβ3 / ανβ6v - 
human 
recombinant Sigma Aldrich F2006 
1 mg 
(lyophilised) 10 μg ml
-1 Func IMF 
Fn as abovev - bovine Sigma Aldrich F1141 5 mg (lyophilised) 10 μg ml
-1 2D-E IMF 
HGF c-Met - human recombinant Sigma Aldrich H9661 
1 mg 
(lyophilised) 50 ng ml
-1 LSA 
LAP ανβ6 - 
human 
recombinant Sigma Aldrich L3408 
25 μg 
(lyophilised) 0.5 μg ml
-1 2D-E  Func 
LAP-Fc ανβ6 
human IgG1 (Fc’) 
frag 
human 
recombinant Biogen Idec - 
1540 μg ml-1 
(in PBS) 5 μg ml
-1 IMF IP 








(lyophilised) 5 μg ml
-1 IMF IP 
Table 2.10: Ligands utilised in this study.  
Cognate integrin receptor(s) and applications are indicated. Abbreviations: 2D-E – 2D-enrichment; Col I – collagen I; FCM – flow; Fn – fibronectin; Func – functional assays; 
IMF – immunofluorescence; IP – immunoprecipitation; LAP – latency-associated peptide of TGF-β1; TfRC – transferrin receptor complex; v – list of cognate receptors not 












Target kinase Inhibitor 






c-MET PHA665752 477575-56-7 2693 R & D Systems 
[Tocris] 
9 641.61 C32H34Cl2N4O4S 
Selective ATP-competitive inhibitor of MET kinase. Anti-




TC-S 7006 871307-18-5 5240/10 
R & D Systems  
[Tocris] 
50 404.83 C21H14CIFN6 
ATP-competitive inhibitor, selectively inhibits Tpl2 over p38, 
MEK, Src, MK2, PKC & EGFR. 
EGFR Gefitinib 
(IRESSA®)  
184475-35-2 - AstraZeneca 33 446.902 C22H24CIFN4O3 
Selective ATP-competitive inhibitor of EGFR tyrosine kinase. 
Blocks ATP-binding site ablating autophosphorylation of C-
terminal tyrosine residues (DrugBankv5.0 2017). 
MAPKAPK2 






8.5 404.83 C21H16N4OH2O 
Selective ATP-competitive inhibitor demonstrating activity 
against PRAK & 3pK (IC50= 81 & 210 nM respectively) with little 
or no activity against 8 other related kinases. 
MAPKAPK2 
(MAPK2 / MK2) PF 3644022 1276121-88-0 4279/10 
R&D Systems  
[Tocris] 
5.2 374.46 C21H18N4OS¾H2O  
ATP-competitive inhibitor. Reported inhibition of TNFα 
(IC50=160 nM) in PBMCs. 
Nuak1 
(ARK5) HTH-01-015 1613724-42-7 5622/10 
R&D Systems  
[Tocris] 
100 468.55 C26H28N8O 
No significant inhibition against a panel of 139 kinases 
(including 10 AMPK family members). Blocks Nuak1-mediated 
phosphorylation of MYPT1. Exhibits >100-fold specificity for 




BX-795 702675-74-9 204001 
R&D Systems  
[Tocris] 
5 591.50 C23H26IN7O2S 
ATP-competitive inhibitor multi-kinase inhibitor. Also inhibits 
PDK1 & TBK1 (IC50=111 & 6 nM respectively).  
Table 2.11 (part i): Kinase inhibitors used for functional validation of phosphoproteomic hits identified as putative candidates for the molecular regulation of integrin 
ανβ6 signalling events inducted upon ligand-induced internalisation. 





























6 282.30 C15H14N4O2 
ATP-competitive inhibitor suppressing phosphorylation of Akt 
at Thr308. Reported to affect PKA & 7 other kinases at higher 
concentrations (IC50=1.6 μM & ≥600 nM)  
PDPK1 
(PDK1) GSK2334470 1227911-45-6 4143/10 
R&D Systems  
[Tocris] 
10 462.59 C25H34N8O 
No effect on other kinases including PI3K, p38, ROCK & 
Aurora. Diminishes T-loop phosphorylation & downstream 
activation of PDPK1 substrates RSK, S6K1 & SGK but exhibits 
limited inhibition of Akt activation. 
TBK1 Amlexanox 68302-57-8 4857/10 R&D Systems  
[Tocris] 
1000 298.29 C16H14N2O4 
Selective TBK1 & IKKε inhibitor. No activity against IKKα or 
IKKβ at these concentrations. Reported to bind Hsp90 & 
impede C-terminal chaperone function in vitro. 
Table 2.11 (part ii): Kinase inhibitors used for functional validation of phosphoproteomic hits identified as putative candidates for the molecular regulation of integrin 
ανβ6 signalling events inducted upon ligand-induced internalisation. Abbreviations: 3pK – MAPK-protein kinase 3 (MK3/MAPKAPK3); AMPK – adenosine monophosphate protein 
kinase; ARK5 – AMPK-related kinase 5; ATP – adenosine triphosphate; COT – Cancer Osaka Thyroid oncogene (MAP3K8/Tpl2); EGFR – epidermal growth factor receptor; IKKα/β/ε – IκB kinase 
α/β/ε; MAPK – mitogen-activated protein kinase; MAPKAPK2 – MAPK-activated protein kinase 2; MEK – mitogen-activated protein kinase kinase (MKK/MAP2K); MET – MET kinase (hepatocyte 
growth factor receptor [HGFR]); MK2 – MAPK-activated protein kinase-2 (MAPKAPK2); MYPT1 – myosin phosphatase target subunit 1; Nuak1 – (nua) kinase family 1; p38 – family of 4 p38 MAPKs; 
PBMCs – peripheral blood mononuclear cells; PDPK1 – 3-phosphoinositide dependent protein kinase 1 (PDK1); PI3K – phosphoinositide 3-kinase; PKC – protein kinase C; PRAK – p38-
regulated/activated protein kinase (MK5/MAPKAPK5); RSK – ribosomal S6 kinase; ROCK – Rho-associated protein kinase; S6K1 – p70 ribosomal S6 kinase 1; SGK – serum & glucocorticoid-
inducible kinase; Src – non-receptor tyrosine kinase; TBK1 – TANK-binding kinase 1; TNFα – tumour necrosis factor α; Tpl2 – Tumour progression locus-2 (COT/MAP3K8). Information compiled 
from manufacturer and supplier’s datasheets. IC50 values for in vitro inhibitory activity against target kinase. 
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 2.3     adherent cell preparation and harvesting 
 
Adherent cells required for experiments were harvested by washing the confluent 
monolayer once in 10 ml phosphate buffered saline (PBS-) prior to addition of 
sufficient trypsin-EDTA ([1x] (1:250) trypsin 0.5 mg ml-1, ethylenediaminetetraacetic 
acid (EDTA) 0.22 mg ml-1 in PBS, L11-004 PAA Laboratories GmbH) to cover the 
adherent monolayer. Upon complete detachment, trypsin was deactivated by 
addition of 5 – 10 ml FBS-supplemented complete medium and cells were 
pelleted by centrifugation [1200 rpm, 3 min; RT] (PK121 ANNITA II Multispeed 




2.4    flow cytometry screening for cell-surface integrins 
           and other moieties 
 
Flow cytometry was performed to quantitatively demonstrate cell surface 
abundance of integrin receptor species, activation-induced revelation of 
conformation-dependent epitopes or to detect cell-surface binding of biotinylated 
or human IgG (Fc’)-tagged ligands. As a means of robustly acquiring quantitative 
data at single-cell level with ease, rapidity and reliability, flow cytometry 




2.4.1  cell preparation 
 
After harvesting (see section 2.3), cells were washed twice by centrifugation [1200 
rpm, 3 min] (PK121 ANNITA II Multispeed Centrifuge, ALC® International) and 
resuspended at 4 x 106 cells ml-1 in DMEM/0.1/0.1 buffer [0.1% (w/v) bovine serum 
albumin (BSA) (A7906, Sigma Aldrich® Co. LLC) / 0.1% (w/v) sodium azide (NaN3) 
(S8032, Sigma Aldrich) prepared in unsupplemented DMEM (D6429, Sigma 
Aldrich)]. Aliquots (50 μl) of the cell suspension were incubated on wet ice for 1 
hour in primary antibody prepared to yield a final concentration of either 5 μg ml-1 
(antibodies 6.2E5, 6.2G2 & mouse IgG1 isotype control) or 10 μg ml-1 (all other 
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 Cells were washed by centrifugation prior to incubation on wet ice in the dark for 30 min in 50 μl of appropriate species-specific AlexaFluor®488-conjugated 
secondary antibody (see Table 2.9) prepared at 16 μg ml-1. Cells were washed and 
resuspended to 500 μl final volume and kept on wet ice in the dark until 
acquisition. All washing, centrifugation and preparation of antibody solutions were 




2.4.2  gating & acquisition  
 
Data were acquired either on the BD FACSCalibur™ flow cytometer equipped 
with a 488 nm blue laser and a 635 nm red laser, or on the BD LSRFortessa™ 
equipped with 488 nm blue, 640 nm red, 405 nm violet and 561 nm yellow-green 
PMT lasers (both BD Biosciences©, Becton, Dickinson & Co). Following instrument 
calibration, samples prepared with isotype-matched negative control antibodies 
were used to define the first logarithmic decade (101) of mean fluorescence 
intensity (MFI) signal output detected in FL-1: 530/30 (BD FACSCalibur™)/Green 
Channel detector array (BD LSRFortessa™) to establish the negative threshold, 
prior to running test samples.  
 
 
A total of 1 x 104 gated events were acquired for each sample. All samples were 
acquired in the presence of 5 μg ml-1 propidium iodide (P4170, Sigma Aldrich) cell 
viability dye detected in FL-3 (670 LP) (BD FACSCalibur™) /Red Channel detector 
array (BD LSRFortessa™) to define acquisition gates ensuring data capture on 
viable cells only and exclusion of doublets. On board cytometer settings and 
acquisition metrics were monitored in-flight using either CellQuestPro™ (BD 
FACSCalibur™) or FACSDiva™ v8.0 (BD LSRFortessa™) software (all BD 




2.4.3  analysis of flow cytometry data  
 
Following acquisition, flow cytometry data were analysed using either BD 
CellQuestPro™ software (BD Biosciences©, Becton, Dickinson & Co) or FlowJo© 
software (FlowJo© LLC) to ascertain geometric mean fluorescence intensity 
(geoMean MFI) values as a read-out for level of cell surface-bound antibody. Test 
sample geoMean MFI values were normalised by subtraction of geoMean MFI 
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 values acquired for the relevant isotype-matched negative control antibody to discount any inherent noise within the assay matrix or instrumentation.  
 
 
Given the large number of data-points (1 x 104 events) acquired with rapidity per 
individual sample, it was probable that extreme outlier events not truly reflective of 
the sample population may be captured. Therefore the geometric mean MFI as 
opposed to the arithmetic mean MFI was used. Unlike the arithmetic mean, the 
geometric mean is less sensitive to skewing by extreme outlier values and was 
deemed to generate more reliable results reflecting the overall sample population 
more accurately (McAlister 1879).   
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 2.5     immunofluorescence microscopy  
 
Both non-permeabilised and permeabilised immunofluorescence (IMF) 
microscopy strategies were performed to evaluate distribution of epitopes 
recognised by a panel of anti-integrin ανβ6 antibodies at the cell-surface or 
subcellular level respectively. These IMF methods were also used to track the 
internalisation kinetics and localisation of human IgG (Fc’)-tagged ligands. As 
outlined by Carman (2012), IMF microscopy imaging modalities remain a 





2.5.1  preparation of coverslips 
 
Cells were seeded on sterile non-derivatised 13 mm diameter glass coverslips (2 x 
104 cells per coverslip) and left to adhere overnight in complete media under 
standard culture conditions [8% CO2, humidified atmosphere, 37°C]. Prior to 
experimental use, satisfactory cell adherence, morphology and confluence was 




2.5.2  non-permeabilised immunofluorescence microscopy  
(demonstration of cell-surface molecules) 
 
Cell surface distribution of moieties of interest (proteins or tagged ligands) was 
evaluated by non-permeabilised immunofluorescence microscopy. Coverslips 
were washed in PBS and fixed with 4% (w/v) paraformaldehyde (P6148, Sigma 
Aldrich) for 8 min at ambient laboratory temperature (RT). After washing in PBS, 
coverslips were blocked for 30 min in normal goat serum (VECTASTAIN® Elite® ABC 
(rabbit IgG) Kit component PK-6101, Vector Laboratories Inc) to prohibit non-
specific antibody binding, washed and incubated for 1 hr in primary antibody 
prepared in DMEM/0.1/0.1 before washing and labelling with the appropriate 
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 Nuclei were demonstrated with the cell membrane permeant nuclear stain Hoechst 33342  (1 μg ml-1, H3570, Life Technologies) prior to washing and 
mounting coverslips (Mowiol®4-88, 81381, Sigma-Aldrich) ready for microscopic 
review and image acquisition.  
 
 
NB: Details of specific primary and secondary antibodies used in each experiment 




2.5.3  permeabilised immunofluorescence microscopy 
(demonstration of subcellular molecules) 
 
To evaluate subcellular distribution of moieties of interest (proteins or tagged 
ligands), permeabilised immunofluorescence methods were performed. 
Coverslips were washed in PBS, fixed with cytoskeletal fixative buffer [4% (v/v) 
formaldehyde (10170052, Fisher Scienitifc); 10 mM 2-(N-
Morpholino)ethanesulphonic acid (MES) at pH6.1 (M3671, Sigma Aldrich); 125 mM 
KCl (P9333, Sigma Aldrich); 3 mM (MgCl2) (M8266, Sigma Aldrich); 2 mM ethylene-
bis(oxyethylenenitrilo)tetraacetic acid (EGTA) (03777, Fluka); 10% (w/v) sucrose 
(10346150, Fisher Scientific)] and permeabilised in 0.1% (v/v) Triton X-100/PBS 
(AAA16046AE, Alfa Aesar© ThermoFisher Scientific Inc) prior to washing and 
blocking in normal goat serum (VECTASTAIN® Elite® ABC (rabbit IgG) Kit 




For single labelling, coverslips were incubated for 1 hr in primary antibody 
prepared in DMEM/0.1/0.1 before washing and labelling with appropriate species-
specific fluorophore-conjugated secondary antibody (see Table 2.9). For dual- and 
triple-labelling, coverslips were incubated for 1 hr concomitantly with a cocktail of 
primary antibodies as required, washed and incubated simultaneously for 30 min 
in a cocktail of the appropriate secondary antibodies. Antibody cocktails were first 
validated in-house to evaluate any cross-reactivity or steric hindrance that would 
yield false positive or false negative results.  
 
 
Nuclei were demonstrated with 4’,6-diamidino-2-phenylindole at 1 μg ml-1 (DAPI, 
D1306, Invitrogen). Actin filaments (F-actin) were stained using 50 μg ml-1 
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 phalloidin conjugated to either fluorescein isothiocyanate (FITC) (P2582, Sigma Aldrich) or tetramethylrhodamine (TRITC) (R415, Molecular Probes© Invitrogen). 
Coverslips were then washed and mounted (Mowiol®4-88, Sigma-Aldrich) prior to 




2.5.4  vital immunofluorescence microscopy 
(capturing epitopes in live cells) 
 
The fixation process is known to alter protein conformation and stability, 
potentially inducing artefacts and affecting efficacy of antibodies to detect their 
cognate epitope. Conformation-dependent epitopes may be particularly sensitive 
to biochemical or structural modification by fixation procedures (Melan 1995). To 
obviate this, distribution of putative conformationally distinct integrin ανβ6 
subpopulations were evaluated by labelling live cells with antibody, prior to 
fixation with 4% (w/v) PFA or cytoskeletal fixative buffer supplemented with 4%, 
(v/v) formaldehyde as outlined previously, in an attempt to map subcellular 




Cells seeded overnight on coverslips were washed twice in PBS and labelled for 15 
min at RT with primary antibody prepared in an azide-free buffer [0.1% (w/v) 
BSA/DMEM]. Cells were washed twice with PBS and fixed with either 4% (w/v) 
paraformaldehyde for surface immunofluorescence or a cytoskeletal fixative buffer 
for permeabilised immunofluorescence as previously described (Sections 2.5.2 
and 2.5.3 respectively). Following fixation, coverslips were incubated for 30 min 
with appropriate species-specific secondary antibody prior to washing, nuclear 
staining and mounting for microscopic review (as outlined previously).  
 
 
NB: Details of specific primary and secondary antibodies used in each experiment 
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 2.5.5     immunofluorescence microscopy review & image acquisition 
 
Immunofluorescence microscopy review and representative image acquisition 
were performed using either of the following instruments:  
 
 i) Zeiss LSM710 confocal microscope (Barts Cancer Institute Microscopy 
 Core Facility, QMUL, London) equipped with a laser diode [405 nm DAPI 
 excitation], Argon laser [488 nm fluorochrome excitation], Helium Neon 
 543 laser [546 nm fluorochrome excitation] and interfaced with Zeiss Zen 
 image analysis software (all Carl Zeiss®, AG)  
 
 ii) 3i Marianas™ (Department of Cellular & Molecular Physiology, University 
 of Liverpool, Liverpool) custom-built instrument equipped with SlideBook™ 
 5 image analysis software (all Intelligent Imaging Innovations (3i) © Inc).  
 
 
Microscope instrument acquisition settings were applied universally across all 
images for comparative analysis and acquired in a single session for each 
experimental procedure to ensure comparability. 
 
 
The platform used for image acquisition and analysis is indicated in the relevant 
result figure legends. Additional image analyses and quantification where 
required, were performed using ImageJ software (ImageJ64 v1.46r, National 
Institutes of Health) and are also outlined in result figure legends.  Images were 
prepared for presentation using Photoshop® for generation of composite figures 
in Illustrator®  (both Adobe® CreativeSuite™ CS6 v 16.0.0, Adobe Systems 
Software Ltd).  
 
 
2.5.6     quantification of immunofluorescence signal intensity 
 
Where shown, signal intensities from immunofluorescence studies were quantified 
by calculating corrected total cell fluorescence expressed in arbitrary units (CTCF, 
AU) using ImageJ software using the formula: 
 
CTCF = Integrated Density – (Area of Selected Cell – Average Mean Background Fluorescence) 
 
 as published by McCloy et al (2014) and later described in technical detail 
by Burgess (2015).  
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 2.6     Western blotting 
 
First described by Towbin et al (1979), Western blotting (immunoblotting) is well 
established as a means of protein identification and quantification in biological 
research. Following size separation based upon molecular weight (MW, kDa) using 
gel electrophoresis, proteins are transferred to a solid support medium, typically a 
nitrocellulose membrane, to permit specific identification of blotted proteins using 
antibodies specific to moieties of interest (Kurien and Scofield 2006, Mahmood 
and Yang 2012).  
 
 
Western blotting permits evaluation and quantification of many post-translational 
modifications (PTM) including phosphorylation, ubiquitinylation, methylation, 
SUMOylation and glycosylation at defined amino acid residues. This has expedited 
characterisation of the critical modulatory effects of PTM in both health and 
disease processes (Bass et al 2017). The longstanding utility and widespread 
application of the Western blotting technique remains given its ability to detect 
proteins of low abundance, routinely within the nanogram (ng) and reportedly 
down to the picogram (pg), range when using detection by peroxidase reaction 
products (Towbin et al 1979). 
 
 
Two detection platforms were used for Western blotting procedures. 
Immunoblotting undertaken at the Centre for Tumour Biology, Barts Cancer 
Institute was developed by enhanced chemiluminescence (ECL) either manually 
using X-ray film (BioMax XAR Film, 165-1454, Carestream Health Inc.) or digitally 
using the Amersham™ Imager 600 (GE Healthcare Life Sciences Ltd). An infrared 
(IR) detection system (Odyssey®Sa, LI-COR© Inc) was employed for experiments 
performed at the Institute of Translational Medicine, University of Liverpool. The 




NB: Details all of primary, secondary and loading control antibodies used in WB 
analyses are provided in Tables 2.6, 2.7 & 2.9. Experiment-specific details, along 
with protein loading quantities, are provided in the relevant result figure legends. 
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 2.6.1    Western blotting with ECL detection (Tumour Biology, Barts Cancer Institute) 
 
After washing the adherent cell monolayer 3 times in TBS pre-chilled to 4°C, 
lysates were harvested by manual scraping in the presence of Nonidet P-40 
(FNN0021, Invitrogen™) supplemented with protease and phosphatase inhibitors 
diluted 1:100 in Nonidet P-40 (Protease Inhibitor Cocktail Set I 539131 and 
Phosphatase Inhibitor Cocktail Set II 524625, both Calbiochem®). Lysates were 
centrifuged [12 000 rpm; 10 min; 4°C) (SORVAL® fresco microcentrifuge, Sorval™) 
to collect supernatants and aliquoted to prevent freeze-thaw artefacts or 
degradation of protein moieties prior to storage at −20°C before evaluation by 




Lysate protein concentrations were determined using a commercial modified 
Lowry colorimetric assay (Bio-Rad DC™ Protein Assay Kit, 500-0116, Bio-Rad 
Laboratories Inc). Colorimetric changes correlating to protein concentrations were 
read at 650 nm using the TECAN Infinite® F50 microplate reader (Tecan Trading 
AG) and quantified as optical density (OD) units. Sample lysates were quantified 
against in-house protein standards (0 – 2000 mg ml-1 BSA, A7906, Sigma Aldrich 
dissolved in Nonidet P-40) tested concomitantly to yield a protein standard curve. 
A minimum threshold for the linear regression of the protein standard curve 
generated was set at R2=0.98 to ensure accuracy of readings before the curve was 
used to interpolate sample lysate concentrations.  
  
 
Sample and control lysate protein concentrations were equalised to yield a 
concentration of 1 μg ml-1 by dilution (where necessary) in the required volume of 
Nonidet P-40. Equalised lysates were mixed (1:1) in an equal volume of [2x] 
Laemmli buffer (S3401, Sigma Aldrich). Proteins were then reduced by boiling for 




Proteins were resolved by SDS-PAGE in 10% acrylamide gels prepared in-house 
(see Section 2.6.3 for details) in the presence of Tris-Glycine-SDS running buffer 
(BP1341-1, Fisher Scientific) using the Mini-PROTEAN® Tetra Cell Module 
(1658029, Bio-Rad Laboratories Inc). Gels were run using the at 90V for 20 min 
through stacking gel and at 120V for 1h30 through resolving gel, or until sample 
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 front reached the base of the resolving gel. Once resolved, proteins were blotted onto a nitrocellulose membrane (Amersham Hybond™ ECL™ RPN303D, GE 
Healthcare©) by wet electrophoretic transfer using the BioRad Mini-PROTEAN® 
Trans-Blot® Module (1658029, Bio-Rad Laboraties Inc). Transfer was performed 
overnight at 4°C running at 15 V in the presence Glycine-SDS transfer buffer 
(BP1306-1, Fisher Scientific) supplemented with 20% ethanol. 
 
 
Following transfer, membranes were stained with Ponceau S (P7170, Sigma 
Aldrich) to confirm transfer success. Membranes were then rinsed in distilled H2O 
to remove Ponceau S before additional washing in either 5% milk [5% (w/v) 
skimmed milk powder (70166, Sigma Aldrich) dissolved in 1% (v/v) Tween®20 
(P1379, Sigma Aldrich) / TBS] or with 5% BSA [5% (w/v) BSA (A2058, Sigma 
Aldrich) dissolved in 1% (v/v) Tween®20/TBS] until all Ponceau S was removed. 
Membranes were then blocked for 30 min at RT in either 5% milk or 5% BSA to 
inhibit non-specific antibody binding during immunoblotting. Membranes to be 
probed for the β6 subunit using antibody C-19 were blocked in 5% milk. All other 
membranes were blocked in 5% BSA. 
 
 
Once blocked, membranes were probed overnight at 4°C in primary antibody 
prepared in appropriate blocking buffer (please refer to Tables 2.6 – 2.9 for target 
and application specific antibody dilutions). After probing, membranes were 
washed for 30 min at RT in 5 changes of washing buffer [0.1% (v/v) Tween®20 / 
TBS]. Membranes were then incubated for 1h at RT with the relevant species-
specific HRP-conjugated secondary antibody diluted in either 5% milk or 5% BSA 
blocking buffer (see Table 2.9 for details), before washing for 30 min at RT as 
previously described prior to detection.  
 
 
Protein bands were revealed by enhanced chemiluminescence (Amersham ECL 
Western Blotting Detection Kit RPN2106, GE Healthcare) according to 
manufacturer’s guidelines and detected by exposure to and development of 
conventional X-ray film (BioMax XAR Film, 165-1454, Carestream Health Inc.) or 
visualised using the Amersham™ Imager 600 (GE Healthcare Life Sciences Ltd) 
digital imaging system. Membranes were then washed and reprobed using a 
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 2.6.2 Western blotting with IR detection (Translational Medicine, University of Liverpool) 
 
Lysates were harvested by manual scraping in [2X] RIPA buffer prepared in-house 
[300 mM sodium chloride (NaCl) (10326390, Fisher Scientific); 2% (v/v) 
IGEPAL®630 (I8896, Sigma); 1% (w/v) deoxycholic acid sodium salt (10346653, 
Fisher Scientific); 0.2% (w/v) sodium dodecyl sulphate (SDS) (10090490, Fisher 
Scientific); 100 mM Tris pH 8.0 (Trizma®Base, 93349 Fluka); 0.2% (w/v) sodium 
azide (NaN3) (S8032, Sigma Aldrich)] supplemented with protease [(10 μg ml-1 
aprotinin (A1153, Sigma Aldrich) and leupeptin hemisulphate (L2884, Sigma 
Aldrich); 200 μM 4-(2-aminoethyl)benzenesulphonyl fluoride hydrochloride 
(AEBSF-HCl) (1056-3165, Fisher Scientific)] and phosphatase inhibitors [15 mM 
sodium fluoride (NaF) (10244540, Fisher Scientific); 1.5 mM sodium orthovanadate 
(NaVO4) (10114740, Acros Organics)].  
 
 
Protein concentrations were determined by colorimetric assay and equalised (as 
previously described). Proteins were then denatured by boiling at 100°C for 5 min 
in a heat-block in the presence of reducing [2X] SDS sample buffer prepared in-
house [50 mM Tris (Tris(hydroxymethyl)methylamine-hydrochloride) pH 6.8  
(10152400, Fisher Scientific); 10% (v/v) glycerol (10579570, Fisher Scientific); 4% 
(w/v) sodium dodecyl sulphate (SDS) supplemented with 0.04% β-
mercaptoethanol (M3148, Sigma Aldrich)]. NB: For 2D-enrichment (2D-E) studies, 
samples were harvested by manual scraping directly into [2X] SDS sample buffer, 
prohibiting protein quantification. In these latter situations comparisons were 
based on identical numbers of cells plated (i.e 5 x 106 cells per 10 cm dish). 
 
 
Proteins were resolved by SDS-PAGE in NuPAGE® 4 – 12% 1.0 mm Bis-Tris Gels 
(NP0322 or NP00323, Invitrogen™) using the Novex® XCell SureLock™ Mini-Cell 
Electrophoresis System (EI0002, Invitrogen™). Gels were electrophoresed in the 
presence of NuPAGE® MES SDS running buffer (NP002-02, Invitrogen™) for 15 min 
at 90V through stacking gel, and run for 65 min at 150V through resolving gel. 
Transfer was achieved in the presence of Novex®Tris-Glycine Transfer Buffer 
(LC3675, ThermoFisher Scientific) using the XCell II™ Blot Module (EI0002, 
Invitrogen™) embedded in wet ice. Proteins were blotted onto a nitrocellulose 
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 After transfer, membranes were blocked for 30 min in a casein-based buffer (B6429, Sigma Aldrich) before probing overnight at 4°C with primary antibody. 
Membranes were washed [0.1% (v/v) Tween®20 / TBS] and incubated for 30 min 
with species-specific fluorophore-conjugated secondary antibody before scanning 
on the Odyssey®Sa (LI-COR© Inc). Loading controls were subsequently evaluated. 
Digital images acquired using this detection platform were reviewed using ImageJ 





2.6.3 preparation of gels for SDS-PAGE 
 
Immediately prior to use, 10% acrylamide gels were prepared in-house according 
to the following protocols. 
 
 




cat. no. supplier 
dH2O 20 - - 
30% (w/v) acrylamide/ 
methylene bisacrylamide (37.5:1) 
16.6 EC-890 National Diagnostics 
1.5M Tris pH 8.8 12.5 - 
prepared in-house from Trizma® (TRIS 
base) (T4661, Sigma Aldrich) & pH 
adjusted with 5M NaOH 
10% (w/v) SDS  0.5 BP2436-1 Fisher Scientific 
10% (w/v) APS 0.5 - prepared in-house from dry stock 
(A3678, Sigma Aldrich) 
TEMED 
(N, N, N’, N’-tetramethylethylene-1,2-diamine) 
0.02 EC-503 National Diagnostics 
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cat. no. supplier 
dH2O 6.8 - - 
30% (w/v) acrylamide/ 
methylene bisacrylamide (37.5:1) 
1.7 EC-890 National Diagnostics 
1.0M Tris pH 6.8 1.25 - 
prepared in-house from Trizma® (TRIS 
base) (T4661, Sigma Aldrich) & pH 
adjusted with 5M NaOH 
10% SDS (w/v) 0.1 BP2436-1 Fisher Scientific 
10% (w/v) APS 0.1 - prepared in-house from dry stock 
(A3678, Sigma Aldrich) 
TEMED 
(N, N, N’, N’-tetramethylethylene-1,2-diamine) 
0.01 EC-503 National Diagnostics 
 
Table 2.13: Preparation of stacking gel solution. 
 
 
Gels were cast in single-use Invitrogen™ Novex™ cassettes (ThermoFisher 
Scientific). For 10-well gels 1.0 mm cassettes (NC2010) were used. For 12 or 15 
well gels 1.5 mm cassettes (NC2015) were used in order to provide ample volume 
for protein loading.  
 
 
2.6.4 densitometric analysis of immunoblots 
 
Where appropriate, densitometric analysis of visualised bands was performed 
using ImageJ software (ImageJ64 v1.46r, National Institutes of Health) as described 
by Miller (2010), with values normalised against a loading control and expressed 
as fold-change compared to the known positive control.   
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 2.7    methods to evaluate the utility of antibodies 6.2E5           
   and 6.2G2 to recognise active integrin ανβ6  
 
 
Extracellular regulation of integrin conformation and activation status by divalent 
cations (Smith et al 1994, Mould et al 1995b, Tiwari et al 2011) or by cognate 
ligand engagement has long been established (Mould et al 1995a, Humphries 
1996, Luo et al 2007). Therefore canonical integrin activation methods utilising 
divalent cations or cognate ligands were performed to determine the ability of the 
monoclonal antibodies 6.2E5 and 6.2G2 to recognise active conformers of the 




2.7.1       integrin ανβ6 activation mediated by divalent cation species  
 
Different species of divalent cation have been shown to elicit specific modulatory 
effects on integrin conformation, activation and ligand affinity. It has been 
reported that Ca2+ species elicit an inhibitory effect on integrin β1 subunit, 
inducing an inactive conformation to prevent its premature activation during 
intracellular trafficking from the endoplasmic reticulum (ER) to the plasma lemma 
(Day et al 2002, Chen et al 2003, Tiwari et al 2011).  
 
 
In contrast, both Mg2+ and Mn2+ species are now known to potentiate integrin 
cognate ligand engagement. Furthermore, a consensus now exists that 
Mn2+cations are potent and universal modulators of integrin priming and activation 
(Shimaoka et al 2002, Zhang and Chen 2012). Therefore, Ca2+, Mg2+ and Mn2+ 
cationic species were used to evaluate whether the antibodies 6.2E5 and 6.2G2 





2.7.1.1    evaluating divalent cation activation induced by 1 mM Ca2+,  Mg2+   
                         or  Mn2+  species 
 
The DX3β6 cell line was allowed to reach 100% confluence as this promotes high 
levels of integrin ανβ6 expression (data not shown). After harvesting cells 
(previously described, section 2.3), residual cations were removed by washing and 
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 centrifugation [1200 rpm, 3 min, 4°C] (Avanti® J-26 RP Centrifuge, Beckman Coulter Inc) in a chelating wash buffer [TBS pH 7.4 (BP24711, Fisher Scientific) 
supplemented with 20 mM EDTA (E6758, Sigma Aldrich)] that had been pre-
chilled to 4°C. Following manual cell counting by phase contrast microscopy using 
a disposable haemocytometer (FastRead Counting Slide, BVS100, Immune 
Systems Ltd), the cell pellet was resuspended in chelating wash buffer to yield a 1 x 
106 cells ml-1 suspension. Aliquots of equal volume were transferred to 4 pre-
chilled 50 ml Falcon (CLS430829, Corning®, Sigma Aldrich) tubes embedded in 
wet ice and pelleted by centrifugation (as previously described).   
 
 
Solutions of divalent cations were prepared at 1 mM in TBS, chilled to 4°C and 
kept on wet ice. Cell pellets were resuspended in 10 ml ice-cold divalent cation 
solutions of either, calcium chloride (CaCl2 / Ca2+) (C7902, Sigma Aldrich), 
magnesium chloride (MgCl2 / Mg2+) (M8266, Sigma Aldrich), manganese (II) 
chloride (MnCl2 / Mn2+) (M3634, Sigma Aldrich) or, in a chelating ion-free buffer 
[0.1% (w/v) BSA (A7906 Sigma Aldrich) / TBS pH 7.4 / 20 mM EDTA], inverted to 
mix thoroughly and left to incubate on wet ice for 10 min.  
 
 
Cells were then centrifuged, resuspended in the appropriate 1 mM cation or ion-
free chelating buffer at 4 x 106 cells ml-1 and stained for flow cytometric evaluation 
of putative integrin ανβ6 subpopulations (previously described, section 2.4.1) using 
the full panel of anti-integrin ανβ6 antibodies (see Table 2.5).  
 
 
All wash steps and antibody preparations for these experiments were performed 
using the relevant 1 mM cation or ion-free buffer. After staining, cells were 
resuspended in the appropriate 1 mM cation or ion-free buffer prior to acquisition 
(previously described, section 2.4.2). All solutions were pre-chilled and 
centrifugation steps performed in a refrigerated centrifuge pre-cooled to 4°C to 




2.7.1.2     evaluating Mn2+-induced activation kinetics 
  
Additional experiments were performed to characterise Mn2+ ion-induced 
activation kinetics specifically. The established cation activation protocol (outlined 
previously in section 2.7.1) was used to test the effects of a range of Mn2+-ion 
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 concentrations upon the binding capacity of antibodies 6.2E5 and 6.2G2. Solutions of magnesium chloride ranging from 0 mM to 10 mM were prepared in 
TBS as previously described. 
 
 
2.7.2        integrin ανβ6 activation mediated by cognate ligand engagement 
 
As cellular adhesion receptors, integrin engagement of cognate ligands within the 
ECM is critical to their extracellular activation and induction of “outside-in” 
signalling (Campbell and Humphries 2011). Therefore, the known integrin ανβ6 
cognate ligands latency associated peptide (LAP) of transforming growth factor β1 
(TGF- β1) and the synthetic peptide A20FMDV2 were used to characterise binding 
kinetics of antibodies 6.2E5 and 6.2G2 upon ανβ6 integrin ligand-engagement and 




2.7.2.1    evaluating A20FMDV2-induced binding kinetics  
 
The foot and mouth disease virus (FMDV)-derived 20mer synthetic peptide 
A20FMDV2 generated by DiCara et al (2007) is known to specifically bind the 
integrin ανβ6 both in vitro and in vivo (Jackson et al 2000, Monaghan et al 2005, 
Hausner et al 2007, Saha et al 2010). A biotinylated formulation of peptide 
A20FMDV2 was used for these experiments to facilitate flow cytometric detection 




The VB6 cell line was harvested at 100% confluence for maximal integrin ανβ6 
expression. Residual cations and ligands were removed by centrifugation in a 
chelating buffer (TBS/20 mM EDTA, previously described). Cells were 
resuspended in 100 nM biotinylated-A20FMDV2 prepared in DMEM/0.1/0.1 and 
kept on wet ice to permit ligand engagement. Ligand binding was quenched at 
designated time-points between 0 and 60 minutes, by flooding and washing with 
ion-free buffer.   
 
 
Cells were stained for flow cytometry analysis using the panel of anti-integrin ανβ6 
antibodies (previously specified). Biotinylated-A20FMDV2 was detected with an 
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 anti-biotin antibody (10 μg ml
-1, ab1227, AbCam). Specifications of the chelating 




2.7.2.2    evaluating LAP-induced binding kinetics  
 
Integrin ανβ6 binding of LAP resulting in TGF-β1 activation is well established 
(Thomas et al 2002, Munger and Sheppard 2011). Recombinant human LAP 
tagged with a human IgG (Fc’) fragment (LAP-Fc) (a kind gift from Biogen Idec) was 
used for the purposes of these ligand-induced activation experiments.  
 
 
Again, the VB6 cell line was harvested at 100% confluence and washed by 
centrifugation in a chelating buffer to remove residual cations or ligands. Cells 
were resuspended in solutions of LAP-Fc prepared at concentrations ranging from 
0 – 10 μg ml-1 in DMEM/0.1/0.1 and incubated on wet ice for 10 minutes to permit 
ligand engagement.  
 
 
Ligand engagement was quenched by flooding with 3 subsequent wash steps in 
an ion-free buffer. Cells were then stained for flow cytometry to evaluate surface 
integrin ανβ6 expression (previously described). Cell-surface LAP-Fc was detected 
using an anti-human IgG(Fc’) antibody (ab113636, AbCam) to confirm successful 
engagement. Time-course activation experiments over a 30 minute period in the 
presence of 2 μg ml-1 LAP-Fc were also performed using the VB6 cell line following 




2.7.3       determining subcellular localisation of epitopes recognised by the 
                antibodies 6.2E5 and 6.2G2 by immunofluorescence   
 
To evaluate the subcellular distribution of the epitopes recognised by antibodies 
6.2E5 and 6.2G2, the VB6 cell line was seeded overnight on non-derivatised 13 
mm glass coverslips as previously described (section 2.5.1). Successful adherence 
and cell morphology was confirmed by phase contrast microscopy, prior to fixation 
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 Coverslips were blocked for 30 min at RT in normal (non-immune) goat serum (1:50, PK-6101, VECTASTAIN® Elite® ABC (rabbit IgG) Kit component, Vector 
Laboratories Inc). Cells were then labelled with either 6.2E5 or 6.2G2 (5 μg ml-1) for 
1 hour at RT, prior to washing and counterstaining with antibody 53A2 (10 μg ml-1) 
for 1 hour at RT.  
 
 
After additional washing, primary antibodies were detected with fluorophore 
conjugated species-specific secondary antibodies. Anti-mouse IgG-
AlexaFluor®488 (16 μg ml-1, A11029, Invitrogen™) was used to detect antibodies 
6.2E5 and 6.2G2. Anti-rat IgG AlexaFluor®546 (16 μg ml-1, A11081, Invitrogen™) 
was used to detect antibody 53A2. Nuclei were demonstrated with DAPI (1 μg ml-1, 
D1306, Invitrogen™) and mounted in Mowiol®-4-88 (81381, Sigma Aldrich) ready 




2.7.4       evaluating the distribution of 6.2E5 and 6.2G2 cognate epitopes  
                in cells adhering to integrin cognate ligands 
  
Non-derivatised 13 mm glass coverslips were coated for 1 hour at RT with either 
human recombinant LAP of TFG-β1 (LAP) (0.5 μg ml-1, L3408, SigmaAldrich), 
human recombinant fibronectin (Fn) (10 μg ml-1, F2006, SigmaAldrich) or rat-tail 
collagen type I (Col I) (10 μg ml-1, 354236, Corning® Inc). Coverslips were then 
washed in serum-free media equilibrated to RT. A suspension of the VB6 cell line 
was prepared in serum-free media, seeded at 2 x 104 cells per coverslip and left to 
adhere to coverslips for 2 hours under standard tissue culture conditions. 
 
 
Cells were then fixed, permeabilised (as previously described in section 2.5.3) and 
labelled with either 6.2E5 or 6.2G2 (5 μg ml-1) for 1 hour at RT prior to detection 
with anti-mouse IgG AlexaFluor®488 (16 μg ml-1, A11029, Invitrogen™). Actin was 
stained with 50 μg ml-1 tetramethylrhodamine phalloidin (R415, Molecular Probes) 
and nuclei demonstrated with DAPI. Coverslips were mounted (Mowiol®-4-88) and 
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 2.7.5       vital staining of live cells with antibodies 6.2E5 and 6.2G2    
The VB6 cell line was seeded at a density of 2 x 104 cells per coverslip on 13 mm 
non-derivatised glass coverslips and left to adhere overnight under standard tissue 
culture conditions. Cells were washed in serum-free media and incubated with 
antibody 6.2E5 or 6.2G2 (5 μg ml-1) or 620W7 (10 μg ml-1) for 10 min at 4°C. After 
washing off unbound antibody, cells were either fixed and permeabilised 
immediately (0’ time-point) or supplemented with complete media pre-warmed to 
37°C and returned to standard culture conditions for 15 minutes to permit 
antibody internalisation prior to fixation and permeabilisation (15’ time-point).  
 
 
Cells labelled with 6.2E5 and 6.2G2 were counterstained post-fixation with 
antibody 53A2 (10 μg ml-1) for 1 hour at RT. Primary antibodies were detected with 
fluorophore-conjugated species-specific secondary antibodies (as previously 
described). After DAPI nuclear staining, coverslips were mounted in Mowiol®-4-88 





2.7.6       immunohistochemical evaluation of antibodies 6.2E5 and 6.2G2 in 
                FFPE and fresh frozen primary human breast tumour samples  
  
Fourteen FFPE and 5 case-matched fresh frozen human primary breast tumour 
samples were obtained with kind permission from Barts Cancer Institute Breast 
Tissue Bank (Research Ethics Ref: 15/EE/0192). Research samples were obtained 
from surgical resections, formalin fixed and processed in accordance with Tissue 
Bank local protocols (information not provided). Case-matched fresh frozen 
samples were taken prior to formalin fixation and snap frozen in liquid nitrogen 
and stored at −80°C, again in accordance with Tissue Bank protocols and in full 
compliance with the requirements of the Human Tissue Act (HTA) 2004. Cases 
were kindly retrieved by Dr Sally Dreger (Breast Tissue Bank Co-Ordinator, Barts 
Cancer Institute, QMUL). 
 
 
The 14 FFPE samples were sectioned at 4 μm, dewaxed and stained with 
haematoxylin and eosin (H&E) (ST5010 Autostainer XL using 3801698 H&E Staining 
System Kit, both Leica Biosystems). Additional 4 μm sections were dewaxed ready 
chapter II: 
materials & methods 
 83 
 for staining using the VENTANA™ BenchMark™XT automated immunohistochemistry instrument (Ventana Medical Systems Inc).  
 
 
Endogenous peroxidases were blocked in 3% (v/v) H2O2 (H1009, Sigma Aldrich) 
diluted in methanol (1.00837, Sigma Aldrich for 10 min. For antibody CSβ6 
(MAB2076, Calbiochem/Merck Millipore), sections were subjected to on-board 
endopeptidase enzyme-induced epitope retrieval (EIER) using Protease 1 solution 
(760-2018, Ventana Medical Systems Inc) prior to labelling with CSβ6 prepared at 
a 1:200 dilution (5 μg ml-1). For antibodies 6.2E5 and 6.2G2, on-board heat-
induced epitope retrieval (HIER) was achieved using ULTRA™ Cell Conditioning 
Solution 1 (ULTRA CC1) (950-224, Ventana Medical Systems Inc) before labelling 
with antibody 6.2E5 or 6.2G2 prepared at 5 μg ml-1. Primary antibodies were 
detected with 3,3’-diaminobenzidine (DAB) chromogen (ultraView Universal DAB 
Detection Kit, 760-500, Ventana Medical Systems Inc) and sections counterstained 




The 5 fresh frozen tissue samples were equilibrated to −20°C, mounted in Optimal 
Cutting Temperature (OCT) compound (O.C.T.™ 4583, Tissue-Tek® Sakura®) and 
cryosectioned at 6 μm onto positively charged slides (3800211, X-tra® Slides, Leica 
Biosystems Nussloch GmbH). Sections were fixed briefly in 10% (v/v) neutral 
buffered formalin (HT501128, Sigma Aldrich) and stained immediately either with 
H&E (previously described) or by IHC. For IHC, fresh frozen tissue sections were 
not subject to endogenous peroxidase blocking nor on-board antigen retrieval 
protocols. Sections were labelled with CSβ6, 6.2E5 and 6.2G2 primary antibodies, 
detected with DAB chromogen and counterstained with haematoxylin as 
described above.  
 
 
Clinical samples were collected by authorised members of the Barts Cancer 
Institute Breast Tissue Bank under the direction of Dr Sally Dreger and Dr Sally 
Smith. Processing, embedding, microtomy, cryotomy and staining of sections was 
performed by Barts Cancer Institute Pathology Core Service under the supervision 
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 2.8    physiomimetic 3D-mini-organotypic gels  
 
The use of physiomimetic 3D-culture systems using ECM-based hydrogels is now 
widespread practice in cancer research (Froeling et al 2009, Li et al 2013, Coleman 
et al 2014a, Carapuca et al 2016). These 3D-culture “organotypic” models facilitate 
physiologically relevant characterisation of tumour cell behaviour within the 
context of a surrounding stromal matrix. This better recapitulates the complexities 
and influence of the in vivo tumour microenvironment on incipient, neoplastic and 
malignant epithelial cells (Baker and Chen 2012).  
 
 
Furthermore, these organotypic models can be readily customised to address 
specific research themes through co-culture with tissue-specific stromal cells and 
modulation of the presence and concentration of extracellular mediators including 
cytokines, hormones or ECM ligands as required. They also prove a useful means 
of pre-clinical screening to determine the efficacy and putative therapeutic benefit 




The commercially available Matrigel® matrix (Corning Inc®) comprising a 
solubilised preparation of ECM proteins extracted from Engelbreth-Holm-Swarm 
mouse sarcoma cells has been applied in both 2D and 3D-culture systems (Kibbey 




2.8.1        precautions for experimental set-up 
 
All reagents used to prepare collagen (I)-Matrigel®-based mini-gels for mini-
organotypic assays were thawed whilst embedded in wet ice to preserve integrity. 
All equipment and reagents used were kept sterile, with all procedures performed 
in a Class II Microbiological Safety Cabinet (laminar flow tissue culture hood) to 
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 2.8.2       preparation of collagen (I)-Matrigel®-based mini-gels  
Mini-organotypic cultures were prepared in a 24-well plate format using 6.5 mm 
Transwell® 0.4 μm Pore Polycarbonate 10 μm Membrane Inserts (#3413, 
Corning®). Transwell® membranes were pre-treated by coating each individual 
membrane with 300 μl of 1% (v/v) rat-tail collagen type I (collagen (I), #354236, 
Corning®) diluted in sterile ice-cold PBS. Collagen-coated membranes were 
placed in a standard tissue culture incubator [37°C, 8%CO2, humidified 
atmosphere] for 1 hour to permit saturation of membranes with collagen (I). 
 
 
Immediately prior to use, the collagen (I)-Matrigel® gel solution was prepared 
according to the following protocol and kept on wet ice until required to prevent 




(μl) cat. no. supplier 
Collagen Type I (rat tail) 525 354236 Corning® 
Matrigel® 175 354248 Corning® 
[10X] DMEM 100 D2429 SigmaAldrich 
fibroblast culture media 100 in-house refer to Table 2.15 
filtered FBS 100 10500-064 Gibco® ThermoFisher 
1M NaOH 95 S0899 SigmaAldrich  
(prepared in-house from NaOH pellets) 
Table 2.14: Preparation of collagen (I)-Matrigel® gel solution for mini-organotypic culture.  
The protocol yields ~1 ml 48% (v/v) collagen (I)-16% (v/v) Matrigel® gel solution sufficient for 
preparation of nine x 6.5 mm Transwells® each requiring 120 μl gel mix per membrane. 
 
 
Depending on number of gels required, sufficient volume of organotypic gel mix 
was prepared to ensure 120 μl solution per Transwell® with additional redundant 
volume to allow for pipetting loss. On completion of pre-treatment coating of 
Transwell® membranes, residual 1% (v/v) collagen (I)/PBS was removed by 
pipetting and discarded. Ensuring that membranes did not desiccate, 120 μl of 
48% (v/v) collagen (I)-16% (v/v) Matrigel® gel solution was pipetted onto each 
Transwell® membrane and into the base of a spare well in the 24-well plate 
housing the Transwells® to facilitate monitoring of gel polymerisation.  
 
 
The Transwell® membranes were then returned to the tissue culture incubator for 
1 hour to permit gel polymerisation. Once set, 300 μl culture media was pipetted 
below the Transwell® insert and 120 μl culture media added to the top of the gel 
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 to prevent desiccation whilst cells were prepared for seeding. When cell suspensions were ready, the media was removed by pipetting from above and 




2.8.3       cell seeding and BrCa cell:fibroblast co-culture 
 
Breast cancer cells (see Tables 2.2 and 2.3) and fibroblasts (see Table 2.15) 
required to establish 3D-mini-organotypic cultures were grown and harvested 
subconfluent (as previously described). Cells were prepared to yield a final 
suspension of 1 x 105 cells per 200 μl culture media ready for seeding directly onto 
mini-organotypic gels.  
 
 
For control cultures, 1 x 105 cancer cells alone suspended in 200 μl culture media 
were seeded per Transwell® on top of prepared mini-organotypic gels. For 
organotypic co-cultures, an approximate 2:1 admixture of fibroblasts:cancer cells 
was prepared to yield 6.7 x 104 fibroblasts and 3.3 x 104 cancer cells per 200 μl of 
cell suspension. Once prepared, 200 μl of the fibroblast:cancer cell admixture was 
seeded per organotypic gel. A 2:1 ratio of fibroblast:cancer cells has been 
previously established to recapitulate the tumour-stroma niche (Kadaba et al 2013) 
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Fibroblast Aetiology and Isolation Culture Conditions 
1492N 
Primary human breast fibroblasts derived from the reduction 
mammoplasty tissue obtained from a 27-year old female. 
Fibroblast isolation was achieved by a method adapted from 
Gomm et al (1995) and undertaken at the Barts Cancer Institute 
Tissue Bank. Collagenase (1 mg ml-1, C2674, SigmaAldrich) 
and hyaluronidase (1 mg ml-1, H3506, SigmaAldrich) were used 
to isolate fibroblasts from resected mammary tissue yielding 
organoids and stromal fibroblast compartments. Three 
successive sedimentation steps were used to harvest 
fibroblasts into the supernatant for propagation into cell 
culture.  Fibroblasts were isolated and kindly gifted by Dr J 
Gomm, Breast Tissue Bank, Barts Cancer Institute, QMUL. 
Adherent growth 
DMEM/10% FBS/2 mM L-Glu/ 
amphotericin B [1 μg ml-1] 
3137N 
Primary human breast fibroblasts derived from the reduction 
mammoplasty tissue obtained from a 49-year old female. 
Fibroblasts were isolate and kindly gifted as above. 
Adherent growth 
DMEM/10% FBS/2 mM L-Glu/ 
amphotericin B [1 μg ml-1] 
FSF2 
Primary human foreskin fibroblasts isolated from the prepuce 
of a 19-day old male. De-epidermisation of skin tissue was 
achieved with dispase (D4693, SigmaAldrich). Fibroblasts were 
mechanically separated in the presence of collagenase D 
(11088866001, Roche Holding AG) and filtered through cell 
strainers (22363548, Fisherbrand). Fibroblasts were isolated 
and kindly gifted by Dr Su Marsh, Blizard Institute, QMUL. 
Adherent growth 
DMEM/10% FBS/2 mM L-Glu/ 
amphotericin B [1 μg ml-1] 
 
Table 2.15: Human fibroblasts used for mini-organotypic co-culture with breast cancer cell lines.  
 
 
After either cancer cells alone or the 2:1 fibroblast:cancer cell admixture were 
seeded, 600 μl complete culture media was added beneath each Transwell® insert 
containing the now seeded mini-organotypic gel. Mini-organotypic gels were 





2.8.4       feeding and maintenance of mini-organotypic cultures 
 
Seeded cells were left to adhere to the mini-organotypic gels for 24 hours. At 24 
hours post-seeding, the residual media/cell suspension on top of the mini-
organotypic gel was carefully removed by pipetting and discarded. The 600 μl 
culture media beneath the mini-organotypic gel/Transwell® insert was also 
removed and discarded.  
 
 
The mini-organotypic cultures were then fed by pipetting 350 μl of complete 
culture media beneath, and 200 μl of serum-free media on top of each mini-
organotypic gel to establish a haptotactic gradient. Cultures were maintained by 
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2.8.5       treatment regimens using 264RAD and Gefitinib (IRESSA®) 
For mini-organotypic cultures testing the efficacy of targeted therapies, the 
feeding and maintenance regimen was modified to include therapeutics of 
interest. The integrin ανβ6 function-blocking antibody 264RAD (a kind gift from 
Oncology, iMED AstraZeneca, see Table 2.6) was used to abrogate integrin ανβ6. It 
is also reported to block integrin ανβ8 function (Eberlein et al 2013). The Gefitinib 
(IRESSA®) small molecule inhibitor was used to ablate EGFR signalling 
(AstraZeneca, see Table 2.11).  
 
Mini-organotypics were treated by supplementing both complete culture media 
and serum-free media used for feeding and maintenance with the desired 
therapeutic agent(s) as previously described. The antibody 264RAD was used at 10 
μg ml-1 final treatment concentration as previously published (Eberlein et al 2013, 
Moore et al 2014). An isotype-matched human IgG (31154, Invitrogen™, 
ThermoFisher) control antibody at 10 μg ml-1 was used as a negative control to 
determine treatment effect.  
 
Based on pharmacokinetic data from Phase I clinical trials and U.S Food and Drug 
Administration (FDA) approved dosing of 250 mg/day, Mukohara et al (2005) 
determined that 1 μM is the maximum achievable plasma concentration of 
gefitinib. Therefore gefitinib treatment was administered at 1 μM. Because the 
lyophilised gefitinib had been dissolved in DMSO and aliquoted for long-term 
storage at -20°C, a control treatment of 0.1% DMSO was used to reflect the final 
concentration of DMSO in organotypic cultures treated with 1 μM gefitinib.  
 
For combined therapy, complete culture and serum-free media were prepared to 
comprise 10 μg ml-1 264RAD and 1 μM gefitinib. The corresponding control 
comprised 10 μg ml-1 human IgG and 0.1% DMSO.  
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2.8.6       harvesting, fixation and processing of mini-organotypic gels 
 
After 10 days in culture, mini-organotypic gels were formalin-fixed (10% neutral 
buffered formalin, BAF-0010-25A, CellStor™, CellPath Ltd) for 24 hours before 
saturation in 70% ethanol for a minimum of 30 minutes. Gels were then harvested 
from Transwell® inserts and bisected ready for overnight vacuum-infiltration 
processing (VIP) (Tissue-Tek VIP-6, Sakura®) and paraffin wax embedding. 
Specimens were then sectioned at 4 μm and stained with haematoxylin and eosin 
(H&E) (ST5010 Autostainer XL using 3801698 H&E Staining System Kit, both Leica 
Biosystems). Processing, embedding, microtomy and H&E staining was kindly 
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 2.9     an immunoprecipitation method to isolate integrin 
           ανβ6 and its trafficking partners during LAP ligand- 
           stimulated internalisation  
 
To identify novel binding partners associated with the integrin ανβ6 during its 
ligand-stimulated internalisation and trafficking, an experimental method coupling 
a cognate ligand-induced internalisation assay with immunoprecipitation (IP) of a 
human IgG (Fc’)-tagged cognate ligand to isolate ligand-engaged integrin ανβ6 
receptor complexes for downstream proteomic interrogation by label-free LC-
MS/MS was provisionally developed.  
 
 
Again, the known integrin ανβ6 cognate ligand LAP was used to specifically 
engage integrin ανβ6 (Thomas et al 2002). The transferrin receptor was used as a 
control and stimulated with its cognate ligand, transferrin (Hopkins and 
Trowbridge 1983).  The BT-20 TNBC cell line was used as it exhibits endogenous, 




2.9.1   validation of LAP-Fc specificity for integrin ανβ6 engagement 
 
The specificity of an Fc-tagged LAP ligand (LAP-Fc) (a kind gift from Biogen Idec) 
for integrin ανβ6 was evaluated by flow cytometry. The BT-20 cell line was 
harvested from adherent culture as previously described and subjected to integrin 
ανβ6 functional blockade using antibody 53A2. Cells were treated with 50 μg ml-1 
53A2 prepared in DMEM/0.1/0.1 and incubated for 30 min on wet ice with 
intermittent mixing by inversion.  
 
 
Cells were then washed by centrifugation in DMEM/0.1/0.1 and then incubated for 
30 min on wet ice with LAP-Fc prepared at 25 μg ml-1. Cells were washed by 
centrifugation [1200 rpm; 3 min; 4°C] (Avanti® J-26 RP Centrifuge, Beckman 
Coulter Inc), labelled with an anti-human IgG (Fc’) antibody (10 μg ml-1, ab113636, 
AbCam) to demonstrate surface bound LAP-Fc and detected with anti-mouse 
AlexaFluor®488 antibody. Cells were analysed by flow cytometry in the presence 
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 2.9.2      LAP-Fc ligand-induced integrin ανβ6 internalisation assay  
BT-20 cells were seeded in 10 cm culture dishes (664160, CELLSTAR® Greiner 
BioOne GmbH) at a density of 5 x 106 cells per dish in complete culture medium 
and allowed to adhere overnight at 37°C in the presence of 8% CO2. Adherence 
and density was first confirmed by phase contrast microscopy (OLYMPUS IMT-2, 
Olympus Corp) prior to assay. 
 
 
Adherent cell monolayers were washed in calcium-/magnesium-free PBS (PBS-) 
(D8537, Sigma Aldrich) at RT prior to 4 hr serum starvation under standard tissue 
culture conditions in the presence of low serum media (1% FBS/α-MEM) 
supplemented with 25 mM HEPES pH7.0 – 7.6 (H3375, Sigma Aldrich). Cells were 
washed with PBS- and treated for 15 min on a gyratory rocker at 4°C with Fc-
tagged ligand (LAP-Fc, Biogen Idec or transferrin-Fc, Hölzel Diagnostika) prepared 
at 5 μg ml-1 in calcium-/magnesium-replete (PBS+) (D8662, Sigma Aldrich).  
 
 
Upon completion of Fc-tagged ligand treatment for cognate receptor 
engagement, cells were washed with PBS- to remove unbound ligand. Complete 
media (α-MEM/15% FBS) supplemented with 20 mM HEPES and pre-warmed to 
37°C was added to each 10 cm dish and returned to standard tissue culture 
conditions to permit internalisation of Fc-ligand-engaged receptors.  
 
 
At designated time points, cells were washed with PBS- and held on wet ice prior 
to lysis in ice cold IP lysis buffer prepared in-house: [20 mM HEPES; 1%(v/v) 
IGEPAL®CA-630 (I8896, Sigma); 50 mM sodium chloride (NaCl) (10326390, Fisher 
Scientific); 1 mM calcium chloride (CaCl2) (10171800, Fisher Scientific); 3 mM 
magnesium chloride (MgCl2) (10518060, Fisher Scientific); 300 mM sucrose 
(10346150, Fisher Scientific); 0.1% (w/v) sodium azide (NaN3) (S8032, Sigma 
Aldrich)] supplemented with protease [(10 μg ml-1 aprotinin (A1153, Sigma Aldrich) 
and leupeptin hemisulphate (L2884, Sigma Aldrich); 200 μM 4-(2-
aminoethyl)benzenesulphonyl fluoride hydrochloride (AEBSF-HCl) (1056-3165, 
Fisher Scientific)] and phosphatase inhibitors [15 mM sodium fluoride (NaF) 
(10244540, Fisher Scientific); 1.5 mM sodium orthovanadate (NaVO4) (10114740, 
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 Given the highly labile nature of receptor-protein interactions, stabilisation of ligand-receptor-protein complexes was tested using the membrane permeant 
cross-linker dimethyl 3,3'dithiobispropionimidate2HCl (DTBP) (20665, 
Pierce/Thermo Scientific) (Corgiat et al 2014). On completion of internalisation 
assay, the cell monolayer was treated with 3 mM DTBP for 30 min, before washing 




2.9.3     receptor-ligand complex isolation by IP 
 
Lysates were tumbled overnight with unconjugated protein G beads (101243, 
Invitrogen™) at 4°C to immunoprecipitate Fc-tagged ligand/receptor complexes. 
Beads were then washed by centrifugation [3 000 rpm; 1 min; 4°C] (eppendorf® 
5417R centrifuge, Eppendorf AG) in a series of stringency IP wash buffers at 4°C. 
First in a high salt buffer [1M NaCl; 0.1M Tris pH 8.0 (Trizma®Base, 93349 Fluka); 
0.1% (v/v) IGEPAL®CA-630; 0.1% (v/v) NaN3] and then in a high detergent buffer 
[0.1M NaCl; 0.1M Tris pH 8.0; 1% (v/v) IGEPAL®CA-630; 0.3% (w/v) SDS; 0.1% (v/v) 
NaN3]. Wash cycles were repeated with a final wash in a salt-free buffer [0.1M Tris 
pH 8.0; 0.1% (v/v) IGEPAL®CA-630; 0.1% (v/v) NaN3].  
 
 
On completion of stringency washing, supernatant was removed and beads were 
boiled in an equal volume of [2X] reducing SDS sample buffer (previously 
described) at 100°C for 5 min. Beads were pelleted by centrifugation [3 000 rpm; 1 
min; RT] (eppendorf® 5417R centrifuge, Eppendorf AG) and the supernatant kept 





2.9.4 preparation of IP samples for LC-MS/MS 
 
Immunoprecipitation samples were not prepared for proteomic analysis (as  
intended)  owing to inconsistency of IP yields. Therefore, a proteomic dataset for 
bioinformatic analysis of IP-experiments was not generated. However, results from 
IP experiments were used to validate use of LAP-Fc to interrogate the integrin ανβ6 
during LAP ligand-induced internalisation in the BT-20 cell line, as LAP-Fc 
successfully and reproducibly immunoprecipitated the integrin β6 subunit 
detected by WB. 
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 2.10    defining an integrin ανβ6–dependent “adhesome” 
    using 2D-enrichment for adhesion complexes 
  
In order to define an integrin ανβ6-dependent adhesion environment 
(“adhesome”), an established method for the isolation, enrichment and proteomic 
interrogation of transmembrane receptor-ligand complexes first reported by 
Humphries et al (2009) was adopted. This protocol permits stabilisation of 
notoriously labile integrin-mediated adhesion complexes facilitating their 
enrichment by sonication in an astringent detergent extraction buffer compatible 
with downstream proteomic investigation.  
 
 
Again, the concept of integrin receptor-ligand specificity was exploited in order to 
modulate the species of integrin engaged upon different cognate ligands 
designed to simulate distinct, integrin-specific 2-dimensional (2D) adhesion 
environments.  Since ligand-engagement induces integrin activation, these 
experiments will provide valuable insight into the nature of the adhesome 
downstream of integrin ανβ6 activation.  The endogenous integrin ανβ6 





2.10.1 experimental work up:  
determining specificity of ανβ6–mediated LAP-engagement  
 
The ability of BT-20 cells to bind LAP was evaluated following integrin ανβ6 
functional abrogation using the integrin ανβ6 blocking rat monoclonal antibody 
(clone 53A2) as previously described (Section 2.9.1). 
 
 
2.10.2      adhesion assay 
 
Cell culture dishes (100mm, 664160, CELLSTAR® Greiner BioOne GmbH) were 
coated overnight at 4°C with the ligands LAP (LAP) (0.5 μg ml-1; L3408, Sigma 
Aldrich), fibronectin (Fn) (10 μg ml-1; L3408, Sigma Aldrich) or collagen I (Col I) (10 
μg ml-1; 354236, Corning® Inc) prepared in ice-cold PBS+ (D8862, Sigma Aldrich). 
After coating, dishes were washed in PBS- (D8537, Sigma Aldrich) and blocked in 
10 mg ml-1 BSA (A7906, Sigma Aldrich) for 1 hr at 4°C on a gyratory rocker. Dishes 
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 were washed again in PBS- before adding DMEM5 [25 mM HEPES prepared in unsupplemented DMEM] to each dish and left to equilibrate at 37°C in the 
presence of 5% CO2 in preparation for the adhesion assay. 
 
 
After harvesting, cells were washed twice by centrifugation [1400 rpm, 4 min; RT] 
in PBS- pre-warmed to 37°C, resuspended in pre-warmed DMEM5 and held in 
suspension for 30 min at 37°C with 5% CO2 to permit internalisation of cell surface 
receptor pool. Cells were washed again by centrifugation in PBS-, resuspended in 
pre-warmed DMEM5 and seeded on ligand-coated dishes (prepared as described 
above) at 5 x 106 cells per dish. Cells were left to adhere for 2 hr 30 under standard 
culture conditions. Successful cellular adhesion to ligand-coated surfaces was 
confirmed by phase contrast microscopy (AxioVert.A1, Carl Zeiss® AG).  
 
 
2.10.3       2D-enrichment for adhesion complexes 
 
Upon completion of the assay, formed adhesion complexes were stabilised with 
the membrane permeant cross-linker dimethyl 3,3'dithiobispropionimidate2HCl 
(DTBP) (20665, Pierce/Thermo Scientific) prepared in DMEM5. Cells were treated 
with 3mM DTBP pre-warmed to 37°C and left to incubate for 30 min under 
standard culture conditions. Cross-linkage was then quenched with 20 mM Tris at 
pH 8.0 for 5 min at RT. Cells were washed in ice cold PBS- and held at 4°C ready 
for adhesion complex enrichment by sonication.  
 
 
Dishes were sonicated in the presence of ice cold extraction buffer [20 mM 
ammonium hydroxide (NH4OH) (221228, Sigma Aldrich), 0.5 % (v/v) TritonX-100 
prepared in PBS-] for 1 min per dish using a SONICS® Vibra-Cell™ sonicator 
(Sonics & Materials Inc.) set to 20% amplitude and equipped with a 13 mm tapered 
tip probe.  Cells were washed in ice cold PBS- and lysis efficiency confirmed by 
phase contrast microscopy. Dishes were kept at 4°C until adhesion complex 
harvesting by manual scraping in the presence of  [2X] SDS sample buffer 
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 2.10.4         proteomic analysis of 2D-E samples by LC-MS/MS  
Peptides were prepared and interrogated by tandem mass-spectrometry (LC-
MS/MS) using the LTQ Orbitrap XL™ ETD Hybrid Ion Trap-Orbitrap Mass 
Spectrometer (Thermo Scientific) as outlined below. 
 
 
2.10.4.1     peptide preparation 
 
Adhesion complex-enriched samples for proteomic analysis were separated by 
SDS-PAGE in NuPAGE® 4 – 12% Bis-Tris Gels (Invitrogen™) and allowed to run 16 
mm into the gel permitting dissection of gel lanes into 16 x 1 mm slices per 
sample. After staining with InstantBlue (ISB1L, Expedeon) for 60 min at ambient 
laboratory temperature, gels were destained in Milli-Q® ultra-pure water (EMD 
Millipore, Merck KGaA) before excision of gel lanes for manual slicing into 1 mm 
bands using single edge blades (12443170/YSJ-762-Q, Fisher Scientific). Samples 
were then subject to in-gel tryptic digestion using a 96-well plate format 
(Humphries et al 2009, Jacquemet et al 2013) adapted from established methods 
(Shevchenko et al 1996).  
 
 
Perforated 96-well (CB0801, Proxeon/Thermo Scientific) and U-shaped collection 
plates (AB-0796 AbGene/ThermoScientific) were assembled for the procedure. 
Briefly, gel bands were further diced into 1mm3 cubes and subjected to chemical 
washing and dehydration. Samples were washed twice for 30 min at RT in 50% 
(v/v) acetonitrile (ACN) (14261 Fluka/LC-MS Ultra CHROMASOLV®, Sigma Aldrich) 
prepared in 25 mM ammonium bicarbonate (NH4HCO3) (09830 Fluka, Sigma 
Aldrich) with removal of wash by centrifugation [1500 rpm, 2 min]. Next, gel pieces 
were chemically dehydrated in 100% ACN and subsequently dried by vacuum 
centrifugation at 45°C (V-AQ mode, Vacufuge®, Eppendorf AG) until dry. 
 
 
Proteins were then reduced by 60 min incubation with 10 mM dithiothreitol (DTT) 
(D5545, BioXtra, Sigma Aldrich) at 56°C prior to alkylation in the presence of 55 
mM iodoacetamide (IAA) (I1149, BioUltra, Sigma Aldrich) at 37°C for 45 min. Gel 
pieces were successively washed and dehydrated by respective, alternate 
incubations for 5 min at RT in 25 mM NH4HCO3 (washing) and 100% ACN 
(dehydration) before drying by vacuum centrifugation as previously described. 
Once gel pieces were dry, proteins underwent overnight tryptic digest at 37°C in 
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 the presence of 1.25 ng μl




Following digestion, peptides were extracted by incubating gel pieces for 30 min 
at RT first with 0.2% (v/v) formic acid (FA)/99.8% (v/v) ACN, and then 0.1% FA/50% 
ACN. Peptides were collected by centrifugation [1500 rpm, 2 min] and evaporated 
to dryness by vacuum centrifugation (as previous). Desiccated peptides were 
resuspended in 5% ACN prepared in 0.1% FA, transferred to glass sample vials 
(186000385C, Waters Ltd) and stored at -20°C until acquisition.  
 
 
2.10.4.2 LC-MS/MS data acquisition 
 
Peptides were analysed by ultra performance liquid chromatography (UPLC) 
tandem mass spectrometry (LC-MS/MS) on a nanoACQUITY UPLC® ultra 
performance liquid chromatography system (Waters Ltd) coupled to an LTQ 
Orbitrap XL™ ETD Hybrid Ion Trap-Orbitrap Mass Spectrometer (Thermo 
Scientific).  Peptides were concentrated, desalted and separated on a 75-minute 
linear gradient from 1% to 25% (v/v) ACN in 0.1% (v/v) FA. Peptides were 
automatically selected for fragmentation by data-dependent analysis.  
 
 
2.10.4.3 proteomic data analysis  
 
Raw SEQUEST.dta data files from LC-MS/MS runs were searched using Mascot 
Daemon (version 2.2.2, Matrix Science©) for peptide identification based on peak 
intensities against entries held in the International Protein Index (IPI) Human 
database (version 3.70, released 4th March 2010). Searches were submitted to a 
Mascot server located at the Wellcome Trust Centre for Cell Matrix Research, 




Cysteine (C) residue carbamidomethylation was set as a fixed modification. 
Phosphorylation of serine (S), tyrosine (Y) and threonine (T) residues was permitted 
as variable modifications. Additionally, oxidation of methionine (M) residues and 
hydroxylation of proline (P) residues were also assigned permissible as variable 
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 modifications. Only tryptic peptides were considered with allowance for up to 2 miscleavages. Both peptide and fragment ion tolerance were set at 0.5 Da with 
only double and triply charged fragment ions considered.  
 
 
Mascot (.mgf) files were reviewed in Scaffold™ v4.3.2 (Proteome Software© Inc, 
USA) for data pre-processing to exclude ambiguities in peptide assignment and 
validate spectral count data. For all LC-MS/MS datasets, identification threshold 
criteria were set to ≥99% at the protein level and ≥50% at the peptide level with 
identification of ≥ 2 unique validated peptides. Once validated, peptides were 
quantified using an established spectral counting method reported for analysis of 
label free proteomic strategies (Kito and Ito 2008). Spectral counts for each 
identified protein were normalised against both the total number of spectra 
detected in a given sample and molecular weight (kDa) of the protein of interest.  
 
 
Network mapping of protein-protein interactions was performed using the well-
established open source software Cytoscape v3.1.1 (Cytoscape Consortium©, 
National Resource for Network Biology) for visualizing molecular interaction 
networks and biological pathways (Shannon et al 2003, Cline et al 2007, Smoot et 
al 2011, Saito et al 2012). A human protein interaction network comprising entries 
curated by the Protein Interaction Network Analysis (PINA, 10th December 2012) 
(Wu et al 2009, Cowley et al 2012) with adaptations to encompass the Integrin 
Adhesome (Zaidel-Bar et al 2007) and Matrisome Project (Hynes and Naba 2012, 




2.10.5 bioinformatic analysis of 2D-E/LC-MS/MS datasets 
 
After data pre-processing and spectral count validation, 2D-E datasets were 
provisionally analysed using a logic-gating strategy in Microsoft®Excel® for Mac 
2011 v.14.2.5. Inclusion criteria for validated peptides for PPI network mapping 
were set at a ≥ 2-fold enrichment with ≥5 unweighted spectral counts (USC) in a 
single experiment, or ≥4 unweighted spectral counts in at least two biological 
replicate experiments. Peptides compliant with these criteria were mapped as 
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 2.11   phosphoproteomic   definition  of   active,  LAP  
   ligand-engaged integrin ανβ6–mediated signalling  
 
  
Little is currently known regarding specific downstream signalling events inducted 
upon integrin ανβ6 ligand engagement and subsequent receptor activation. The 
integrin ανβ6 is known to recognise and engage the LAP sequence of TGF-β1, 
leading to TGF-β1 activation and signalling (Thomas et al 2002, Munger and 
Sheppard 2011, Khan and Marshall 2016). Therefore, to define integrin ανβ6–
dependent signalling, phosphoproteomic interrogation of lysates generated from 
a LAP-ligand stimulation assay was undertaken to characterise the active integrin 
ανβ6 kinome. Time-points were selected to capture early (5’), intermediate (15’) 
and late (30’) signalling events, in addition to a baseline control time-point (0’).    
 
 
Acknowledgements and thanks are given to Dr Pedro Cutillas and Dr Edmund 
Wilkes (Cell Signalling & Proteomics Group, Centre for Haemato-Oncology, Barts 
Cancr Institute, QMUL) for their collaboration with the phosphoproteomic 
investigations. Particular thanks are extended to Dr Wilkes who kindly supervised 




2.11.1     LAP-ligand stimulation assay 
 
The TNBC BT-20 cell line was seeded in 10 cm culture dishes (664160, CELLSTAR® 
Greiner BioOne GmbH) at 5 x 106 cells per dish in complete culture medium and 
left to adhere overnight under standard culture conditions (37°C/8% CO2). 
Immediately prior to assay, adherence and density were confirmed by phase 
contrast microscopy (OLYMPUS IMT-2, Olympus® Corp) to ensure sufficient cell 
volume for protein yield. 
 
 
Adherent cell monolayers were washed in TBS (BP24711, Fisher Scientific) at RT 
prior to 4 hr serum starvation under standard tissue culture conditions in the 
presence of low serum media comprising charcoal-stripped FBS (126760929, 
Gibco™, ThermoFisher Scientific) supplemented with 25 mM HEPES pH 7.0 – 7.6 
(H3375, Sigma Aldrich) (1%FBS/α-MEM/25 mM HEPES) Following serum 
starvation, cell monolayers were treated with human recombinant LAP (0.5 μg ml-1, 
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 L3408, Sigma Aldrich) for 10 min whilst buried on wet ice and placed on an orbital shaker in a walk-in cold room at 4°C. Monolayers were washed (x3) in pre-chilled 
serum-free α-MEM to remove all unbound ligand. Complete media (15% charcoal-
stripped FBS/α-MEM) supplemented with 25 mM HEPES was equilibrated to 37°C 
and added to the 30’, 15’ and 5’ time-point dishes respectively (5 ml per dish) and 
returned to standard culture conditions (8%CO2/37°C /humidified atmosphere) to 




Ligand internalisation was quenched by flooding with TBS pre-chilled to 4°C and 
supplemented with phosphatase inhibitors: 1 mM sodium orthovandate (Na3VO4; 
450243, Sigma Aldrich) and 0.5 mM sodium fluoride (NaF; 01151, Sigma Aldrich).  
 
 
A total of four biological replicates were performed across two experiments; each 










Schematic overview of LAP-ligand stimulation and internalisation assay for phosphoproteomic 
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 2.11.2    cell lysis, peptide digestion and solid-phase extraction 
 
Cells were lysed and manually harvested by scraping on wet ice in the presence of 
pre-chilled (4°C) phosphoproteomic lysis buffer comprising 8 M urea/20mM 
HEPES pH 8.0 (U4883 and H3375 respectively, both Sigma Aldrich) supplemented 
with: 0.5 M NaF, 0.1 M Na3VO4, 1M disodium β-glycerophosphate (CH3H7Na2O6P; 
50020, Sigma Aldrich) and 0.25 M disodium pyrophosphate (Na2H2P2O7; 71501, 
Sigma Aldrich). Lysates were sonicated at 20% intensity for 3 x 10 s (SONICS® 
Vibra-Cell™ Ultrasonic Liquid Processor VCX750, Sonics & Materials Inc.) whilst 
buried in ice, prior to centrifugation at 13 000 rpm for 10 min at 4°C (eppendorf® 
5417R, Eppendorf AG).  
 
 
Lysis supernatants were decanted into pre-labelled, pre-chilled 2 ml Eppendorf® 
Protein Lo-bind microcentrifuge tubes (Z666513, Sigma Aldrich) using low-binding 
pipette tips (Corning® DeckWorks™) to preserve protein yield. Lysates were then 
stored at −80°C prior to protein concentration assay in preparation for peptide 
desalting, titanium oxide (TiO2) phosphoenrichment, solid-phase extraction and 
interrogation of phosphopeptides by LC-MS/MS. 
 
 
Lysates were thawed on wet ice and protein concentrations determined using a 
Pierce™ BCA Protein Concentration Assay (23227, ThermoFisher Scientific) in 
accordance with manufacturer’s guidelines. Samples were then normalised to a 
final concentration of 250 μg protein in 250 μl sample volume (1 μg μl-1) in pre-
chilled phosphoproteomic lysis buffer. 
 
 
Cysteine residues were reduced in the presence of 10 mM dithiothreitol (DTT; 
D5545, Sigma Aldrich) for 30 min in the dark at RT prior to alkylation in the 
presence of 40 mM iodoacetamide (IA; I1149, Sigma Aldrich), again for 30 min in 
the dark at RT. Proteins were digested in suspension using L-(tosylamido-2-phenyl) 
ethyl chloromethyl ketone (TPCK)-treated trypsin immobilised on agarose resin 
beads (20230, ThermoFisher Scientific) which had been pre-conditioned by 
washing and centrifugation (2000 g, 5°C, 5 min) in 20 mM HEPES pH 8.0. Samples 
were incubated with immobilised trypsin beads for 16 hr at 37°C with constant 




materials & methods 
 102 
 Trypsin beads were then removed by centrifugation [2000 g, 5°C, 5 min] (eppendorf® 5430R, Eppendorf AG). The resulting peptide solutions were desalted 
by reversed solid-phase extraction (SPE) using OASIS® HLB (Hydrophilic-Lipophilic 
Balance) Extraction Cartridges (186000383, Waters Corp) rigged to a 12-port 
Visiprep™ SPE Vacuum Manifold (57030-U SUPELCO, Sigma Aldrich) to control 
flow rate (P=5.0 inHg ±0.5 inHg).  
 
 
Columns within the cartridge were first conditioned each with 1 ml 100% 
acetonitrile (ACN; 1.00029, EMD Millipore) before equilibration with 1 ml 1% 
ACN/0.1% TFA (trifluoroacetic acid; 302031-M EMD Millipore, Sigma Aldrich) (v/v) 
prepared in molecular grade water (mH2O; W4502, Sigma Aldrich) and washing 
with 500 μl 1% ACN/0.1% TFA (v/v) in mH2O. Peptide samples were then loaded 
into conditioned, equilibrated cartridge columns and purged at a low flow rate. 
Columns (with peptides now bound to sorbent) were washed in 1 ml 1% 
ACN/0.1% TFA (v/v) in mH2O prior to elution of desalted peptides in 250 μl 1 M 
glycolic acid (G8284, Sigma Aldrich) prepared in a solution of 50% ACN/5% TFA 





2.11.3    TiO2 metal oxide affinity chromatography (MOAC) 
 
Samples were enriched for phosphopeptides by metal oxide affinity 
chromatography (MOAC) using titanium dioxide (TiO2). Desalted peptides were 
normalised to 500 μl with 1 M glycolic acid/80%ACN/5%TFA. Next, 125 mg dry 
weight of Titansphere® TiO 10 μm particles (5020-75010, GL Sciences Inc) 
(equivalent to 12.5 mg particles per sample) was reconstituted in 250 μl 1% TFA 
and vortexed to ensure a homogenous suspension of Titansphere® particles.  
 
 
Normalised peptide samples were then incubated with 25 μl of this Titansphere® 
slurry (equivalent to 12.5 mg Titansphere® particles per sample) for 5 min at RT 
with constant agitation. Next, the enriched phosphopeptides were eluted by 
centrifugation [2 min, 1500 rcf] (eppendorf® 5430R, Eppendorf AG) using 
TopTip™ micro-spin columns (TT3, Glygen Corp) previously washed with 100% 
ACN. Titansphere® particles were sequentially washed on a gradient accordingly: 
1 M glycolic acid/80% ACN/5% TFA (x 1), 100 mM ammonium acetate 
(NH4CH3CO2)/25% ACN (x 1) and 10% ACN (x 3).  
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Bound phosphopeptides were eluted from Titansphere® particles by washing with 
50 μl 5% NH4OH/10% ACN/mH2O per elution and centrifuging for 2 min at 1500 
rcf. A total of 5 elutions were performed. Once eluted, phosphopeptide samples 
were immersed in dry ice to permit sublimation of NH4OH and desiccated 
overnight using a Vacufuge® Vacuum Concentrator (Eppendorf Ltd). Samples were 




2.11.4    nanoflow-liquid chromatography tandem mass spectrometry 
 
Immediately prior to use, samples for analysis were reconstituted with 20 μl 50 nM 
enolase peptide digest (MassPREP™ Enolase Digest Phosphopeptide Mix, 
186003286, Waters Corp) dissolved in 5% ACN/0.1% TFA, subjected to bath 
sonication (15 min, RT) and centrifugation (5 min, 5°C) to recover supernatants for 
LC-MS analysis.  
 
 
Phosphopeptide liquid chromatography (LC) separations were performed using a 
Dionex UltiMate™ 3000 RSLCnano UHPLC system (ThermoFisher Scientific) with an 
Acclaim™ PepMap™ 100 C18 RSLC Analytical Column (75 μm x 25 cm, 3 μm, 
100Å) (164261, ThermoFisher Scientific) and Acclaim™ PepMap™ 100 C18 Trap 
Column (100 μm x 5 cm, 5 μm, 100Å) (160434, ThermoFisher Scientific). Solvents 
used for LC separation comprised; solvent A: 2% ACN/0.1% formic acid (FA) and 
solvent B: 80% ACN/0.1% FA. Sample injections of 3 μl were loaded onto the trap 
column at a flow rate of 8 μl min-1 over 5 min. After loading, samples were eluted 
along an 85 min gradient from 6.3% to 43.8% solvent A prior to column cleaning in 
90% solvent B for 10 min and equilibration with 6.3% solvent A for 10 min. 
 
 
All analyses were performed on the Thermo Scientific LTQ Orbitrap™-Velos™ 
Hybrid FT spectrometer. The instrument was operated in data-dependent 
acquisition (DDA) mode, whereby a full MS1 survey scan (m/z 350 – 1500) was 
completed at a resolution of 30 000 FWHM (m/z 400) and ions were analysed in 
the Orbitrap™.  The top 7 most intense multiply charged precursor ions detected 
in the MS1 survey scan were automatically mass-selected for fragmentation by 
collision-induced dissociation (CID) with multi-stage activation enabled and 
analysed in the LTZ-Velos™ linear ion trap (m/z 190 – 2000). Dynamic exclusion 
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2.11.5    identification and quantification of phosphopeptides 
 
Mascot Daemon and Distiller software (v2.3.0.0 and v2.4.2.0 respectively, both 
Matrix Science) were used to convert exported LTQ Orbitrap™-Velos™ .raw files 
into .mgf files for peak list searches against the UniProtKB/SwissProt human 
proteome database (UniProtConsortium 2017). Data were searched according to 
the following criteria: ±10 ppm precursor and ±600 mmu fragment ion m/z 
tolerances; digestion enzyme = trypsin (2 missed cleavages tolerated); fixed 
modification: carbamidomethyl (C); variable modifications: oxidation (M), phospho 




Mascot search engine results for phosphopeptide identification were collated 
using Perl script (Perl® 5, Perl.org) and Post Analysis Data Acquisition v1.1 (PAnDA) 
software (Hoopmann et al 2009). Data were curated algorithmically to include only 
unique phosphopeptide ions with a q-value ≤0.05, calculated by comparison to 
searches against a randomised database. All phosphopeptides assigned a Mascot 
delta score ≥10 were reported as the specific phosphorylation site.  
 
 
Phosphopeptides were quantified using PEak Statistical CALculator (PESCAL) 
(Barts Cancer Institute, QMUL) (Cutillas and Vanhaesebroeck 2007) to generate 
extracted ion chromatograms for the first three isotopes of each phosphopeptide 
ion within the database (±7 ppm m/z tolerance, ±1.5 min retention time tolerance, 
isotope correlation >0.8) enabling calculation of peak height for each constructed 
extracted ion chromatogram.  
 
 
Using the R statistical programming environment (R 3.2.5, The R Foundation), the 
peak heights for each phosphopeptide ion were then log2-transformed, quantile 
normalised and fitted to a linear model where difference in magnitude and 
statistical significance between time-points was calculated using Bayes shrinkage 
of standard deviations (Smyth 2004). The p-values generated were then subject to 
Benjamini-Hochberg post-hoc analyses to correct for multiple testing. Kinase 
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 Substrate Enrichment Analysis (KSEA) was performed on the dataset as previously described (Casado et al 2013a), in order to infer phosphoproteomic network 
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 2.12    kinase inhibition studies to investigate putative  
            mechanisms  regulating  integrin  ανβ6  activation 
 
Putative regulatory nodes of kinase activity downstream of integrin ανβ6 LAP 
ligand-mediated activation were identified by both raw and inferential KSEA 
analyses of the phosphoproteomic dataset. To evaluate the role of the identified 
kinases during LAP-mediated integrin ανβ6 activation and downstream signalling, 
preliminary kinase inhibition studies were undertaken.  
 
 
Commercial small molecule kinase inhibitors (listed in Table 2.11) were used to 
ablate kinase function prior to stimulation assays with known integrin cognate 
ligands. The effects of a functional loss of the targeted kinase on integrin ανβ6–





2.12.1 kinase inhibition assay to dissect integrin ανβ6–dependent signalling 
 
Breast cancer cell lines (BT-20, MDA-MB-468 and SUM159) were seeded in 6 cm 
tissue culture dishes at a density of 3 x 106 cells per dish in complete media and 
allowed to adhere overnight under standard culture conditions. Prior to assay, cell 
condition, adherence and confluence were confirmed by phase contrast 
microscopy (OLYMPUS IMT-2, Olympus® Corp). 
 
 
Cell monolayers were washed in serum free media (3 x 2 ml per dish) to remove all 
residual FBS and growth factors, prior to serum starvation in the presence of low-
serum culture media (1% (v/v) FBS/20 mM HEPES/cell line-specific media; 2 ml per 
dish) for 4 hr under standard culture conditions.  
 
 
Kinase inhibitors (EGFR: gefitinib (IRESSA®); c-MET: PHA665752; COT: TC-S7006) 
were prepared to yield 1 μM treatment concentration in the appropriate low-
serum culture media. Vehicle control treatments (veh) were also prepared 
comprising 0.1% DMSO. Upon completion of serum starvation, media was 
removed from culture dishes and replaced with 2 ml per dish of required kinase 
inhibitor or control treatment prepared in low serum media and equilibrated to 
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 37°C. Cells were subject to inhibitor or vehicle control treatments for 30 min under standard culture conditions. 
 
 
At the end of inhibition treatments, human recombinant ligands were spiked in at 
the final stimulating concentrations as follows: LAP (0.5 μg ml-1, L3408, Sigma 
Aldrich), EGF (50 ng ml-1, E9644, Sigma Aldrich) or HGF (50 ng ml-1, H9661, Sigma 
Aldrich). In the unstimulated dishes, an equivalent volume of serum-free media 
alone was spiked in, in lieu of inhibitor volume. Cells were ligand stimulated for 10 
min under standard culture conditions. 
 
 
Ligand stimulation was quenched by burying dishes in wet ice and flooding with 
pre-chilled (4°C) TBS supplemented with: 1 mM sodium orthovandate (Na3VO4; 
450243, Sigma Aldrich) and 0.5 mM sodium fluoride (NaF; 01151, Sigma Aldrich). 
Lysates from each sample and treatment condition were harvested manually by 
scraping in the presence of pre-chilled Nonidet P-40 (FNN0021, Invitrogen™) 
supplemented with protease and phosphatase inhibitors diluted 1:100 in Nonidet 
P-40 (Protease Inhibitor Cocktail Set I 539131 and Phosphatase Inhibitor Cocktail 
Set II 524625, both Calbiochem®).  
 
 
Lysates were aliquoted to prevent freeze-thaw artefacts or degradation of protein 
moieties prior to storage at −20°C before evaluation by WB. When required, 
lysates were thawed on wet ice ready for protein concentration quantification and 
immunoblotting (as previously described, Section 2.6.1) to evaluate changes in 











Schematic overview of kinase inhibition/LAP-ligand stimulation assay to investigate the regulatory 





materials & methods 
 109 
 2.12.2    kinase inhibition assay to dissect integrin ανβ6–ligand engagement 
               and cell surface receptor activation 
 
The BT-20 and VB6 cell lines were cultured to 80% confluence prior to harvesting 
by trypsinisation (as previously described, section 2.4). Cells were manually 
counted, resuspended to 4 x 106 cells ml-1 and serum starved in low-serum media 
(1% FBS (v/v)/20 mM HEPES/media) in suspension in a vented 50 ml Falcon tube 
for 4 hr under standard culture conditions. 
 
 
Following serum starvation, aliquots of the cell suspension were subject to 1 μM 
kinase inhibition or 0.1% DMSO vehicle control treatment for 30 min, again in 
suspension and under standard culture conditions. Cell/treatment preparations 
were inverted to mix thoroughly to ensure a homogenous cell suspension prior to 
commencement of treatment time. 
 
 
Next, cells were subject to canonical integrin ανβ6 activation methods by 
stimulation with either: 1 mM Mn2+ ions (MgCl2 / Mg2+: M8266, Sigma Aldrich) or 
cognate ligand LAP-Fc (2 μg ml-1, Biogen Idec), as previously described in sections 
2.7.1.2 and 2.7.2.2 respectively.  
 
 
Cells were then labelled for flow cytometric evaluation of: integrin ανβ6 activation 
status (demonstrated by antibody clone 6.2E5, Biogen Idec), cell-surface bound 
LAP (demonstrated by an anti-Fc antibody, ab113636, AbCam) and total surface 
integrin ανβ6 expression (demonstrated by antibody clone 53A2, CR-UK) in the 
presence and absence of functional kinase moieties targeted by the small 
molecule inhibitors used.  
 
 
Labelling, gating, acquisition and analysis of samples by flow cytometry was 









materials & methods 
 110 
  
2.12.3    metabolic  MTT  cell  viability  assay  to compare  target  kinase  
    requirement for cell proliferation in an integrin β6 positive and an 
    integrin β6 negative cell line 
 
The A375puro (integrin ανβ6 null) and A375B6 (integrin ανβ6 positive) malignant 
melanoma (MM) cell lines were seeded in complete media at 3.6 x104 cells per 
well in a 96-well tissue culture plate (3595, Corning® Inc) and left to adhere 
overnight. Adherence and cell density were checked by phase contrast 
microscopy (OLYMPUS® TM-2, Olympus Corp) before treatment with small 
molecule inhibitors (SMI) of kinase activity.  
 
 
An inhibitor targeting MAP3K8/COT kinase (TC-S 7006, 5240/10, Tocris, R&D 
Systems) and an inhibitor targeting MAPKAPK2 kinase (MK-II, sc-221948, Santa 
Cruz Biotechnology) were prepared in serum-free media. Cells were treated (6 
replicate wells per concentration) with TC-S7006 or MK-II over a concentration 
range of 0 – 1000 nM (0 – 1 μM) for 72 hours under standard culture conditions.  
 
 
On completion of 72-hour culture in the presence of SMI, media was removed and 
replaced with 100 μl 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 
bromide (MTT, M5655, Sigma Aldrich) prepared at 0.2 mg ml-1 in serum free 
media. Cells were incubated in the presence of MTT at 37°C for 1 hr in the dark. At 
the end of incubation, MTT was removed and replaced with 100 μl 100% DMSO to 
solubilise the MTT-formazan reaction product ready for reading optical density 
(OD) per well at 570 nm using the Infinite®F-50 (Tecan Trading AG) platereader to 
determine cell viability per well.  
 
 
Values for OD (AU) readings were normalised against assay matrix background 
OD values and converted to % viability values based on OD values for 0 nM SMI 
being equivalent to 100% cell viability. Values for % viability for each concentration 
were plotted using GraphPad Prism Software to generate curves of best fit using 
the non-linear regression curve analysis (log(inhibitor) vs normalised response – 
variable slope)  function.   
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  2.13    quality control procedures 
To ensure biological and technical validity of results, all methods employed were 
subject to quality control procedures. For biological validation, matched pair cell 
lines known to be positive and negative for integrin ανβ6 expression (see Table 2.1, 
section 2.1) were prepared in conjunction with target BrCa cell lines of interest for 
FCM, WB and IMF procedures.  
 
 
Technical validation was achieved by inclusion of isotype-matched negative 
control antibodies (see Table 2.8, section 2.2). Untreated controls were included 
where methodologically appropriate. Cross-reactivity and off-target binding of 





2.14      other considerations 
 
2.14.1   ethical considerations 
 
The established human cell lines utilised in this study (outlined in Tables 2.1 – 2.3) 
are not deemed “relevant material” under the terms of the Human Tissue Act (HTA) 
2004 and are not subject to statutory regulation therein (HTA 2004). Primary 
human breast tissue samples were obtained from the Breast Cancer Now Tissue 
Bank (R02/16), Barts Cancer Institute, QMUL, London. Informed consent for 
storage and research use was given (Ethics Code: 15/EE/0192).  No animal 
procedures were undertaken, obviating requirements for personal licensure under 
the terms of the Animals (Scientific Procedures) Act (ASPA) 1986 (ASPA 1986). 
 
 
2.14.2    health & safety considerations 
 
All national and local guidelines governing Health & Safety, Control of Substances 
Hazardous to Health (COSHH), Manual Handling, Risk Assessments (Equipment & 
Reagents) and use of personal protective equipment (PPE) were reviewed prior to, 
and strictly adhered to, whilst undertaking experimental work at both host 
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2.15 statistical analyses 
Graphical representation of data and their accompanying statistical analyses were 
undertaken using GraphPad Prism® 5.0b for MacOSX (GraphPad Software Inc.) 
unless otherwise stated. Details of statistical tests, where applied, and significance 
levels are given within the relevant methods sections and/or results figure legends.  
results part I
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to study the active subpopulation of integrin ανβ6 
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identifying the active conformer of integrin ανβ6  









3. introduction  
Bidirectional signalling is an irrefutable tenet of integrin functional biology. 
Regulatory modulation of integrin activation via recruitment of intracellular 
molecular regulators to the β–subunit cytoplasmic tail (“inside-out” signalling), or 
by exposure of the extracellular domain to extracellular regulators including 
growth factors, cognate ligands, presence of divalent cations or changes in ECM 
spatio-tensile forces (“outside-in” signalling) have been extensively characterised 
and validated as canonical integrin activation modalities (Humphries 1996, 
Shimaoka et al 2002, Shattil et al 2010, Campbell and Humphries 2011, Kim et al 
2011a, Kim et al 2011b, Pouwels et al 2012, Welf et al 2012, Bouvard et al 2013, 
Calderwood et al 2013).  
 
 
Since extracellular regulation of integrin activation mediated by the presence of 
divalent cations (Smith et al 1994, Mould et al 1995b, Tiwari et al 2011) or by 
cognate ligand engagement (Humphries 1996, Luo et al 2007) are such well-
established concepts, canonical “outside-in” integrin activation methods utilising 
divalent cations or cognate ligands were performed to evaluate the ability of 2 
novel monoclonal antibodies, clones 6.2E5 and 6.2G2 (Biogen Idec), to recognise 
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the integrin ανβ6 in its active conformation. Following their generation, these 
clones were first briefly described by Weinreb et al (2004) as non-blocking anti-
integrin ανβ6 antibodies, based on their inability to abrogate integrin ανβ6 ligand 
engagement in solid phase LAP-binding and cell adhesion assays.  
 
 
However, unpublished data previously generated in-house provided a rationale 
for considering the possibility that antibodies 6.2E5 and 6.2G2 may recognise 
active conformers of the integrin ανβ6. DiCara and Saha (2006) conducted 
preliminary experiments screening the binding affinities of antibodies 6.2E5 and 
6.2G2 in comparison with the well-characterised ligand-mimetic antibody 10D5 
(data not published). Flow cytometry results indicated that antibodies 6.2E5 and 
6.2G2 bound less cell surface integrin ανβ6 than antibody 10D5. To ascertain 
whether differences in antibody affinity were the cause of this observed difference 
in binding kinetics, ELISA screens were performed.  
 
 
Binding kinetics were evaluated against purified, secreted recombinant full-length 
integrin ανβ6 and a truncated variant lacking the transmembrane and cytoplasmic 
domains of the β6-subunit as first engineered in CHO cells by Weinacker et al 
(1994). The antibodies 6.2E5 and 6.2G2 bound both full length and truncated 
recombinant integrin ανβ6 by ELISA more abundantly than had been observed for 
native cell surface integrin ανβ6 in flow cytometry experiments. These findings 
excluded affinity as the reason for observed differences in binding kinetics (data 
not shown).  
 
 
Furthermore, since recombinant integrins immobilised in an ELISA assay are 
unable to modify conformation, they are deemed to mimic constitutively active 
integrins. Since the antibodies 6.2E5 and 6.2G2 bound immobilised recombinant 
integrin ανβ6 with greater efficacy than native cell surface integrin ανβ6, it was 
hypothesised that these antibodies may recognise an activation epitope. 
Therefore, further characterisation of the properties of antibodies 6.2E5 and 6.2G2 
was deemed prudent to fully evaluate their potential efficacy in future 
investigations into the biological and pathological functions of the integrin ανβ6.  
 
 
Validation of the utility of antibodies 6.2E5 and 6.2G2 to discriminate the active 
subpopulation of integrin ανβ6 would permit future research into the biological 
significance of integrin ανβ6 activation status using a monoclonal antibody-based 
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approach, as discussed by Byron et al (2009) and successfully employed by 
Arjonen et al (2012) to unpick the complexities of the distinct, differential 
trafficking kinetics of the active and inactive conformers of β1 integrin. Thus, it is 
hoped that the antibody clones 6.2E5 and 6.2G2 will prove valuable, novel tools to 
dissect the putative aetiological relevance of integrin ανβ6 activation status during 





          overview of key findings 
 
To summarise the key findings, results from canonical integrin activation 
experiments demonstrate that both antibodies 6.2E5 and 6.2G2 each recognise a 
cation-induced activation-associated epitope and a ligand-induced binding site 
(LIBS) on the integrin ανβ6 revealed respectively by extracellular activation methods 
including treatment with manganese ions (Mn2+) (Figures 3.1.1 and 3.1.2) or 
cognate ligands bearing an RGD motif (Figures 3.2.1 and 3.2.2).  
 
 
Comparison of these results with activation kinetics of a ligand-mimetic (clone 
10D5) and a non-ligand mimetic (clone 53A2) anti-integrin ανβ6 functional 
blocking antibody suggests the antibodies 6.2E5 and 6.2G2 are non-ligand 
mimetic and do not bind via the RGD cleft requisite for ligand binding (Figure 
3.2.3). Antibody binding kinetics were quantified by flow cytometry using the 
geometric mean fluorescence intensity (geoMean MFI) of surface-bound antibody 
as a read out for cell surface abundance of integrin ανβ6 sub-populations 
recognised by each anti- integrin ανβ6 specific antibody. 
 
 
Qualitative, observational immunofluorescence (IMF)-based characterisation of 
antibodies 6.2E5 and 6.2G2 confirmed their efficacy for in vitro studies to visualise 
the subcellular distribution of the active subpopulation of integrin ανβ6 in adherent 
cells (Figure 3.3.1), cells adhering to and spreading on integrin cognate ligands 
(Figure 3.3.2) and live cells (Figure 3.3.3).  
 
 
Finally the utility of these antibodies to distinguish the active fraction of integrin 
ανβ6 in clinical samples was evaluated by comparison of the tissue-distribution of 
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the 6.2E5 and 6.2G2 epitopes in both fresh frozen and FFPE integrin ανβ6–positive 
primary breast tissue samples from 5 patients kindly supplied by Barts Cancer 
Institute Breast Tissue Bank (Ethics code 15/EE/0192) (Figures 3.4.1 and 3.4.2).  
 
 
After initial IHC screening for integrin ανβ6 expression to identify suitable cases 
(Figure 3.4.1), subsequent IHC analysis of the immunopositive distribution of 
epitopes recognised by antibodies 6.2E5 and 6.2G2 in FFPE versus fresh frozen 
tissue samples (Figure 3.4.2) did not conclusively demonstrate their ability to 
recognise a unique integrin ανβ6 subpopulation definitively distinct from gross 






















chapter III:  
results part I 
 117 
 
3.1 antibodies 6.2E5 and 6.2G2 each recognise an activation-associated 
 epitope revealed by canonical extracellular activation of integrin 
 ανβ6 using divalent Mn2+ cations 
 
Both the species of divalent cation and the metal-ion binding site within the 
integrin that it occupies have been widely reported to modulate integrin activation 
and affinity for cognate ligand (Day et al 2002, Chen et al 2003, Shimaoka and 
Springer 2003). Several metal-ion binding motifs that modulate integrin 




In their review, Zhang and Chen (2012) comprehensively précised current 
understanding of integrin metal-ion binding motifs. A metal-ion-dependent 
adhesion site (MIDAS) has been described in the α-subunit β-propeller region. 
Specifically, this MIDAS is located in the αI domain of αI-bearing integrins, and in 
the βI domain of non-αI domain integrin species. In non-αI integrins, a βI domain 
metal ion cluster has been characterised. It comprises an interlinked linear array of 
a central MIDAS flanked by two distinct metal-ion binding motifs; the adjacent to 
MIDAS (ADMIDAS) and synergistic metal ion-binding site (SyMBS), the latter 
formerly being named ligand-associated metal-ion binding site (LIMBS).   
 
 
Both the αI and βI domain MIDAS critically regulate metal ion coordination and 
subsequent ligand engagement. Mutational abrogation of MIDAS metal-ion 
coordination abolished integrin ligand interactions in both αI and non-αI bearing 
integrin species, demonstrative of the essential role of MIDAS in integrin-ligand 
engagement (Michishita et al 1993, Kamata et al 1994, Valdramidou et al 2008). 
Regarding ligand engagement, current literature assigns a negative regulatory 
role to ADMIDAS, and a positive regulatory role to SyMBS (Chen et al 2003). 
Indeed, integrin activation is now deemed dependent upon SyMBS occupation by 
a metal ion (Valdramidou et al 2008, Zhu et al 2008). Thus integrin conformation, 
ligand-affinity and engagement may be modulated by the presence of divalent 
cation species and the metal ion-binding motif that they occupy. 
 
 
Within the α-subunit β-propeller region between blades 4 to 7, three to four Ca2+-
binding sites have been mapped in the integrin ανβ3 and αIIbβ3 integrin species. A 
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further Ca2+-binding site has been determined on the α-subunit genu, although its 
biological function remains unclear (Xie et al 2004).  
 
 
The inhibitory effect of Ca2+ binding has been found requisite for β subunit folding 
during biogenesis and assembly in the endoplasmic reticulum, remaining bound 
during trafficking to prevent premature activation of the nascent integrin receptor 
or untimely induction of intracellular integrin-mediated signalling en route to the 
plasma lemma (Tiwari et al 2011). Displacement of Ca2+ ions with Mg2+ or Mn2+ 
ions facilitates cognate ligand engagement and thus, cell surface integrin 
activation. Indeed, integrin ligand binding is dependent upon MIDAS occupation 
by Mg2+ or Mn2+ cations (Leitinger et al 2000, Chen et al 2003, San Sebastian et al 
2006, Valdramidou et al 2008, Tiwari et al 2011, Zhang and Chen 2012).  
 
 
Thus, it is thought that Ca2+ ions mediate an inhibitory effect upon integrin-ligand 
interactions, whilst Mg2+ and Mn2+ prime integrin ligand engagement and 
subsequent activation. Notably, Mn2+ is deemed to universally and potently 
support ligand binding, requiring the presence of Mn2+ ions in only the low μM 
range to potentiate integrin-mediated adhesive phenomena (Smith et al 1994). 
Cation sequestration by means of a chelating agent such as EDTA ablates integrin-
ligand binding, demonstrative of divalent cations as critical intrinsic and extrinsic 
regulators of integrin activation, function and associated downstream signalling 
induction (Dransfield et al 1992, Shimaoka et al 2002, Zhang and Chen 2012).  
 
 
Given the established biological relevance and significance of Ca2+, Mg2+ and 
Mn2+ cations as canonical modulators of integrin activation, it was deemed 
appropriate to utilise these cationic species specifically to evaluate the ability of 
antibodies 6.2E5 (Figure 3.1.1) and 6.2G2 (Figure 3.1.2) to recognise the integrin 
ανβ6 in its active conformation. Treatment with 1 mM divalent cations (Ca2+, Mg2+ 
or Mn2+) or a chelating ion-free buffer (TBS-20mM EDTA) demonstrated that 
although binding of both antibodies 6.2E5 (Figure 3.1.1C) and 6.2G2 (Figure 
3.1.2C) to their respective cognate epitopes is cation-independent, their 
respective binding affinities are significantly increased in the presence of 
physiomimetic concentrations of cations across all treatment groups compared to 
a chelating ion-free buffer (Kruskall-Wallis test with Dunn’s multiple comparison 
post-hoc test; 6.2E5: p<0.05, p=0.0064; 6.2G2: p<0.001, p=0.0003). 
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Concordant with literature reporting Mn2+-ions as a potent, universal integrin 
activation modality (Shimaoka et al 2002), a significant increase in antibody 
binding was observed in the presence of 1 mM Mn2+-ions compared with TBS for 
both 6.2E5 (Figure 3.1.1C) and 6.2G2 (Figure 3.1.2C) (Kruskall-Wallis test with 
Dunn’s multiple comparison post-hoc test, adjusted p values; 6.2E5: p<0.05, 
p=0.0194; 6.2G2: p<0.05, p=0.0194).  
 
 
The biphasic nature of Ca2+-ion–mediated allosteric regulation of integrin 
conformation and ligand affinity has been widely reviewed (Leitinger et al 2000, 
San Sebastian et al 2006, Zhang and Chen 2012). Interestingly, the presence of 
Ca2+-ions did not inhibit binding of antibody 6.2E5 to its cognate epitope in 
comparison with Mg2+-ions. Conversely, the epitope recognised by antibody 
6.2G2 proved sensitive to the reported inhibitory effects of Ca2+-ions, again in 
comparison with Mg2+-ions (Kruskall-Wallis test with Dunn’s multiple comparison 




Antibody binding kinetics for clone 6.2E5 (Figure 3.1.1D) and clone 6.2G2 (Figure 
3.1.2D) performed in the presence of assay buffer alone confirmed that intrinsic 
cations present within the assay matrix did not markedly alter binding affinity of 
these antibodies over a 30 min timescale. It was therefore deduced that binding of 
antibodies 6.2E5 and 6.2G2 to their cognate epitopes did not itself induce integrin 
ανβ6 activation and thus could be eliminated as a confounding factor for future 
activation studies utilising these antibodies.  
 
 
Furthermore, titration of antibody 6.2E5 (Figures 3.1.1E – G) binding across a 
range of Mn2+-ion concentrations elicited canonical integrin activation kinetics 
yielding a significant correlation between levels of surface-bound 6.2E5 
(represented by detected geometric MFI, AU) and Mn2+-ion concentration ranging 
from (Figure 3.1.1F) 0 to 1 mM Mn2+ (Spearman’s correlation r=0.782, p<0.01, 
p=0.0053) and (Figure 3.1.1G) 0 to 200 μM Mn2+ (Spearman’s correlation r=0.943, 
p<0.01, p=0.0083).   
 
 
Similarly, titration of antibody 6.2G2 binding over a range of Mn2+-ion 
concentrations exhibited archetypal integrin activation kinetics (Figure 3.1.2E – G), 
comparable to the activation profiles discerned using antibody 6.2E5 (Figure 
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3.1.1E – G). In both the presence of 0 to 1 mM Mn2+ (Figure 3.1.2F) and 0 to 200 
μM Mn2+ (Figure 3.1.2G), a significant correlation between surface-bound 6.2G2 
and Mn2+ concentration was observed (Spearman’s rank correlation; 0 to 1 mM: 
r=0.927, p<0.001, p=0.0002; 0 to 200 μM: r=1, p<0.002, p=0.0014).  Collectively, 
the findings from divalent cation-induced activation studies (Figures 3.1.1 and 
3.1.2) confirm that both clones 6.2E5 and 6.2G2 each recognise an activation-
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The antibody 6.2E5 recognises an activation-associated epitope located on integrin ανβ6 that is revealed by treatment with divalent manganese (Mn2+) cations 
Abbreviations: ADMIDAS – adjacent to MIDAS; AU – arbitrary units; concn – concentration; LIMBS – ligand-associated metal-binding site; MIDAS – metal-ion dependent adhesion 
site; MFI – mean fluorescence intensity; TBS – Tris-buffered saline. 
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Figure 3.1.1 
The antibody 6.2E5 recognises an activation-associated epitope located on integrin ανβ6 
that is revealed by treatment with divalent manganese (Mn2+) cations 
 
(3.1.1 A) Divalent cation regulation of integrin conformation, activation status and signalling capacity 
is well established. Thus, canonical divalent cation activation experiments using the known integrin-
regulatory species of divalent cations Ca2+, Mg2+ & Mn2+, were performed and compared with a 
chelating ion-free buffer (Tris-buffered saline/20 mM EDTA – TBS) to evaluate the ability of the 
antibody 6.2E5 to recognise the active conformer of integrin ανβ6. (3.1.1 B) Antibody 6.2E5 was 
titrated at doubling dilutions ranging from 10 to 0 μg ml-1 to determine a suitable concentration for 
labelling surface integrin ανβ6 on live DX3β6 cells to permit detection by flow cytometry (n=2). A 
concentration of 5 μg ml-1 was deemed both suitably economical and efficient for surface labelling 
and flow cytometric detection of integrin ανβ6 using antibody 6.2E5. (3.1.1 C) Canonical integrin 
activation in the presence of 1 mM divalent cations (Ca2+, Mg2+, Mn2+) or a chelating ion free buffer 
supplemented with 20 mM EDTA (TBS) was performed on the DX3β6 cell line (n=3). Flow cytometric 
analysis of treated cells subsequently labelled with 6.2E5 (Biogen Idec, 5 μg ml-1) revealed a 
statistically significant difference in detected mean fluorescence intensity (MFI) across all treatment 
groups (Kruskall-Wallis test with Dunn’s multiple comparison test, p=0.0064) and a statistically 
significant increase in 6.2E5 binding post treatment with 1 mM Mn2+ compared to TBS (Dunn’s 
multiple comparison test, p=0.0194). (3.1.1 D) Binding kinetics of 6.2E5 in the presence of 
DMEM/0.1/0.1 flow cytometry buffer alone was evaluated briefly to determine effects of intrinsic 
cations within this assay buffer that may confound activation studies, but no observable change was 
noted (n=2). (3.1.1 E - G) Titration of 6.2E5 binding over a range of Mn2+-ion concentrations, again 
using the DX3β6 cell line, demonstrated classical activation kinetics (3.1.1 E), yielding a significant 
positive correlation between concentration of Mn2+ ions and MFI from (3.1.1 F) 0 to 1 mM 
(Spearman’s correlation r=0.782, p=0.0053, n=3) and (3.1.1 G) 0 to 200 μM (Spearman’s correlation 
r=0.943, p=0.0083, n=3). Graphs show mean with error bars for s.e.m for triplicate experiments (3.1.1 
C, E, F & G). All other graphs show individual replicates with a line transecting the mean average 
(3.1.1 B & D). All data were acquired on live cells only by flow cytometry acquisition (BD 
FACSCalibur™, BD Biosciences) in the presence of a cell viability indicator (propidium iodide, P4170, 
Sigma Aldrich, 5 μg ml-1). Following normalisation against isotype matched control antibodies, 
geometric-MFI values were obtained by analysis in BD CellQuestPro™ software (BD Biosciences). 
Statistical analyses were performed using GraphPad Prism® 5.0b for MacOSX (Graphpad Software 
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Treatment with divalent manganese (Mn2+) cations reveals an activation-associated epitope located on integrin ανβ6 that is recognised by antibody 6.2G2 
Abbreviations: ADMIDAS – adjacent to MIDAS; AU – arbitrary units; concn – concentration; LIMBS – ligand-associated metal-binding site; MIDAS – metal-ion dependent adhesion 
site; MFI – mean fluorescence intensity; TBS – Tris-buffered saline. 
chapter III:  
results part I 
 124 
Figure 3.1.2 
Treatment with divalent manganese (Mn2+) cations reveals an activation-associated epitope 
located on integrin ανβ6 that is recognised by antibody 6.2G2 
 
(3.1.2 A) Divalent cation regulation of integrin conformation, activation status and signalling capacity 
is well established. Thus, canonical divalent cation activation experiments using the known integrin-
regulatory species of divalent cations Ca2+, Mg2+ & Mn2+, were performed and compared with a 
chelating ion-free buffer (Tris-buffered saline/20 mM EDTA – TBS) to evaluate the ability of the 
antibody 6.2G2 to recognise the active conformer of integrin ανβ6. (3.1.2 B) Antibody 6.2G2 was 
titrated at doubling dilutions ranging from 10 to 0 μg ml-1 to determine a suitable concentration for 
labelling surface integrin ανβ6 on live DX3β6 cells to permit detection by flow cytometry (n=2). A 
concentration of 5 μg ml-1 was deemed both suitably economical and efficient for surface labelling 
and flow cytometric detection of integrin ανβ6 using antibody 6.2G2. (3.1.2 C) DX3β6 cells were 
treated with either a chelating ion free buffer supplemented with 20 mM EDTA (TBS) or 1 mM divalent 
cations (Ca2+, Mg2+, Mn2+) to induce integrin activation (n=3). Flow cytometric analysis of cells 
subsequently labelled with 6.2G2 (Biogen Idec, 5 μg ml-1) revealed a statistically significant difference 
in detected mean fluorescence intensity (MFI) across all treatment groups (Kruskall-Wallis test with 
Dunn’s multiple comparison test, p=0.0003) and a statistically significant increase in 6.2G2 binding 
post treatment with 1 mM Mn2+ compared to TBS (Kruskall-Wallis test with Dunn’s multiple 
comparison test, p=0.0194). (3.1.2 D) Binding kinetics of 6.2G2 in the presence of DMEM/0.1/0.1 flow 
cytometry buffer alone was evaluated briefly to determine effects of intrinsic cations within this assay 
buffer that may confound activation studies, but no observable change was noted (n=2). (3.1.2 E - G) 
Titration of 6.2G2 binding over a range of Mn2+-ion concentrations, again using the DX3β6 cell line, 
demonstrated classical activation kinetics (3.1.2 E), yielding a significant positive correlation between 
concentration of Mn2+ ions and MFI from (3.1.2 F) 0 to 1 mM (Spearman’s correlation r=0.927, 
p=0.0002, n=3) and (3.1.2 G) 0 to 200 μM (Spearman’s correlation r=1, p=0.0014, n=3). Graphs show 
mean with error bars for s.e.m for triplicate experiments (3.1.2 C, E, F & G). All other graphs show 
individual replicates with a line transecting the mean average (3.1.2 B & D). All data were acquired on 
live cells only by flow cytometry acquisition (BD FACSCalibur™, BD Biosciences) in the presence of a 
cell viability indicator (propidium iodide, P4170, Sigma Aldrich, 5 μg ml-1). Following normalisation 
against isotype matched control antibodies, geometric-MFI values were obtained by analysis in BD 
CellQuestPro™ software (BD Biosciences). Statistical analyses were performed using GraphPad 
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3.2 antibodies 6.2E5 and 6.2G2 are non-ligand mimetic and each 
 recognise a LIBS revealed upon engagement of the integrin ανβ6 
 with its cognate ligands A20FMDV2 or LAP  
 
Results from ligand-induced activation experiments qualitatively indicate that 
antibodies 6.2E5 (Figure 3.2.1) and 6.2G2 (Figure 3.2.2) each recognise a LIBS. In 
the presence of integrin ανβ6–cognate ligands A20FMDV2 or LAP, the antibodies 
6.2E5 (Figure 3.2.1B and D) and 6.2G2 (Figure 3.2.2B and D) bound with an 
observable increasing affinity to an epitope revealed upon RGD-ligand-induced 
integrin ανβ6 activation. This suggests that the respective epitopes for 6.2E5 and 
6.2G2 are each ligand-inducible. However, only a significant positive correlation 
between antibody binding and ligand-engagement was yielded for clone 6.2G2 
following A20FMDV2-engagement (Spearman’s correlation, 6.2E5: r=0.8, p>0.05, 
p=0.1667; 6.2G2: r=1, p<0.05, p=0.0417).  
 
 
Concordant with literary evidence that integrin-mediated binding of their cognate 
ligands is cation-dependent; the presence of cations within the assay matrix was 
found requisite for integrin ανβ6 engagement of the synthetic peptide and non-
physiological ligand A20FMDV2 (Figures 3.2.1C and 3.2.2C). Furthermore, in 
these experiments where cation sequestration using a chelating ion-free buffer 
ablated integrin ανβ6-A20FMDV2 interaction, binding kinetics of both 6.2E5 and 
6.2G2 were unaltered in the absence of ligand-engagement.  
 
 
This lack of an observable increase in 6.2E5 or 6.2G2 antibody binding in the 
absence of ligand-engagement adds credence to the conclusion that these 
antibodies each recognise a LIBS. Furthermore, the ability of antibodies 6.2E5 and 
6.2G2 to bind integrin ανβ6 even in its ligand-free conformation fits with Humphries 
(2004) explanation that epitopes comprising LIBS are present even in the absence 
of cognate ligand.  
 
 
However, it is only when the integrin adopts a primed or ligand-engaged 
conformation that the LIBS is revealed permitting favourable steric interaction with 
its cognate anti-LIBS monoclonal antibody. As acknowledged by Humphries (2004) 
the term LIBS may not be an entirely accurate description as expression of the LIBS 
is not induced upon ligand engagement as it is already present within the integrin 
amino acid sequence. Rather, it is the ability of an anti-LIBS antibody to detect an 
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increase in the abundance of its cognate epitope residing within the LIBS that is 
revealed due to the favourable sterics induced once the integrin is ligand-engaged. 
Thus, since adoption of a primed or ligand-engaged conformation favours revelation 
and detection of LIBS, the anti-LIBS class of monoclonal antibodies may be used to 
demonstrate integrin activation status. 
 
 
Divalent cation-mediated and ligand-induced activation studies were also 
performed concomitantly using the well characterised, commercially available 
integrin ανβ6 function blocking antibody clones 10D5 (ligand mimetic) and 53A2 
(non-ligand mimetic) for technical validation of experiments (Figure 3.2.3), and to 
serve as comparators for the kinetics observed for clones 6.2E5 and 6.2G2. 
 
 
Activation experiments performed in the presence of 1 mM divalent cations (Ca2+, 
Mg2+ or Mn2+) or a chelating ion-free buffer (TBS/20 mM EDTA) demonstrated that 
the ligand mimetic, integrin ανβ6 heterodimer specific antibody 10D5 did not bind 
in the absence of divalent cations (Figure 3.2.3A). Concordant with literature, 
cation modulation of integrin ανβ6 ligand (or ligand-mimetic antibody) binding 
affinity was also observed for clone 10D5. Notably, Mn2+-ions yielded a significant 
increase in 10D5 binding (Kruskall Wallis with Dunn’s multiple comparison test, 
p<0.05, p=0.0372) compared to ion-free buffer.  
 
 
As anticipated, sequestration of cations in a chelating ion-free buffer ablated the 
ability of antibody 10D5 to bind integrin ανβ6. In contrast, binding of the function 
blocking antibody 53A2 was not significantly altered in the presence or absence of 
divalent cations (Kruskall Wallis with Dunn’s multiple comparison test, p>0.05, 
p=0.4747) (Figure 3.1.3B) inferring expression of its cognate epitope is not 
determined by integrin ανβ6 conformation nor activation status.  
 
 
The antibody 10D5 is known to be ligand-mimetic, binding via the RGD-
recognising cleft of the integrin ανβ6 heterodimer (Lawrence et al 2015). As 
anticipated, canonical competitive inhibition kinetics were generated for 10D5 
binding in experiments where ανβ6–positive cells were pre-treated with known 
integrin ανβ6 cognate ligands A20FMDV2 or LAP (Figure 3.2.3C and D 
respectively). A significant negative correlation between abundance of surface-
bound ligand and 10D5 binding was discerned for both A20FMDV2 (Figure 
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3.2.3C; Spearman’s correlation r=-1, p<0.05, p=0.0417) and LAP (Figure 3.2.3D; 
Spearman’s correlation r=-1, p<0.01, p=0.0083).  
 
 
Given the cation-sensitivity of clone 10D5, binding kinetics in the presence of 
intrinsic cations within the assay buffer was briefly evaluated (Figure 3.2.3E). No 
observable increase in 10D5 binding was observed, thus eliminating cations 
inherent within the assay matrix as a potential confounding factor in the evaluation 
of antibody binding kinetics.  
 
 
As previously noted, antibody-binding kinetics elicited post-integrin ανβ6 ligand 
occupancy for clone 6.2E5 (Figure 3.2.1B and D) and clone 6.2G2 (Figure 3.2.2B 
and D) show an observable positive correlation between ligand-engagement and 
surface antibody binding. This contrasts with the corresponding classic inhibition 
profiles obtained for the ligand-mimetic antibody clone 10D5 (Figure 3.2.3C and 
D). Therefore, it may be concluded that clones 6.2E5 and 6.2G2 not only each 
recognise a LIBS, but are also non-ligand mimetic antibodies. 
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The antibody 6.2E5 recognises a LIBS on integrin ανβ6 that is revealed upon engagement of the cognate ligands A20FMDV2 and LAP  
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Figure 3.2.1 
The antibody 6.2E5 recognises a LIBS on integrin ανβ6 that is revealed upon engagement 
of the cognate ligands A20FMDV2 and LAP  
 
(3.2.1 A) It is believed that like other integrin moieties, upon engagement of an RGD-bearing cognate 
ligand, the integrin ανβ6 undergoes ligand-induced activation, adopting a signalling replete, fully 
active conformation permitting induction of downstream signalling events. Two well established 
integrin ανβ6 cognate ligands (the biotin-tagged 20mer synthetic peptide A20FMDV2 and a human 
IgG (Fc’)-tagged human recombinant LAP) were therefore used to perform ligand-induced activation 
experiments on the known ανβ6–positive VB6 cell line to evaluate the ability of antibody 6.2E5 to 
recognise the ligand-induced active conformation of integrin ανβ6 (3.2.1 B – E). Ligand-engagement 
was confirmed by flow cytometric detection of their respective tags using either an anti-biotin 
antibody (ab1227, AbCam, 10 μg ml-1) or an anti-human IgG (Fc’) antibody (ab113636, AbCam, 10 μg 
ml-1). Although binding of 6.2E5 (Biogen Idec, 5 μg ml-1) observably increased in the presence of 
(3.2.1 B) 100 nM biotin-tagged A20FMDV2 (n=3) and (3.2.1 D) 0 – 10 μg ml-1 Fc-tagged LAP (n=3), 
neither ligand elicited a statistically significant difference in detected geometric MFI (AU) 
representative of surface-bound 6.2E5 (Spearman’s correlation; A20FMDV2: r=0.8, p>0.1, p=0.1667 
and LAP-Fc: r=0.6, p>0.1, p=0.1750). Binding kinetics of 6.2E5 in the presence of 100 nM A20FMDV2 
in a chelating ion free buffer (TBS supplemented with 20 mM EDTA) was evaluated briefly (n=2) (3.2.1 
C) and confirmed that the observed increase in 6.2E5 binding was attributable to ligand binding and 
not the presence of intrinsic cations within the assay buffer used in (3.2.1 B). Activation timecourse 
experiments in the presence of 2 μg ml-1 LAP-Fc (3.2.1 E) elicited an increase in 6.2E5 binding 
reaching maxima at 15 min (n=2). Graphs show mean with error bars for s.d for triplicate experiments 
(3.2.1 B & D). All other graphs show individual replicates with a line transecting the mean average 
(3.2.1 C & E). All data were acquired on live cells only by flow cytometry acquisition (BD 
FACSCalibur™, BD Biosciences) in the presence of a cell viability indicator (propidium iodide, P4170, 
Sigma Aldrich, 5 μg ml-1). Following normalisation against isotype matched control antibodies, 
geometric-MFI values were obtained by analysis in BD CellQuestPro™ software (BD Biosciences). 
Statistical analyses were performed using GraphPad Prism® 5.0b for MacOSX (Graphpad Software 
Inc., CA, USA). 
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Figure 3.2.2 
Engagement of the cognate ligand A20FMDV2 or LAP reveals a LIBS located on the 
integrin ανβ6 that is recognised by antibody 6.2G2 
 
(3.2.2 A) Following cognate ligand-engagement, the integrin ανβ6 undergoes ligand-induced 
activation, adopting a signalling replete, fully active conformation permitting induction of downstream 
signalling events. Two well established integrin ανβ6 cognate ligands (the 20mer synthetic peptide 
A20FMDV2 bearing a biotin tag and human recombinant LAP tagged with a human IgG (Fc’) 
fragment) were therefore used to perform ligand-induced activation experiments on the known ανβ6–
positive VB6 cell line to evaluate the ability of antibody 6.2G2 to recognise the ligand-induced active 
conformation of integrin ανβ6  (3.2.2 B – E). Ligand-engagement was confirmed by flow cytometric 
detection of their respective tags using either an anti-biotin antibody (ab1227, AbCam, 10 μg ml-1) or 
an anti-human IgG (Fc’) antibody (ab113636, AbCam, 10 μg ml-1). (3.2.2 B) Binding of 6.2G2 (Biogen 
Idec, 5 μg ml-1) significantly increased in the presence of 100 nM biotin-tagged A20FMDV2 (n=3) 
(Spearman’s correlation r=1, p<0.05 p=0.0417). (3.2.2 C) Binding kinetics of 6.2G2 in the presence of 
100 nM A20FMDV2 in a chelating ion free buffer (TBS supplemented with 20 mM EDTA) was 
evaluated briefly (n=2). In the absence of divalent cations, binding of antibody 6.2G2 appeared to 
decline over the 30 min timecourse. However the significance of this observable decrease could not 
be statistically evaluated as only duplicate experiments were performed. Furthermore, these 
experiments confirmed that the observed increase in 6.2G2 binding was attributable to ligand binding 
and not the presence of intrinsic cations within the assay buffer used in (3.2.2 B) nor attributable to the 
process of 6.2G2 binding its cognate epitope in the manner of an integrin activating antibody. (3.2.2 
D) Titration of antibody 6.2G2 binding against concentrations of LAP-Fc ranging from 0 to 10 μg ml-1 
yielded an observable, but not significant, increase in 6.2G2 binding (Spearman’s correlation r=0.7, 
p>0.1, p=0.1167, n=3). (3.2.2 E) Activation timecourse experiments in the presence of 2 μg ml-1 LAP-
Fc elicited an observable increase in 6.2G2 binding reaching maxima at 15 min (n=2). Graphs show 
mean with error bars for s.d for triplicate experiments (3.2.2 B & D). All other graphs show individual 
replicates with a line transecting the mean average (3.2.2 C & E). All data were acquired on live cells 
only by flow cytometry acquisition (BD FACSCalibur™, BD Biosciences) in the presence of a cell 
viability indicator (propidium iodide, P4170, Sigma Aldrich, 5 μg ml-1). Following normalisation against 
isotype matched control antibodies, geometric-MFI values were obtained by analysis in BD 
CellQuestPro™ software (BD Biosciences). Statistical analyses were performed using GraphPad 
Prism® 5.0b for MacOSX (Graphpad Software Inc., CA, USA). 
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Figure 3.2.3  
The ligand-mimetic (clone 10D5) and non-ligand mimetic (clone 53A2) integrin ανβ6 
function blocking antibodies evaluated in tandem with antibodies 6.2E5 and 6.2G2 during 
integrin activation experiments suggest that 6.2E5 and 6.2G2 are not ligand-mimetic 
 
As previously described, DX3β6 cells were treated with either a chelating ion free buffer 
supplemented with 20 mM EDTA (TBS) or 1 mM divalent cations (Ca2+, Mg2+ or Mn2+) to induce 
integrin activation (n=3). Flow cytometric analysis of cells subsequently labelled with either (3.2.3 A) 
10D5 (MAB2077Z, Merck Millipore, 10 μg ml-1) or (3.2.3 B) 53A2 (CR-UK, 10 μg ml-1) revealed ligand-
mimetic antibody 10D5 binding is cation-dependent but binding of non-ligand mimetic antibody 
53A2 is cation-independent. Classic competitive inhibition kinetics were observed for ligand-mimetic 
10D5 binding on VB6 cells pre-treated with integrin cognate ligands biotin-tagged-A20FMDV2 (100 
nM) (3.2.3 C) or human IgG (Fc’)-tagged-LAP (0 - 10 μg ml-1) (3.2.3 D) (both n=3), eliciting a 
significant negative correlation between surface-bound and 10D5 binding capacity (Spearman’s 
correlation; A20FMDV2: r=-1, p<0.05, p=0.0417; LAP-Fc: r=-1, p<0.01, p=0.083). Bound ligand was 
detected by means of their respective tags using either an anti-biotin antibody (ab1227, AbCam, 10 
μg ml-1) or an anti-human IgG (Fc’) antibody (ab113636, AbCam, 10 μg ml-1). (3.2.3 E) Binding kinetics 
of antibody 10D5 in the presence of assay buffer alone was briefly evaluated and confirmed that 
intrinsic cations present within the assay matrix used for ligand-induced activation studies did alter 
cation-sensitive 10D5 binding kinetics (n=2). All graphs show mean and s.d where n=3. For n=2, 
individual replicates with a line transecting the mean average is shown. All flow cytometric data were 
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3.3 antibodies 6.2E5 and 6.2G2 may be used to visually discriminate 
 the subcellular localisation of the active population of the 
 integrin ανβ6 by immunofluorescence microscopy 
 
The spatiotemporal properties of cognate epitopes each recognised by antibodies 
6.2E5 and 6.2G2 were evaluated by permeabilised immunofluorescence 
microscopy in a 2D-environment to determine their subcellular localisation (Figure 
3.3.1), ligand-engaged distribution (Figure 3.3.2) and ability to trace the integrin 
ανβ6 active subpopulation in live cells using these antibodies (Figure 3.3.2). 
 
 
In untreated adherent cells unexposed to integrin ανβ6–specific cognate ligands, 
immunopositivity for antibody 6.2E5 was observed at the cell periphery and in 
filopodial structures but was excluded from cell-cell contacts (Figure 3.3.1A). 
Interestingly, immunopositivity for antibody 6.2G2 under the same conditions was 
also observed at the peripheral edges of spreading cells and was also absent from 
cell-cell junctions. However, in contrast with 6.2E5, antibody 6.2G2 was not 
detected in filopodial structures (Figure 3.3.1B).   
 
 
Given that both antibodies 6.2E5 and 6.2G2 were each found to recognise a LIBS 
by flow cytometry (Figure 3.2), their respective subcellular distributions in a 2D-
environment were evaluated in both the presence and absence of ligand (Figure 
3.3). The subcellular distributions of antibody 6.2E5 in cells spreading in the 
absence of ligand (nil) or in the presence of an integrin ανβ6–specific ligand (LAP) 
or a non-integrin ανβ6–binding ligand (col I) were compared (Figure 3.3.2A). The 
antibody 6.2E5 was excluded from cell-cell junctions. Marked vesicular 
accumulations of 6.2E5 immunopositivity were observed in cells spreading on the 
integrin ανβ6 cognate ligand LAP. This vesicular staining pattern was not observed 
on collagen type I (col I), a ligand that does not engage integrin ανβ6, nor under 
ligand-free conditions (nil). This may suggest that in the presence of LAP, the 
integrin ανβ6 is subject to LAP ligand-induced regulatory internalisation and 
trafficking events.  
 
 
Under ligand-free conditions (nil), the antibody 6.2E5 appears to localise at actin 
fibre-rich protusions at the edges of spreading cells. This is concordant with 
previous observations that 6.2E5 was observed in filopodial structures in cells 
adhering to untreated non-derivatised glass coverslips (Figure 3.3.1A). 
chapter III:  
results part I 
 134 
Interestingly, in the presence of either LAP or collagen type I, the antibody 6.2E5 
was absent from such actin-rich protusions or filopodial structures.  
 
 
In the case of LAP-ligand binding, the role of integrin ανβ6–mediated LAP-
engagement is predominantly one of mechano-tensile “traction”-induced TGF-β1-
activation, as opposed to stable ECM-adhesion formation and may account for its 
exclusion from filopodial structures (Munger and Sheppard 2011). With regard to 
collagen type I, the integrin ανβ6 is not known to mediate adhesion to collagens. 
Instead, binding to ECM collagens is dependent on integrin β1 species, notably 
α1β1 and α2β1 (Jokinen et al 2004). Since adhesion to collagen type I is an integrin 
ανβ6–independent process, it is logical that in cells spreading on collagen type I, 
no 6.2E5 immunopositivity was observed either at the peripheral edges of cells, in 
filopodial structures nor in vesicular accumulations given that ligand-induced 
activation of integrin ανβ6 would not be expected. 
 
 
The subcellular distribution of antibody 6.2G2 in cells spreading either in the 
absence of ligand (nil), or in the presence of the RGD motif-bearing ECM ligand 
fibronectin (Fn), were reviewed by permeabilised immunofluorescence (Figure 
3.3.2B). As observed previously in Figure 3.3.1B, antibody 6.2G2 was again 
excluded from cell-cell junctions and appeared to localise at the periphery of cells 
adhering in the absence of ligand (nil). Upon fibronectin engagement (Fn), marked 
and abundant immunopositivity for antibody 6.2G2 was observed at the tips of 
actin-rich protusions of the plasma lemma. This contrasted with an absence of 
6.2G2 immunopositivity in filopodial structures under ligand-free conditions. Thus, 




Surface distribution of the 6.2E5 cognate epitope in unstimulated live cells 
labelled with was briefly evaluated by non-permeabilised immunofluorescence 
(Figure 3.3.2C). The antibody 6.2E5 was seen to localise in clusters at the cell 
periphery in what appear to be membrane ruffles. This phenomenon of integrin 
clustering is associated with activated, high-affinity integrin conformers (Cluzel et 
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Collectively, these observations from immunofluorescence studies infer that the 
antibodies 6.2E5 and 6.2G2 each recognise a distinct subpopulation of integrin 
ανβ6 that is involved in dynamic cellular processes associated with integrin 
activation including cell spreading, ligand-engagement, filopodia formation and in 
the case of antibody 6.2E5, integrin ανβ6 receptor clustering.  
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Figure 3.3.1 (A)  
The antibody 6.2E5 localises at the peripheral edges of cells spreading in 2D and is 
observed at the distal tips of filopodial projections, but is excluded from cell-cell junctions 
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Figure 3.3.1 (B)  
The antibody 6.2G2 localises at the peripheral edges of cells spreading in 2D but is absent 
from the distal tips of filopodial projections, and is excluded from cell-cell junctions where 
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Figure 3.3.1  
The antibodies 6.2E5 and 6.2G2 may be used to discriminate and visualise the subcellular 
localisations of the active subpopulation of the integrin ανβ6 by immunofluorescence 
microscopy 
 
(3.3.1 A & B) The utility of antibodies 6.2E5 (3.3.1 A) and 6.2G2 (3.3.1 B) to study the subcellular 
distribution of the active subpopulation of ανβ6 by immunofluorescence methods was evaluated in the 
VB6 cell line. Cells were seeded on non-derivatised 13 mm glass coverslips (2 x 104 cells per 
coverslip) and left to adhere overnight in complete media under standard culture conditions prior to 
fixation and permeabilisation in cytoskeletal fixative buffer supplemented with 4% (w/v) formaldehyde. 
Total integrin ανβ6 was demonstrated with antibody 53A2 (CR-UK, 10 μg ml-1) whilst the active 
subpopulations of integrin ανβ6 were labelled with either antibody 6.2E5 or 6.2G2 (both Biogen Idec, 
5 μg ml-1). Nuclei were labelled with DAPI (Invitrogen, 1 μg ml-1). (3.3.1 A) In contrast with 53A2, an 
antibody established to recognise the mature fully glycosylated form of ανβ6 which was prevalent at 
cell-cell junctions (red arrows), the antibody 6.2E5 localised at the leading edge of spreading cells and 
was observed at the tips of filopodia (green arrows) where 53A2 was not detected by permeabilised 
immunofluorescence. Some co-localisation with 53A2 was observed (yellow arrows). The antibody 
6.2E5 appeared to be excluded from cell-cell junctions where 53A2 predominated. (3.3.1 B) As 
observed for antibody 6.2E5, the antibody 6.2G2 was also excluded from cell-cell junctions where 
antibody 53A2 predominated (red arrows). The antibody 6.2G2 localised at leading edges of 
spreading cells (green arrows), but unlike antibody 6.2E5 was not observed in filopodia and did not 
appear to co-localise with antibody 53A2. Images were acquired by confocal microscopy using the 
ZEISS LSM710 equipped with ZEISS Zen image analysis software (all Carl Zeiss AG, DE). Images were 
prepared for presentation using Image J (National Institutes of Health) and Adobe® Photoshop© CS6, 
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Figure 3.3.2 (A)  
The antibody 6.2E5 reveals the subcellular distribution of the active integrin ανβ6 
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Figure 3.3.2 (B)  
The antibody 6.2G2 reveals the subcellular distribution of the active integrin ανβ6 
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Figure 3.3.2 (C)  
The antibody 6.2E5 reveals the cell surface distribution of the active integrin ανβ6 localising 
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Figure 3.3.2  
The antibodies 6.2E5 and 6.2G2 reveal the subcellular distribution of the active integrin 
ανβ6 subpopulation during ligand engagement 
 
(3.3.2 A & B) The utility of antibodies 6.2E5 (3.3.2 A) and 6.2G2 (3.3.2 B) to study the subcellular 
distribution of the active subpopulation of ligand-engaged integrin ανβ6 was evaluated in the VB6 cell 
line by permeabilised immunofluorescence. In addition, the ability of antibody 6.2E5 to characterise 
the cell-surface distribution of active integrin ανβ6 was briefly evaluated (3.3.2 C), again in the VB6 cell 
line, by non-permeabilised immunofluorescence. (3.3.2 A & B) Non-derivatised 13 mm glass 
coverslips were coated overnight at 4°C with either; serum-free media (nil), human recombinant LAP 
(LAP, L3408, Sigma Aldrich, 0.5 μg ml-1), human recombinant fibronectin (Fn, F2006, Sigma Aldrich, 
10 μg ml-1) or murine collagen I (col I, 354236, Corning, 10 μg ml-1). Cells were then seeded (2 x 104 
cells per coverslip) and left to adhere for 2 hours in serum-free media under standard culture 
conditions prior to fixation and permeabilisation in cytoskeletal fixative. The integrin ανβ6 was labelled 
with either antibody 6.2E5 or 6.2G2 (both Biogen Idec, 5 μg ml-1), cytoskeletal actin was demonstrated 
with tetramethylrhodamine-phalloidin (R415, Molecular Probes, 50 μg ml-1) and nuclei were stained 
with DAPI (Invitrogen, 1 μg ml-1). (3.3.2 A) Marked vesicular clustering of 6.2E5 immunopositivity was 
observed in VB6 cells spreading on the integrin ανβ6 cognate ligand LAP (LAP), distinct from the 
peripheral pattern of 6.2E5 immunopositivity observed on untreated (nil) coverslips (white and green 
arrows). In the absence of cognate ligand, 6.2E5 appears to localise at the tips of actin rich projections 
at the cell periphery, which may be filopodia or possibly invadopodia, given the propensity of the VB6 
cell line to form the latter. In cells spreading on the non-ανβ6 cognate ligand collagen I (col I), no 
distinct pattern of 6.2E5 immunopositivity was observed. Instead, 6.2E5 positivity was diffusely 
cytoplasmic, proximal to cell nuceli. In contrast with LAP, no vesicular accumulations nor localisation at 
actin fibre tips were discernible for 6.2E5 in the presence of collagen I.  (3.3.2 B) In VB6 cells 
spreading on fibronectin (Fn), 6.2G2 immunopositivity (white and green arrows) was predominantly 
localised at actin fibre tips (filopodia) protruding at the leading edges of spreading cells. Some 
vesicular accumulations of 6.2G2 immunopositivity were also observed. As with antibody 6.2E5, the 
antibody 6.2G2 was seen to localise at the periphery of cells spreading in the absence of ligand (nil). 
Accumulations at actin fibres were less marked in the absence of ligand (nil) compared to in the 
presence of fibronectin (Fn). Owing to technical failure and limited supply of antibodies 6.2G2 and 
6.2E5 complete evaluation of each antibody on VB6 cells spreading on a panel of cognate  (3.3.2 C) 
Cells (2 x 104 cells per coverslip) were left to adhere overnight on uncoated glass coverslips. Surface 
integrin ανβ6 was labelled on live cells using antibody 6.2E5 (Biogen Idec, 5 μg ml-1) for 10 min at 4°C 
prior to fixation in 4% PFA. Nuclei were demonstrated with membrane-permeant Hoechst 33342 
(H3570, Life Technologies, 1 μg ml-1). Cell-surface labelling revealed a clustered pattern of 
immunopositivity for antibody 6.2E5 at the cell periphery in what appear to be membrane ruffles 
(white arrow and green arrows). Images were acquired by confocal microscopy using the ZEISS 
LSM710 equipped with ZEISS Zen image analysis software (all Carl Zeiss AG, DE). Images were 
prepared for presentation using Image J (National Institutes of Health) and Adobe® Photoshop© CS6, 
with composites generated in Adobe® Illustrator© CS6 (Adobe Systems Software© Ltd). 
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Figure 3.3.3 (A)  
The antibodies 6.2E5 and 6.2G2 may be used to label the active subpopulation of integrin 
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Figure 3.3.3 (B)  
The antibodies 6.2E5 and 6.2G2 may be used to label the active subpopulation of integrin 
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Figure 3.3.3 (C)  
The antibodies 6.2E5 and 6.2G2 may be used to label the active subpopulation of integrin 
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Figure 3.3.3  
The antibodies 6.2E5 and 6.2G2 may be used to label the active subpopulation of the 
integrin ανβ6 in live cells to demonstrate the spatiotemporal subcellular distribution of 
activation-associated epitopes  
 
(3.3.3 A - C) The utility of antibodies 6.2E5 (3.3.3 A) and 6.2G2 (3.3.3 B) to determine the 
spatiotemporal distribution of integrin ανβ6 activation-associated epitopes in live cells was performed 
by vital staining and permeabilised immunofluorescence using the VB6 cell line. The localisations of 
6.2E5 and 6.2G2 cognate epitopes were compared concomitantly with the distribution of the cognate 
epitope for antibody 53A2 (CR-UK, 10 μg ml-1), a function-blocking antibody with no association to 
integrin ανβ6 activation status or conformation. The antibody 620W7, an anti-integrin ανβ6 antibody 
that recognises total integrin ανβ6 (both mature and immature-data not shown) in its various 
glycosylation states, was also evaluated (3.3.3 C). Live cells allowed to adhere overnight on uncoated 
non-derivatised 13 mm glass coverslips were labelled with antibody 6.2E5, 6.2G2 (both Biogen Idec, 5 
μg ml-1) or antibody 620W7 (CR-UK, 10 μg ml-1) for 10 min at 4°C. Cells were either washed, fixed and 
permeabilised immediately post-labelling (0’) or supplemented with complete media and returned to 
standard culture conditions for 15 min to permit early internalisation events (15’). After 15 min, cells 
were washed, fixed and permeabilised as previously described. Cells that had been live-labelled with 
6.2E5 and 6.2G2 were post-labelled with antibody 53A2. After labelling with appropriate fluorophore-
conjugated secondary antibodies and addition of DAPI nuclear stain (Invitrogen, 1 μg ml-1), coverslips 
were mounted and reviewed by immunofluorescence microscopy. (3.3.3 A) The antibody 6.2E5 was 
seen to predominate at the peripheral edges of spreading cells and was excluded from cell-cell 
junctions where 53A2 localised in abundance. After 15 min, punctate cytoplasmic immunopositivity 
was observed for 6.2E5. (3.3.3 B) The antibody 6.2G2 demonstrated weak, punctate immunopositivity 
at the peripheral edges of spreading cells and diffusely throughout the cytoplasm. Following 15 min 
of internalisation, marked clusters of vesicular-like accumulations of 6.2G2 were noted at the 
peripheral edges of cells which did not appear to co-localise with 53A2, which again predominated at 
cell-cell junctions and whose localisation at cell-cell junctions was not observably altered following 15 
minutes internalisation. (3.3.3 C) Cells live-labelled with antibody 620W7 revealed the distribution of 
620W7 cognate epitopes were not visibly altered following internalisation. Isotype and species-
matched negative control antibodies (mouse IgG1: MABC002, Merck Millipore, 5 μg ml-1 or rat IgG: 
ab37361, AbCam, 10 μg ml-1) were also reviewed for technical validation. Images were acquired by 
confocal microscopy using the ZEISS LSM710 equipped with ZEISS Zen image analysis software (all 
Carl Zeiss AG, DE). Images were prepared for presentation using Image J (National Institutes of 
Health) and Adobe® Photoshop© CS6, with composites generated in Adobe® Illustrator© CS6 (Adobe 
Systems Software© Ltd). 
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3.4 antibodies 6.2E5 and 6.2G2 may be used in FFPE and fresh 
 frozen human primary breast cancer tissue samples to 
 demonstrate integrin ανβ6 histological distribution but may not 
 reliably discriminate receptor activation status 
 
To ascertain whether the antibodies 6.2E5 and 6.2G2 may be used to histologically 
distinguish the integrin ανβ6 active subpopulation by immunohistochemistry (IHC), 
their distribution was evaluated in match-paired FFPE and fresh frozen sections of 
human primary breast tumour samples kindly obtained from the Barts Cancer 
Institute Breast Tissue Bank (Research Ethics Code 15/EE/0192). Discrimination 
between the spatiotemporal distributions of active versus inactive integrin ανβ6 
receptor populations in primary human BrCa samples would permit novel 
evaluation of the relevance of integrin ανβ6 activation status and ανβ6–mediated 




To date, only IHC appraisal and histological analysis of gross integrin ανβ6 
expression without delineation of receptor activation status has been published. 
This approach has successfully demonstrated that total integrin ανβ6 is 
overexpressed in a variety of cancers including pancreatic (Sipos et al 2004), 
ovarian (Ahmed et al 2002b) and oral squamous cell carcinoma (Thomas et al 
2001b); and is a poor prognostic indicator in colorectal (Bates et al 2005), lung 
(Elayadi et al 2007), cervical (Hazelbag et al 2007) and breast (Moore et al 2014) 
cancers. However, this strategy has failed to demonstrate a robust, definitive link 
between integrin ανβ6 receptor activation specifically and disease progression.  
 
 
Thus, it was deemed prudent to ascertain whether the antibody clones 6.2E5 and 
6.2G2 could discriminate between active and inactive pools of integrin ανβ6 in 
histopathological human BrCa samples. This characterisation was particularly 
prescient given that all of the studies described above (excluding Sipos and 
colleagues’ (2004) pancreatic cancer study), utilised antibody 6.2G2 to 
histologically demonstrate integrin ανβ6 expression.  
 
 
Therefore, ability to demonstrate integrin ανβ6 activation status within clinical 
samples of known grade, stage, therapeutic responsiveness and long-term patient 
outcome would refine our understanding of the causal, effective or reciprocal 
chapter III:  
results part I 
 148 
function of integrin ανβ6–mediated phenotypic outputs during neoplastic 




Data presented earlier in this chapter have shown that the antibodies 6.2E5 and 
6.2G2 each recognise an activation-associated epitope and LIBS at a single-cell 
level by flow cytometry (Figures 3.1 and 3.2) and immunofluorescence (Figure 3.3). 
However, given the conformational-dependency of these epitopes inferred from 
these data, the ability of these antibodies to recognise active integrin ανβ6 




Formalin fixation, tissue processing and subsequent antigen retrieval by heat-
induced epitope retrieval (HIER) or enzyme-induced epitope retrieval (EIER) 
techniques are known to alter protein gross conformation, induce disulphide 
cross-linkage formation and modify critical residues which will determine the 
accurate and successful detection of retrieved epitopes by their cognate antibody 
(Shi et al 2011). These factors render FFPE-IHC application of conformer-specific 
antibodies particularly problematic since the conformational epitope may be lost, 
or revealed in artefact, by the FFPE process. Therefore, case-matched fresh frozen 
tumour samples were compared in tandem since these snap-frozen tissues are 




To obviate any sample selection bias, 14 anonymised breast cancer cases were 
screened by FFPE-IHC to determine their integrin ανβ6 status using the CSβ6 
(Calbiochem) monoclonal anti-integrin β6–subunit antibody well established in-
house for use in FFPE human tissue samples (Figure 3.4.1). Five cases were 
selected for additional staining and review based upon their strong integrin ανβ6 
expression and superior histological preservation of tissue morphology (Figure 
3.4.1B). Human placental tissue, known to express the integrin ανβ6 (Ahmed et al 
2004), was used as a positive control to validate IHC detection of integrin ανβ6 
expression by this method.  
 
 
Each of the five FFPE cases (Figure 3.4.2A, C, E, G & I), along with their respective 
fresh frozen counterpart samples (Figure 3.4.2B, D, F, H & J) were sectioned and 
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stained using the antibodies 6.2E5 and 6.2G2 to evaluate and compare the 
immunopositive distributions of epitopes recognised by each antibody in FFPE 
versus fresh frozen human BrCa tissue (Figure 3.4.2A – J). 
 
 
Both the antibodies 6.2E5 and 6.2G2 clearly delineated integrin ανβ6-positive 
mammary ductal structures in a similar pattern to antibody CSβ6 in both FFPE and 
fresh frozen samples. Furthermore, like the antibody CSβ6, the antibodies 6.2E5 
and 6.2G2 each distinguished integrin ανβ6-positive breast parenchyma even in 
the absence of ductal morphology (or the vestiges thereof) in transformed breast 
tissues as shown in Figure 3.4.2H. Collectively this confirms the suitability of 
antibodies 6.2E5 and 6.2G2 to demonstrate gross morphological detail of integrin 
ανβ6–positive structures within human breast tissue architecture.  
 
 
However, the marked membranous localisation of integrin ανβ6 expression 
principally observed in fresh frozen tissue samples (Figures 3.4.2B, D, F, H and J) 
contrasted with predominantly diffuse cytoplasmic immunopositivity in FFPE 
matched samples (Figures 3.4.2A, C, E, G and I) revealed by each of the antibodies 
CSβ6, 6.2E5 and 6.2G2. The exquisite cell surface membrane immunopositivity 
demonstrated by each of these antibodies is clearly shown in frozen tissue samples 
presented in Figures 3.4.2D and F.  
 
 
Notably, Figure 3.4.2D highlights that no marked observable difference in patterns 
of immunopositivity for the epitopes recognised by antibodies CSβ6, 6.2E5 and 
6.2G2 is appreciable in fresh frozen tissue. Here, the vestiges of the same 
mammary gland may be compared directly for the localisation of CSβ6, 6.2E5 and 
6.2G2. A distinct and prominent membranous pattern of immunopositive 
localisation of integrin ανβ6 is observed for each of these antibodies. Indeed their 
respective IHC staining patterns appear identical.  
 
 
To date, the antibody CSβ6 has not been screened to determine whether it 
recognises an activation-associated or conformation-specific epitope. Therefore, it 
may be possible that this antibody detects an epitope revealed upon integrin ανβ6 
activation or conformational priming. This would account for the similarity in 
immunopositive tissue and cellular distribution shared between antibodies CSβ6, 
6.2E5 and 6.2G2 observed in fresh frozen tissue sections. Therefore, it would be 
informative to define antibody kinetics for clone CSβ6 following canonical modes 
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of integrin activation to ascertain whether its cognate epitope is conformation-
dependent. Until the nature of the epitope recognised by antibody CSβ6 has been 
more clearly defined, it must be concluded that the antibodies 6.2E5 and 6.2G2 
do not robustly discriminate conformation-specific integrin ανβ6 receptor pools, 
even in fresh frozen human tissue samples more likely to capture tertiary and 
quaternary protein structures reflective of their in vivo biochemical and 
ultrastructural state at the time of tissue excision.   
 
 
The observation of a predominantly diffuse cytoplasmic IHC appearance of 
integrin ανβ6 in FFPE samples compared to a markedly membranous localisation of 
integrin ανβ6 in fresh frozen samples infers that the exquisite cellular localisation of 
epitopes recognised by each of these antibodies is altered by FFPE processing. 
Therefore, integrin ανβ6 cellular distribution observed in FFPE samples may not 
accurately reflect the in vivo subcellular morphological fine detail requisite to 
robustly characterise the precise spatiotemporal role of integrin ανβ6 in neoplastic 
transformation and malignant progression using histopathological samples. 
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Figure 3.4.1 (A)  
Identifying integrin ανβ6 positive human primary breast cancer tissue samples to histologically evaluate the utility of antibodies 6.2E5 and 6.2G2 to 
discriminate activation specific receptor subpopulations  
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Figure 3.4.1 (B)  
Identifying integrin ανβ6 positive human primary breast cancer tissue samples to histologically evaluate the utility of antibodies 6.2E5 and 6.2G2 to 
discriminate activation specific receptor subpopulations  
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Figure 3.4.1  
Identifying integrin ανβ6 positive human primary breast cancer tissue samples to evaluate 
the utility of antibodies 6.2E5 and 6.2G2 to histologically discriminate activation specific 
receptor subpopulations  
 
In order to identify suitable cases of human-derived primary breast cancer tissue samples to permit 
evaluation of the ability of antibodies 6.2E5 and 6.2G2 to histologically discriminate the active and 
inactive conformers of integrin ανβ6, FFPE samples from 14 cases kindly donated by Barts Cancer 
Institute Breast Tissue Bank (Research Ethics Code: 15/EE/0192) were screened by IHC for gross 
integrin ανβ6 expression using an antibody directed against the integrin β6 subunit (CSβ6 
(Calbiochem), MAB2076Z, Merck Millipore, 1:200). (3.4.1 A) Following review by brightfield 
microscopy, 9 cases were excluded based upon their; integrin β6 negative status (anonymised case 
no. 1, 5 and 7), weak integrin β6 expression (cases 3, 6, 8) or poor morphological preservation (cases 
2, 4, 9) which was confirmed by second independent review. (3.4.1 B) The 5 cases selected for 
additional evaluation exhibited strong integrin β6 expression and satisfactory morphological 
preservation. Integrin β6 immunopositivity localised at and clearly delineated mammary ductal 
structures (black arrows) distinct from surrounding stroma and inflammatory infiltrate where present. 
At a cellular level, diffuse cytoplasmic pattern of integrin β6 immunopositivity was observed using 
antibody CSβ6 (Calbiochem) in FFPE tissues evaluated. Human placental tissue, known to express 
integrin ανβ6 was included as a positive control sample. Following endopeptidase protease antigen 
retrieval with VENTANA™ Protease 1 solution (#760-2018), immunohistochemistry was performed 
using the VENTANA™ BenchMark GX using the VENTANA™ ultraView Universal DAB Detection Kit 
(#760-500) (all Ventana Medical Systems Inc, Roche Holdings AG). Slides were scanned and images 
acquisitioned on Pannoramic 250 Flash II digital scanner prior to review using Panoramic Viewer 
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Figure 3.4.2 (A)   
Evaluating the utility of antibodies 6.2E5 and 6.2G2 to histologically study the active population of integrin ανβ6 in FFPE and matched frozen clinical 
samples of human breast cancer specimens 
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Figure 3.4.2 (B)   
Evaluating the utility of antibodies 6.2E5 and 6.2G2 to histologically study the active population of integrin ανβ6 in FFPE and matched frozen clinical 
samples of human breast cancer specimens  
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Figure 3.4.2 (C)   
Evaluating the utility of antibodies 6.2E5 and 6.2G2 to histologically study the active population of integrin ανβ6 in FFPE and matched frozen clinical 
samples of human breast cancer specimens 
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Figure 3.4.2 (D)   
Evaluating the utility of antibodies 6.2E5 and 6.2G2 to histologically study the active population of integrin ανβ6 in FFPE and matched frozen clinical 
samples of human breast cancer specimens 
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Figure 3.4.2 (E)   
Evaluating the utility of antibodies 6.2E5 and 6.2G2 to histologically study the active population of integrin ανβ6 in FFPE and matched frozen clinical 
samples of human breast cancer specimens 
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Figure 3.4.2 (F)   
Evaluating the utility of antibodies 6.2E5 and 6.2G2 to histologically study the active population of integrin ανβ6 in FFPE and matched frozen clinical 
samples of human breast cancer specimens 
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Figure 3.4.2 (G)   
Evaluating the utility of antibodies 6.2E5 and 6.2G2 to histologically study the active population of integrin ανβ6 in FFPE and matched frozen clinical 
samples of human breast cancer specimens 
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Figure 3.4.2 (H)   
Evaluating the utility of antibodies 6.2E5 and 6.2G2 to histologically study the active population of integrin ανβ6 in FFPE and matched frozen clinical 
samples of human breast cancer specimens 
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Figure 3.4.2 (I)   
Evaluating the utility of antibodies 6.2E5 and 6.2G2 to histologically study the active population of integrin ανβ6 in FFPE and matched frozen clinical 
samples of human breast cancer specimens 
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Figure 3.4.2 (J)   
Evaluating the utility of antibodies 6.2E5 and 6.2G2 to histologically study the active population of integrin ανβ6 in FFPE and matched frozen clinical 
samples of human breast cancer specimens
chapter III:  
results part I 
 164 
Figure 3.4.2 
Evaluating the utility of antibodies 6.2E5 and 6.2G2 to histologically study the active 
population of integrin ανβ6 in FFPE and matched frozen clinical samples of human breast 
cancer specimens 
 
The ability of antibodies 6.2E5 and 6.2G2 to histologically distinguish the integrin ανβ6 active 
subpopulation in human clinical breast cancer samples was evaluated by immunohistochemistry in 
matched FFPE and frozen tissue sections from 5 anonymised cases kindly obtained from the Barts 
Cancer Institute Breast Tissue Bank (Research Ethics Code: 15/EE/0192). Following formalin fixation 
and VIP-processing (FFPE) or snap freezing (frozen), samples were sectioned at 4 μm. FFPE samples 
(3.4.2 A, C, E, G & I) only were subject to on-board endopeptidase protease antigen retrieval using 
VENTANA™ Protease 1 solution (#760-2018). Fresh frozen samples (3.4.2 B, D, F, H & J) were not 
subject to antigen retrieval protocols. Sections were stained with the following anti-integrin ανβ6 
antibodies: Calbiochem-CSβ6 (MAB2076Z, Merck Millipore, 1:150), 6.2E5 and 6.2G2 (both Biogen 
Idec, 1:200) using the VENTANA™ BenchMark GX automated IHC stainer (Ventana Medical Systems 
Inc, Roche Holdings AG) and detected using the biotin-free polymer system Novolink™ DAB 
(polymer) chromogen (RE7230-K, Novocastra, Leica Microsystems UK Ltd). Integrin ανβ6 delineation of 
mammary ducts was demonstrated immunohistochemically (block black arrows) by all antibodies 
across both the FFPE and frozen tissue panels. Diffuse, intracellular cytoplasmic immunopositivity for 
integrin ανβ6 (green arrows) was observed in parenchymal cells, again across all tissue samples and 
with all antibody moieties. Distinct localisation of integrin ανβ6 immunopositivity at parenchymal cell 
surface membranes and at cell-cell junctions (black outline arrows) was observed most frequently in 
fresh frozen tissue samples and occasionally in FFPE sections. Slides were scanned and images 
acquired using the Pannoramic™ 250 Flash II digital scanner and reviewed using Panoramic Viewer 
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The use of monoclonal antibodies to discriminate specific integrin conformers and 
their associated activation status is now a well-established method in the field of 
integrin research (Mould et al 1995a, Humphries 1996, Mould et al 1996, 
Humphries 2004, Byron et al 2009, Campbell and Humphries 2011). The 
application of such monoclonal antibody-based approaches has proven the critical 
link between receptor activation and integrin-mediated functional biology driving 
phenotypic cellular responses to; cognate ligand engagement, crosstalk with GFR-
mediated signalling and ECM remodelling as reviewed by Kim et al (2011a).  
 
 
Validated, conformer specific anti-integrin antibodies have been successfully 
employed previously to delineate activation-specific integrin internalisation and 
trafficking kinetics (Arjonen et al 2012), ligand engagement, adhesion complex 
formation and associated signalling (Mould et al 1995b, Askari et al 2009, Askari et 
al 2010, Yu et al 2012). Furthermore, antibodies as functional probes to specifically 
and reversibly modulate integrin activation or inhibition have revealed novel 
insights into the significance of aberrant integrin activation and downstream 
signalling in the aetiopathology of various human diseases (Humphries 1996, 
Wehrle-Haller and Imhof 2003, Humphries 2004) including early characterisation 
of thrombasthaenic disorders (Ginsberg et al 1990),  periodontal disease (Larjava 
et al 2014) and many cancer types (Thomas et al 2001a, Thomas et al 2006, White 
and Muller 2007, Virtakoivu et al 2012, Yang et al 2012), recently permitting 
refinement of subtypes and invasive-risk stratification (Allen et al 2014).  
 
 
Excitingly, two monoclonal antibodies 6.2E5 and 6.2G2 (Biogen Idec) have 
demonstrated their novel utility to recognise the integrin ανβ6 in its active 
conformation in vitro. Based upon the results of canonical extracellular integrin 
activation experiments using divalent cations and cognate ligands they have each 
been found to recognise a conformationally-dependent activation-associated 
epitope and LIBS. Thus, they may be used to study the active subpopulation of 
integrin ανβ6 in future in vitro investigations. However, their ability to discriminate 
active from inactive populations of integrin ανβ6 could not be validated in a panel 
of FFPE and matched-pair fresh frozen primary human breast cancer tissue 
samples. This precludes their use to histopathologically study integrin ανβ6 
activation status at present. 
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It is not claimed that these antibodies recognise exquisitely specific activation 
epitopes, rather that they recognise activation-associated epitopes based upon 
the fact that these antibodies still engage integrin ανβ6 in the absence of known 
activating moieties such as divalent cations (Figures 3.1.1 and 3.1.2) or cognate 
ligands (Figures 3.2.1 and 3.2.2). This may be attributable to the presence of a 
base-line pool of integrin ανβ6 adopting the active conformation to which these 
antibodies favourably bind. This would fit with the hypothesis that integrins exist in 
a continuum of activation states and may continually flux between inactive, primed 
and high-affinity conformations (Humphries 1996, Shimaoka et al 2002, Shimaoka 
and Springer 2003, Arnaout et al 2007, Campbell and Humphries 2011, Bouvard 
et al 2013).  
 
 
Furthermore, based upon results from ligand-mediated integrin activation 
experiments, it was concluded that antibodies 6.2E5 (Figures 3.2.1) and 6.2G2  
(Figure 3.2.2) each recognise a LIBS. As acknowledged by Humphries (2004), the 
term LIBS is not entirely accurate, given that the epitope comprising the LIBS is not 
in the strictest sense “expressed” upon ligand-engagement. Because the 
constituent amino acid sequence comprising the LIBS is already present within the 
integrin homodimers’ amino acid sequences, it therefore may be bound by its 
cognate epitope even in the absence of ligand. This is concordant with the ability 
of antibodies 6.2E5 and 6.2G2 to engage the integrin ανβ6 even in the absence of 
ligand, lending further credence to the conclusion that these may be deemed anti-
LIBS monoclonal antibodies.  
 
 
Frelinger et al (1990) first described the concept of LIBS and outlined the 
generation of a panel of specific anti-LIBS monoclonal antibodies that could be 
used to dissect the complexities of integrin-mediated functional biology post 
ligand occupancy. Using these monoclonal anti-LIBS antibodies they identified two 
distinct LIBS on GPIIb (αIIb) and one on GPIIIa (β3). In combination with function-
blocking antibodies, Frelinger et al (1990) further deduced that certain LIBS they 
identified modulate integrin αIIbβ3 function. Abrogation of a LIBS was found to 
ablate fibrin clot contraction even when ligand-occupied αIIbβ3 engaged fibrin.  
 
 
Later, Ginsberg et al (1990) used this panel of anti-LIBS antibodies recognising 
resting, primed or ligand occupied integrin αIIbβ3 receptor forms to refine the 
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hierarchical ontogeny of defects in thrombocytic pathways resulting in haemostatic 
disorders. They successfully characterised the key αIIbβ3–mediated events 
determining thrombocyte aggregation as being; i) αIIbβ3 receptor priming by an 
agonist to reveal the fibrinogen binding site, ii) ligand (fibrin)-engagement itself 
and iii) effects inducted post-occupancy (downstream signalling). Using these 
antibodies in a flow cytometry screen of patient platelet-rich plasma or peripheral 
whole blood samples, Ginsberg et al (1990) first identified a defect in αIIbβ3 ligand-
engagement in a variant of Glanzmann’s thrombasthaenia and deficient agonist-
induced αIIbβ3 activation in myelofibrosis as the causative deficiencies resulting in 
pathologically diminished platelet aggregation.  
 
 
This early example of the clinical utility and application of anti-LIBS antibodies to 
refine classifications of human disease and identify specific pathway defects that 
may be exploited for targeted therapeutic intervention is demonstrative of the 
significance of identifying novel anti-LIBS antibodies. Their ongoing contribution to 
our understanding of integrin activation and signalling will only expedite the 
possibility to explore the translatability of integrin functional biology research into 
new screening, stratification, imaging and therapeutic strategies to improve 
clinical intervention and patient management strategies. Thus, the potential 
significance of the antibodies 6.2E5 and 6.2G2 to dissect the role of integrin ανβ6 
activation status and downstream signalling during breast tumourigenesis and 
disease progression, amongst other integrin ανβ6–associated pathologies, should 
not be underestimated. 
 
 
Several fundamental limitations are acknowledged with the antibody 
characterisation data presented here. Firstly, the activation methods employed 
only relate to extracellular modes of integrin activation and do not truly reflect the 
bidirectional nature of integrin activation. For completeness, a more robust 
validation of the specificity of these antibodies to discriminate active conformers of 
the integrin ανβ6 could encompass characterisation of the binding kinetics and 
spatiotemporal distribution of the antibodies 6.2E5 and 6.2G2 following 
intracellular modes of integrin activation and inhibition targeting the array of 
emergent molecular regulators modulating integrin function.  
 
 
For example, genetic silencing or overexpression of molecular regulators reported 
in literature to activate or inhibit integrin function (see Table 3.1) and/or 
downstream signalling would provide additional data with which the utility of 
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antibodies 6.2E5 and 6.2G2 to recognise activated or primed integrin ανβ6 
conformers could be evaluated with greater physiological relevance.  
 
 
Admittedly, molecular regulators of integrin activation have been demonstrated 
for specific integrin species, not yet including the integrin ανβ6, which may add 
complexity to antibody validation data as these molecular regulators themselves 
would require validation as intracellular modulators of integrin ανβ6 function. 
However, a review of integrin literature highlights several strong candidates, 




regulator action reported regulatory mechanism  
PIPKIγ INHIBITOR overexpression suppresses integrin activation  bind talin F3 PTB domain (competitive inhibition) 
FILAMIN “ filamin binds β-tail at site overlapping talin binding site also thought to compete with kindlin for β-tail binding 
SHARPIN “ inhibits talin & kindlin binding to β-tail – mechanism unknown 
ICAP-1 “ binds distal kindlin NpxY motif & inhibits talin binding in β1 integrin. Inhibitory effect not via direct competition 
TALIN ACTIVATOR 
talin F3 domain complexes with membrane-proximal NpxY motif β-
tail requisite for talin-mediated integrin activation  
FAK mediates recruitment of talin 
KINDLIN “ degree of homology with talin head but bears inserted PH domain and preferentially bind membrane-distal NpxY motif  
MIGFILIN “ filamin-binding protein – expression enhances integrin activation 
α-actinin PLEIOTROPIC binding site overlaps talin binding site. Competitive inhibition reported in β3; enhances talin binding to β1 
Table 3.1: Published intracellular molecular regulators of integrin activation exhibiting inhibitory, 
activating or pleiotropic effects. Abbreviations: FAK – focal adhesion kinase; ICAP-1 – integrin 
cytoplasmic domain associated protein-1; Sharpin – SHANK-associated RH-domain interacting 
protein; PIPKIγ – phosphatidylinositol 4-phosphate 5-kinase type Iγ; PTB - phosphotyrosine binding 
domain. Information compiled from: (Humphries 1996, Hynes 2002, Shimaoka et al 2002, Luo et al 




The antibody validation dataset presented here focuses on extracellular integrin 
activation modalities using cognate ligands and divalent cations that come with 
their own inherent limitations. In their review of experimental strategies to 
reconstruct integrin activation in vitro, Ye et al (2012) highlight the ongoing debate 
concerning the physiological relevance of data acquired from Mn2+-induced 
integrin activation studies. Admittedly, this strategy alone may prove of limited 
physiological significance to dissect the complexities of integrin receptor 
activation, induction of downstream functional sequelae including signal activation 
and integration into other signalling networks in vivo.  
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Therefore, it is acknowledged that using divalent cations alone as an activation-
agonist, in the absence of a truly physiomimetic integrin-ECM ligand interaction 
reflective of the in vivo context of integrin behaviour and function, is undoubtedly 
of limited relevance to characterise integrin-ECM or integrin-GFR mediated 
signalling. However, for the purposes of antibody validation to evaluate whether 
an antibody specifically or preferentially recognises an active integrin conformer, 
use of divalent Mn2+-cations as a proven and expedient method of exogenous 
integrin activation was deemed appropriate given its successful application for this 
purpose in previous studies generating and characterising conformer-specific anti-
integrin antibodies (Frelinger et al 1990, Weinreb et al 2004).  
 
 
In their structural biochemistry modelling and analyses of the Lymphocyte 
Function-Associated Antigen-1 (LFA-1) (integrin αLβ2) MIDAS and its interactions 
with a ligand-mimetic acetate molecule, San Sebastian et al (2006) acknowledged 
that although Mg2+-ions may be the most physiologically abundant divalent cation 
species, they are not necessarily the biochemically optimal species for favourable 
MIDAS occupation to potentiate ligand-integrin interactions.  Indeed, the authors 
acknowledged that Zn2+ or Mn2+ ions exhibited the most favourable coordination 
to MIDAS facilitating ligand engagement, further demonstrative of the utility of 
Mn2+-activation studies for the defined purposes of conformer-specific antibody 
validation as used here. 
 
 
Furthermore, since the allosteric regulation of integrin conformation and ligand 
affinity by Ca2+-ion species is known to be biphasic with elicited effects varying as a 
function of Ca2+ concentration (San Sebastian et al 2006), the evaluation of 6.2E5 
and 6.2G2 binding kinetics in the presence of a single (1 mM) concentration of 
Ca2+-ions hinders additional interpretations regarding the location and nature of 
the epitopes recognised by these antibodies.  
 
 
In their review, Leitinger et al (2000) summarise the existence of 1 high affinity and 
3 – 4 low affinity Ca2+-ion binding sites as characterised using equilibrium dialysis 
studies on purified platelet integrin  αIIbβ3 first published by Rivas and Gonzalez-
Rodriguez (1991). The authors outline how the high affinity Ca2+-binding site is 
sensitive to μM Ca2+ concentrations and promotes ligand binding in α5β1 and β3 
integrins. Conversely, the low affinity binding sites responsive to mM Ca2+ 
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concentrations allosterically compete for Mg2+ occupation eliciting an inhibitory 
effect on ligand engagement. 
 
 
Additional evaluation of antibody binding kinetics in the presence of Ca2+-ion 
concentrations ranging from the μM to mM for clones 6.2E5, but more presciently 
6.2G2, which already appears Ca2+ sensitive (Figure 3.1.2C), would determine with 
greater acuity whether these epitopes are truly Ca2+-dependent or independent. If 
either antibody 6.2E5 or 6.2G2 were found to recognise Ca2+-dependent epitopes, 
they would prove useful tools to further probe modulation of integrin ανβ6 
conformational arrangement.  
 
 
Xie et al (2004) successfully employed two murine monoclonal anti-human αL 
antibodies (clones NKI-L16 and AO3) that each recognise a Ca2+-ion and 
activation-dependent epitope to study the cell-surface conformational 
arrangement of integrin αLβ2. The authors mapped the cognate epitopes of these 
antibodies to the αL-thigh domain and hypothesised that conformational 
rearrangements during priming, activation and αL–leg extension occur between 
the genu and thigh domains, not the genu and calf-1 domain. Thus if similar 
epitope mapping studies and evaluation of Ca2+-ion dependency could be 
completed for 6.2E5 and 6.2G2 cognate epitopes, these antibodies may be used 
to characterise the conformational arrangement and cation regulation of activation 
of cell-surface integrin ανβ6, about which is little currently known. 
 
 
The use of synthetic peptide A20FMDV2 to evaluate ligand-induced binding 
kinetics of antibodies 6.2E5 and 6.2G2 was deemed suitable for the defined 
purpose of antibody validation, given its established high affinity and specificity for 
integrin ανβ6 and previous application in integrin ανβ6–specific investigations, 
including in vivo tumour imaging (Saha et al 2010). It is acknowledged that this is 
not a natural ECM ligand and so may prove to be of limited physiological 




However, to establish whether antibodies 6.2E5 and 6.2G2 recognise a LIBS, the 
use of a high affinity, specific ligand, although synthetic, is deemed justifiable. 
Ligand-induced activation studies were also performed using human recombinant 
LAP of TGF-β1 in order to provide antibody characterisation data within the 
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context of a physiologically relevant integrin ανβ6 ligand known to be present 
within the ECM. 
 
  
Furthermore, it is noted that epitope-mapping for the residues recognised by 
these antibodies has not yet been performed, but some inferences as to their 
location have been deduced based on observations to date. Flow cytometric 
evaluation of 6.2E5 and 6.2G2 binding kinetics on live, non-permeabilised cells 
suggests logically that they bind the extracellular integrin ανβ6 domain. Since they 
are non-ligand mimetic and are capable of binding integrin ανβ6 in its ligand-
engaged state (Figures 3.2.1 and 3.2.2), it is inferred that these epitopes do not lie 
within, or proximal to the RGD ligand binding cleft. If either were the case, these 
antibodies would not bind ligand-engaged integrin ανβ6 either due to direct 
competitive inhibition with ligand or due to steric hindrance about the binding site 
once ligand is bound.  
 
 
It is possible that the LIBS recognised by antibodies 6.2E5 and 6.2G2 may reside 
on the β6 subunit. Indeed, previous publications have used antibody 6.2E5 to 
detect the integrin ανβ6 by Western blot, indicating its cognate epitope must 
reside within the β6 subunit sequence (Azare et al 2007). The marked similarity in 
immunopositive distribution of the epitope recognised by the β6-subunit specific 
antibody CSβ6 with the immunohistochemical localisation of epitopes recognised 
by antibodies 6.2E5 and 6.2G2 in fresh frozen primary breast tissue (Figure 3.4.2D) 
would infer this. Other LIBS monoclonal antibodies have been mapped to integrin 
β-subunits. Mould et al (1995a) first identified that the antibody clone 12G10 
recognised a LIBS on the β1 subunit. They conducted epitope mapping by 
competitive inhibition studies using a panel of antibodies directed against β1-
bearing integrin species previously characterised by Takada and Puzon (1993).  
 
 
A similar competitive inhibition strategy using the known RGD-ligand mimetic and 
ανβ6 heterodimer-specific antibody clone 10D5 would permit confirmation that the 
antibodies 6.2E5 and 6.2G2 do not bind via, or proximal to, the heterodimeric 
RGD cleft. It would be useful to identify the specific extracellular portion of integrin 
ανβ6 to which these antibodies bind to further understand the nature of 
conformational regulation of integrin ανβ6 activation status.  
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This could be achieved by combining mutational analysis of the β6 subunit with 
evaluation of antibody binding kinetics, in a strategy recapitulating that 
successfully employed by Takada and Puzon (1993) and later by Bazzoni et al 
(1995) to characterise antibody clone 9EG7 and Faull et al (1996) to define 
antibody clone QE.2E5. Using CHO cells as a host, Takada and Puzon (1993) 
generated chimaeras transfected with human β1 cDNA to express either WT 
human β1 or variants bearing known mutations in the β1 subunit amino sequence. 
Flow cytometric analysis of antibody binding characteristics in the presence of 
these known β1-subunit mutations was then performed.  
 
 
This permitted successful epitope mapping for a panel of anti β1-antibodies 
studied to specific regions of the β1 subunit, including mapping the cognate 
epitope recognised by antibody A1A5 to a region mapping to residues 207 – 218 
of the human β1 subunit domain. Such an approach using WT β6 cDNA and β6 
cDNA variants bearing known mutations generated by site directed mutagenesis, 
prior to flow cytometric evaluation of antibody binding capacity, the location of 
epitopes recognised by antibodies 6.2E5 and 6.2G2 could be mapped. 
Knowledge of the precise regions where these epitopes reside would provide 
further insight into mechanisms governing integrin ανβ6 conformation and the 
elicitation of downstream phenotypic and functional responses inducted upon 
integrin ανβ6 activation.  
 
 
Immunofluorescence studies provided useful preliminary insights into the utility of 
antibodies 6.2E5 and 6.2G2 to track spatiotemporal distributions of active integrin 
ανβ6 conformers. However, the inferences from this observational dataset are 
limited, requiring additional follow up in order to deduce more robust conclusions 
regarding the application of antibodies 6.2E5 and 6.2G2 to dissect mechanisms 
and sequelae of integrin ανβ6 activation.  
 
 
For example, integrin clustering associated with activated, high-affinity integrin 
conformers was observed when live cells were surface labelled with 6.2E5 (Figure 
3.3.2C). Confirmation that 6.2E5 is detecting integrin in high-affinity clusters could 
be obtained by co-labelling for markers associated with integrin activation, high-
affinity state clustering and signalling such as pFAK, talin, vinculin and α-actinin 
(Cluzel et al 2005, Welf et al 2012, Roca-Cusachs et al 2013, Hirata et al 2014).  
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It is also regrettable that the immunofluorescence dataset for antibodies 6.2E5 and 
6.2G2 is incomplete owing to technical errors and prohibitively limited availability 
of these antibodies. Thus, completion of each dataset to ensure both antibodies 
are fully evaluated is necessary for fair comparisons.  
 
 
Immunohistochemical assessment of antibodies 6.2E5 and 6.2G2 in human 
primary breast tumour histopathology samples was limited to only 5 cases due to 
restricted availability of these antibodies and access to human primary tissues. 
Undoubtedly this small sample size would prohibit broader interpretation of the 
utility of antibodies 6.2E5 and 6.2G2 to stratify or refine breast cancer subtypes in 
terms of their integrin ανβ6 activation status, or abundance of 6.2E5 or 6.2G2 
cognate epitopes, within the context of histopathological diagnosis and patient 
outcome. However, for the defined purpose of preliminary evaluation of the ability 
of antibodies 6.2E5 and 6.2G2 may be used to discriminate the integrin ανβ6 active 
subpopulation in clinically derived tissues, this sample size was deemed sufficient, 
if limited.  
 
 
Disappointingly it has not been possible to validate the use of antibodies 6.2E5 
and 6.2G2 to distinguish a conformationally distinct integrin ανβ6 receptor 
subpopulation in either FFPE or fresh frozen histological samples. It is likely that 
the protein-modifying biochemical processes involved in FFPE-processing and 
protease-mediated EIER protocols employed in this investigation partially ablate 
the finer detail of epitope distribution as would be found in vivo.  
 
 
This is best exemplified by the predominantly cytoplasmic immunopositivity for 
antibody CSβ6 observed in FFPE samples, compared to the abundance of a 
membranous distribution of CSβ6 in fresh frozen tissues. The phenomenon of 
epitope instability has been widely reported (Dabbs 2008, Shi et al 2008, Shi et al 
2011) and informed the inclusion of fresh frozen tissues as it was anticipated that 
FFPE and EIER protocols may either destroy or unmask the putative conformation-




If it were possible to identify an antibody capable of reliably detecting active 
integrin ανβ6 conformers within clinical histopathological samples, large-scale 
screening of human primary breast tumour cases may be undertaken to 
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investigate any correlation between expression of the active integrin ανβ6, 
histopathological classification, tumour staging and patient outcome, as 
successfully undertaken for total integrin ανβ6 (Moore et al 2014). If a positive 
correlation were to be established between integrin ανβ6 activation status, 
metastatic potential and patient outcomes, this would refine current 
understanding of the epidemiological role of aberrant integrin ανβ6 activation in 
breast tumourigenesis and disease progression.  
 
 
Indeed, Felding-Habermann et al (2001) successfully demonstrated in vitro and in 
vivo the functional significance of integrin ανβ3 activation status in human breast 
cancer. The authors demonstrated that integrin ανβ3 in its active state was requisite 
for tumour cell-thrombocyte attachments to circumvent anoikis in the MDA-MB-
435 human breast cancer cell line and also in freshly isolated primary human 
metatstatic breast cancer cells (PE02JA cells).  
 
 
In addition, using MDA-MB-435 mutant variants transfected to stably overexpress 
constitutively active integrin ανβ3D723R, the authors showed that activated integrin 
ανβ3 strongly promoted metastasis when injected into SCID mice, compared to 
their ανβ3WT counterpart MDA-MB-435 cells. A similar strategy could be employed 
to determine the biological role of active integrin ανβ6 in human breast cancer, 
utilising the antibodies 6.2E5 and 6.2G2 to distinguish the active forms of integrin 
ανβ6. If such studies could be augmented with demonstration of functionally 
distinct activation integrin ανβ6 states within clinically-derived human tissue 
samples of known histopathological grade and status, a robust case for integrin 




It is acknowledged that variegation in digital scan quality and inter-batch variance 
in IHC staining intensity compounded any attempts at direct quantification of 
signal strength as a read out for integrin ανβ6 expression levels in the FFPE and 
fresh frozen histopathological sample set evaluated. Furthermore, direct 
comparisons between histological distributions of epitopes recognised by 
antibodies 6.2E5 and 6.2G2 in comparison with antibody CSβ6 could not be 
accurately made. In order to characterise the specific immunohistochemical 
subcellular localisation or abundance of epitopes recognised by these antibodies 
with greater confidence, serial sections would need to be prepared. This would 
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enable review of the localisation of these epitopes within a defined region of tissue 
and within a 4 μm to 8 μm spatial range to facilitate direct comparison. 
 
 
At present, studies have only characterised integrin ανβ6 gross expression without 
demonstrating receptor activation status. This is largely due to a hitherto lack of 
available biological means to distinguish integrin ανβ6 conformers. Now, the 
antibodies 6.2E5 and 6.2G2 may be used to address this gap in our current 
understanding of the significance of integrin ανβ6 activation status in the natural 
history of human breast cancer. 
 
 
The critical caveat to their use is acknowledgement that recognition of a 
conformation-dependent epitope is sensitive to certain experimental procedures 
that may reveal the epitope in a manner that does not truly recapitulate the in vivo 
morphological status of integrin ανβ6. But with this in mind to guide selection of 
suitable experimental techniques and to temper data interpretation, these 




To conclude, it has been demonstrated for the first time that the antibodies 6.2E5 
and 6.2G2 each recognise a primed or active integrin ανβ6 conformer. 
Furthermore, they may be classified as anti-LIBS antibodies and excitingly shall 
facilitate future investigations seeking to dissect the complexities of integrin ανβ6 
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             derailed  internalisation  and  trafficking  of  the  integrin ανβ6  in  its  active 
state is  implicated in  breast cancer  progression  
        
 
 
4. introduction  
 
Activation of invasion and metastasis is a seminal cancer hallmark (Hanahan and 
Weinberg 2000, Hanahan and Weinberg 2011). Dysregulation of cellular adhesive 
repertoires facilitating acquisition of an invasive phenotype as a critical event 
promoting progression from localised in situ disease to disseminated, metastatic 
malignancy is now well established and widely reviewed (Behrens 1993, Van't Veer 
and Weigelt 2003, Duffy et al 2008, Aoudjit and Vuori 2012, Bendas and Borsig 
2012, Hale et al 2012, Zhong and Rescorla 2012, Quail and Joyce 2013). 
 
Cellular adhesion profiles determining cell-cell interactions and cell-ECM 
(including cell-basal lamina) anchorage are established by a variety of adhesion 
receptor family classes including: cadherins, selectins, immunoglobulins, 
proteoglycans (syndecans) and integrins (Gumbiner 1996, Maller et al 2010, Kim et 
al 2011a, Lu et al 2012, Oskarsson 2013, Pickup et al 2014).  
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As the predominant cell-ECM receptor superfamily, the integrins are known to 
regulate a wide array of phenotypic traits in both health and disease (Felding-
Habermann 2003). These include: cellular proliferation (Moreno-Layseca and 
Streuli 2014), senescence (Rapisarda et al 2017), cell fate via anchorage-
dependent survival signalling or induction of anoikis (Guadamillas et al 2011); 
growth factor receptor (GFR) signalling integration (Ivaska and Heino 2010, Hamidi 
et al 2016); modulation of cell-ECM interactions and coordination of ECM 
remodelling (Bonnans et al 2014, Oudin et al 2016).  
 
 
Given the diversity of cellular functions subject to integrin-mediated regulation, it 
is logical that different integrin heterodimer species may mediate distinct tumour 
suppressive or oncogenic functions, driving tumourigenesis and facilitate disease 
dissemination. Indeed, literature reviewed by Hurst and Welch (2011) highlighted 
the importance of integrin repertoire modulation during tumour progression. 
Broadly, previous studies have shown tumour suppressive integrin moieties (α2β1, 
α3β1) promoting stable adhesions and a differentiated, quiescent phenotype are 
down regulated (Zutter et al 1995, Varzavand et al 2016), whilst oncogenic 
moieties driving proliferation and migration (ανβ3, ανβ6, α6β4) are up-regulated, by 
incipient tumour cells (Petitclerc et al 1999, Diaz et al 2005, Sloan et al 2006). 
However, the cell-type specific nature and pleiotropy of integrin function is also 
acknowledged (Desgrosellier and Cheresh 2010, Shattil et al 2010, Hurst and 
Welch 2011).  
 
 
Taherian et al (2011) investigated the phenotypic effects of differential integrin 
expression and resultant alterations in integrin-mediated signalling in BrCa cells 
that determined their tumourigenic and metastatic potential. Their study revealed 
that BrCa cells vary in their integrin expression profiles, ability to form focal 
adhesions and capacity for integrin-mediated signalling. This was concordant with 
findings previously published by Havaki et al (2007) who also investigated the 
phenotypic role of distinct integrin ανβ3 expression using human primary cancer 
cells derived from clinical breast tumour biopsies. 
 
 
In addition to overexpression of gross (total) integrin ανβ3, high expression of 
integrin ανβ3 specifically in its active conformation has been linked to breast 
tumourigenesis.  The functional significance of activated integrin ανβ3 driving a 
pro-metastatic phenotype in human BrCa both in vitro and in vivo, was first 
reported by Felding-Habermann et al (2001) using the MDA-MB-435 cell line 
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model. The authors demonstrated that active integrin ανβ3 enabled tumour cell-
thrombocyte interactions that circumvented anoikis, establishing a favourable 
metastatic niche.  
 
 
Later, Verbisck et al (2009) identified the type I transmembrane glycoprotein 
disintegrin and metalloproteinase domain-containing protein 23 (ADAM23) as a 
negative regulator of integrin ανβ3 activation that was perturbed in BrCa. ADAM23 
was previously shown to directly, physically interact with integrin ανβ3 in human 
astrocytoma and blastoma cell lines via its disintegrin domain (Cal et al 2000, 
White 2003). Verbisck et al (2009) confirmed the direct ανβ3/ADAM23 physical 
interaction in the MDA-MB-435 cell line using a glutathione S-transferase (GST)-
pull down assay. Since ανβ3 is the only β3 integrin expressed in this cell line, the 
authors concluded that ADAM23 directly binds integrin ανβ3 via its disintegrin 
domain in MDA-MB-435 cells. 
 
 
Furthermore, molecular rescission of ADAM23 through shRNA silencing in MDA-
MB-435 cells was found to promote integrin ανβ3 activation by up to 4-fold, 
enhancing adhesion to and migration on the canonical integrin ανβ3 ligands 
fibronectin and vitronectin. To evaluate the clinical relevance of ADAM23 during 
disease progression, Verbisck and colleagues evaluated a cohort of 94 primary 
human invasive ductal carcinomas (IDC) of the breast. They demonstrated that 
DNA promoter hypermethylation-induced silencing of ADAM23 significantly 
correlated with reduced distal metastases-free and disease-specific survival rates. 
In addition, loss of ADAM23 expression was found to be an independent 
prognostic factor for poor disease outcome within this IDC cohort.  
  
 
The specific significance of active rather than inactive integrin species facilitating 
metastatic potential and disease progression has also been demonstrated in 
prostate cancer. Using the activation conformer-specific anti-integrin β1 
monoclonal antibody 9EG7, Lee et al (2013) showed that integrin β1 was 
constitutively active in the PC3 and PC3-mm2 human prostate cancer cell lines of 
known high metastatic potential, in comparison with the LNCaP and C4-2B4 
prostate cancer cell lines of low metastatic potential. Immunohistochemical 
assessment of total integrin β1 and FAK phosphorylation at tyrosine 397 (pFAKY397) 
in 58 human primary prostate cancer tissues revealed that integrin β1 and 
associated integrin-induced FAK autophosphorylation levels were elevated in 
samples of primary prostate cancer tissue (20 cases) and prostate cancer 
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secondary lymph node metastases (18 cases), in comparison with normal prostate 
tissue (20 cases). Thus, Lee et al (2013) deduced that integrin β1 activation 
occurred during metastatic disease progression in prostate cancer. 
 
 
The authors evaluated the effects of integrin β1 activation on prostate cancer 
metastasis in vivo by orthotopic injection of SCID mice with PC3-mm2 cells. Mice 
were treated with control antibody IgG or the integrin β1–specific neutralising 
monoclonal antibody 33B6 first described by Bednarczyk et al (1993). Two-week 
systemic therapy with antibody 33B6 significantly reduced lymph node metastasis 
in comparison with IgG treatment (p<0.001).  
 
 
In a separate study cohort of SCID mice with metastatic tumours derived from 
disseminated PC3-mm2 cells already established in distal lymph nodes, 33B6 
therapy was seen to significantly slow rate of tumour growth and reduce tumour 
volume in comparison with the IgG-treated control arm. The authors concluded 
that activation of β1 integrin species promotes tumour cell survival and 
extravasation, enabling dissemination to distal sites establishing increased 
metastatic disease burden and poor survival (Bednarczyk et al, 1993). 
 
 
Based on previous studies reporting the significance of integrin ανβ3 and integrin 
β1 activation state during tumourigenesis, it is clear that both the nature of integrin 
species grossly expressed, along with their associated activation status, elicit 
significant effects determining tissue transformation, tumourigenesis and disease 
progression to disseminated, metastatic disease. Of growing clinical interest is the 
relevance of integrin species activation during tumour initiation and disease 
progression for therapeutic intervention (Jin and Varner 2004, Staunton 2006, 
Eberlein et al 2013, Lee et al 2013, Parvani et al 2013, Moore et al 2014, Truong et 
al 2014). Indeed, Felding-Habermann et al (2001) demonstrated the importance 
integrin activation during BrCa progression over a decade ago.  
 
 
Unusually, expression of the epithelial-restricted integrin ανβ6 is not constitutive in 
healthy adult tissues. It is upregulated during tissue remodelling associated with 
wound-healing responses and carcinogenesis (Breuss et al 1995, Thomas et al 
2006). In breast cancer, overexpression of the integrin ανβ6 (Allen et al 2014), 
together with its efficacy as a target in multi-agent combination therapy modalities 
(Moore et al 2014) is now well established.  
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Given the importance of integrin ανβ6 expression during breast tumourigenesis, it 
was deemed pertinent to investigate whether the integrin ανβ6 in its active, 
signalling-replete state is requisite for establishing a neoplastic phenotype and 
pro-metastatic niche during mammary cell transformation and disease progression 





        overview of key findings 
 
Integrin ανβ6 expression is associated with poor prognosis and risk of progression 
in BrCa (Allen et al 2014, Moore et al 2014). Therefore, gross (total) and active 
integrin ανβ6 conformations were screened in breast cancer cell lines comprising 
the MCF10 isogenic in vitro model of breast tumourigenesis to investigate the 
relevance of integrin ανβ6 activation status at each stage of breast carcinogenesis 
from neoplastic transformation through to malignant progression.  
 
 
A series of monoclonal antibodies validated in house for the detection of distinct 
integrin ανβ6 subpopulations were used to define the population of total integrin 
ανβ6: clones 10D5, 53A2 and 620W7, (Desai 2011) in addition to antibody clones 
6.2E5 and 6.2G2 now established to recognise the pool of active integrin ανβ6 (see 
Chapter 3: Results Part I). Using this monoclonal antibody-based approach, relative 
cell surface abundance of total and active integrin ανβ6 conformers was quantified 
by flow cytometry, with their respective subcellular distributions defined by 
confocal immunofluorescence microscopy.  
 
 
Critically, it was found that in the presence of a relatively stable cell surface pool of 
active integrin ανβ6, the activation-associated epitopes recognised by antibodies 
6.2E5 and 6.2G2 underwent notable subcellular redistribution upon neoplastic 
transformation and malignant progression in the MCF-10AT and MCF-10CA1h 
variants respectively, where large vesicular-like accumulations of active integrin 
ανβ6 were observed. This implicated derailed integrin ανβ6 receptor internalisation 
and intracellular trafficking kinetics as oncogenic drivers during breast 
tumourigenesis, as opposed to cell surface overexpression of the active integrin 
ανβ6 subpopulation alone.  
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4.1 cell surface and whole cell abundance of total integrin ανβ6 varies 
 demonstrably across the MCF10 model, but the relative surface 
 fraction of active integrin ανβ6 is not significantly altered    
 
The MCF-10 isogenic cell line series has been used extensively in breast cancer 
research to provide a simple, in vitro 2D-model recapitulating breast 
tumourigenesis and disease progression (Soule et al 1990, Dawson et al 1996, 
Heppner et al 2000, Santner et al 2001).  
 
 
The MCF-10 panel, derived from the non-neoplastic MCF-10A parent cell line, 
subsequent neoplastic variants (MCF-10AT, MCF-10Kcl.2), malignant variants 
(MCF-10CA1a, MCF-10CA1h) together with a variant recapitulating in situ ductal 
disease (MCF-10DCIS.com), was deemed appropriate for preliminary 
investigations into integrin ανβ6 expression and activation status. Exemplifying the 
utility of the MCF-10 cell line model, Tang et al (2003) successfully used this panel 
previously to highlight TGF-β1 pleiotropy during breast tumourigenesis, defining a 
novel switch from tumour suppressor in early stage disease, to a prometastatic 
factor in advanced disease.  
 
 
Cell surface abundance of distinct integrin ανβ6 receptor populations (both total 
and activated) were quantified by flow cytometry using a panel of anti-integrin ανβ6 
monoclonal antibodies (as outlined previously in Chapter 3: Results Part I). 
Geometric mean fluorescence intensity (geoMean MFI, AU) values were detected 
for each of the antibodies used and subsequently normalised against geoMean 
MFI values obtained for the relevant species-specific isotype-matched negative 
control antibodies evaluated in tandem.  
 
 
These data served as a quantitative readout of cell surface total integrin ανβ6 
expression (demonstrated by antibody clones 10D5, 53A2 and 620W7; Figure 
4.1A) or the activated integrin ανβ6 receptor pool (labelled using antibody clones 
6.2E5 and 6.2G2; Figure 4.1C and D respectively). Whole cell integrin subunit 
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Figure 4.1 (A & B) 
Total surface expression of the integrin ανβ6 is significantly altered across the MCF-10 
isogenic model of breast tumourigenesis and disease progression, however, relative 
surface abundance of the active subpopulation of integrin ανβ6 recognised by antibodies 
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Figure 4.1 (C & D) 
Total surface expression of the integrin ανβ6 is significantly altered across the MCF-10 
isogenic model of breast tumourigenesis and disease progression, however, relative 
surface abundance of the active subpopulation of integrin ανβ6 recognised by antibodies 
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Figure 4.1 
Total surface expression of the integrin ανβ6 measured by flow cytometry is significantly 
altered across the MCF-10 isogenic model of breast tumourigenesis and disease 
progression, however, relative surface abundance of the active subpopulation of integrin 
ανβ6 recognised by antibodies 6.2E5 and 6.2G2 is not significantly altered 
 
The MCF-10A series of breast cancer cell lines (MCF10 isogenic model) generated to recapitulate 
neoplastic transformation and malignant progression were used to explore the putative role of active 
integrin ανβ6 during breast tumourigenesis. Cell surface abundance of total integrin ανβ6 recognised 
by antibodies 10D5, 53A2 and 620W7 was determined by flow cytometry (4.1 A) and total cellular 
integrin ανβ6 evaluated by Western blot (4.1 B). The active subpopulation of integrin ανβ6 was 
assessed by flow cytometry in terms of total cell surface abundance using antibodies 6.2E5 (4.1 C) and 
6.2G2 (4.1 D) and as a relative fraction of total integrin ανβ6 by normalising MFI values against values 
for 10D5. (4.1 A) The ligand mimetic antibody 10D5 (10 μg ml-1, Merck Millipore) which was used to 
identify the total surface pool of integrin ανβ6 by flow cytometry was significantly altered across the 
MCF-10A series (n=5, Friedman Test with Dunn’s multiple comparison test, p<0.05, p=0.0321). 
Surface binding of antibodies 53A2 and 620W7 (both 10 μg ml-1, CR-UK) was also used to identify the 
total pool of integrin ανβ6 and was again significantly altered across the MCF-10A panel (p=0.0066 
and p=0.0101 respectively, Friedman Test with Dunn’s multiple comparison test). (4.1 B) Total cell 
expression of the integrin β6 subunit was determined across the MCF10 model by immunoblot 
(antibody C-19, 0.2 μg ml-1, SCBT), technically validated against known integrin ανβ6 positive (DX3β6) 
and negative (DX3puro) control cell lines and quantified by densitometry (n=3). Protein was loaded at 
25 μg per well. Blots were developed using ECL and exposed manually onto X-ray film 
(CARESTREAM, Carestream Health Ltd) before scanning blot hardcopies to digitise images (Epson 
PERFECTION V39 Scanner, Seiko Epson Corp.). (4.1 C) Neither total surface bound (MFI values) nor 
relative fraction (% of total ανβ6) of 6.2E5 (5 μg ml-1, Biogen Idec) normalised against 10D5 MFI values 
were significantly altered across the MCF-10A series (n=5, Friedman Test with Dunn’s multiple 
comparison test p=0.1955 and p=0.0922 respectively). (4.1 D) Total surface abundance of 6.2G2 
measured by detected MFI was significantly altered across the MCF-10A panel (n=5, Friedman test 
with Dunn’s multiple comparison p=0.0481). However, the relative fraction of 6.2G2 (5 μg ml-1, Biogen 
Idec) normalised against 10D5 MFI values were not significantly altered across the panel (n=5, 
Friedman test with Dunn’s multiple comparison, p=0.4895). Graphs represented in (4.1 A, C and D) 
show median with interquartile range, except for graphs representing relative expression of 6.2E5 & 
6.2G2 normalised to 10D5, which show means and error bars for s.e.m.  Densitometry graph in (4.1B) 
shows mean with error bars for s.d. All flow cytometry data was acquired on live cells in the presence 
of a cell viability indicator (5 μg ml-1 propidium iodide, P4170, Sigma Aldrich) using the BD 
FACSCalibur™ (BD Biosciences). Following normalisation against isotype matched negative control 
antibodies, geometric MFI values were determined by analysis in BD CellQuestPro™ software (BD 
Biosciences). Statistical analyses were performed using GraphPad Prism® 5.0b for MacOSX (Graphpad 
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It was consistently found that cell surface abundance of the total pool of integrin 
ανβ6 receptors recognised by antibodies 10D5, 53A2 and 620W7, was visibly 
altered across the MCF10 cell line series (Figure 4.1A). Statistical analyses revealed 
this variation in cell surface expression of total integrin ανβ6 amongst the MCF10 
panel to be significant (n=5, Friedman test with Dunn’s multiple comparison: 10D5 
p=0.0321; 53A2 p=0.0066; 620W7 p=0.0101).  
 
 
When compared to a variant representing neoplastic but non-invasive disease 
(MCF-10AT), total integrin ανβ6 expression was notably increased in MCF10A 
derived cell lines representing: a neoplastic variant with invasive potential (MCF10-
Kcl.2), invasive variants representing either well differentiated (MCF10-CA1h) or 
poorly differentiated (MCF10-CA1a) disease and a variant recapitulating in situ 
ductal disease (MCF10-DCIS.com). This suggested an association between 
increased integrin ανβ6 surface expression during breast cancer cell transformation 
and acquisition of a more invasive phenotype. 
 
 
Next, it was deemed pertinent to establish whether the observed variation in total 
integrin ανβ6 expression across the MCF10 panel (as defined by flow cytometric 
evaluation) was specifically a cell-surface receptor spatial restriction phenomenon, 
or attributable to altered whole cell (gross) expression. Therefore, whole cell 
abundance of integrin ανβ6 was determined in the MCF10 panel by Western 
blotting using a β6–subunit specific antibody (Figure 4.1B).  
 
 
Across three independent biological replicates, whole cell integrin β6–subunit 
expression was seen to vary in a similar pattern to that observed for cell-surface 
abundance. Densitometric analysis of blots was reviewed to aid comparison of 
enhanced chemiluminescence signal strength as a read-out for whole cell β6–
subunit abundance. This revealed that again, in comparison with the neoplastic 
but non-invasive MCF-10AT variant, integrin β6–subunit expression was markedly 
upregulated in both the neoplastic with invasive potential MCF-10Kcl.2 variant and 
the malignant variants MCF10-CA1h, MCF-10CA1a and MCF-10DCIS.com.  
 
 
Concordant with flow cytometric data, the Western blotting results also suggested 
an association between total integrin β6-subunit (and thus, integrin ανβ6) 
expression during breast cancer cell transformation and acquisition of a more 
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invasive phenotype. However, it was not confirmed from these data alone whether 
spatial restriction of the integrin ανβ6 receptor pool was implicated as a driving 
factor during breast tumourigenesis or progression to metastatic disease.  
 
 
Interestingly, data obtained for the MCF10-DCIS.com cell line did point to the 
possible aetiopathological significance of integrin ανβ6 spatial distribution during 
breast tumour progression. Western blotting revealed that amongst the entire 
MCF10 panel, the MCF10-DCIS.com cells expressed the highest levels of whole 
cell integrin-β6 subunit. Notably, this whole cell abundance was not translated to 
cell surface abundance of the total integrin ανβ6 receptor pool. Flow cytometry 
data had revealed that the MCF10-CA1h and MCF10-CA1a malignant, invasive 
variants expressed the highest levels of total integrin ανβ6 receptor at their cell 
surface. Therefore, it was postulated that upregulation of the integrin ανβ6 receptor 
at the cell surface, rather than whole cell overexpression, may drive acquisition of 
the invasive phenotype requisite for breast cancer disease progression.  
 
 
Curiously, it was noted that the MCF-10A parent cell line (derived from benign, 
fibrocystic breast tissue) which is intended to represent benign, non-neoplastic, 
non-tumourigenic, non-invasive mammary epithelial cells, consistently expressed 
more integrin ανβ6 than the transformed, neoplastic but non-invasive MCF-10AT 
variant. This finding (for both cell surface and whole cell abundance) was 
unexpected. It had been anticipated that the MCF-10A cells would express little 
integrin ανβ6, since this integrin moiety is only expressed in healthy adult tissues 
during wound healing. Therefore it was hypothesised that total integrin ανβ6 
expression (already associated with neoplastic transformation and invasive 
progression during breast carcinogenesis) would show a successive increase in 
expression across the MCF10 panel, from benign (MCF10A) through neoplastic 
(MCF-10AT, MCF10-Kcl.2) to malignant (MCF10-CA1h, MCF-10CA1a, MCF10-
DCIS.com) variants, positively correlating with neoplastic transformation and 
malignant progression concordant with the established multi-step model of breast 
tumourigenesis (Crum et al 2003, Schedin and Elias 2004, Bateman and Shaw 
2013, Lakhtakia and Chinoy 2014, WHO 2014).  
 
 
It was postulated that integrin ανβ6 expression in the MCF-10A cell line could be an 
artefact from 2D-culture on rigid, uncoated plastic tissue culture vessels inducting 
a wound healing response. It is now established that ECM stiffness regulates many 
epithelial cell phenotypic traits including differentiation, survival, polarisation and 
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migration (Butcher et al 2009, Allen et al 2012, Du et al 2016). These physical ECM 
forces generate specific tensile biomechanical cues that are transduced into 
meaningful intracellular signals by mechanotransduction receptor classes, such as 
the integrin superfamily (Sun et al 2016). Therefore, it may be that the rigid tissue 
culture vessel surface recapitulated a stiffened ECM-environment known to occur 
during fibrosis (Saneyasu et al 2016), inducing a fibrotic or wound healing 
phenotypic response in MCF10A cells during culture. The integrin ανβ6 is known to 
regulate fibrosis via TGF-β1 signalling (Sheppard 2015) in: lung (Tatler and Jenkins 
2012) and renal (Hahm et al 2007) tissues.  
 
 
Indeed, the primacy of integrin ανβ6-mediated TGF-β1 activation and signalling in 
inflammatory diseases such as idiopathic pulmonary fibrosis (Porte and Jenkins 
2014) is indicative of the importance of this integrin moiety within a fibrotic 
environment, and potentially in the pseudo-fibrotic environment of culture on stiff, 
uncoated plastic. In addition, it may be that the spontaneously immortalised 
MCF10A parent cell line natively expresses integrin ανβ6, given its isolation from 
resected fibrocystic mammary epithelium (Soule et al 1990), where pro-fibrotic 
integrin ανβ6/TGF-β1 signalling pathways would be anticipated and account for its 
expression in this cell line. 
  
 
After evaluating cell surface expression of the total integrin ανβ6 receptor, the 
abundance of integrin ανβ6 in its activated conformation was quantitatively 
determined across the MCF10 panel by flow cytometry using antibody clones 
6.2E5 (Figure 4.2C) and 6.2G2 (Figure 4.2D). Again, geoMean MFI values for 
antibodies 6.2E5 and 6.2G2 were normalised against geoMean MFI values 





Cell surface abundance of active integrin ανβ6 recognised by antibody 6.2E5 
(Figure 4.1C) was not significantly altered across the MCF10 panel (n=5, Friedman 
test with Dunn’s multiple comparison, p=0.1955). In contrast, the cell surface pool 
of active integrin ανβ6 detected by antibody 6.2G2 (Figure 4.1D) was significantly 
altered amongst the MCF10 isogenic breast cancer cell lines (n=5, Friedman test 
with Dunn’s multiple comparison p=0.0481).  
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It was acknowledged that cell surface expression of active integrin ανβ6 would be 
affected by the total abundance of gross integrin ανβ6 present at the cell surface 
capable of activation. For a fairer comparison of the role of the active fraction of 
integrin ανβ6 (i.e what proportion of integrin ανβ6 being expressed is activated), 
geoMean MFI values for total surface 6.2E5 or 6.2G2 were then expressed as a 
relative percentage of gross surface integrin ανβ6 expression.  
 
 
This was achieved by normalising expression of epitopes recognised by antibodies 
6.2E5 and 6.2G2 (representing the active integrin ανβ6) against the epitope 
recognised by antibody 10D5 (representing total integrin ανβ6 surface expression). 
Given that the ligand-mimetic inhibitory antibody 10D5 is a commercial, well-
characterised inhibitory antibody known to detect an intact heterodimeric-
dependent epitope, it was deemed most suitable for labelling the total pool of 
integrin ανβ6 without inducting canonical downstream activation owing to the 
function blocking properties of this antibody. 
 
 
The relative surface fraction of active integrin ανβ6 expression (“normalised 6.2E5” 
and “normalised 6.2G2”; Figures 4.2C & 4.2D respectively) proportional to total 
integrin ανβ6 expression (10D5) was not significantly altered across the MCF10A 
panel (n=5, Friedman test with Dunn’s multiple comparison: 6.2E5 p=0.0922; 
6.2G2 p=0.4895). However, it was observed that between the malignant, invasive 
variants (MCF-10CA1h and MCF10-CA1a), the poorly differentiated MCF-10CA1a 
cells expressed a greater proportion of active integrin ανβ6 recognised by 
antibodies 6.2E5 and 6.2G2, in comparison with the well-differentiated MCF10-
CA1h variants. Therefore, it may be that integrin ανβ6 activation is a driving factor 
in advanced disease, determining differentiation status and tumour grade. 
 
 
This suggested that in isolation, the abundance of activated integrin ανβ6 at the cell 
surface may not be a significant factor during breast tumourigenesis and disease 
progression. Therefore, the possibility of alternative integrin ανβ6–mediated 
mechanisms driving neoplastic transformation and malignant progression 
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4.2 total integrin ανβ6 is stably expressed at cell-cell junctions and the 
 cell periphery across the MCF10 in vitro model of breast 
 tumourigenesis,  but   active  integrin  ανβ6  undergoes    cytoplasmic  
 subcellular redistribution upon neoplastic transformation and 
 malignant progression 
 
Given the emerging importance of derailed adhesion receptor internalisation 
kinetics and intracellular trafficking routes during carcinogenesis (Mosesson et al 
2008), it was deemed pertinent to next characterise the subcellular localisation of 
integrin ανβ6 receptor populations (total and active) in the MCF10 cell line panel. 
Indeed, the work of Arjonen et al (2012) characterised distinct intracellular 
trafficking routes for active and inactive integrin β1, highlighting the importance of 
not just integrin receptor activation status, but also subcellular localisation and 
internalisation kinetics.   
 
 
Evaluating three independent lung, prostate and breast cancer cell lines (NCI-
H460, PC-3 and MDA-MB-231 respectively), Arjonen et al (2012) found that 
integrin β1 in its inactive form (recognised by antibodies mAB13 and 4B4) 
predominated at the cell surface, where only 20% of cell surface integrin β1 were 
active conformers (recognised by antibodies 12G10 and 9EG7); which was 
concordant with the previous findings of Tiwari et al (2011). Furthermore, confocal 
microscopy revealed that active integrin β1 was predominantly cytoplasmic in 
localisation, whilst inactive predominated at cell edges and was enriched at cell 
membrane protusions, suggesting differential trafficking routes for active versus 
inactive integrin β1 (Arjonen et al, 2012). 
 
 
Arjonen and colleagues (2012) also determined that active integrin β1 is 
endocytosed more efficiently and co-traffics with cognate ligand. In addition, it was 
shown that both active and inactive β1 integrins traffic to the same early 
endosomes (Rab5-, Rab4a and Rab21-GTPase positive compartments) within 30 
minutes from initial endocytosis. Interestingly, only active β1 integrin was present 
in Rab7-positive compartments 30 minutes post-internalisation. Inactive integrin β1 




Therefore, Arjonen et al (2012) concluded that active integrin β1 exhibits higher 
net internalisation kinetics and recycles at a slower rate than inactive integrin β1; 
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and although both inactive and active integrin β1 conformers initially share the 
same early endosomal trafficking routes, active β1 integrin is directed to a Rab7-
GTPase endosomal compartment whilst inactive integrin internalisation is 
equilibrated with rapid Rab-4/F-actin-dependent recycling shunting β1 integrins 
back to ARF6-positive plasma lemma protrusions. Collectively their findings 
provide evidence that integrin traffic is differentially regulated and dependent 
upon integrin receptor activation status.  
 
 
Thus, confocal immunofluorescence (IMF) microscopy was performed on the 
MCF10 panel of cell lines to characterise the subcellular localisation of the total 
integrin ανβ6 population labelled with antibody 10D5 (Figure 4.2B), in comparison 
with active integrin ανβ6 demonstrated by antibodies 6.2E5 (Figure 4.2C) and 
6.2G2 (Figure 4.2D). The MCF10 isogenic variants were routinely monitored in 
culture by phase microscopy (Figure 4.2A) to assess their phenotypic appearance 
and condition prior to experimental use.  
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Figure 4.2 (A & B) 
Total integrin ανβ6 demonstrated by antibody 10D5 appears to stably localise at cell-cell junctions in all MCF-10 isogenic variants but the active 
subpopulation of integrin ανβ6 recognised by antibodies 6.2E5 and 6.2G2 undergoes subcellular redistribution upon neoplastic transformation and 
malignant progression as represented by the MCF-10 cell line series 
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Figure 4.2 (C) 
Total integrin ανβ6 demonstrated by antibody 10D5 appears to stably localise at cell-cell junctions in all MCF-10 isogenic variants but the active 
subpopulation of integrin ανβ6 recognised by antibodies 6.2E5 and 6.2G2 undergoes subcellular redistribution upon neoplastic transformation and 
malignant progression as represented by the MCF-10 cell line series 
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Figure 4.2 (D) 
Total integrin ανβ6 demonstrated by antibody 10D5 appears to stably localise at cell-cell junctions in all MCF-10 isogenic variants but the active 
subpopulation of integrin ανβ6 recognised by antibodies 6.2E5 and 6.2G2 undergoes subcellular redistribution upon neoplastic transformation and 
malignant progression as represented by the MCF-10 cell line series 
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Figure 4.2  
Total integrin ανβ6 demonstrated by antibody 10D5 appears to stably localise at cell-cell 
junctions in all MCF-10 isogenic variants but the active subpopulation of integrin ανβ6 
recognised by antibodies 6.2E5 and 6.2G2 undergoes subcellular redistribution upon 
neoplastic transformation and malignant progression as represented by the MCF-10 cell 
line series 
 
The MCF-10A series of breast cancer cell lines (MCF10 isogenic model) generated to recapitulate 
neoplastic transformation and malignant progression (4.2 A) were used to explore the putative role of 
active integrin ανβ6 during breast tumourigenesis. The subcellular localisation and surface abundance 
of integrin ανβ6 recognised by antibodies 10D5, 6.2E5 and 6.2G2 were evaluated by permeabilised 
immunofluorescence (4.2 B, C and D) respectively. (4.2 A) The MCF-10 isogenic variants were 
routinely phenotypically monitored in culture by phase contrast microscopy morphological 
assessment (OLYMPUS™ IMT-2, Olympus® Corp). (4.2 B) The antibody 10D5 (10 μg ml-1, Merck 
Millipore) was used to identify the total pool of integrin ανβ6 and was seen to localise at cell-cell 
junctions (white arrows) across the entire MCF-10A panel of cell lines. Occasional cytoplasmic, 
vesicular accumulations (yellow arrow) were observed in the MCF-10A-KCl.2 neoplastic with invasive 
potential isogenic variant. (4.2 C) Antibody 6.2E5 (5 μg ml-1, Biogen Idec) was seen to localise at cell-
cell junctions (white arrows) in non-transformed (MCF-10A) and neoplastic cells (MCF-10AT, -KCl.2 
and –DCIS.com) but this pattern of immunopositivity was deregulated in malignant variants (MCF-10A-
CA1h and –CA1a). In neoplastic variants with invasive potential (-KCl.2 and –DCIS.com) 6.2E5 was seen 
to localise at leading edges of spreading cells (blue arrows). This was also observed in the malignant 
variants, where marked intracellular vesicular accumulations (yellow arrows) were noted. (4.2 D) 
Antibody 6.2G2 (5 μg ml-1, Biogen Idec) was observed at cell-cell junctions (white arrows) in the non-
transformed and neoplastic variants, but not in the malignant variants. In the neoplastic variant MCF-
10AT, 6.2G2 was seen to localise at the edges of spreading cells (blue arrows) and intracellular 
vesicular accumulations (yellow arrows) were also observed. Intracellular accumulations of 6.2G2 
immunopositivity were present in both the –CA1h and –CA1a malignant variants, as had been 
observed for antibody 6.2E5. Images were acquired by confocal microscopy using the ZEISS LSM710 
equipped with ZEISS Zen image analysis software (both Carl Zeiss AG, DE). Images were prepared for 
presentation in Image J software (National Institutes of Health) and Adobe®Photoshop©CS6 with 
composites generated in Adobe®Illustrator©CS6 (Adobe Systems Software© Ltd). 
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The total pool of integrin ανβ6 recognised by antibody 10D5 was seen to 
predominate at cell-cell interfaces across the MCF10 model when evaluated by 
permeabilised IMF microscopy (Figure 4.2B), but only weakly expressed at the cell 
periphery. Similarly, the antibody 53A2 (Figures 4.2C and 4.2D) was also seen to 
localise most markedly at cell-cell junctions, and weakly at the cell periphery. 
Occasional cytoplasmic accumulations of 53A2 immunopositivity were observed in 
the malignant variants MCF10-CA1h and MCF-10CA1a. 
 
 
Interestingly, the integrin ανβ6 activation-associated epitopes recognised by 
antibodies 6.2E5 (Figure 4.2C) and 6.2G2 (Figure 4.2D) underwent subcellular 
redistribution following neoplastic transformation and malignant progression. In 
the non-tumourigenic, non-invasive MCF-10A benign parent cell line, these 
activation-associated epitopes were weakly expressed and localised at cell-cell 
junctions. However, in the MCF-10AT neoplastic variant, these epitopes appeared 
weakly immunopositive and predominantly cytoplasmic in localisation. This 
suggested that although the active integrin ανβ6 was only present at low levels, it 
had undergone visible cytoplasmic redistribution upon neoplastic transformation 
in the MCF-10AT variant in comparison with the non-neoplastic MCF-10A parent 
cell line.   
 
 
Furthermore, vesicular-like cytoplasmic accumulations of the active integrin ανβ6 
(as demonstrated by antibodies 6.2E5 and 6.2G2) were apparent in variants with 
invasive potential (MCF10-Kcl.2) and invasive, malignant variants (MCF10-CA1h, 
MCF10-CA1a). The most marked alteration in subcellular localisation was 
observed in the MCF-10CA1h malignant variant, where notably large cytoplasmic 
accumulations of active integrin ανβ6 were observed. This may suggest that 
derailed internalisation and trafficking of the active integrin ανβ6 are implicated in 
advanced stages of breast cancer, facilitating an invasive phenotype requisite for 
metastatic dissemination.  
 
 
Curiously, the MCF10-DCIS.com variant recapitulating in situ disease, exhibited 
little or no cytoplasmic integrin ανβ6, either in its active or inactive state. Instead, 
both the active and inactive integrin ανβ6 conformers were seen to stably localise 
at cell-cell interfaces in a similar patter to that observed for the MCF-10A parent 
cell line. The notable absence of cytoplasmic integrin ανβ6 active conformers in the 
non-invasive, in situ disease variant (MCF10-DCIS.com) contrasts with the marked 
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vesicular, cytoplasmic abundance of active integrin ανβ6 conformers in the 
malignant, highly invasive variants (MCF10-CA1h, MCF10-CA1a).  
 
 
Collectively, these observations indicate that subcellular redistribution of active 
integrin ανβ6 may be necessary during invasion in late-stage disease. However, the 
mechanism driving this cellular re-localisation is unclear. It may be attributable to: 
increased internalisation kinetics for the active conformer resulting in greater 
cytoplasmic abundance; slower recycling kinetics yielding an accumulation of 
active conformers awaiting lysosomal degradation or perhaps aberrant 
intracellular receptor activation due to perturbed molecular regulation of integrin 
ανβ6 activation.  
 
 
Undoubtedly these findings warrant further investigation to define whether this 
subcellular redistribution of the active ανβ6 conformer is a cause or effect during 
acquisition of an invasive phenotype; what regulates integrin ανβ6 internalisation 







4.3 isogenic variants comprising the MCF10 in vitro model of breast 
 tumourigenesis may be successfully co-cultured with human 
 fibroblasts employed in physiomimetic 3D-miniorganotypic gel 




The seminal importance of integrin adhesion receptors as the nexus integrating 
bidirectional signalling cues exchanged between cells and their encompassing 
three-dimensional (3D) environment has long been established (Hood and 
Cheresh 2002, Hynes 2002, Luo et al 2007, Harburger and Calderwood 2009, 
Campbell and Humphries 2011, Kim et al 2011a, Welf et al 2012, Byron et al 2014).  
 
 
Given that integrins modulate many aspects of cell-fate in response to cognate 
ligand-patterning, composition and tensile forces determined by the ECM, many 
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researchers seek to establish biomimetic models that better recapitulate the 
structural and biochemical complexities of the native 3D cellular-environment than 
conventional 2D-culture systems alone permit (Baker and Chen 2012).   
 
 
Zutter et al (1995) published an early example of the utility of even a rudimentary 
3D model to characterise the critical role of integrin-mediated ECM cues during 
tissue morphogenesis. The authors demonstrated integrin α2β1 expression is 
critical during murine mammary morphogenesis using natural ECM-based 
hydrogels comprising unsupplemented commercial Matrigel® preparation to 
recapitulate basal laminae 3D-matrices.  
 
 
They observed that α2–null Mm5MT murine mammary epithelial cells cultured 
within these gels formed aggregates mesenchymal in appearance and devoid of 
any discernible structural organisation. In contrast, Mm5MT cells transfected to 
stably express the α2-subunit formed highly organised, branching 3D alveolar and 
ductal structures within 3 to 4 days of in-gel culture.  
   
  
Subsequently, 3D-physiomimetic culture models have been refined to better 
recapitulate the emerging complexities of the tumour microenvironment. 
Parenchymal cells may be co-cultured with tissue-specific stromal cells to reflect 
the importance of tumour-stroma cellular crosstalk now known to initiate, enable 
and enhance established cancer hallmarks in many malignancies (Hanahan and 
Weinberg 2011, Quail and Joyce 2013), including breast cancer (Criscitiello et al 
2014, Bussard et al 2016).  
 
 
Furthermore, these 3-D assay matrices may be customised by treatment with 
physiological and/or pharmaceutical supplements to study the effects of defined 
extracellular mediators including cytokines and growth factors, or evaluate the 
efficacy of novel therapeutics, on tumour cell behaviour (Coleman et al 2014b). 
Therefore it was deemed pertinent to establish the utility of the MCF10 isogenic 
panel in an established 3D-miniorganotypic gel fibroblast co-culture assays (Figure 
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Figure 4.3 (A & B) 
Establishing the utility of cells comprising the MCF-10 isogenic model of breast tumourigenesis and disease progression in 3D-organotypic cultures  
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Figure 4.3 (C) 
Establishing the utility of cells comprising the MCF-10 isogenic model of breast tumourigenesis and disease progression in 3D-organotypic cultures  
 chapter IV: 
results part II 
200 
Figure 4.3 
Establishing the utility of cells comprising the MCF-10 isogenic model of breast 
tumourigenesis and disease progression in 3D-organotypic cultures  
 
Organotypic cultures using the MCF-10A, MCF-10AT and MCF-10A.CA1h alone, or co-culture in a 2:1 
ratio with (4.3 B) human foreskin fibroblasts (FSF2) or (4.3 C) primary human fibroblasts isolated from 
a reduction mammoplasty (1492N) were prepared to evaluate the potential utility and feasibility of this 
model in future investigations seeking to characterise the role of the active integrin ανβ6 
subpopulation in neoplastic transformation of mammary epithelium and malignant progression within 
a physiomimetic 3D-context. (4.3 A) An aliquot of cell suspensions used to prepare organotypic 
cultures were seeded in spare wells of the 24-well tissue culture plate housing the organotypics to 
confirm adherent morphology by phase contrast microscopy (OLYMPUS IMT-2, Olympus® Corp). (4.3 
B and C) Organotypic cultures were maintained over a 10-day period, and media replenished every 
48 hours. (4.3 B) As previously reported, cancer cells alone did not invade, but in the presence of 
human foreskin fibroblasts (FSF2), invasion into the gel was observed even with the benign, non-
invasive MCF-10A parental cell line. (4.3 C) Similar observations were made for organotypic cultures 
established with human mammary fibroblasts isolated from a reduction mammoplasty (1492N). 
Following completion of 10-day culture, organotypic gels were harvested, formalin fixed overnight 
and immersed in 70% ethanol for a minimum of 12 hours prior to processing. Sections from FFPE 
samples were stained with haematoxylin and eosin (H&E) and images acquired using the ZEISS 
AxioPlan brightfield microscope equipped with ZEISS AxioVision v4.8.1 imaging software (both Carl 
Zeiss AG, DE). Scale bars represent 50 μm.   
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It was hoped this approach would contextualise the role of integrin ανβ6 activation 
during breast tumourigenesis and disease progression within a biomimetic, 3D-
environment that would better recapitulate the complexities of the tumour 
microenvironment than in vitro 2D studies alone. However, the phenotypic 
instability of the MCF10 variants in routine culture (Figure 4.4) hindered their 
successful application for the purposes of this investigation. 
 
 
To establish the suitability of the MCF10 panel to characterise integrin ανβ6 
activation within a 3D physiomimetic environment, mini-organotypic gel cultures 
were prepared using co-culture with FSF2 normal human foreskin fibroblasts 
(Figure 4.3A and B), or tissue-specific 1492N normal breast fibroblasts derived 
from reduction mammoplasty tissue (Figure 4.3C). Concordant with previous 
literature (Wang et al 2002), the presence of fibroblasts promoted breast cancer 
cell invasion. Invasion into the mini-organotypic gels was not observed in the 
presence of cancer cells alone.  
 
 
Concordant with the findings of Qu et al (2015), MCF-10A cells in 2D-culture 
exhibited a cuboidal epithelial morphology. In 3D-organotypic cultures in the 
presence of Matrigel and collagen type I, MCF-10A cells formed spheroid 
structures as previously described by Qu and colleagues. A similar formation of 
spheroid, pseudo-ductal structures were seen to form in MCF-10A co-cultures with 
both FSF2 and 1492N fibroblasts. However staining for epithelial and 
mesenchymal markers to distinguish the MCF-10A cell compartment from the co-
cultured fibroblast component of the organotypic model would need to be 
undertaken to establish whether these spheroid, ductal-like structures were 
formed by MCF-10A cells, as described by Qu et al (2015).   
 
 
Curiously, seeded cells were seen to invade gels when the benign, non-invasive 
MCF10A cell line was co-cultured with FSF2 normal human foreskin fibroblasts 
(Figure 4.3B) and 1492N normal human breast fibroblasts (Figure 4.3C). Similarly, 
co-cultures of the reportedly neoplastic but non-invasive MCF-10AT cell line with 
FSF2 fibroblasts, also exhibited unexpected invasion into mini-organotypic gels. 
Invasion was observed for the well differentiated, invasive MCF-10CA1h variant co-
cultured with FSF2 fibroblasts, although this appeared to be to a lesser extent than 
for the MCF-10A and MCF-10AT variants. 
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It had been anticipated that little or no invasion would be observed for the MCF-
10A and MCF-10AT cell lines. It is possible that the observed invasion is 
attributable to the fibroblast component in the absence of cancer cell invasion for 
mini-organotypics using these non-invasive breast cancer cell lines. In the absence 
of robust immunohistochemical confirmation of the epithelial (cancer cell) versus 
mesenchymal (fibroblast) cellular compartments to conclusively determine 
location of cancer cells and fibroblasts within the gel, it is difficult to draw 
meaningful conclusions.  
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Instability of integrin ανβ6 expression and phenotypic loss of the MCF-10 isogenic cell line series in routine culture 
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Figure 4.4 (D) 
Instability of integrin ανβ6 expression and phenotypic loss of the MCF-10 isogenic cell line 
series in routine culture: Emergence of two morphologically distinct subpopulations within 
the MCF-10AT cell line coincided with acquisition of integrin ανβ6 weakly and highly 
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Figure 4.4 (E) 
Instability of integrin ανβ6 expression and phenotypic loss of the MCF-10 isogenic cell line 
series in routine culture: Uniformity of integrin ανβ6 expression in MCF-10 variants in 
comparison with distinct weak and strong positive subpopulations observed in the MCF-
10AT cells 
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Figure 4.4 
Instability of integrin ανβ6 expression and phenotypic loss of the MCF-10 isogenic cell line 
series in routine culture 
 
The MCF10 panel of isogenic cell lines were monitored daily by phase contrast microscopy during 
routine culture. Representative images for the (4.4 A) MCF10A, (4.4 B) MCF-10AT and (4.4 C) MCF-
10CA1h variants are shown. Passage numbers (p) indicate the number of passages after thawing (n + 
11) frozen cells. It was observed that the morphological appearance of these cell lines drifted notably 
during the course of routine tissue culture. (4.4 A) MCF10A cells appeared to lose their epithelial 
morphology and differentiate into two distinct morphological subtypes (outlined in black dashed line 
and highlighted with block arrows), suggesting a mixed population of cells. (4.4 B) Similarly, the MCF-
10AT and (4.4 C) MCF-10CA1h variants appeared to differentiate into two distinct morphological 
subtypes indicating loss of cell line clonal homogeneity. With progressive passage in culture, the 
phenotypic loss observed coincided with the emergence of two distinct populations within the MCF-
10AT cell line in terms of integrin ανβ6 expression (weak and high) observed on FCM histogram plots 
(4.4 D), which contrasted with uniformity of integrin expression observed in the other MCF-10 
isogenic variants (4.4 E) Disappointingly, the phenotypes were not recovered. Phase contrast images 
were acquired using the OLYMPUS™ IMT-2 phase contrast microscope (Olympus® Corp). All images 
were acquired at x20 magnification. All flow cytometry data was acquired on live cells labelled with 
clone 10D5 (10 μg ml-1, Merck Millipore) in the presence of a cell viability indicator (5 μg ml-1 
propidium iodide, P4170, Sigma Aldrich) using the BD FACSCalibur™ (BD Biosciences). Following 
normalisation against isotype matched negative control antibodies, geometric MFI values were 
determined by analysis in BD CellQuestPro™ software (BD Biosciences). Statistical analyses were 
performed using GraphPad Prism® 5.0b for MacOSX (Graphpad Software Inc, CA, USA). 
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Based upon altered microscopic appearance and the emergence of two distinct 
morphological phenotypes observed by phase contrast microscopy during routine 
tissue culture, the in-house stocks of the MCF-10A cell line and its derived variants 
were deemed to be phenotypically unstable (Figure 4.4). The MCF-10AT variants 
were phenotypically unstable in routine culture. The observation of distinct 
morphological phenotypes coincided with a shift in integrin ανβ6 expression which 
suggested the emergence of two subpopulations that were either weakly, or 
strongly integrin ανβ6 positive (Figure 4.4D). In light of phenotypic instability and 
loss of stable integrin ανβ6 expression, the continued experimental use of the MCF-
10 model was not deemed justifiable for the purposes of this study.   
 
 
The spontaneous emergence of distinct morphological subpopulations in the 
MCF-10A variants has been previously published. Zantek et al (2001) reported the 
emergence of a spontaneous novel variant arising during routine culture of the 
T24 human bladder carcinoma Ha-Ras-oncogene transformed MCF-10AT 
(previously designated MCF-10NeoT). The authors described the differentiation of 
MCF-10NeoT cells into a novel variant of spindled mesenchymal morphology. 
Naming this novel, spontaneously arising variant “NeoST”, Zantak and colleagues 
noted that this acquired phenotype was irreversible.  
 
 
Furthermore, functional characterisation of the MCF-10NeoST revealed their in 
vitro recapitulation of traits ascribed to metastatic breast cancer cells including: 
loss of plasmalemma E-cadherin, invasiveness in 3D assays, anchorage-
independent growth (circumvention of anoikis) and increased activity of FAK 
tyrosine kinase. Zantak and colleagues concluded that the spontaneously arising 
NeoST represented a novel, distinct phenotypic variant in both functional traits 
and morphological appearance. 
 
 
Therefore, given previous reports of a novel variant arising spontaneously in 
culture from the MCF10 panel that was both morphologically and functionally 
distinct in phenotype, it was deemed inadvisable to continue experimental work 
with the MCF10 panel in light of this emerging morphological phenotypic 
instability. In addition, further immunohistochemical or molecular characterisation 
of the emergent morphological subpopulations observed was not undertaken as it 
was not deemed of potential value to the aims of this project. 
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4. discussion  
 
In summary, it was found that in the presence of a relatively stable cell surface pool 
of active integrin ανβ6 (quantified by flow cytometry), the activation-associated 
epitopes recognised by antibodies 6.2E5 and 6.2G2 underwent subcellular 
redistribution upon neoplastic transformation and malignant progression in the 
MCF-10AT and MCF-10CA1h variants respectively (as demonstrated by confocal 
IMF microscopy).  
 
 
Based upon these observations, it is postulated that derailed internalisation 
kinetics and intracellular trafficking routes of active integrin ανβ6 may be involved 
in tumour initiation and acquisition of an invasive, metastatic phenotype in 
mammary epithelial cells undergoing transformative changes. This theory fits with 
Ramsay et al (2007) observation that HAX-1-mediated clathrin-dependent 
endocytosis of integrin ανβ6 was requisite for carcinoma cell invasion in an OSCC 
model. In addition, emerging evidence suggests that it is the active integrin 
conformer that mediates invasive and metastatic potential (Lee et al 2013). 
Collectively, this would justify further investigation into a putative role for aberrant 
active integrin ανβ6 internalisation determining invasive potential in BrCa cells.  
 
 
It is acknowledged that additional data would strengthen the case for such 
investigations, which so far are based predominantly on observational data. 
Characterisation of active versus inactive integrin ανβ6 internalisation kinetics could 
be quantitatively determined using a biochemical surface-biotinylation 
endocytosis assay established by Roberts et al (2001), or using a flow cytometric, 
activation-specific monoclonal antibody approach as employed by Arjonen et al 
(2012). Furthermore, it would be valuable to characterise and compare specific 
mechanisms of internalisation and intracellular trafficking routes for the active and 
inactive integrin ανβ6 conformers. It would be interesting to investigate whether 
the integrin ανβ6 is subject to distinct activation-specific internalisation, trafficking 
and recycling kinetics in cancer, as defined by Arjonen et al (2012) in breast, lung 
and prostate cancer cell lines.  
 
 
Definition of differential trafficking and recycling of distinct receptor 
conformations, could be achieved by IMF co-labelling of integrin ανβ6 conformers 
with endosomal compartment markers at defined time-points. Results from such 
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investigations would inform whether integrin ανβ6 trafficking routes are activation-
status dependent and/or altered during the course of breast tumourigenesis and 
progression to malignant disease.  
 
 
It was observed that between the malignant, invasive variants (MCF-10CA1h and 
MCF10-CA1a), the poorly differentiated MCF-10CA1a cells expressed a greater 
proportion of active integrin ανβ6 recognised by antibodies 6.2E5 and 6.2G2, in 
comparison with the well-differentiated MCF10-CA1h variants. This may indicate 
that integrin ανβ6 activation is a driving factor in advanced disease, determining 
differentiation status and tumour grade. Indeed, this would fit with the findings of 
Tang et al (2003) who defined a pleiotropic TGF-β1 signalling switch during breast 
tumourigenesis and malignant progression using the MCF10 isogenic model.  
 
 
The authors concluded that TGF-β1 signalling was tumour suppressive in early 
stage disease, but switched to a prometastatic factor in advanced disease. Given 
that the integrin ανβ6 is known to regulate TGF- β1 activation (Thomas et al 2002, 
Margadant and Sonnenberg 2010, Munger and Sheppard 2011, Khan and 
Marshall 2016), it is logical that integrin activation may play a role in establishing 




Felding-Habermann et al (2001) proposed a “two hit hypothesis” for the role of 
integrin ανβ3 during breast carcinogenesis and metastatic dissemination. The 
authors suggested that integrin ανβ3 expression was necessary, but on its own 
insufficient, for breast cancer metastasis. Instead, they argued that additional 
factors governing the activation state of integrin ανβ3 were requisite for metastatic 
dissemination. However, these factors were as yet undefined. Felding-Habermann 
and colleagues concluded that tumours (and their microenvironments) favouring 
aberrant integrin activation would elicit an adverse effect on the course and 
outcome of human breast cancer.  
 
 
This hypothesis of a “two-hit” model for integrin-mediated outcomes in breast 
cancer is concordant with results discussed in this chapter. Flow cytometry data 
suggested that relative cell surface abundance of integrin ανβ6 expression alone 
may be insufficient to drive neoplastic transformation or malignant progression in 
the human breast. Instead, the requisite “second hit” determining an unfavourable 
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outcome in the course of breast cancer may arise from perturbed intracellular 
trafficking of the active integrin ανβ6 receptor pool, as intimated from the 
subcellular redistribution of 6.2E5 and 6.2G2 epitopes upon neoplastic 
transformation and malignant progression demonstrated by confocal 
immunofluorescence studies.  
 
 
A notable limitation is acknowledged regarding the use of the MCF10 isogenic 2D 
model of breast tumourigenesis and disease progression. In light of the 
phenotypic complexities of human mammary epithelium, the suitability of the 
MCF-10A series to characterise the mechanisms by which normal breast cell 
functions are perturbed during neoplastic transformation, has been increasingly 
called into question. Given the abundance of BrCa research published using the 
MCF-10 isogenic cell line series as a surrogate pathogenetic model recapitulating 
breast tumourigenesis in vitro, Qu et al (2015) evaluated the biological relevance 
and reliability of the parent MCF-10A cell line itself to represent “normal” human 
mammary epithelial cells.  
 
 
It was demonstrated that MCF-10A cells exhibit unique, culture dimension-specific 
phenotypes. In 2D culture, MCF-10A cells comprising a well-established 
monolayer expressed markers for luminal, basal and progenitor phenotypes. 
Strong expression of the basal markers alpha smooth muscle actin (α-SMA), 
vimentin and N-cadherin suggest MCF-10A cells are of basal ontogeny. 
Myoepithelial markers showed mixed expression with strong CK5 expression 
observed in approximately 50% of cells, moderate expression of CK17 in 10% of 
cells and less than 1% of cells expressing CK14.  
 
 
In 2D-culture, concomitant expression of luminal markers was also observed, with 
50% of cells showing positivity for CK8, but less than 10% of cells exhibiting 
expression of other luminal markers including mucin-1, CK18 and CK7. 
Furthermore, expression of breast-tissue specific milk proteins α-lactalbumin and 
β-casein was absent in the MCF-10A 2D-monolayer. Interestingly, Qu et al (2015) 
also found that a sub-population of MCF-10A cells in 2D-culture highly expressed 
the stem cell-associated transcription factors Sox-2 and Oct4. 
  
However, MCF-10As in mammospheres and 3D-culture expressed both luminal 
and basal markers. It was observed that MCF-10A cells formed acinar structures in 
3D culture demonstrating positivity for basal and luminal markers in addition to 
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expression of the milk proteins α-lactalbumin and β-casein. It is argued that the 
although MCF-10A cells in 3D-culture recapitulate some features of human luminal 
epithelial cells in terms of structure and function, the co-localisation of milk 
proteins and basal markers alongside luminal markers in branches and acini has 
not yet been robustly demonstrated in normal human mammary gland tissue.  
 
 
Qu et al (2015) concluded that the differentiated MCF-10A phenotype uniquely 
observed in 3D-culture is unlikely to exist in normal human breast tissue in vivo; 
which restricts the biological relevance and translational applications of this cell 
line. Although the MCF10 isogenic cell line series may still have merit as a basic in 
vitro model, the ontogeny of transformative events and clonal selection criteria for 
neoplastic and malignant variants, culture-specific and highly variable phenotypes 
exhibited by the MCF-10A cell line and its derivatives, mean that interpretation of 
experimental data should be appropriately contextualised within the limitations of 




However, this model was deemed suitable for the purposes of preliminary 
investigations to justify future investigations into the putative role of integrin ανβ6 
activation during breast tumourigenesis and metastatic disease progression. Using 
this model, an exciting avenue for future research was successfully identified. It 
was observed that the active integrin conformer underwent subcellular 
redistribution upon neoplastic transformation and malignant progression across 
the MCF10 panel. Given that cell surface abundance of the active integrin ανβ6 
remained stable across cell lines comprising the MCF10 model, it was 
hypothesised that derailed internalisation and intracellular trafficking, rather than 
overexpression of active integrin ανβ6, may be critical oncogenic and metastatic 
drivers in BrCa.  
 
 
Attempts were made to dissect this hypothesis further, including development of 
an internalisation assay to co-immunoprecipate LAP-ligand-engaged integrin ανβ6 
internalisation complexes for proteomic interrogation to identify novel regulators 
of integrin ανβ6 endocytic regulation that may be derailed in BrCa. Although this 
assay could not be satisfactorily optimised for proteomics, it was used to validate 
subsequent experimental strategies developed to define th integrin –kinome 
associated with LAP-ligand internalisation (Chapter VI: Results Part IV; Figures 6.1.1 
and S6.1).  
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A flow cytometry-based internalisation assay was developed to characterise 
internalisation kinetics (broadly defined as downregulation from the cell surface) 
for the active versus inactive integrin ανβ6 conformers. Disappointingly this assay 
performed in suspension could not be robustly validated as a biologically relevant 
read-out for the internalisation of an adhesion receptor and development was 
halted (Supplementary Figure S4.1). 
 
 
Although a method to mechanistically dissect the putative derailed internalisation 
of the active integrin ανβ6 associated with neoplastic transformation and malignant 
progression could not be established within this body of work, this interesting 
finding most assuredly warrants further investigation. Indeed, definitions of 
integrin ανβ6 endocytic regulation and intracellular trafficking routes would be 
informative as this adhesion receptor is of emerging clinical significance in a 
variety of human pathologies, including BrCa.      
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Supplementary Information (Figure) S4.1 
Optimisation attempts for a flow cytometry-based internalisation assay to quantitatively 
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Supplementary Information (Figure) S4.1 
Optimisation attempts for a flow cytometry-based internalisation assay to quantitatively 
define internalisation kinetics of integrin ανβ6 conformers  
 
To characterise putative integrin ανβ6 conformer-specific internalisation kinetics, a flow cytometry 
(FCM)-based internalisation was tested using monoclonal antibodies or a synthetic peptide to 
specifically label cell-surface integrin ανβ6 populations. Representative examples of experiments using 
MCF10-CA1a cells are shown. Cells were labelled in suspension on wet ice for 10’ with anti-integrin 
ανβ6 moieties including the 20mer synthetic –RGD- motif bearing peptide A20FMDV2 (250 nM, in-
house), a ligand mimetic antibody (clone 10D5, 10 μg ml-1, Merck Millipore) or a non-ligand mimetic 
antibody (clone 620W7, 10 μg ml-1, CR-UK). Cells were then washed and immersed in pre-warmed 
(37°C) complete media and returned to standard culture conditions to permit internalisation. At 
designated time-points internalisation was quenched by flooding and washing with ice-cold 
DMEM/0.1/0.1 FACS buffer prior to labelling residual surface bound antibody with fluorophore-
conjugated secondary antibody to permit detection by FCM. Inclusion of 0.6 mM primaquine (PQ), a 
known-reversible inhibitor of integrin endocytic recycling (Reid and Watts 1990, van Weert AW 2000), 
was tested to prevent recycling of internalised antibody-bound integrin ανβ6 back to the 
plasmalemma. The “in-suspension’ internalisation assay was not pursued given concerns regarding 
the biological relevance of characterising the properties of a cellular adhesion receptor in the absence 
of physiologically relevant adhesion cues. Flow cytometry was performed as previously described.  
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 DMBT-1,   MARCKS,    MXRA5,  MYH9,   MYH10,   SEPT6   and  SEPT9   are  
     implicated in the BT-20 LAP-engaged β6-adhesome; whilst EGFR 




5. introduction  
 
Integrin activation induced by cognate ligand-engagement during adhesive 
processes is well established (Humphries 1996, Shimaoka et al 2002, Humphries 
2004, Luo et al 2007, Shattil et al 2010, Campbell and Humphries 2011, Kim et al 
2011b). Thus, characterisation of an integrin ανβ6–driven adhesion environment 
(“β6-adhesome”) would provide valuable insights into putative molecular 
mediators of ligand-induced integrin ανβ6 activation and subsequent signalling 
induction. Proteomic dissection of the β6-adhesome was undertaken by coupling a 
two-dimensional enrichment (2D-E) method for adhesion complexes to 
downstream label-free mass-spectrometry (LC-MS/MS) and bioinformatic 
interrogation (summarised schematically in Figure 5.1). Kind thanks are extended 
to Dr Mark R Morgan, (Principal Investigator at the Receptor Dynamics in Cancer 
Laboratory, Institute of Translational Medicine, Centre for Molecular Physiology, 
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University of Liverpool), who hosted and supervised experimental 2D-E work 
undertaken in his laboratory and presented here.    
The 2D-E/LC-MS/MS method employed was first described by Humphries et al 
(2009) and later refined by Byron et al (2011) to successfully: characterise integrin 
α4β1–mediated adhesion complexes (Byron et al 2012), refine tissue-specific ECM 
definitions (Rashid et al 2012, Byron et al 2013, Lennon et al 2014), identify novel 
glomerular cell cross-talk during renal ECM assembly and modification (Byron et al 
2014), reveal integrin activation state-dependent regulation of cortical microtubule 
arrays (Byron et al 2015) and define a fibronectin (Fn)-induced integrin-dependent 
phospho-adhesome (Robertson et al 2015).  
 
 
In order to define an integrin ανβ6-dependent adhesion environment (“β6-
adhesome”), an established method for the isolation, enrichment and proteomic 
interrogation of transmembrane receptor-ligand complexes first reported by 
Humphries et al (2009) was adopted. This protocol permits stabilisation of 
notoriously labile integrin-mediated adhesion complexes via biochemical cross-
linkage using the membrane permeant cross-linker dimethyl 3,3’-
dithiobispropionimidate2HCl (DTBP) (Corgiat et al 2014) to facilitate adhesion 
complex enrichment by sonication in an astringent detergent extraction buffer 
compatible with downstream proteomic investigation.  
 
 
Successful application of this 2D-enrichment (2D-E) method to elucidate novel 
molecular (Byron et al 2011, Byron et al 2012, Jacquemet et al 2013) and 
phosphorylation (Paul 2014, Robertson 2014) signatures associated with integrin 
activation and signalling at sites of integrin-mediated adhesions is clearly now 
well-established. Recently this strategy has enabled characterisation of distinct, 
cell-type specific extracellular matrix (ECM) environments that modulate adhesion 
receptor crosstalk, matrix assembly and organisation within the renal glomerulus 
(Byron et al 2014, Lennon et al 2014) and to define novel integrin-associated multi-
protein complexes isolated from mesenchymal stem cells (Ajeian et al 2016). Such 
investigations will be of growing importance given the emerging aetiological 
significance of the cellular microenvironment and ECM constitution as regulators 
of disease outcome in a variety of pathologies, including cancer (Lu et al 2012, 
Pickup et al 2014).   
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Byron and Frame (2016) recently reviewed the significance and impact that this 
strategy for proteomic analysis of integrin-mediated adhesion complexes has had 
on expanding our previously limited understanding of protein-protein-interaction 
(PPI) networks and associated signalling induction downstream of focal adhesion 
(FA) assembly. Indeed, Eke and Cordes (2015) highlight the importance of FA-
mediated signalling as a driver of therapeutic resistance in cancer within the 
context of both cell adhesion-mediated drug resistance (CAMDR) and cell 
adhesion-mediated radiotherapy-resistance (CAMRR). The authors acknowledge 
that due to their upstream localisation and role as nexūs integrating adhesion- and 
growth factor (GF)-mediated signals within the complex network of ECM-derived 
signalling, FA appear a logical place to initiate therapeutic intervention.  
 
 
However, citing their previous studies characterising signalling events associated 
with chemoresistance to the anti-EGFR agent cetuximab (Eke et al 2013a, Eke et al 
2013b), Eke and Cordes highlight network plasticity, complexity and redundancy 
as confounding factors limiting the efficacy of single-agent therapeutic strategies. 
Instead, the authors postulate that multi-agent/multi-modal treatment regimens 
may provide a more effective means of administering targeted therapies; limiting 
the capacity for resistance to develop if network redundancy and by-pass 
mechanisms are simultaneously targeted.  
 
 
Given the established cross-talk between integrin receptor classes and receptor 
tyrosine kinase (RTK) moieties, the possibility of establishing effective multi—modal 
cancer therapies targeting known tumourigenic growth factor receptors (GFRs) in 
tandem with modulation of synergistic integrin signalling (and ergo function), 
appears a logical area to focus integrin-based cancer therapy research (Jin and 
Varner 2004, Desgrosellier and Cheresh 2010). For example, functional abrogation 
of integrin ανβ6 using the therapeutic inhibitory antibody 264RAD (Oncology 
iMED, AstraZeneca UK Ltd) has already been shown to potentiate trastuzumab 
efficacy in an in vivo murine model of HER-2 positive BrCa (Moore et al 2014). 
 
 
Interestingly, Lesniak et al (2009) demonstrated that integrin β1 expression is an 
independent prognostic factor for tumour progression in human epidermal 
growth factor-2 (HER-2) positive metastatic breast cancer (MBC) patients treated 
with trastuzumab-based therapy. The authors immunohistochemically evaluated 
integrin β1 expression in a cohort of HER-2 positive MBC patients, of whom 83 had 
received trastuzumab-based therapy and 30 had received chemotherapy without 
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trastuzumab (vinorelbine, capecitabine or docetaxel). Kaplan-Meier analysis 
revealed that integrin β1 overexpression showed a strong and significant 
correlation with short time-to-tumour progression (TTP) in the trastuzumab cohort 
(HR 2.04; 95% CI 1.02 – 3.4; p=0.0081) but not the treated without trastuzumab 
cohort (p=0.75).   
 
 
To define the mechanism by which integrin β1 overexpression accelerates TTP in 
trastuzumab treated MBC patients, Lesniak et al (2013) performed in vitro studies 
using the trastuzumab-sensitive, HER-2 positive, integrin β1 low/null SKBR-3 cell 
line transfected with a Flag-tagged human integrin β1-subunit vector. In 
comparison with untransfected SKBR-3 cells and cells transfected with empty 
vector, expression of integrin β1 was associated with increased phosphorylation of 
AktS473 and ERK1/2. Interestingly, the authors also demonstrated that functional 
abrogation of integrin β1 using a blocking monoclonal antibody (clone AIIB2) in 
tandem with trastuzumab therapy, decreased AktS473 and ERK1/2 phosphorylation 
and also inhibited cell proliferation and colony forming ability in vitro. Lesniak and 
colleagues concluded that integrin β1 is a driver of chemoresistance, facilitating 
circumvention of the anti-proliferative effects of trastuzumab via integrin β1–
mediated increased phosphorylation of AktS473 and ERK1/2.  
 
 
Collectively, this research points to the potential clinical benefit of combination 
therapy strategies exploiting both established molecular targets (such as HER-2) 
and novel regulators of specific resistance mechanisms (for example integrin β1). 
Therefore, exploration of integrin ανβ6–mediated adhesion complex signalling in 
tumour establishment, progression – and even chemotherapeutic resistance – may 
be of similar value to improve outcomes in BrCa patients. 
 
 
The concept of integrin receptor-ligand specificity (Hynes 2002, Kapp et al 2017) 
was exploited in order to modulate the species of integrin engaged upon different 
cognate ligands designed to simulate distinct, physiologically relevant integrin-
specific 2-dimensional (2D) adhesion environments. Since ligand-engagement 
induces integrin activation, the experiments outlined in this chapter were intended 
to provide valuable insight into the nature of the adhesion environment 
(adhesome) assembled downstream of activated integrin ανβ6 engaged in 









          overview of key findings 
 
 
To characterise the molecular nature of an integrin ανβ6–dependent adhesion 
environment (“β6-adhesome”) a 2D-E strategy (Figure 5.1.1A) first described by 
Humphries et al (2009) was modified to specifically address the research intention 
to specifically characterise a ligand-engaged integrin ανβ6–dependent adhesion 
environment (Figure 5.1.1B).  
 
 
Owing to loss of reliably stable phenotypes amongst variants comprising the MCF-
10 isogenic cell line series (outlined in Chapter IV: Results part II), the use of this in 
vitro model of breast tumourigenesis and disease progression was excluded from 
future studies. Therefore, a panel of known integrin ανβ6-positive BrCa lines 
comprising: the triple negative BT-20, SUM159 and MDA-MB-468; and triple 
positive BT-474 cell lines, were screened by flow cytometry (FCM) to evaluate 
stability of endogenous cell surface integrin ανβ6 expression and identify a cell line 
suitable for 2D-E/LC-MS/MS-experimental work-up (Figure 5.1.2).   
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adhesion assay: formation of
ligand-specific adhesion complexes
formed adhesion complex stabilisation
by DTBP cross-linking
enrich for adhesion complexes
by sonication in extraction buffer
sample separation by SDS-PAGE
16 1 mm gel slices per sample
for in-gel tryptic digest 
peptides analysed by LC-MS/MS 
(nanoACQUITY UPLC - LTQ Orbitrap)
peptide identification (Mascot Daemon)
peptide validation (Scaffold)
spectral normalisation: 
total spectra & protein size (kDa)






































































Figure 5.1.1 (A)  
Proteomic pipeline for the definition of a ligand-engaged integrin ανβ6–dependent 
adhesion environment (“β6-adhesome”) using a 2D-enrichment adhesion assay coupled to 
label-free LC-MS/MS interrogation 
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Figure 5.1.1 (B)  
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Figure 5.1.1  
Summary of the proteomic pipeline and schematic overview of the 2D-enrichment protocol 
used to isolate ligand-engaged integrin ανβ6–mediated adhesion complexes for proteomic 
definition of the β6-adhesome 
 
(5.1.1 A) A proteomics pipeline based upon that described by Humphries et al (2009) and Byron et al 
(2011) was modified for the purposes of defining a ligand-engaged integrin ανβ6 adhesion 
environment (β6-adhesome) by label-free tandem mass spectrometry (LC-MS/MS). (5.1.1 B) A method 
permitting 2D-enrichment of integrin ανβ6–mediated adhesion complexes ready for isolation and 
downstream interrogation by LC-MS/MS was followed. Briefly, adherent cells are trypsinised, washed 
to remove residual trypsin and held in suspension in complete media for 30 min under standard 
culture conditions to permit internalisation of surface integrin receptor pools and dissociation from 
cognate ligand (if still bound), prior to assay. Next, cells are left to adhere for 2h30 (again under 
standard culture conditions) to ligand coated 10 cm culture dishes (human recombinant LAP: 0.5 μg 
ml-1; bovine Fn: 10 μg ml-1; rat tail Col I: μg ml-1). Three known integrin cognate ligands were used to 
promote differential integrin receptor species engagement to compare differences, or indeed 
similarities, between integrin receptor-specific adhesion environments. The process of adhesion in 2D 
was checked by phase contrast microscopy throughout the course of assay and confirmed at the 2h30 
end-point. Adhesion complexes were enriched and isolated by sonication in the presence of a 2D-E 
extraction buffer (prepared in-house). Adhesion complexes were then manually harvested by scraping 
in 5X Lysis Buffer (prepared in-house) ready for validation by Western blot and interrogation by LC-
MS/MS. A detailed description of the 2D-E protocol and reagents/buffers used is provided in the 










Given the woeful lack of therapeutic molecular targets in TNBC (Herold and 
Anders 2013), it was deemed pertinent to focus the remaining body of research 
presented here on TNBC; with the intent of identifying putative candidates for 
novel therapeutic strategies to improve patient outcomes. The BT-20 TNBC cell 
line was selected due to its stable, high endogenous integrin ανβ6 cell surface 
expression (Figure 5.1.2A), expedient tissue culture and triple negative receptor 
status. Functional abrogation of the integrin ανβ6 receptor using the blocking 
antibody 53A2 abolished binding of LAP, confirming that the integrin ανβ6 is the 
predominant LAP receptor in BT-20 cells (Figure 5.1.2C).  
 
 
With LAP specificity for integrin ανβ6 validated, 2D-enrichment (2D-E) experiments 
were performed to isolate ligand-specific adhesion complexes formed on latency-
associated peptide of TGF-β1 (LAP), fibronectin (Fn) and collagen type I (Col I) for 
proteomic interrogation. Adhesion to ligand was confirmed by phase contrast 
microscopy and evaluated by confocal immunofluorescence (IMF) microscopy; 
isolated adhesion complexes for proteomic analysis were validated by Western 
blot (WB) (Figure 5.2).  
 
 
The integrin ανβ6 was reproducibly enriched during adhesion to its cognate ligand 
LAP across four biological replicate 2D-E experiments.  Engagement of other 
integrin species on the Fn and Col I conditions could not be reliably validated by 
WB. Technical validation markers to confirm specificity of technique were 
identified by WB with varying success. The proteins talin and vinculin associated 
with integrin-mediated adhesion complexes (Hirata et al 2014, Atherton et al 2015, 
Atherton et al 2016) were observed on the LAP condition only. The pro-apoptotic 
mitochondrial membrane protein Bak, excluded from integrin adhesion 
complexes was used as a non-specific marker to confirm purity of adhesion 
enrichment as previously described (Paul 2014, Robertson 2014).  
 
 
Adhesion complex-enriched samples from the four-biological replicate 2D-E 
experiments were subject to in-gel tryptic digest to generate peptides for label-
free LC-MS/MS analysis (Institute of Translational Medicine Mass Spectrometry 
Core Facility, Centre for Molecular Physiology, University of Liverpool). Following 
proteomic analysis, peptides were identified, validated and quantified by 
unweighted spectral counting using Mascot Daemon v2.2.2 (Matrix Science©) and 
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Scaffold™ v4.3.2 (Proteome Software© Inc, USA) open source software 
programmes. A total of 24 410 spectra were identified, with sequences mapping 
to 196 proteins. 
 
 
Protein-protein-interaction (PPI) networks of proteins showing a two-fold or greater 
(≤2-fold) enrichment to LAP in comparison with Fn (Figure 5.3A) or Col I (Figure 
5.3B) were mapped in Cytoscape v3.1.1 (Cytoscape Consortium©, National 
Resource for Network Biology) using a literature-curated database of the human 
adhesome comprising entries curated by Protein Interaction Network Analysis 
(PINA, 10th December 2012) (Wu et al 2009, Cowley et al 2012, Soteriou et al 2013) 
with adaptations to encompass the Integrin Adhesome (Zaidel-Bar et al 2007) and 
Matrisome Project (Hynes and Naba 2012, Naba et al 2012a, Naba et al 2012b). 
Based on these PPI networks, 7 candidate proteins of interest (Table 5.1) deemed 
putative molecular regulators of a LAP-ligand-engaged integrin ανβ6–dependent 
adhesion environment (β6-adhesome) characterised in the BT-20 TNBC cell line 
were selected for functional validation based on a combination of existing GO 
entries, available peer-reviewed literature and unpublished in-house data.  
 
 
Seeking to investigate the broader biological relevance of the LAP-engaged β6-
adhesome in TNBC, it was intended to conduct further enrichment experiments in 
additional TNBC cell lines for comparison. A single 2D-E experiment comprising 2 
technical replicates was performed using the MDA-MB-468 TNBC cell line and 
used to generate a PPI network of LAP versus Fn enrichment which interestingly 
revealed the epidermal growth factor receptor (EGFR) is uniquely enriched to 
integrin ανβ6 mediated adhesions to LAP in comparison with Fn-induced 

















Figure 5.1.2  
2D-enrichment experimental work up: Cell line selection and validation of LAP ligand 
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Figure 5.1.2  
2D-enrichment experimental work up: Cell line selection and validation of LAP ligand 
specificity for the integrin ανβ6  
 
(5.1.2 A) A panel of known integrin ανβ6 positive TNBC cell lines were screened to identify a cell line 
with stable, endogenous high integrin ανβ6 expression suitable 2D-E/LC-MS/MS definition of a ligand-
engaged integrin ανβ6–mediated adhesion environment. Cell lines were screened by flow cytometry 
using antibody clone 53A2 (10 μg ml-1, CR-UK) to demonstrate cell surface abundance of integrin 
ανβ6; an isotype matched rat IgG antibody was also included in the screen as a negative control (n=3; 
three biological repeats).  (5.1.2 B) Owing to reliability of culture and stably high integrin ανβ6 
expression, the BT-20 cell line was selected for experimental work up for 2D-E proteomic 
interrogation. The BT-20 cell line was screened by flow cytometry for surface expression of other RGD-
binding integrin species reported as putative LAP-ligand cognate receptors including: β1 (clone 
P4C10, 10 μg ml-1, in-house), ανβ3 (clone LM609, 10 μg ml-1, MAB1976Z, Merck Millipore), ανβ5 (clone 
P1F6, 10 μg ml-1, MAB1961Z, Merck Millipore) and α5 (clone P1D6, 10 μg ml-1, MAB1956Z, Merck 
Millipore). Four biological repeats were performed (n=4). In addition, the BT-20 cell line was also 
screened for integrin ανβ6 receptor populations using the panel of anti-integrin ανβ6 antibodies 
(previously described). Five biological repeats (n=5) were performed to assess stability of expression. 
Where suitable antibodies were available, integrin species expression was also confirmed by Western 
blot: β1 (clone EP1041Y, 2 μg ml-1, ab52971, AbCam), β6 (c-19, 10 μg ml-1, sc-6632, SantaCruz 
Biotechnology), α5 (1 μg ml-1, 4705S, Cell Signalling Technology) and β8 (5 μg ml-1, ab80673, 
AbCam). β-tubulin was used as a loading control (1 μg ml-1, ab21057, AbCam). Finally, to confirm 
integrin ανβ6 specificity for LAP-engagement in the BT-20 cell line, functional abrogation studies using 
the blocking antibody 53A2 were performed (5.1.2 C). Cells were treated with either antibody 53A2 
(40 μg ml-1, CR-UK) or non-immune rat IgG negative control antibody (40 μg ml-1, ab37361, AbCam) 
for 30 min to abrogate surface integrin ανβ6. Next, cells were incubated with an Fc-tagged LAP ligand 
for 10 min and washed prior to evaluation of surface bound LAP-Fc abundance by flow cytometry 
using an anti-Fc antibody (clone ABM121, 10 μg ml-1, ab113636, AbCam). Across four biological 
repeats, functional abrogation of integrin ανβ6 significantly abolished binding of LAP ligand in 
comparison with the rat IgG negative control treatment (one-tailed 2-sample t-test; p<0.05, p=0.0104) 
confirming LAP ligand specificity for the integrin ανβ6 receptor in the BT-20 cell line. Flow cytometry 
experiments were performed on the BD LSRFortessa™ equipped with FACSDiva™ v8.0 acquisition 
software to gate 104 events per sample and analysed using FlowJo® to obtain geoMean MFI values. 
Propidium iodide cell viability indicator (10 μg ml-1) was used to define gating strategy to ensure data 
were obtained on live cells only. Each plot on flow cytometry graphs show mean values of technical 
triplicates performed for each biological replicate. Mean of the biological repeats are shown with error 
bars indicating s.d. Western blotting was performed at the University of Liverpool using the LI-COR© 
Odyssey®Sa System (as described in detail in the relevant Materials & Methods section); 20 ng protein 
per well was loaded. Statistical analyses were performed using GraphPad Prism® 5.0b for MacOSX 















5.1     cell  line   selection  and   proof  of  concept  for  an  adhesion   assay 
           to define an integrin ανβ6–dependent adhesion environment 
 
The lack of defined, molecular targets suitable for therapeutic intervention in 
TNBC is a known significant limiting factor and impediment to patient outcomes 
burdened with this disease (Herold and Anders 2013). Therefore, the prescient 
need to augment the existing knowledge base regarding the aetiopathology of 
TNBC informed the decision to focus this initial characterisation of the “β6-
adhesome” within the context of TNBC.   
 
 
A panel of BrCa cell lines comprising: the triple negative BT-20, MDA-MB-468 and 
SUM159 cell lines, together with the triple positive BT-474 cell line, were screened 
for cell surface integrin ανβ6 expression by FCM; stability of morphological 
phenotype was monitored in culture by phase contrast microscopy (Figure 5.1.2A). 
The antibody clone 53A2 (CR-UK) was used to detect total cell surface integrin 
ανβ6 in an activation-state/conformation-independent manner (as previously 
outlined in Chapter 3: results part I). Three biological repeat screens, each 
comprising intra-assay technical triplicates, were performed. Detected geometric 
mean fluorescence intensity (geoMean MFI, AU) values (normalised against an 
isotype, species-matched negative rat IgG control antibody) served as a read-out 
for surface integrin ανβ6 expression (as previously described).  
 
 
The BT-20 cell line exhibited consistently high and stable endogenous cell surface 
integrin ανβ6 expression, which remained in the order of ~6 x104 geoMeanMFI, AU 
across three biological replicates. Therefore, the BT-20 cell line was selected for 
2D-E assays given its stably high, endogenous integrin ανβ6 expression and 
relatively expedient culture to yield sufficient cell volume for assay.  
 
 
In order to specifically engage integrin ανβ6–mediated adhesion complexes, it was 
hypothesised that use of the known integrin ανβ6 cognate ligand LAP (Munger et al 
1999, Thomas et al 2002) would elicit the desired specific integrin ανβ6 receptor 
engagement and thus, β6–mediated adhesion complex formation on 2D-
immobilised LAP. However, an emerging body of literature, reviewed by Munger 
and Sheppard (2011), suggest that other RGD integrin receptor species may 
interact with LAP inducing activation of ECM-bound latent TGF-β1 by mechanical 
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traction; the integrins ανβ3, ανβ5 (Wipff et al 2007) and ανβ8 (Mu et al 2008) are also 
reported to bind LAP and mediate TGF- β1 activation. 
 
Therefore, to establish the specificity of integrin ανβ6 for LAP-ligand, the BT-20 cell 
line was screened by FCM (Figure 5.1.2B) for integrin species reported to bind LAP 
(integrins ανβ3, ανβ5); in addition to the RGD-binding integrin β1-subunit and α5-
subunit, known to engage the comparator ligand-specific adhesion complexes 
that would be elicited during adhesion to Fn (integrins ανβ3, α5β1) and Col I 
(integrins α1β1, α2β1). Four biological replicates each comprising intra-assay 
technical triplicates were performed.  
 
 
Integrin ανβ6 cell-surface subpopulations were also characterised by flow 
cytometry using a panel of anti-integrin ανβ6 antibodies (previously described). 
Here, five biological repeats were performed, again with each comprising intra-
assay technical triplicates. Finally, whole cell expression of the integrin subunits: 
α5, β1, β6 and β8, were evaluated by WB.  
 
 
It was found by FCM that the BT-20 cell line expressed relatively high levels (!	≈ 38 
x 103 geoMean MFI, AU) of cell surface integrin β1, with marked whole cell integrin 
β1 expression confirmed by WB. Interestingly, integrin α5 surface abundance was 
low (!	≈ 5 x 103 geoMean MFI, AU) in comparison with whole cell abundance 
demonstrated by WB.  
 
 
Cell surface abundance of integrin ανβ3 was negligible (!	≤ 0.1 x 103 geoMean 
MFI, AU) but integrin ανβ5 was moderately expressed (!	≈ 65 x 103 geoMean MFI, 
AU). Whole cell expression of the integrins β3 and β5 could not be confirmed by 
WB as application-appropriate antibodies were unavailable. Integrin β8 whole cell 
expression was confirmed by WB only using a commercially available antibody 
tested in-house (Supplementary Information S5.1); cell surface screening could not 
be performed, again owing to a lack of application-appropriate antibodies.  
 
 
Screening of integrin ανβ6 subpopulations revealed high cell surface expression of 
total integrin ανβ6 recognised by antibodies 10D5 (!	≈ 75 x 103 geoMean MFI, AU), 
53A2 (!	≈ 110 x 103 geoMean MFI, AU) and 620W7 (!	≈ 60 x 103 geoMean MFI, 
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AU). As anticipated, active integrin ανβ6 conformers recognised by antibodies 
6.2E5 and 6.2G2 were present at lower levels than total integrin ανβ6 (6.2E5: !	≈ 25 
x 103 geoMean MFI, AU; 6.2G2: !	≈ 10 x 103 geoMean MFI, AU). Whole cell 
abundance of integrin β6 was also confirmed by WB.  
 
 
Since the presence of non-β6 integrin species reported to engage LAP (notably 
ανβ5 and ανβ8) were detected in the BT-20 cell line, it was deemed pertinent to test 
the specificity of LAP for integrin ανβ6 engagement before commencing 2D-E 
assays (Figure 5.2C). Functional abrogation of cell surface integrin ανβ6 using the 
inhibitory antibody clone 53A2 significantly abolished binding of a human IgG 
(Fc’)-tagged LAP ligand in comparison with an isotype-matched rat IgG negative 
antibody control treatment (one-tailed 2-sample t-test; p=0.0104). This 
demonstrated that integrin ανβ6 is the predominant LAP receptor in BT-20 cells, 
validating the use of LAP ligand to specifically target integrin ανβ6–mediated 
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Figure 5.2 (A & B) 
Technical validation of 2D-enrichment assays performed to enrich, isolate and extract integrin ανβ6–mediated adhesion complexes ready for label-free 
LC-MS/MS proteomic interrogation to define an integrin ανβ6 adhesome: Evaluation by microscopy methods  
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Figure 5.2 (C) 
Technical validation of 2D-enrichment assays performed to enrich, isolate and extract 
integrin ανβ6–mediated adhesion complexes ready for label-free LC-MS/MS proteomic 
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Figure 5.2  
Technical validation of 2D-enrichment assays performed to enrich, isolate and extract 
integrin ανβ6–mediated adhesion complexes ready for label-free LC-MS/MS proteomic 
interrogation to define an integrin ανβ6 adhesome  
 
Adhesion assays were performed using BT-20 cells adhering in 2D under standard culture conditions 
to the integrin cognate ligands LAP (LAP - 0.5 μg ml-1, L3408, Sigma Aldrich), fibronectin (Fn - 10 μg 
ml-1, F1141, Sigma Aldrich) & collagen I (Col I - 10 μg ml-1, 354236, Corning®) (four biological repeats 
were performed; n=4). (5.2 A) Adherence was checked by phase contrast microscopy (OLYMPUS IMT-
2, Olympus® Corp) during the adhesion assay. Representative images of cell morphology at the start 
(0’) and end of assay (2h30) are shown. Although adhered, BT-20 cells binding to LAP maintained a 
rounded morphology suggesting ligand adhesion in the absence of cell spreading on ligand. This 
contrasted with the flattened appearance of BT-20 cells adhered to Fn and Col I where it appeared 
cells had both adhered to and spread upon ligand. (5.2 B) Morphology of adhesion complexes and 
subcellular distribution of the integrins ανβ6 (red arrows) and integrin β1 (blue arrows) together with 
the adhesion complex-associated protein vinculin (green arrows), were evaluated by permeabilised 
IMF. Proteins of interest were labelled accordingly: integrin ανβ6 (antibody clone 620W7, 10 μg ml-1, 
CR-UK), integrin β1 (antibody clone EP1041Y, 10 μg ml-1, ab52971, AbCam) in addition to the 
adhesion complex protein, vinculin (antibody clone hVIN-1, 10 μg ml-1, ab11194, AbCam). The 
integrin ανβ6 was seen to localise at the cell periphery across all ligand treatments. Curiously, the 
subcellular localisation of integrin β1 showed a marked intracellular, vesicular distribution pattern, 
even on cells adhered to known integrin β1 cognate ligands Fn and Col I. Vinculin clusters at the cell 
periphery were observed across ligand treatments, but appeared most marked in BT-20 cells adhered 
to Fn. (5.2 C) Following stabilisation of formed adhesion complexes by DTBP cross-linking and 
adhesion complex enrichment by sonication in 2D-extraction buffer, lysates were prepared for LC-
MS/MS interrogation and evaluated by WB for integrin engagement and technical validation markers. 
Across four biological replicates, the integrin ανβ6 was successfully and reproducibly enriched in BT-
20 cells adhered to LAP. Integrin ανβ6 enrichment was also observed for cells adhered to Fn, but to a 
visibly lesser extent than on LAP. No enrichment for integrin ανβ6 was observed on cells exposed to 
Col I. Markers to validate adhesion complex formation (FA proteins talin and vinculin) were 
demonstrated with varying success. A protein not known to associate with adhesion complexes (the 
mitochondrial protein Bak) was used as an additional control to demonstrate specificity of adhesion 
complex enrichment. The integrin β1 was not detected by Western blotting. Antibodies were used as 
follows: ανβ6: c-19 (0.2 μg ml-1, sc-6632, SantaCruz Biotech); β1: EP1041Y (2 μg ml-1, ab52971, 
AbCam); Bak: D4E4 (0.2 μg ml-1, 12105S, Cell Signalling Technology); talin: c-20 (0.2 μg ml-1, sc-
7534, SantaCruz Biotech); vinculin: hVIN-1 (0.2 μg ml-1, ab11194, AbCam). All experiments were 
performed at the Institute for Translational Medicine, University of Liverpool. Confocal IMF microscopy 
was undertaken using the 3i© Marianas™ microscope equipped with SlideBook™ 5 image analysis 
software (both Intelligent Imaging Innovations (3i)© Inc). Western blotting was performed using the LI-













5.2      technical validation of 2D-E/LC-MS/MS experiments to proteomically      
            define the β6-adhesome 
 
Having established the utility of LAP to specifically bait the integrin ανβ6 receptor in 
the BT-20 cell line, four biological replicate 2D-E adhesion assays were performed 
on immobilised ligand substrates to preferentially engage specific integrin species 
accordingly: LAP: – ανβ6, Fn: – α5β1 / ανβ6 and Col I: – α1β1 / α2β1.  
 
 
Reyes et al (2008) highlight the need to extend characterisation of ECM ligand-
integrin interactions beyond single ligand-receptor analyses (which have been the 
focus to date) in order to reflect ECM complexity. Therefore, it was hoped that 
formation and analysis of Fn and Col I ligand-specific integrin adhesion complexes 
would provide physiologically relevant comparators when defining the LAP ligand-
engaged, integrin ανβ6–dependent adhesion environment. 
 
 
Cell morphology and successful adhesion to substrate ligand was confirmed by 
phase contrast microscopy during the adhesion assays (Figure 5.2A). Adhesion 
assays were stopped at 2h30 in order to isolate mature adhesion complexes as 
opposed to nascent adhesive structures; such as the spreading initiation centres 
first described by de Hoog et al (2004), and later reported by Serrels et al (2010) to 
modulate cancer cell polarity.  
 
 
Successful cell adherence was again confirmed by phase contrast microscopy 
following initial wash steps at the assay end-point prior to adhesion complex 
enrichment by sonication in 2D-E extraction buffer. It was noted that BT-20 cells 
adhered to LAP maintained a rounded morphology (indicated by plasmalemma 
refringence upon phase contrast microscopy review) even at the 2h30 assay end-
point; suggesting cellular adhesion with minimal spreading upon LAP ligand. This 
contrasted with the flattened appearance of BT-20 cells adhered to Fn and Col I 
that was reminiscent of an established epithelial monolayer at the 2h30 end-point.  
 
 
Adhesion complex morphology was also evaluated by permeabilised confocal IMF 
(Figure 5.3B) to evaluate subcellular localisation of the integrins ανβ6 and β1, 
alongside the known integrin adhesion-complex protein vinculin (Humphries et al 
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2007, Ziegler et al 2008, Carisey et al 2013, Hirata et al 2014, Atherton et al 2015, 
Atherton et al 2016) during adhesion to LAP, Fn and Col I ligands.  
 
 
Carisey et al (2013) demonstrated that vinculin modulates transmission of ECM-
derived mechanotensile signals into the actomyosin cytoskeletal machinery via its 
association with integrin-talin complexes and F-actin. The authors showed that 
vinculin interaction with integrin-talin complexes is necessary for both recruitment 
and release of core FA proteins including: FAK, ILK, parvin, p130Cas, zyxin and 
tensin. Therefore, given its established role in formation of integrin-mediated 
adhesion complexes, vinculin colocalisation with integrin receptors visible by IMF 
was deemed a suitable marker of formed adhesion complexes. 
 
 
Vinculin was seen to localise at the cell periphery, exhibiting marked clusters of 
immunopositivity believed to be adhesion complexes. The canonical, published 
pattern of vinculin immunopositivty associated with adhesion complex formation 
(Humphries et al 2007, Kanchanawong et al 2010, Carisey et al 2013) was most 
notable in BT-20 cells adhered to immobilised Fn. These adhesion complex-
associated clusters of vinculin immunopositivity were observed to a lesser extent in 
BT-20 cells spreading on LAP and Col I. This may indicate fewer, or less mature, 
adhesion complexes were formed on these immobilised substrate ligands 
compared to Fn. 
 
 
However, it is acknowledged that the majority of literature dissecting integrin-
mediated adhesion complexes focuses on the integrin ανβ3 receptor adhering to 
Fn in fibroblasts, or integrin α5β1–mediated adhesions to Fn in monocytes. 
Therefore, it may be that the TNBC BT-20 cell line, although basal in molecular 
subtype (Chavez et al 2010), may inherently form fewer and or/smaller integrin-
mediated complexes on substrate ligand compared to those published for integrin 
ανβ3– and integrin α5β1–mediated adhesions formed on Fn in fibroblasts and 
monocytes respectively.  
 
 
Therefore, the variation in vinculin appearance observed in IMF results shown here 
may not necessarily indicate poor adhesion complex assembly. Instead it may be 
attributable to ligand and cell-type specific adhesion complex formation; and so 
remain experimentally valid for the purposes of the specific research aim to 
characterise the β6-adhesome. 
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It had been intended that the ligand substrates Fn and Col I would elicit integrin 
β1–mediated adhesions. It was anticipated that Fn would partially engage β1–
species in addition to the integrin ανβ6 that was first reported to engage Fn by 
Busk et al (1992); Col I was expected to exclusively engage integrin β1 moieties 
(Leitinger 2011).  
 
 
However, IMF revealed a distinct intracellular, vesicular pattern of 
immunopositivity for β1 integrin on all ligand substrates. The absence of integrin β1 
at the cell periphery and lack of co-localisation at vinculin-rich structures 
(presumed to be adhesion complexes) in BT-20 cells adhered to Fn, suggested 
that β1 species were not mediating adhesion to Fn as expected. Integrin β1 
colocalisation with vinculin, and curiously with integrin ανβ6, was only observed on 
Col I substrate ligand, but appeared limited. 
 
 
An activation/conformation-independent anti-integrin β1 antibody was used to 
label integrin β1 for IMF evaluation of adhesion complexes. It may have been 
pertinent to use an activation-state specific antibody that does not bind the 
heterodimer cleft, such as clone 9EG7 (Byron et al 2009), in order to detect 
activated (presumed ligand-engaged) integrin β1 without eliciting ligand-mimetic 




The integrin ανβ6 (demonstrated by clone 620W7; an antibody recognising both 
mature fully-glycosylated and immature partially-glycosylated integrin ανβ6 
receptors) was seen to cluster at the periphery of cells adhering to LAP and Fn, 
suggesting integrin ανβ6 cognate ligand-engagement as anticipated. On all ligand 
substrates, integrin ανβ6 appeared to cluster at vinculin-rich lamellipodia-like 
membrane protrusions. The observation of integrin ανβ6 co-localisation with 
vinculin and integrin β1 on Col I was curious, given that the integrin ανβ6 is not 
known to engage this ligand.  
 
 
It may be that integrin ανβ6 was recruited to Col I adhesion complexes following 
ligand engagement and adhesion initiation by another Col I cognate receptor 
expressed in BT-20 cells, for example an integrin β1 species. Indeed, integrin 
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receptor lateral clustering following ligand activation is an established concept 
(Welf et al 2012). Cluzel et al (2005) extensively characterised mechanisms of 
integrin ανβ3 lateral clustering in live mouse and hamster melanoma cell lines 
(B16F1 and CS-1 respectively). The authors reported that the head domain of the 
cytoskeletal protein talin was requisite for integrin clustering; concluding that 
talin’s anti-parallel dimer conformation favours its role as a putative intracellular 
integrin cross-linker.  
 
 
Using in silico atomistic molecular dynamic simulations based upon existing 
crystallographic mapping of integrin αIIβ3, Orlowski et al (2015) later hypothesised 
that the membrane phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2) 
works in concert with talin to induce integrin activation. PIP2 has been shown to 
enforce conformational changes in talin, exposing talin’s integrin β–cytoplasmic tail 
binding region that resides within its head domain; thus enabling talin-integrin 
interaction and induction of intracellular priming and/or activation concordant with 
the “inside-out” model of integrin signalling.   
 
 
This in silico evidence is concordant with Cluzel et al’s (2005) earlier in vitro finding 
that specific PIP2-dependent recruitment of talin to active integrins demonstrated 
that the cytoplasmic tail domain of the integrin β3-subunit is essential for lateral 
integrin ανβ3 clustering. Therefore, it may be possible that ligand-engagement, 
receptor activation and lateral clustering of one integrin receptor species, may 
orchestrate intracellular activation and recruitment of other integrin moieties.  
 
 
For example, given that the talin N-terminal FERM domain binds the integrin C-
terminal NPxY motif (Garcia-Alvarez et al 2003, Critchley 2009, Kim et al 2012), it is 
possible that activation of talin mediated either by extracellular integrin-ligand 
engagement, or by conducive changes in membrane phospholipid composition at 
sites of integrin clustering facilitating PIP2-dependent talin activation, may induce 




Therefore, Col I ligand-engaged integrin β1-activation inducing intracellular 
recruitment of talin and membrane phospholipid PIP2 may act in concert to drive 
sequential recruitment of other proximal integrin species, such as integrin ανβ6, via 
talin engagement of the β6–cytoplasmic tail NPxY motif. This hypothesis may 
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account for the observation of integrin ανβ6 at sites of vinculin enrichment on Col I, 
presumed to be sites of adhesion. 
 
 
Similar to demonstration of the integrin β1, an antibody recognising total integrin 
ανβ6 was used. Again, it may have proved informative to use an antibody 
recognising the active integrin ανβ6 (such as 6.2E5 or 6.2G2) to robustly confirm 
the presence of active, ligand-engaged integrin ανβ6 at clusters of vinculin 
immunopositivity presumed to be sites of adhesion.  
 
 
It is also possible that the unexpected observation of integrin ανβ6 at adhesion 
sites on Col I may be a technical artefact. Any conformational or protein 
degradation of substrate ligand Col I fibrils during ligand coating procedures or 
the adhesion assay itself, may liberate or expose Col I RGD-motif bearing regions 
in a spatially favourable presentation for integrin ανβ6 RGD-recognition and 
engagement. The concept of stoichiometric regulation of cognate RGD motif 
binding by integrin species was explored and validated by Davidenko et al (2016) 
using collagen and gelatin gel-based methods, and should be considered a 
possibility when critiquing data discussed here. 
 
 
Despite the curious and unanticipated IMF findings regarding subcellular 
localisation of ανβ6 and β1 integrin species on the immobilised substrate ligands 
LAP, Fn and Col I (Figure 5.2B); four biological replicate 2D-E adhesion assays 
yielded successful, specific and reproducible enrichment for the integrin ανβ6 
receptor on its cognate ligand LAP, that was demonstrably validated by WB 
(Figure 5.2C). This confirmed the specificity of the assay to address the research 
aim of characterising a β6–dependent adhesion environment and so justified 




Partial enrichment of the integrin ανβ6 on Fn substrate ligand was also detected by 
WB. However, integrin ανβ6 enrichment on Fn was markedly less than enrichment 
on LAP. This is concordant with reports that although integrin ανβ6 binds Fn, 
integrin α5β1 is the predominant Fn-binding integrin species (Busk et al 1992, 








Indeed, Bharadwaj et al (2017) recently reported the novel phenomenon of dual 
roles for αν–integrins and integrin α5β1 in MEFs and mouse kidney fibroblasts 
attaching to Fn; the duality of integrin species characterised by initial ligand 
competition and subsequent receptor cooperation to: establish stable adhesions, 
induct integrin clustering and initiate downstream signal activation.  
 
 
The authors demonstrated that αν–integrins initially outcompete α5β1 for Fn 
engagement, but once engaged, signal recruitment of α5β1 integrins to establish 
additional complexes. If a similar phenomenon of integrin-switching occurs in 
mammary-derived epithelial cells, this could account for the partial enrichment of 
integrin ανβ6 in BT-20 cells adhered to Fn demonstrated by WB probing of 
adhesion complexes isolated for LC-MS/MS. 
 
 
Disappointingly, technical validation of the 2D-E procedure to robustly confirm 
purity of adhesion complex isolation and extraction, using markers specific for 
integrin-mediated adhesion complexes (talin and vinculin), alongside proteins 
excluded from adhesion complexes (the mitochondrial protein Bak), was 
inconsistent. Attempts to trouble-shoot this problem identified several possible 
technical causes including: inefficient protein transfer conditions during 
immunoblotting, insufficient stabilisation of highly labile multi-protein adhesion 
complexes by DTBP cross-linkage and primary antibody inter-batch variation.  
 
 
The possibility of a biological explanation to account for the inconsistency of WB 
adhesion complex validation was also considered. Critically, adhesion complexes 
formed in BT-20 cells under 2D-E experimental conditions and reviewed by IMF 
(Figure 5.3B) appear to be smaller and fewer in abundance than published data on 
canonical adhesion complexes as studied in U-2 OS osteosarcoma cells and MEFs 
(Kanchanawong et al 2010, Carisey et al 2013).  
 
 
Thus the low yield or absence of certain adhesion complex proteins may be 
attributable to fundamental, and as yet unpublished, variations between the size 
and constitution of adhesomes derived from cells of mammary epithelial origin 
(BT-20) compared to those as being formed in cells of mesenchymal origin (MEFs 
and U-2 OS).  
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Furthermore, IMF review of the adhesion complexes formed in BT-20 cells under 
2D-E experimental conditions indicated that integrin β1 moieties were not 
discernibly redelivered to the plasma lemma to engage the α5β1 cognate ligand 
Fn. Regarding the α1β1/α2β1 cognate ligand Col I, integrin β1 was detected by IMF 
in a few regions of the plasma lemma and at a lower abundance than anticipated. 
Instead, integrin β1 predominated in intracellular vesicular structures during the 
adhesion phase of the protocol.  
 
 
This observation (and inference that integrin β1 was not abundantly redelivered to 
the plasmalemma to mediate substrate ligand engagement) was concordant with a 
failure to demonstrate integrin β1 in isolated adhesion complex lysates by WB. For 
technical validation of WB procedures, total cell lysates (TCL) samples were loaded 




Where probed, integrin β1 expression was clearly confirmed in TCL. However, 
presence of the integrin β1 in isolated adhesion complexes was not demonstrated 
in any of the four biological replicate experiments. It had been anticipated that 
integrin β1 would be partially enriched on Fn (signifying α5β1-Fn engagement) and 
markedly enriched on Col I (signifying α1β1/α2β1-Col I engagement). The absence 




Although the four replicate 2D-E experiments could not be robustly validated for 
exquisite purity of adhesion complex enrichment and isolation using established 
markers (Paul 2014, Robertson 2014), the successful, reproducible and marked 
LAP-mediated enrichment of integrin ανβ6 was deemed sufficiently convincing and 
reliable to proceed with peptide preparation for LC-MS/MS analysis and PPI 
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Figure 5.3 (A)  
Protein-protein interaction network mapping proteins ≥2-fold enriched to a LAP-ligand induced β6–adhesome compared to a Fn-ligand induced 
adhesion environment in the BT-20 cell line.  
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Figure 5.3 (B)  
Protein-protein interaction network mapping proteins ≥2-fold enriched to a LAP-ligand induced β6–adhesome compared to a Col I-ligand induced 
adhesion environment in the BT-20 cell line  
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Figure 5.3  
Protein-protein interaction networks mapping proteins ≥2-fold enriched to a LAP-ligand 
induced β6–adhesome compared to a Fn or a Col I-ligand induced adhesion environment 
in the BT-20 cell line 
 
Following enrichment and isolation of adhesion complexes formed on LAP, Fn and Col I immobilised 
substrate ligands, peptides were prepared for LC-MS/MS analysis using the nanoACQUITY UPLC® 
ultra performance liquid chromatography system (Waters Ltd) coupled to an LTQ-Orbitrap XL™ ETD 
Hybrid Ion Trap-Orbitrap Mass Spectrometer (Thermo Scientifc Inc). Peptides were identified from raw 
SEQUEST (.dta) files using Mascot Daemon (v2.2.2, Matrix Science®) software and searched against 
entries held in the International Protein Index (IPI) Human Database (v3.70 released 4th March 2010). 
Mascot (.mgf) files were reviewed in Scaffold™ (v4.3.2, Proteome Software© Inc) for data pre-
processing to exclude ambiguous peptide assignments and validate spectral count data. Identification 
threshold criteria were set to ≥99% at the protein level and ≥50% at the peptide level, with ≥2 unique 
validated peptides detected. Protein-protein interaction (PPI) networks for LAP-ligand engaged, 
integrin ανβ6–dependent adhesions were mapped using Cytoscape open source software (v3.1.1, 
Cytoscape Consortium©) in comparison with (5.3 A) Fn-induced and (5.3 B) Col I-induced adhesomes. 
Nodes (circles) represent proteins labelled with gene names. Node colour represents fold enrichment 
to either LAP compared to Fn or Col I (a minimum threshold of 2-fold enrichment was set). Block 
colour represents unique enrichments to either condition. Edges (lines) represent reported 











5.3  PPI network maps comparing fold-enrichment of proteins during   
 BT-20 cell adhesion to LAP, Fn and Col I ligands identify candidate   
 proteins that putatively define the β6-adhesome 
 
Following enrichment and isolation of adhesion complexes formed on LAP, Fn and 
Col I immobilised substrate ligands, peptides were prepared for LC-MS/MS 
analysis (Institute of Translational Medicine Mass Spectrometry Core Facility, Centre 
for Molecular Physiology, University of Liverpool). Peptides were then identified 
(Mascot Daemon, v2.2.2, Matrix Science®) and validated against entries held in the 
International Protein Index (IPI) Human Database (v3.70 released 4th March 2010).  
 
 
Mascot (.mgf) files were reviewed in Scaffold™ (v4.3.2, Proteome Software© Inc) for 
data pre-processing to exclude ambiguous peptide assignments and validate 
spectral count data. Identification threshold criteria were set to ≥99% at the 
protein level and ≥50% at the peptide level, with ≥2 unique validated peptides 
detected. A total of 24 410 spectra were analysed, mapping to 196 identified 
proteins (summarised in Supplementary Information S5.2). 
 
 
Peptides were then quantified using an unweighted spectral count (USC) method 
established for label-free proteomics (Kito and Ito 2008), prior to mapping protein 
interaction networks incorporating fold-enrichment data (Figure 5.3) using 
Cytoscape v3.1.1 (Cytoscape Consortium©). 
 
 
Proteomic analysis of each ligand-specific proteomic dataset consistently 
identified the cognate ligand substrate used to elicit integrin engagement (LAP 
assigned TGF-β1; Fn assigned FN1; Col I assigned COL1A1/COL1A2), serving as 
an internal positive control for technical validation of sample specificity. Peptide 
sequences identified as TGF-β1-derived were checked against TGF-β1 amino acid 
sequence data to confirm that all detected peptide species specifically mapped to 
the LAP sequence residing within TGF-β1 complete sequence (UniProtKB – 
P01137 (TGFB1_HUMAN) online database entry). 
 
 
Furthermore, USC data showed that both integrin αν (ITGAV) and integrin β6 
(ITGB6) were specifically, and uniquely enriched to adhesion complexes formed 
on LAP; ITGAV and ITGB6 spectra were not detected in either Fn- or Col I-
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mediated adhesion complexes isolated for proteomic analysis. This conferred 
additional confidence in LAP specificity for the integrin ανβ6 receptor in the BT-20 
cell line, validating the use of this dataset to address the specific research intent of 
identifying novel molecular mediators associated with an integrin ανβ6–dependent 
adhesion environment.  
 
 
However, the absence of ITGB6 spectra in samples isolated from Fn-mediated 
adhesion complex samples was inconsistent with findings from WB sample 
validation prior to LC-MS/MS analysis (Figure 5.2C). The presence of integrin β6 
was clearly demonstrated by WB in at least 3 of the 4 replicates sent for proteomic 
interrogation, yet were not detectable by more sensitive LC-MS/MS methods.  
 
 
Curiously, vinculin spectra were not detected in any samples across the four 
biological repeats, which again was inconsistent with validation WB data where 
vinculin was detected in 2 replicates. Interestingly, talin (assigned TLN1) spectra 
were uniquely identified in LAP-mediated adhesion complex samples and were 
concordant with validation WBs. Furthermore, other anticipated integrin-mediated 
adhesion complex proteins (e.g kindlin, paxillin, FAK, ILK) were not successfully 
identified by proteomic analysis of 2D-E samples. 
 
 
These inconsistencies between validation WB and LC-MS/MS spectral data, 
together with identification of fewer protein moieties than had been anticipated 
(protein underestimation), elicited concerns regarding LTQ Orbitrap XL™ ETD Ion 
Trap-Orbitrap (ThermoScientific) instrument efficacy and calibration.  
 
 
With the kind assistance of Dr Edmund Wilkes (Barts Cancer Institute), RAW LC-
MS/MS data files were reviewed using the RAWMeat data quality diagnostic 
opensource software tool (RawMeat, Vast Scientific). Disappointingly it was found 
that contrary to information supplied by the Mass Spectrometry Core Facility, the 
instrument was set to fragment the single most abundant ion in MS1, rather than 
selecting the top 6 ions in MS1 for MS2 fragmentation.  
 
 
This would account for the overall underestimation of identified protein species 
and may explain why proteins demonstrated by WB were not detected by 
proteomics. However, despite the obvious limitations this technical issue presents 
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when interpreting the 2D-E/LC-MS/MS dataset, it was felt that the specific 
enrichment of integrin ανβ6 to LAP-mediated adhesions (demonstrated by both 
validation WB and spectral analysis), sufficiently justified additional PPI network 
analyses to putatively and cautiously define a preliminary β6-adhesome.  
 
   
PPI networks were mapped comparing LAP-mediated adhesions with Fn-mediated 
adhesions (Figure 5.3A), and LAP-mediated adhesions with Col I-mediated 
adhesions (Figure 5.3B). It was intended that these analyses would identify 
proteins specifically enriched to LAP to characterise the β6-adhesome and permit 
physiologically relevant exploration of integrin receptor switching through 
comparison with Fn and Col I adhesion environments.  
 
 
Given that integrin switching has been observed previously in vitro (Caswell et al 
2008), has subsequent to this study been shown to occur amongst αν- and α5β1 
integrins during Fn-attachment (Bharadwaj et al 2017), and is associated with 
establishing metastatic competence (Parvani et al 2013, Madamanchi et al 2014) ; 
the 2D-E experiments were performed using 3 different ECM substrates known to 
preferentially engage different integrin species (LAP – ανβ6; Fn –  α5β1/ανβ6; col I – 
β1 species) with the intention of exploring this integrin switching phenomenon in 
the BT-20 BrCa cell line.  
 
 
However, WB to validate isolated adhesion complex lysates used for peptide 
preparation failed to demonstrate integrin β1 enrichment on Fn and Col I 
substrates. Concordant with this, integrin β1 spectra were not detected, even in the 
Fn and Col I sample datasets, as had been anticipated. Thus the anticipated 
integrin-switching phenomenon was not demonstrable by WB or proteomics. 
However, this does not categorically preclude the possibility of integrin switching 
occurring in the BT-20 cell line, nor within the wider context of TNBC.  
 
 
Interestingly, integrin β4 (ITGB4) spectra were identified. The integrin β4 is deemed 
a basal marker in BrCa and was shown to be frequently overexpressed in TNBC 
patient tissue samples and associated with poorer prognosis (Lu et al 2008); 
rendering detection of integrin β4 spectra in the BT-20 TNBC cell line a logical 
finding. Furthermore, integrin β4 comprises the α6β4 receptor for laminins (Stewart 
and O'Connor 2015).  
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Based on a ≥2 fold or unique enrichment to LAP versus Fn or Col I, together with 
published GO entries and existing in-house data (not published), a total of 7 
candidate proteins for functional characterisation were identified from the 2D-


















v. Col I 
DMBT1 Q9UGM3 261 DMBT1  DMBT1 DMBT1 
MARCKS P22966 32 MARCKS  MARCKS MARCKS 
MXRA5 Q9NR99 312  MXRA5  MXRA5 
MYH9 P33579 233 MYH9  MYH9 MYH9 
MYH10 P33580 227 MYH10  MYH10 MYH10 
SEPT6 Q14141 50   SEPT6 SEPT6 
SEPT9 Q9UHD8 65   SEPT9 SEPT9 
Table 5.1  
Summary of seven candidate proteins implicated in establishing a LAP ligand-induced integrin ανβ6–
dependent adhesion environment (β6-adhesome) that were identified by proteomic interrogation of 
isolated adhesion complexes  
Table summarises USC findings; indicating whether the candidate protein was uniquely enriched on 







5.4  strategy for functional validation of seven candidate proteins that 
 putatively define the β6-adhesome 
 
Proteomics-based studies exploring mechanisms of chemotherapeutic resistance 
in BrCa have successfully employed established siRNA gene-silencing strategies to 
investigate the functional role of candidate proteins identified in preliminary 
proteomic screens (Derycke et al 2011, Boyer et al 2013, Browne et al 2013). 
Therefore it was deemed appropriate to use similar siRNA-screening to 
functionally interrogate the role of 7 candidate proteins identified as putative 
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It was intended that candidates would be silenced in a panel of TNBC cell lines 
using siRNA and subject to functional assays to define the effect of a functional loss 
of target candidate on: integrin β6 expression (to establish any co-regulatory link), 
cell proliferation, adhesion, invasion and migration characteristics.  
 
 
Owing to a lack of published, reliable, commercially available antibodies to 
candidates of interest at the time of study, confirmation of knockdown was to be 
performed at the nucleic rather than protein level by quantitative real-time 
polymerase chain reaction (qPCR) (SYBR®Green, Qiagen).  
 
 
Disappointingly, stable siRNA silencing was not demonstrable by qPCR within the 
timescale remaining on this study arm (Supplementary Figures S5.3 to S5.5). It is 
hoped that with additional troubleshooting to address issues encountered with 
primer efficiency and off-target effects of siRNA hindering reliable target 
knockdown, the candidate proteins identified in 2DE-LC-MS/MS experiments will 






5.5  PPI network maps comparing fold-enrichment of proteins during   
 MDA-MB-468 cell adhesion to LAP with adhesion to Fn reveal EGFR 
 is uniquely enriched to the LAP-induced MDA-MB-468 β6-adhesome 
 
Proteomic interrogation of a single 2D-E experiment (comprising two technical 
replicates) performed using MDA-MB-468 cells permitted PPI network mapping of 
the LAP versus Fn-induced adhesomes in an alternative TNBC in vitro model 
(Figure 5.4). Although lacking the accompanying validation WB data, spectral 
analyses of LC-MS/MS data confirmed specific and unique enrichment of integrin 
αν (ITGAV) and integrin β6 spectra (ITGB6) in LAP-mediated adhesion complexes. 
Similar to results obtained using the BT-20 cell line, the integrin ανβ6 was not 
engaged during Fn-mediated adhesions in the MDA-MB-468 cell line as neither 
ITGAV nor ITGB6 spectra were detected.  
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Figure 5.4  
Protein-protein interaction networks mapping proteins ≥1.5-fold enriched to a LAP-ligand induced β6–adhesome compared to a Fn induced adhesion 
environment in the MDA-MB-468 cell line (n=1) 
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Figure 5.4  
Protein-protein interaction networks mapping proteins ≥1.5-fold enriched to a LAP-ligand 
induced β6–adhesome compared to a Fn induced adhesion environment in the MDA-MB-
468 cell line (n=1) 
 
Following enrichment and isolation of adhesion complexes formed on LAP and Fn immobilised 
substrate ligands, peptides were prepared for LC-MS/MS analysis using the nanoACQUITY UPLC® 
ultra performance liquid chromatography system (Waters Ltd) coupled to an LTQ-Orbitrap XL™ ETD 
Hybrid Ion Trap-Orbitrap Mass Spectrometer (Thermo Scientifc Inc). Peptides were identified from raw 
SEQUEST (.dta) files using Mascot Daemon (v2.2.2, Matrix Science®) software and searched against 
entries held in the International Protein Index (IPI) Human Database (v3.70 released 4th March 2010). 
Mascot (.mgf) files were reviewed in Scaffold™ (v4.3.2, Proteome Software© Inc) for data pre-
processing to exclude ambiguous peptide assignments and validate spectral count data. Identification 
threshold criteria were set to ≥99% at the protein level and ≥50% at the peptide level, with ≥2 unique 
validated peptides detected. Protein-protein interaction (PPI) networks for LAP-ligand engaged, 
integrin ανβ6–dependent adhesions were mapped using Cytoscape open source software (v3.1.1, 
Cytoscape Consortium©) in comparison with Fn-induced adhesomes. Nodes (circles) represent 
proteins labelled with gene names. Node colour represents fold enrichment to either LAP (blue) 
compared to Fn (red) (a minimum threshold of ≥1.5-fold enrichment was set). Block colour represents 
unique enrichments to either condition. Edges (lines) represent reported interactions between 2 
proteins based on a literature-curated PPI database detailed by Jacquemet et al (2013). Data shown is 
a composite from a merged report of two technical replicates analysed on two separate LC-MS/MS 
runs using peptides prepared from a single 2D-E experiment.  
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Excitingly, EGFR was uniquely enriched in LAP-mediated, integrin ανβ6–specific 
adhesion complexes in comparison with Fn-induced, integrin ανβ6-null adhesion 
complexes. Although the significance of this finding must be tempered by its 
observation in a single biological experiment comprising two technical replicates, 
this preliminary finding assuredly warrants validation with additional biological 







5.6 discussion  
 
To address our limited understanding of signalling events inducted downstream of 
integrin ανβ6 activation upon ligand engagement and adhesion complex 
formation, a proteomic strategy to characterise the molecular nature of an integrin 
ανβ6–dependent adhesion environment (“β6-adhesome”) in the BT-20 TNBC cell 
line was developed and employed using the 2D-E strategy first described by 
Humphries et al (2009) and refined by Byron et al (2011).  
 
 
Functional abrogation of the integrin ανβ6 receptor using inhibitory monoclonal 
antibody blockade abolished LAP ligand engagement in comparison with an 
isotype, species-matched negative control antibody treatment (one-tailed 2-
sample t-test; p=0.0104). This successful validation of apparent exquisite LAP 
specificity for integrin ανβ6 in the BT-20 cell line (Figure 5.1.2C) firmly established 
the utility of LAP ligand to specifically target the integrin ανβ6 in a physiologically 
relevant manner for studies seeking define ανβ6–dependent functions. It is 
acknowledged that this is not a universal validation of LAP-integrin ανβ6 specificity 
but rather demonstrates that the integrin ανβ6 is the predominant LAP receptor in 
BT-20 cells. Therefore, use of integrin ανβ6 targeting via LAP engagement in other 
cell line models would first need to be validated as cell-type specific integrin-
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Despite a failure to robustly validate purity of isolated adhesion complexes using 
established markers of integrin-mediated complexes by WB (Paul 2014, Robertson 
2014, Robertson et al 2015), the four-biological replicate 2D-E experiments 
successfully yielded specific and reproducible enrichment for the integrin ανβ6 
receptor on its cognate ligand LAP (Figure 5.2). It was concluded that this LAP-
mediated integrin ανβ6-enrichment was sufficient to justify proceeding with 
proteomic interrogation of integrin ανβ6–dependent adhesion complexes; 
provided the limitations rendered by less stringent validation than desired were 
considered during interpretation and contextualisation of findings. 
  
 
Although some results generated were unexpected, they did exhibit a degree of 
consistency. For example, the anticipated integrin β1 enrichment to Fn and Col I 
immobilised ligands was not demonstrated by validation WBs (Figure 5.2C). This 
was concordant with an absence of ITGB1 spectra detected by LC-MS/MS. These 
findings were consistent with the IMF observation that integrin β1 remained 
bounded in an intracellular, vesicular pattern of immunopositivity on all substrate 
ligands; suggesting that integrin β1 was not trafficked to the plasma lemma for 
ligand engagement. Although integrin β1 was seen to co-localise with the 
adhesion complex-associated protein vinculin and the integrin ανβ6 on Col I, these 
regions of integrin β1 at the plasma lemma were sparse. 
 
 
The curious lack of integrin β1 engagement to Fn and Col I may be an artefact, but 
given the emerging significance of derailed internalisation and endocytic 
trafficking of integrin receptors in cancer (Mosesson et al 2008, Rainero et al 2013), 
the perturbed surface membrane delivery of integrin β1 species observed in BT-20 
cells adhering to β1–cognate ligands may warrant additional dissection. Published 
integrin-centric mechanisms governing differential integrin intracellular traffic and 
recycling kinetics may prove a logical starting point for future experiments (such as 
those presented later in Chapter VI, Results Part IV).  
 
 
For example, Src-mediated syndecan-4 phosphorylation was shown to suppress 
Arf6 activity, promoting integrin ανβ3 delivery to the plasma lemma leading to 
preferential engagement of integrin ανβ3 over integrin α5β1 for cellular adhesion to 
Fn (Morgan et al 2013). It would prove interesting to determine whether syndecan-




results part III 
 
 253 
Previous in-house data (unpublished) has demonstrated that syndecan-4 co-
localises with integrin ανβ6 in OSCC cells and HaCaT keratinocytes. Therefore it 
would be logical to establish whether integrin ανβ6 is also subject to Src-mediated 
syndecan-4 regulation. It may be that integrin ανβ6 is preferentially delivered to the 
plasma lemma for initial Fn engagement at the expense of integrin α5β1, in a 
similar manner to that described by Morgan et al (2013) for the integrin ανβ3.  
 
  
Given that integrin switching has been observed previously in vitro (Caswell et al 
2008, Morgan et al 2013) and is associated with establishing metastatic 
competence (Parvani et al 2013, Madamanchi et al 2014), the 2D-E experiments 
were performed using 3 different ECM substrates known to preferentially engage 
different integrin species (LAP – ανβ6; Fn – α5β1/ανβ6; Col I – β1 species). The 
intention of this experimental design was to permit exploration of the integrin 
switching phenomenon within the context of TNBC using the BT-20 BrCa cell line.  
 
 
Although it is disappointing that the postulated integrin switching mechanism was 
not observed in these experiments, the primary remit of the 2D-E/LC-MS/MS 
assays to yield specific and reproducible enrichments for the integrin ανβ6 receptor 
during engagement to its cognate ligand LAP was resoundingly achieved. Across 
the four biological replicates, validation WBs showed that integrin ανβ6 was 
demonstrably enriched in LAP-engaged adhesion complexes; and so validates the 




Curiously, results from proteomic investigation of an integrin ανβ6–dependent 
adhesion environment utilising the 2D-E strategy did not yield consistent hits for 
several canonical integrin-mediated adhesion complex proteins, notably: talin 
(Garcia-Alvarez et al 2003, Critchley 2009, Orlowski et al 2015), vinculin 
(Humphries et al 2007, Ziegler et al 2008, Carisey et al 2013, Hirata et al 2014, 
Atherton et al 2015, Atherton et al 2016), kindlin (Shattil et al 2010, Calderwood et 
al 2013), FAK (Serrels et al 2010, Duperret et al 2015) and paxillin (Crowe and 
Ohannessian 2004, Brown et al 2005). This may be attributable to several factors.  
 
 
Current understanding of integrin-dependent adhesion processes is based 
predominantly on integrin receptors other than ανβ6, notably ανβ3 or β1–bearing 
species, during adhesion to Fn; typically characterised in fibroblasts (Huttenlocher 
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and Horwitz 2011). Critically, adhesion complexes formed in BT-20 cells under 2D-
E experimental conditions and reviewed by IMF appeared to be smaller and fewer 
in abundance than published data on canonical adhesion complexes. Thus the low 
yield or absence of certain adhesion complex proteins may be attributable to 
fundamental variations between the size and constitution of adhesomes derived 




For example, published tandem characterisation of proteomic constitution in 
concert with IMF nanostructural organisation of integrin-driven adhesion 
complexes has been undertaken in: K562 human chronic myelogenous leukaemia 
cells and B16-F10 mouse melanoma cells (Humphries et al 2009, Byron et al 2012), 
A375 human melanoma cells (Robertson et al 2015), human bone marrow-derived 
mesenchymal stem cells (MSC) (Ajeian et al 2016), MEF fibroblasts and U2-OS 
osteosarcoma cells (Kanchanawong et al 2010, Carisey et al 2013); not mammary 
epithelial cells, as has been attempted in this study, rendering appropriate 
literature-based comparisons for observational validation challenging.  
 
 
Adhesion complex morphology observed by IMF in BT-20 cells (Figure 5.2B) was 
subsequently compared with unpublished data characterising murine primary 
mammary epithelial cells adhering to laminin-111 or collagen type I (Paul 2014). 
These comparisons suggested the nature of presumed adhesion complexes 
formed in BT-20 cells (based on clusters of vinculin immunopositivity) adhered to 
immobilised substrate ligands, was indeed comparable to those established and 
validated by Paul (2014); lending credence to the 2D-E assays performed for 
proteomic investigation of the β6-adhesome. 
 
 
Disappointingly, technical validation of the 2D-E procedure by WB using markers 
specific for integrin-mediated adhesion complexes (talin and vinculin) was 
inconsistent (Figure 5.2C). Attempts to trouble-shoot this problem identified 
several possible technical causes including inefficient protein transfer conditions 
and primary antibody inter-batch variation. Furthermore, the mitochondrial protein 
Bak (its absence used to confirm purity of adhesion-complex enrichment) was only 
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In addition, it is possible that suboptimal stabilisation of notoriously labile 
adhesion complexes using the biochemical cross-linker DTBP, may account for the 
underestimation of proteins detected by WB and LC-MS/MS. Although the use of 
such biochemical cross-linkers is well established (Corgiat et al 2014), it would 
have been pertinent to specifically optimise and validate cross-linkage conditions 
(time, DTBP concentration) alongside adhesion complex isolation by sonication in 
the BT-20 cell line to ensure adhesions were suitably stabilised.  
 
 
Inefficient cross-linkage would not sufficiently stabilise adhesion complexes 
leading to dissociation of protein interactions during extraction by sonication; 
resulting in an underestimation or absence of adhesion-associated moieties, as 
observed here. In the interests of time during limited secondment tenure, a 2D-E 
protocol previously established and validated by the host institution for MEFs was 
followed. However, it is acknowledged that this fails to account for cell line-specific 
idiosyncracies often encountered when translating an established protocol to a 
different cell line. 
 
 
Furthermore, owing to time constraints of secondment to complete experiments, 
WB validation of 2D-E lysates was undertaken simultaneously with peptide 
preparation and LC-MS/MS analysis. Therefore, the 2D-E lysate aliquot retained for 
WB (the bulk being used for peptide preparation) proved insufficient to allow for 
technical issues with WB and requirements for additional blots to complete more 
robust, convincing validation. Ideally (and logically) WB validation would be 
performed prior to peptide preparation and LC-MS/MS interrogation.  
 
 
However, it is also acknowledged that the low abundance, or absence of certain 
adhesion-complex markers detected by WB and LC-MS/MS may not necessarily be 
technical artefacts. It is possible that integrin ανβ6–mediated adhesion complexes 
in TNBC BT-20 cells differ in constitution to published adhesion complex 




Thus, as these 2D-E experiments were an exploratory exercise to define a hitherto 
uncharacterised integrin ανβ6–dependent adhesion environment (β6-adhesome), 
the use of published, peer-reviewed, experimentally validated markers for integrin 
ανβ6 adhesions, was not possible. Therefore, the use of talin and vinculin to 
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validate adhesion complex formation during 2D-E assays was inferred from 
literature characterising other integrin species during adhesion.  
 
 
In addition to possible biological causes, technical limitations resulting in low 
abundance, or absence of anticipated protein moieties detected, must also be 
considered. For example, known technical limitations associated with label-free 
LC-MS/MS techniques for quantitative proteomics may also account for the 
absence of anticipated proteins identified from 2D-E samples. Although label-free 
quantitative proteomic strategies are experimentally simpler in comparison with 
conventional stable isotope labelling with amino acids in cell culture (SILAC) 
methods, there are several key limitations with label-free systems that must be 
considered during data processing (Patel et al 2009).  
 
 
Label-free methods are less accurate than their SILAC counterparts but yield high 
coverage, making them amenable to large-scale, exploratory proteomic workflows 
(Kito and Ito 2008, Patel et al 2009), such as that employed in this study arm. 
Furthermore, label-free methods are more error prone owing to systematic inter-
run variability and stochasticity of indices used for quantitation calculations (Wong 
and Cagney 2010). Typically, peptide quantification methods using label-free data 
are based on peptide ion characteristics such as peak intensity or identification 
frequency (spectral count). Thus label-free methods permit relative quantification 
of any protein from which a peptide has been unambiguously identified. Spectral 
counting reportedly shows highest correlation with relative protein abundance so 
is more often used for relative protein quantification than ion peak intensity (Kito 
and Ito 2008).  
 
 
Spectral counting based on MS/MS spectra has been shown to generate good 
estimates of protein abundance, but is limited by instrument MS/MS sampling 
frequency. Thus, for low-abundance proteins yielding solitary peptide 
identifications, low quantitative resolution using this method cannot be overcome 
(Domon and Aebersold 2010, Sandin et al 2014). However, since larger proteins 
will generate a larger number of peptides, precursor ions and MS/MS spectra (and 
so will be detected at greater frequency than smaller proteins), sampling bias must 
be overcome by spectral normalisation prior to calculation of relative protein 
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In this study, unweighted spectral counts (USC) were normalised against protein 
size (kDa), since linear correlation of spectral count per molecular weight with 
protein stoichiometry has been shown (Liu et al 2004) . Samples were analysed in 
data-dependent acquisition (DDA) mode, whereby the most abundant peptide 
peaks are selected for MS/MS fragmentation (Wong and Cagney 2010). A caveat 
to USC-based proteomic analyses is the fact that proteins of low abundance may 
be masked in the presence of contaminant proteins that may mask peak ion 
characteristics, precluding selection in MS1 for fragmentation in MS2 (Liu et al 
2004, Kito and Ito 2008, Domon and Aebersold 2010, Sandin et al 2014).  
 
 
Indeed, post-acquisition analysis of RAW files using RAWmeat data quality 
diagnostic software revealed that contrary to assurances from the Mass 
Spectrometry Core Facility (Institute for Translational Medicine, University of 
Liverpool), the LTQ Orbitrap XL™ ETD Ion Trap-Orbitrap (ThermoScientific 
instrument used was calibrated to fragment the single most abundant ion, not the 
top 6 most abundant ion species in MS1 for fragmentation in MS2. This would 
account for a gross underestimation of identified peptides and thus a markedly 
smaller number of protein species comprising the final dataset merged from the 
four biological replicates.  
 
 
In stark contrast with previous proteomic (Humphries et al 2009, Byron et al 2011, 
Jacquemet et al 2013, Byron et al 2015, Ajeian et al 2016) and phosphoproteomic 
(Robertson et al 2015) analyses of integrin-mediated adhesion complexes that 
identified proteins in the 103 or 104 order of magnitude, only 196 proteins were 
identified in this study. Therefore, it is most probable that key mediators of the β6-
adhesome would not have been identified owing to the lack of requisite 
instrument sensitivity. Curiously, the technical limitations of fragmenting only the 
single most abundant ion in MS1 may in fact confer a modicum of confidence in the 
validity of candidate proteins identified. For example, in light of the inherent 
underestimation of peptides due to instrument limitations, it is more likely that 




However, even in light of technical limitations and unanticipated findings, the 
demonstrable, reproducible and reliable enrichment of integrin ανβ6 to LAP-
mediated adhesions demonstrated by both validation WBs and spectra identified 
by LC-MS/MS should not be discounted entirely. Across four biological replicate 
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experiments, samples were successfully generated and validated that permit 
specific (albeit preliminary in light of protein underestimation) characterisation of 
an integrin ανβ6–mediated adhesion environment in the BT-20 cell line (Figure 5.3).  
 
 
For a more exhaustive, robustly validated dataset to define the β6-adhesome in 
more detail with greater confidence, experiments would need to be repeated for 
analysis on an appropriately calibrated mass-spectrometer as a minimum. 
Furthermore, in-depth validation of adhesion-complex formation by IMF (to 
characterise structural composition) and WB (to confirm purity of isolation) using a 




In spite of the limitations acknowledged thus far, it is important to reiterate the 
reproducible and specific integrin ανβ6–enrichment in LAP-induced adhesion 
complexes; sufficient to undertake provisional characterisation of the β6–
adhesome. Bioinformatic analysis and PPI networking enabled identification of 7 
candidate proteins showing ≥2-fold enrichment (DMBT-1, MARCKS, MXRA5, 
MYH9, MYH10, SEPT6, SEPT9) for functional interrogation of their putative role in 
integrin ανβ6–mediated adhesions using a gene silencing siRNA screening strategy 
successfully employed elsewhere to validate proteomic datasets (Boyer et al 2013, 
Browne et al 2013). 
 
 
Within the LC-MS/MS dataset, it was curious that β1 integrin was not detected in 
either Fn or Col I ligand conditions. However, spectra mapping to β4 integrin 
(ITGB4) were detected. This is of interest as spectra mapping to laminin moieties 
were consistently detected. Laminins are integral components of basal lamina 
providing structural support for the overlying epithelium. Disease progression 
from in situ to invasive disease is marked by epithelial cell acquisition of an 
invasive phenotype facilitating breach of the basal lamina to invade surrounding 
tissues with the potential for metastatic dissemination (Hamill et al 2009, Iorio et al 
2015). Interestingly, derailed endo-exocytic trafficking of laminins has been 
reported in aggressive cancer subtypes (Leonoudakis et al 2014).   
   
 
Curiously, several laminin subunits were uniquely enriched to the LAP condition 
including: α5, β1, β2 and γ1 (assigned LAMA5, LAMB1, LAMB2 and LAMBC1 
respectively). Kim et al (2012) demonstrated that invasive BrCa induced laminin-
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332 upregulation and neoexpression of integrin β4 in myofibroblasts, conferring 
an anoikis-resistant survival advantage during tissue remodelling. Indeed, 
Terranova et al (1983) first reported expression of high-affinity laminin receptors in 
human MCF-7 BrCa cells. 
 
 
Recently, Vieira et al (2014) demonstrated that the integrin α6β4 laminin receptor 
modulates P-cadherin signalling to induct stemness and an invasive phenotype in 
basal-like BrCa cells. The cell-cell adhesion molecule P-cadherin has been shown 
to promote BrCa progression and is associated with poor prognosis. Using the BT-
20 and MDA-MB-468 TNBC cell lines, Vieira et al (2014) demonstrated in vitro that: 
expression of P-cadherin regulated integrin α6β4 expression with P-cadherin 
ablation downregulating integrin α6β4; and integrin α6β4 was requisite for P-
cadherin signalling. In vivo studies using TNBC tumour xenografts revealed that 




Demonstrative of the emerging significance of laminin-integrin coordination in 
BrCa cancer, Carpenter et al (2017) reported the pulmonary endothelial laminin-
332 was a tropic motility factor for BrCa dissemination to the lung; with tumour cell 
motile arrest dependent upon integrin α3β1 expression, as previously described by 
Zhou et al (2014). Therefore, the presence of both integrin β4 and laminin subunit 
spectra within the context of a β6-adhesome defined by proteomics may warrant 
further characterisation of the role of integrin ανβ6 LAP-ligand engagement, 
activation and adhesion complex formation within the context of TNBC matrix-
mediated metastatic dissemination. 
  
 
Interestingly, in line with the concept of matrix-associated responses in cancer, the 
ECM remodelling moiety matrix-remodelling associated protein-5 (MXRA5) was 
found to be uniquely enriched to LAP-mediated, integrin ανβ6–dependent 
adhesions in comparison with Col I-mediated adhesions and showed a >2-fold 




MXRA5 is a protein of relatively unknown function. Proteomic biomarker discovery 
undertaken by Wang et al (2013) revealed MXRA5 to be a novel tissue biomarker 
in human colorectal carcinoma (CRC); utility as a serum marker was not evaluated. 
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The authors evaluated a cohort of human tissue samples comprising 20 colorectal 




IHC evaluation showed that MXRA5 was overexpressed in CRC tissues in 
comparison with corresponding normal mucosa. Furthermore, intensity of MXRA5 
expression positively and significantly correlated with lesion site, TNM staging and 
metastasis, with the highest observed MXRA5 positivity in omental metastasis. 
Wang and colleagues concluded that MXRA5 was of potential clinical value for 
CRC disease detection and prediction of omental metastasis, but would require 
additional validation.  
 
 
Recently (and subsequent to termination of this study arm), Poveda et al (2017) 
demonstrated that MXRA5 was subject to TGF-β1 regulation and exhibited anti-
inflammatory and anti-fibrotic properties within the context of human chronic 
kidney disease. Given that the integrin ανβ6 is known to activate latent TGF- β1 via 
engagement of LAP, it is possible that the integrin ανβ6 may be implicated in this 
MXRA5-TGF-β1-axis and may prove an interesting lead to investigate; especially 
given the association between integrin ανβ6-dependent adhesions and MXRA5 as 
defined by the 2D-E proteomic dataset. 
 
 
Other proteins identified as putative components of the β6-adhesome, showing 
unique enrichment to LAP-mediated adhesion complexes in comparison with 
either Fn- or Col I-mediated adhesions include known regulators of actin 
cytoskeletal dynamics. Notably the filamentous (F)-actin crosslinking protein 
myristolated alanine-rich protein kinase C (MARCKS) known to regulate cell 
motility via actin cytoskeleton regulation (Aderem 1992) was identified; the 
filament forming cytoskeletal small GTPases septin-6 (SEPT6) and septin-9 (SEPT9) 
requisite for cytokinesis were also detected. In their proteomic interrogation of 
signalling networks associated with acquired tamoxifen resistance in MCF-7 BrCa 
cells, Browne et al (2013) demonstrated that MARCKS expression was upregulated 
eight-fold in tamoxifen resistant MCF-7 cells compared to tamoxifen-sensitive 
MCF-7 cells.  
 
 
Furthermore, the authors reported that siRNA silencing of MARCKS significantly 
decreased cell motility. In addition, MARCKS IHC staining in a TMA constructed 
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from samples from a 292 cohort of primary IDC breast tumours was significantly 
higher in basal-like and HER-2 tumours, compared to luminal cancers. Tissue-
expression of MARCKS was also found to be independently predictive of poor 
patient outcome in multivariate analysis of the entire primary BrCa cohort studied. 
 
 
Subsequently, Chen et al (2015) demonstrated that phosphorylation of MARCKS at 
serine 159/163 (pMARCKSS159/163) was (at least in part) contributing to paclitaxel 
resistance in BrCa taxane therapy-based regimens. Inhibition of MARCKS 
phosphorylation using an inhibitory peptide elicited restitution of paclitaxel 
efficacy in vivo in nude mice orthotopically injected with MDA-MB-468 BrCa cells.  
 
 
Most recently, Manai et al (2017) performed IHC evaluation of MARCKS expression 
in pre-therapeutic tissue samples obtained from a cohort of 133 inflammatory 
breast cancer (IBC) patients in comparison with a 369 non-IBC patient cohort. The 
authors found that MARCKS expression was associated with poor metastasis-free 
survival rates. Collectively this literature (Browne et al 2013, Chen et al 2015, Manai 
et al 2017) is indicative of the emerging significance of MARCKS in BrCa, justifying 
additional characterisation of MARCKS within the context of an integrin ανβ6-
dependent adhesion environment in a TNBC model. 
  
 
The septins -6 and -9 (SEPT6 and SEPT9) were also identified; showing a ≥2-fold 
enrichment to LAP compared either Fn or Col I. The septins are of emerging 
importance in cancer (Pous et al 2016). High mutation frequency of SEPT6 has 
been reported in endometrial cancers (Angelis and Spiliotis 2016); whilst SEPT9 
overexpression has been demonstrated in a variety of solid tumours including: 
serous ovarian cancer (Scott et al 2006), high-grade prostate cancer (Gilad et al 
2015) and breast cancer (Connolly et al 2011).  
 
 
Integrin-septin crosstalk has been reported to modulate ECM-stiffness regulated 
endothelial cell proliferation. Yeh et al (2012) demonstrated integrin ανβ3 
inactivation upregulated SEPT9 expression in human umbilical vein endothelial 
cells (HUVECs) adhered on high-stiffness hydrogels. This in turn attenuated Src 
phosphorylation and inhibited RhoA-dependent HUVEC proliferation. Therefore, it 
is possible that the integrin ανβ6 may also act in concert with SEPT6 or SEPT9 to 
modulate proliferative signalling and warrants further functional characterisation. 
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In addition, the non-muscle myosin II (NM-II) isoforms myosin-9 (II-A) and -10 (II-B) 
(assigned MYH9 and MYH10 respectively) were specifically enriched during 
integrin ανβ6–mediated adhesions to LAP in comparison with Fn-derived adhesions 
(Figure 5.4A), and showed partial enrichment to Col I adhesions over LAP (Figure 
5.4B). The role of non-muscle myosin motor proteins during BrCa progression, 
promoting invasion and metastasis, is of growing research interest (Derycke et al 
2011, Arjonen et al 2014, Ouderkirk and Krendel 2014, Li and Yang 2016).  
 
 
In a comparative proteomic analysis of invasive (MCF-7/6) and non-invasive (MCF-
7/AZ) MCF-7 BrCa cell variants, Derycke et al (2011) discovered a single, 
significant difference between their proteomes. The authors identified NM II-A 
(MYH9) expression was restricted to the invasive MCF-7/6 variant, suggesting 
MYH9 may confer an invasive phenotype. MYH9 blockade, using genetic silencing 
with stable shRNA transduction or pharmacological functional abrogation with 
blebbistatin, successfully abolished MCF-7/6 invasion in embryonic chick heart 
fragments or Col I gels serving as invasion 3D-substrata. Derycke and colleagues 
thus concluded that MYH9 is a decisive protein for MCF-7 invasion and may prove 
a useful molecular target for anti-invasive therapy in BrCa. 
 
 
Recently, high expression of MYH9 (as determined by IHC in primary patient 
cohorts) has been associated with poorer clinicopathological features of 
malignancy and poor survival probability in: resected non-small cell lung 
carcinoma (NSCLC) (Katono et al 2015), osteosarcoma (Zhou et al 2016) and 
colorectal cancer (CRC) (Liu et al 2017). Given the emerging clinical significance of 
MYH9 expression in malignant disease, evaluation of MYH9 expression in BrCa 




Indeed, MYH10 (NM II-B) has also been reported to potentiate invasion in BrCa. It 
has been shown that MYH10 promotes invasion in BrCa via directing integrin traffic 
to filopodial tips and is requisite for invadopodial formation and ECM degradation 
via engagement of the MYH10 pleckstrin homology domain with the membrane 
phospholipid phosphatidylinositol (3,4,5)-triphosphate (PtdIns(3,4,5)P3) (Arjonen 
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Later, Arjonen et al (2014) concluded that MYH10 upregulation is requisite for 
mutant p53-driven BrCa invasion. Gene expression profiling of 2 BrCa clinical 
datasets revealed MYH10 was highly expressed in aggressive BrCa subtypes. 
Furthermore, in vitro expression of mutant p53 upregulated MYH10 expression in 
BrCa cells, but suppression of endogenous mutant p53 constrained MYH10 
expression; suggesting mutant p53 modulates MYH10 expression in BrCa cells.  
 
 
The authors also conducted mutational studies using MYH10 mutants lacking their 
integrin-binding domain. This revealed MYH10-mediated delivery of integrin β1 to 
filopodial tips was necessary for invasion. These findings highlight the importance 
of integrin-synergy with other molecular mediators to drive disease progression in 
BrCa, and justify further investigation of proinvasive MYH10-integrin transport 
within the context of other integrin species, such as the integrin ανβ6. 
 
 
The mucin-like protein deleted in malignant brain tumours-1 (DMBT1) was also 
found to be specifically and uniquely enriched to LAP-mediated integrin ανβ6–
dependent adhesions. Research into the role of DMBT1 in cancer has revealed it to 
be pleiotropic; with dual roles in epithelial protection and differentiation, it cannot 
be categorically termed a classical tumour suppressor (Mollenhauer et al 2002). 
Early studies reported DMBT1 is down-regulated in BrCa (Braidotti et al 2004) and 




Tchatchou et al (2010) identified 5’-region polymorphisms in DMBT1 that resulted 
in loss of DMBT1 promoter activity conferring increased risk of BrCa in a cohort of 
1 195 BRCA1/2 mutation-negative BrCa families and 1 466 unrelated controls that 
were analysed. This was concordant with previous studies associating decrease of 
DMBT1 with BrCa risk. In their evaluation of the functional role of DMBT1 in 
vascular endothelial cells, Muller et al (2012) reported a coincidental finding that 
integrin β3 expression was attenuated in DMBT-/- mice; leading to the authors 
tentatively proposing a functional link between integrin β3 and DMBT1. In light of 
this, and given that DMBT1 was uniquely enriched to the LAP-mediated β6-
adhesome in BT-20 cells, it would be logical to explore the functional role of 
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Therefore, it is disappointing that siRNA functional screening targeting these 
exciting candidate proteins implicated during establishment of an integrin ανβ6–
adhesion-mediated proteome environment (β6-adhesome), could not be validated 
and developed within the time constraints of this study. However, it is hoped that 
this work will be continued, particularly in light of emerging research that appears 
to independently validate the significance of these moieties in malignant disease: 
DMBT-1 (Mollenhauer et al 2002, Mollenhauer et al 2002, Braidotti et al 2004, 
Blackburn et al 2007, Tchatchou et al 2010, Muller et al 2012); MARCKS (Aderem 
1992, Chen et al 2015, Manai et al 2017); MXRA5 (Wang et al 2013, Poveda et al 
2017); MYH9 (Derycke et al 2011, Katono et al 2015, Zhou et al 2016, Liu et al 
2017); MYH10 (Arjonen et al 2014, Cao et al 2014, Ouderkirk and Krendel 2014, Li 
and Yang 2016); SEPT6 (Angelis and Spiliotis 2016, Pous et al 2016) and SEPT9 
(Scott et al 2006, Connolly et al 2011, Yeh et al 2012, Gilad et al 2015).  
 
 
The preliminary identification of EGFR specificity within the MDA-MB-468 LAP-
mediated β6-adhesome is exciting, suggesting the possibility of integrin 
ανβ6/EGFR cross-talk during ECM-ligand-mediated adhesions, which is concordant 
with previous findings (Caswell et al 2008). Undoubtedly this warrants further 
investigation to provide sufficient evidence to determine whether EGFR/integrin 
ανβ6 receptor cooperation is a cell line specific phenomenon (as observed here in 
the MDA-MB-468 cell line but not the BT-20 cell line) or has broader relevance 
within the context of TNBC. 
 
 
Validation of EGFR/integrin ανβ6 reciprocity would offer the potential for 
therapeutic intervention and possible receptor co-targeting in a manner similar to 
that described by Moore et al (2014) who successfully abrogated integrin ανβ6 
function using 264RAD to potentiate trastuzumab efficacy in HER-2 driven BrCa.  
 
 
Therefore, this body of data represents a springboard from which additional 
exploration of the TNBC β6-adhesome may be launched; in the hope of identifying 
cancer-specific, intracellular regulators of integrin ανβ6–mediated adhesions and 
putative EGFR-integrin ανβ6 cross-talk that may be therapeutically targeted in 
multi-modal treatment regimens to prevent disease progression and metastatic 





























Supplementary Information (Figure) S5.1  
Immunoblots to test an integrin β8 antibody by dual probing for integrin β8 (red channel) and integrin β6 (green channel)  
To test an integrin antibody not previously used in-house, lysates from integrin β6 high expressors (BT-20) and a moderate-to-low expressor (MDA-MB-468) were probed for 
integrin β6 subunit (c-19, 0.2 μg ml-1, sc-6632, SantaCruz BioTech) and integrin β8 (5 μg ml-1, ab80673, AbCam) subunit using the LI-COR ODYSSEY®Sa dual 










































Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 P60709 ACTB_HUMAN ACTB 42 
Agrin OS=Homo sapiens GN=AGRN PE=1 SV=5 O00468 AGRIN_HUMAN AGRN 217 
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 P02768 ALBU_HUMAN ALB 69 
Annexin A2 OS=Homo sapiens GN=ANXA2 PE=1 SV=2 P07355 ANXA2_HUMAN ANXA2 39 
Adenine phosphoribosyltransferase OS=Homo sapiens GN=APRT PE=1 SV=2 P07741 APT_HUMAN APRT 20 
Isoform 1 of Transcriptional regulator ATRX OS=Homo sapiens GN=ATRX P46100 ATRX_HUMAN ATRX 260 
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 (Fragment) OS=Homo sapiens GN=GNB2 PE=2 
SV=1 C9JIS1 C9JIS1_HUMAN GNB2 26 
Cadherin-1 OS=Homo sapiens GN=CDH1 PE=1 SV=3 P12830 CADH1_HUMAN CDH1 97 
Caprin-1 OS=Homo sapiens GN=CAPRIN1 PE=1 SV=2 Q14444 CAPR1_HUMAN CAPRIN1 78 
Cell division control protein 42 homolog OS=Homo sapiens GN=CDC42 PE=1 SV=2 P60953 CDC42_HUMAN CDC42 21 
Uncharacterized protein C8orf59 OS=Homo sapiens GN=C8orf59 PE=1 SV=2 Q8N0T1 CH059_HUMAN C8orf59 11 
Coiled-coil-helix-coiled-coil-helix domain-containing protein 1 OS=Homo sapiens GN=CHCHD1 PE=1 SV=1 Q96BP2 CHCH1_HUMAN CHCHD1 13 
Collagen alpha-1(I) chain OS=Homo sapiens GN=COL1A1 PE=1 SV=5 P02452 CO1A1_HUMAN COL1A1 139 
Collagen alpha-2(I) chain OS=Homo sapiens GN=COL1A2 PE=1 SV=7 P08123 CO1A2_HUMAN COL1A2 129 
Isoform 4 of Collagen alpha-1(XII) chain OS=Homo sapiens GN=COL12A1 Q99715 COCA1_HUMAN COL12A1 325 
Ubiquinone biosynthesis monooxygenase COQ6 OS=Homo sapiens GN=COQ6 PE=1 SV=2 Q9Y2Z9 COQ6_HUMAN COQ6 51 
Cancer/testis antigen family 45 member A1 OS=Homo sapiens GN=CT45A1 PE=2 SV=1 Q5HYN5 CT451_HUMAN CT45A1 21 
Protein CYR61 OS=Homo sapiens GN=CYR61 PE=1 SV=1 O00622 CYR61_HUMAN CYR61 42 
Deleted in malignant brain tumors 1 protein OS=Homo sapiens GN=DMBT1 PE=1 SV=2 Q9UGM3 DMBT1_HUMAN DMBT1 261 
Supplementary Information (Table) S5.2  
Scaffold™ merged report of proteins identified by LC-MS/MS interrogation of adhesion complexes isolated from BT-20 cells adhering to LAP, Fn or Col I 
to characterise the β6-adhesome (n=4) 
Summary table of proteins identified from LC-MS/MS analysis. Peptides were identified and validated using Mascot Daemon and exported to Scaffold for worklist analysis. 
Candidate proteins are highlighted in blue. 
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Developmentally-regulated GTP-binding protein 1 OS=Homo sapiens GN=DRG1 PE=1 SV=1 Q9Y295 DRG1_HUMAN DRG1 41 
Cytoplasmic dynein 1 heavy chain 1 OS=Homo sapiens GN=DYNC1H1 PE=1 SV=5 Q14204 DYHC1_HUMAN DYNC1H1 532 
Nascent polypeptide-associated complex subunit alpha OS=Homo sapiens GN=NACA PE=2 SV=1 E9PAV3 NACAM_HUMAN NACA 205 
Serine/arginine repetitive matrix protein 1 OS=Homo sapiens GN=SRRM1 PE=2 SV=2 E9PCT1 E9PCT1_HUMAN SRRM1 104 
Heat shock cognate 71  protein (Fragment) OS=Homo sapiens GN=HSPA8 PE=2 SV=1 E9PI65 E9PI65_HUMAN HSPA8 18 
Elongation factor 1-alpha 1 OS=Homo sapiens GN=EEF1A1 PE=1 SV=1 P68104 EF1A1_HUMAN EEF1A1 50 
Elongation factor 2 OS=Homo sapiens GN=EEF2 PE=1 SV=4 P13639 EF2_HUMAN EEF2 95 
rRNA 2'-O-methyltransferase fibrillarin OS=Homo sapiens GN=FBL PE=1 SV=2 P22087 FBRL_HUMAN FBL 34 
Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=4 P02751 FINC_HUMAN FN1 263 
Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4 P21333 FLNA_HUMAN FLNA 281 
Ras GTPase-activating protein-binding protein 1 OS=Homo sapiens GN=G3BP1 PE=1 SV=1 Q13283 G3BP1_HUMAN G3BP1 52 
Isoform B of Ras GTPase-activating protein-binding protein 2 OS=Homo sapiens GN=G3BP2 Q9UN86 G3BP2_HUMAN G3BP2 51 
Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 P04406 G3P_HUMAN GAPDH 36 
Translational activator GCN1 OS=Homo sapiens GN=GCN1L1 PE=1 SV=6 Q92616 GCN1L_HUMAN GCN1L1 293 
Uncharacterized protein (Fragment) OS=Homo sapiens PE=4 SV=1 H0YHG0 H0YHG0_HUMAN H0YHG0 59 
Histone H1.0 OS=Homo sapiens GN=H1F0 PE=1 SV=3 P07305 H10_HUMAN H1F0  21 
Histone H1.2 OS=Homo sapiens GN=HIST1H1C PE=1 SV=2 P16403 H12_HUMAN HIST1H1C 21 
Histone H1.5 OS=Homo sapiens GN=HIST1H1B PE=1 SV=3 P16401 H15_HUMAN HIST1H1B 23 
Histone H2A type 1-J OS=Homo sapiens GN=HIST1H2AJ PE=1 SV=3 Q99878 H2A1J_HUMAN HIST1H2AJ 14 
Histone H2B type 1-B OS=Homo sapiens GN=HIST1H2BB PE=1 SV=2 P33778 H2B1B_HUMAN HIST1H2BB 14 
Histone H2B type 1-D OS=Homo sapiens GN=HIST1H2BD PE=1 SV=2 P58876 H2B1D_HUMAN HIST1H2BD 14 
Histone H3.3 OS=Homo sapiens GN=H3F3A PE=1 SV=2 P84243 H33_HUMAN H3F3A 15 
Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2 P62805 H4_HUMAN HIST4H4 11 
High mobility group protein HMG-I/HMG-Y OS=Homo sapiens GN=HMGA1 PE=1 SV=3 P17096 HMGA1_HUMAN HMGA1 12 
High mobility group protein B1 OS=Homo sapiens GN=HMGB1 PE=1 SV=3 P09429 HMGB1_HUMAN HMGB1 25 








Heterogeneous nuclear ribonucleoprotein K OS=Homo sapiens GN=HNRNPK PE=1 SV=1 P61978 HNRPK_HUMAN HNRNPK 51 
Heterogeneous nuclear ribonucleoprotein L OS=Homo sapiens GN=HNRNPL PE=1 SV=2 P14866 HNRPL_HUMAN HNRNPL 64 
Heterogeneous nuclear ribonucleoprotein R OS=Homo sapiens GN=HNRNPR PE=1 SV=1 O43390 HNRPR_HUMAN HNRNPR 71 
Heterogeneous nuclear ribonucleoprotein U OS=Homo sapiens GN=HNRNPU PE=1 SV=6 Q00839 HNRPU_HUMAN HNRNPU 91 
Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 SV=4 P08238 HS90B_HUMAN HSP90AB1 83 
Heat shock protein beta-1 OS=Homo sapiens GN=HSPB1 PE=1 SV=2 P04792 HSPB1_HUMAN HSPB1 23 
Insulin-like growth factor-binding protein 5 OS=Homo sapiens GN=IGFBP5 PE=1 SV=1 P24593 IBP5_HUMAN IGFBP5 31 
Eukaryotic translation initiation factor 2 subunit 1 OS=Homo sapiens GN=EIF2S1 PE=1 SV=3 P05198 IF2A_HUMAN EIF2S1 36 
Eukaryotic translation initiation factor 2 subunit 3 OS=Homo sapiens GN=EIF2S3 PE=1 SV=3 P41091 IF2G_HUMAN EIF2S3 51 
Isoform 2 of Eukaryotic initiation factor 4A-II OS=Homo sapiens GN=EIF4A2 Q14240 IF4A2_HUMAN EIF4A2 46 
Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 PE=1 SV=2 P01876 IGHA1_HUMAN IGHA1 38 
Ig gamma-1 chain C region OS=Homo sapiens GN=IGHG1 PE=1 SV=1 P01857 IGHG1_HUMAN IGHG1 36 
Ras GTPase-activating-like protein IQGAP1 OS=Homo sapiens GN=IQGAP1 PE=1 SV=1 P46940 IQGA1_HUMAN IQGAP1 189 
Integrin alpha-V OS=Homo sapiens GN=ITGAV PE=1 SV=2 P06756 ITAV_HUMAN ITGAV 116 
Integrin beta-4 OS=Homo sapiens GN=ITGB4 PE=1 SV=5 P16144 ITB4_HUMAN ITGB4 202 
Integrin beta-6 OS=Homo sapiens GN=ITGB6 PE=1 SV=2 P18564 ITB6_HUMAN ITGB6 86 
Probable ATP-dependent RNA helicase DDX5 OS=Homo sapiens GN=DDX5 PE=3 SV=1 J3KTA4 J3KTA4_HUMAN DDX5 69 
Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 P13645 K1C10_HUMAN KRT10 59 
Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 P02533 K1C14_HUMAN KRT14 52 
Keratin, type I cytoskeletal 18 OS=Homo sapiens GN=KRT18 PE=1 SV=2 P05783 K1C18_HUMAN KRT18 48 
Keratin, type I cytoskeletal 19 OS=Homo sapiens GN=KRT19 PE=1 SV=4 P08727 K1C19_HUMAN KRT19 44 
Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 P35527 K1C9_HUMAN KRT9 62 
Keratin, type I cuticular Ha1 OS=Homo sapiens GN=KRT31 PE=2 SV=3 Q15323 K1H1_HUMAN KRT31 47 
Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 P35908 K22E_HUMAN KRT2 65 
Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 P04264 K2C1_HUMAN KRT1 66 








Keratin, type II cytoskeletal 7 OS=Homo sapiens GN=KRT7 PE=1 SV=5 P08729 K2C7_HUMAN KRT7 51 
Isoform 2 of Keratin, type II cytoskeletal 8 OS=Homo sapiens GN=KRT8 P05787 K2C8_HUMAN KRT8 57 
Pyruvate kinase isozymes M1/M2 OS=Homo sapiens GN=PKM PE=1 SV=4 P14618 KPYM_HUMAN PKM 58 
Keratin, type I cuticular Ha6 OS=Homo sapiens GN=KRT36 PE=1 SV=1 O76013 KRT36_HUMAN KRT36 52 
Keratin, type II cuticular Hb2 OS=Homo sapiens GN=KRT82 PE=1 SV=3 Q9NSB4 KRT82_HUMAN KRT82 57 
Keratin, type II cuticular Hb3 OS=Homo sapiens GN=KRT83 PE=1 SV=2 P78385 KRT83_HUMAN KRT83 54 
Keratin, type II cuticular Hb5 OS=Homo sapiens GN=KRT85 PE=1 SV=1 P78386 KRT85_HUMAN KRT85 56 
Leydig cell tumor 10  protein homolog OS=Homo sapiens GN=C19orf53 PE=1 SV=1 Q9UNZ5 L10K_HUMAN C19orf53 11 
Laminin subunit alpha-5 OS=Homo sapiens GN=LAMA5 PE=1 SV=8 O15230 LAMA5_HUMAN LAMA5 400 
Laminin subunit beta-1 OS=Homo sapiens GN=LAMB1 PE=1 SV=2 P07942 LAMB1_HUMAN LAMB1 198 
Laminin subunit beta-2 OS=Homo sapiens GN=LAMB2 PE=1 SV=2 P55268 LAMB2_HUMAN LAMB2 196 
Laminin subunit gamma-1 OS=Homo sapiens GN=LAMC1 PE=1 SV=3 P11047 LAMC1_HUMAN LAMC1 178 
Lipocalin-1 OS=Homo sapiens GN=LCN1 PE=1 SV=1 P31025 LCN1_HUMAN LCN1 19 
Lysozyme C OS=Homo sapiens GN=LYZ PE=1 SV=1 P61626 LYSC_HUMAN LYZ 17 
U1 small nuclear ribonucleoprotein A (Fragment) OS=Homo sapiens GN=SNRPA PE=4 SV=1 M0R2B8 M0R2B8_HUMAN SNRPA 17 
Myristoylated alanine-rich C-kinase substrate OS=Homo sapiens GN=MARCKS PE=1 SV=4 P29966 MARCS_HUMAN MARCKS 32 
Pyrin OS=Homo sapiens GN=MEFV PE=1 SV=1 O15553 MEFV_HUMAN MEFV 86 
Matrix Gla protein OS=Homo sapiens GN=MGP PE=1 SV=2 P08493 MGP_HUMAN MGP 12 
Myosin regulatory light chain 12A OS=Homo sapiens GN=MYL12A PE=1 SV=2 P19105 ML12A_HUMAN MYL12A 20 
Mannosyl-oligosaccharide glucosidase OS=Homo sapiens GN=MOGS PE=1 SV=5 Q13724 MOGS_HUMAN MOGS 92 
Major vault protein OS=Homo sapiens GN=MVP PE=1 SV=4 Q14764 MVP_HUMAN MVP 99 
Matrix-remodeling-associated protein 5 OS=Homo sapiens GN=MXRA5 PE=2 SV=3 Q9NR99 MXRA5_HUMAN MXRA5 312 
Isoform 4 of Myosin-10 OS=Homo sapiens GN=MYH10 P35580 MYH10_HUMAN MYH10 233 
Myosin-9 OS=Homo sapiens GN=MYH9 PE=1 SV=4 P35579 MYH9_HUMAN MYH9 227 
Myosin light polypeptide 6 OS=Homo sapiens GN=MYL6 PE=1 SV=2 P60660 MYL6_HUMAN MYL6 17 








Non-POU domain-containing octamer-binding protein OS=Homo sapiens GN=NONO PE=1 SV=4 Q15233 NONO_HUMAN NONO 54 
Putative ribosomal RNA methyltransferase NOP2 OS=Homo sapiens GN=NOP2 PE=1 SV=2 P46087 NOP2_HUMAN NOP2 89 
Nucleolin OS=Homo sapiens GN=NCL PE=1 SV=3 P19338 NUCL_HUMAN NCL 77 
Polyadenylate-binding protein 1 OS=Homo sapiens GN=PABPC1 PE=1 SV=2 P11940 PABP1_HUMAN PABPC1 71 
Plasminogen activator inhibitor 1 RNA-binding protein OS=Homo sapiens GN=SERBP1 PE=1 SV=2 Q8NC51 PAIRB_HUMAN SERBP1 45 
Protein piccolo OS=Homo sapiens GN=PCLO PE=1 SV=4 Q9Y6V0 PCLO_HUMAN PCLO 553 
Isoform 4 of Plectin OS=Homo sapiens GN=PLEC Q15149 PLEC_HUMAN PLEC 516 
Peroxiredoxin-1 OS=Homo sapiens GN=PRDX1 PE=1 SV=1 Q06830 PRDX1_HUMAN PRDX1 22 
60S ribosomal protein L5 OS=Homo sapiens GN=RPL5 PE=2 SV=1 Q5T7N0 Q5T7N0_HUMAN RPL5 14 
Ras-related protein Ral-B OS=Homo sapiens GN=RALB PE=2 SV=1 P11234 RALB_HUMAN RALB 26 
Ras-related C3 botulinum toxin substrate 1 OS=Homo sapiens GN=RAC1 PE=1 SV=1 P63000 RAC1_HUMAN RAC1 21 
Radixin OS=Homo sapiens GN=RDX PE=1 SV=1 P35241 RADI_HUMAN RDX 69 
RNA-binding protein Raly OS=Homo sapiens GN=RALY PE=1 SV=1 Q9UKM9 RALY_HUMAN RALY 32 
GTP-binding nuclear protein Ran OS=Homo sapiens GN=RAN PE=1 SV=3 P62826 RAN_HUMAN RAN 24 
RNA-binding motif protein, X chromosome OS=Homo sapiens GN=RBMX PE=1 SV=3 P38159 RBMX_HUMAN RBMX 42 
60S ribosomal protein L10 OS=Homo sapiens GN=RPL10 PE=1 SV=4 P27635 RL10_HUMAN RPL10 25 
60S ribosomal protein L11 OS=Homo sapiens GN=RPL11 PE=1 SV=2 P62913 RL11_HUMAN RPL11 20 
60S ribosomal protein L13 OS=Homo sapiens GN=RPL13 PE=1 SV=4 P26373 RL13_HUMAN RPL13 24 
60S ribosomal protein L13a OS=Homo sapiens GN=RPL13A PE=1 SV=2 P40429 RL13A_HUMAN RPL13A 24 
60S ribosomal protein L14 OS=Homo sapiens GN=RPL14 PE=1 SV=4 P50914 RL14_HUMAN RPL14 23 
60S ribosomal protein L15 OS=Homo sapiens GN=RPL15 PE=1 SV=2 P61313 RL15_HUMAN RPL15 24 
60S ribosomal protein L17 OS=Homo sapiens GN=RPL17 PE=1 SV=3 P18621 RL17_HUMAN RPL17 21 
60S ribosomal protein L18 OS=Homo sapiens GN=RPL18 PE=1 SV=2 Q07020 RL18_HUMAN RPL18 22 
60S ribosomal protein L21 OS=Homo sapiens GN=RPL21 PE=1 SV=2 P46778 RL21_HUMAN RPL21 19 
60S ribosomal protein L22 OS=Homo sapiens GN=RPL22 PE=1 SV=2 P35268 RL22_HUMAN RPL22 15 








60S ribosomal protein L23a OS=Homo sapiens GN=RPL23A PE=1 SV=1 P62750 RL23A_HUMAN RPL23A 18 
60S ribosomal protein L24 OS=Homo sapiens GN=RPL24 PE=1 SV=1 P83731 RL24_HUMAN RPL24 18 
60S ribosomal protein L26 OS=Homo sapiens GN=RPL26 PE=1 SV=1 P61254 RL26_HUMAN RPL26 17 
60S ribosomal protein L27 OS=Homo sapiens GN=RPL27 PE=1 SV=2 P61353 RL27_HUMAN RPL27 16 
60S ribosomal protein L27a OS=Homo sapiens GN=RPL27A PE=1 SV=2 P46776 RL27A_HUMAN RPL27A 17 
60S ribosomal protein L29 OS=Homo sapiens GN=RPL29 PE=1 SV=2 P47914 RL29_HUMAN RPL29 18 
60S ribosomal protein L30 OS=Homo sapiens GN=RPL30 PE=1 SV=2 P62888 RL30_HUMAN RPL30 13 
60S ribosomal protein L31 OS=Homo sapiens GN=RPL31 PE=1 SV=1 P62899 RL31_HUMAN RPL31 14 
60S ribosomal protein L35 OS=Homo sapiens GN=RPL35 PE=1 SV=2 P42766 RL35_HUMAN RPL35 15 
60S ribosomal protein L35a OS=Homo sapiens GN=RPL35A PE=1 SV=2 P18077 RL35A_HUMAN RPL35A 13 
60S ribosomal protein L36a-like OS=Homo sapiens GN=RPL36AL PE=1 SV=3 Q969Q0 RL36L_HUMAN RPL36AL 12 
60S ribosomal protein L37a OS=Homo sapiens GN=RPL37A PE=1 SV=2 P61513 RL37A_HUMAN RPL37A 10 
60S ribosomal protein L38 OS=Homo sapiens GN=RPL38 PE=1 SV=2 P63173 RL38_HUMAN RPL38 8 
60S ribosomal protein L4 OS=Homo sapiens GN=RPL4 PE=1 SV=5 P36578 RL4_HUMAN RPL4 48 
60S ribosomal protein L6 OS=Homo sapiens GN=RPL6 PE=1 SV=3 Q02878 RL6_HUMAN RPL6 33 
60S ribosomal protein L7 OS=Homo sapiens GN=RPL7 PE=1 SV=1 P18124 RL7_HUMAN RPL7 29 
60S ribosomal protein L8 OS=Homo sapiens GN=RPL8 PE=1 SV=2 P62917 RL8_HUMAN RPL8 28 
60S ribosomal protein L9 OS=Homo sapiens GN=RPL9 PE=1 SV=1 P32969 RL9_HUMAN RPL9 22 
39S ribosomal protein L34, mitochondrial OS=Homo sapiens GN=MRPL34 PE=1 SV=1 Q9BQ48 RM34_HUMAN MRPL34 10 
40S ribosomal protein S10 OS=Homo sapiens GN=RPS10 PE=1 SV=1 P46783 RS10_HUMAN RPS10 19 
40S ribosomal protein S11 OS=Homo sapiens GN=RPS11 PE=1 SV=3 P62280 RS11_HUMAN RPS11 18 
40S ribosomal protein S13 OS=Homo sapiens GN=RPS13 PE=1 SV=2 P62277 RS13_HUMAN RPS13 17 
40S ribosomal protein S14 OS=Homo sapiens GN=RPS14 PE=1 SV=3 P62263 RS14_HUMAN RPS14 16 
40S ribosomal protein S15 OS=Homo sapiens GN=RPS15 PE=1 SV=2 P62841 RS15_HUMAN RPS15 17 
40S ribosomal protein S15a OS=Homo sapiens GN=RPS15A PE=1 SV=2 P62244 RS15A_HUMAN RPS15A 15 








40S ribosomal protein S17-like OS=Homo sapiens GN=RPS17L PE=2 SV=1 P0CW22 RS17L_HUMAN RPS17L 16 
40S ribosomal protein S18 OS=Homo sapiens GN=RPS18 PE=1 SV=3 P62269 RS18_HUMAN RPS18 18 
40S ribosomal protein S19 OS=Homo sapiens GN=RPS19 PE=1 SV=2 P39019 RS19_HUMAN RPS19 16 
40S ribosomal protein S2 OS=Homo sapiens GN=RPS2 PE=1 SV=2 P15880 RS2_HUMAN RPS2 31 
40S ribosomal protein S20 OS=Homo sapiens GN=RPS20 PE=1 SV=1 P60866 RS20_HUMAN RPS20 13 
40S ribosomal protein S23 OS=Homo sapiens GN=RPS23 PE=1 SV=3 P62266 RS23_HUMAN RPS23 16 
40S ribosomal protein S24 OS=Homo sapiens GN=RPS24 PE=1 SV=1 P62847 RS24_HUMAN RPS24 15 
40S ribosomal protein S25 OS=Homo sapiens GN=RPS25 PE=1 SV=1 P62851 RS25_HUMAN RPS25 14 
40S ribosomal protein S26 OS=Homo sapiens GN=RPS26 PE=1 SV=3 P62854 RS26_HUMAN RPS26 13 
Ubiquitin-40S ribosomal protein S27a OS=Homo sapiens GN=RPS27A PE=1 SV=2 P62979 RS27A_HUMAN RPS27A 18 
40S ribosomal protein S27-like OS=Homo sapiens GN=RPS27L PE=1 SV=3 Q71UM5 RS27L_HUMAN RPS27L 9 
40S ribosomal protein S28 OS=Homo sapiens GN=RPS28 PE=1 SV=1 P62857 RS28_HUMAN RPS28 8 
40S ribosomal protein S29 OS=Homo sapiens GN=RPS29 PE=1 SV=2 P62273 RS29_HUMAN RPS29 7 
40S ribosomal protein S3 OS=Homo sapiens GN=RPS3 PE=1 SV=2 P23396 RS3_HUMAN RPS3 27 
40S ribosomal protein S30 OS=Homo sapiens GN=FAU PE=1 SV=1 P62861 RS30_HUMAN FAU 7 
40S ribosomal protein S3a OS=Homo sapiens GN=RPS3A PE=1 SV=2 P61247 RS3A_HUMAN RPS3A 30 
40S ribosomal protein S4, X isoform OS=Homo sapiens GN=RPS4X PE=1 SV=2 P62701 RS4X_HUMAN RPS4X 30 
40S ribosomal protein S5 OS=Homo sapiens GN=RPS5 PE=1 SV=4 P46782 RS5_HUMAN RPS5 23 
40S ribosomal protein S6 OS=Homo sapiens GN=RPS6 PE=1 SV=1 P62753 RS6_HUMAN RPS6 29 
40S ribosomal protein S7 OS=Homo sapiens GN=RPS7 PE=1 SV=1 P62081 RS7_HUMAN RPS7 22 
40S ribosomal protein S8 OS=Homo sapiens GN=RPS8 PE=1 SV=2 P62241 RS8_HUMAN RPS8 24 
40S ribosomal protein S9 OS=Homo sapiens GN=RPS9 PE=1 SV=3 P46781 RS9_HUMAN RPS9 23 
28S ribosomal protein S21, mitochondrial OS=Homo sapiens GN=MRPS21 PE=1 SV=2 P82921 RT21_HUMAN MRPS21 11 
Small nuclear ribonucleoprotein F OS=Homo sapiens GN=SNRPF PE=1 SV=1 P62306 RUXF_HUMAN SNRPF 10 
Septin-2 OS=Homo sapiens GN=SEPT2 PE=1 SV=1 Q15019 SEPT2_HUMAN SEPT2 41 








Septin-7 OS=Homo sapiens GN=SEPT7 PE=1 SV=2 Q16181 SEPT7_HUMAN SEPT7 51 
Septin-9 OS=Homo sapiens GN=SEPT9 PE=1 SV=2 Q9UHD8 SEPT9_HUMAN SEPT9 65 
D-3-phosphoglycerate dehydrogenase OS=Homo sapiens GN=PHGDH PE=1 SV=4 O43175 SERA_HUMAN PHGDH 57 
Splicing factor, proline- and glutamine-rich OS=Homo sapiens GN=SFPQ PE=1 SV=2 P23246 SFPQ_HUMAN SFPQ 76 
Small nuclear ribonucleoprotein Sm D1 OS=Homo sapiens GN=SNRPD1 PE=1 SV=1 P62314 SMD1_HUMAN SNRPD1 13 
Small nuclear ribonucleoprotein Sm D3 OS=Homo sapiens GN=SNRPD3 PE=1 SV=1 P62318 SMD3_HUMAN SNRPD3 14 
Serine/arginine-rich splicing factor 2 OS=Homo sapiens GN=SRSF2 PE=1 SV=4 Q01130 SRSF2_HUMAN SRSF2 25 
Serine/arginine-rich splicing factor 3 OS=Homo sapiens GN=SRSF3 PE=1 SV=1 P84103 SRSF3_HUMAN SRSF3 19 
Tubulin alpha-1A chain OS=Homo sapiens GN=TUBA1A PE=1 SV=1 Q71U36 TBA1A_HUMAN TUBA1A 50 
Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2 P07437 TBB5_HUMAN TUBB 50 
Activated RNA polymerase II transcriptional coactivator p15 OS=Homo sapiens GN=SUB1 PE=1 SV=3 P53999 TCP4_HUMAN SUB1 14 
Transforming growth factor beta-1 OS=Homo sapiens GN=TGFB1 PE=1 SV=2 P01137 TGFB1_HUMAN TGFB1 44 
Protein-glutamine gamma-glutamyltransferase 2 OS=Homo sapiens GN=TGM2 PE=1 SV=2 P21980 TGM2_HUMAN TGM2 77 
THO complex subunit 4 OS=Homo sapiens GN=ALYREF PE=1 SV=3 Q86V81 THOC4_HUMAN ALYREF 27 
Talin-1 OS=Homo sapiens GN=TLN1 PE=1 SV=3 Q9Y490 TLN1_HUMAN TLN1 270 
tRNA methyltransferase 112 homolog OS=Homo sapiens GN=TRMT112 PE=1 SV=1 Q9UI30 TR112_HUMAN TRMT112 14 
Lactotransferrin OS=Homo sapiens GN=LTF PE=1 SV=6 P02788 TRFL_HUMAN LTF 78 
Thrombospondin-1 OS=Homo sapiens GN=THBS1 PE=1 SV=2 P07996 TSP1_HUMAN THBS1 129 
Pre-rRNA-processing protein TSR1 homolog OS=Homo sapiens GN=TSR1 PE=1 SV=1 Q2NL82 TSR1_HUMAN TSR1 92 
Zinc finger protein 593 OS=Homo sapiens GN=ZNF593 PE=1 SV=2 O00488 ZN593_HUMAN ZNF593 15 

















SMARTpool [5 nmol] 
product code 
DMBT1 M-007883-01-0005 





SEPT9 M-006373-04-0005  
  siGENOME non-targetting 
control pool #2 [20 nmol] 
D-001810-10-20 
 
Supplementary Information (Table) S5.3 
Table summarising siRNA purchased to silence candidate proteins identified by proteomics as 
putative molecular regulators of an integrin ανβ6 adhesion environment (“adhesome”). To functionally 
validate candidate proteins, siRNA were purchased (siGENOME, Dharmacon, GE Healthcare). Cells were 
transfected with siRNA using the INTERFERin® regent protocol (Polyplus). Knockdowns were evaluated by qRT-
PCR. Abbreviations: DMBT-1 – deleted in malignant brain tumours; MARCKS – myristoylated alanine-rich C-kinase 
substrate; MXRA5 – matrix-remodelling associated protein 5; SEPT-6 – septin-6; SEPT-9 – septin-9; MYH-9 – 












PLUS 20 68.6 55 








PLUS 19 64.5 63.2 
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PLUS 21 66.6 52.4 








PLUS 21 65.1 47.7 








PLUS 21 65.8 47.7 
      R TGCAGGTATTTCTCGTACTGGT MINUS 22 62.4 45.5 
Supplementary Information (Table) S5.4 
Primers used for qPCR validation of candidates identified by 2D-enrichment LC-MS/MS strategies as putative molecular regulators of an integrin ανβ6 
adhesion environment (“adhesome”). To validate siRNA knockdown of candidates identified by LC-MS/MS analysis of 2D-enrichment experiments to evaluate their 
functional putative regulatory role(s) in mediating integrin ανβ6-dependent adhesions, the primers described above were used. Primers were designed using NCBI Primer-
BLAST, primer sequences confirmed using NCBI BLAST and compared with primers logged in the Harvard PrimerBank repository (PrimerBank ID numbers are provided). 
Abbreviations: DMBT-1 – deleted in malignant brain tumours; MARCKS – myristoylated alanine-rich C-kinase substrate; MXRA5 – matrix-remodelling associated protein 5; 
SEPT-6 – septin-6; SEPT-9 – septin-9; MYH-9 – myosin 9; MYH-10 – myosin 10. 
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Supplementary Information (Figure) S5.5 
Preliminary attempts to establish siRNA-mediated genetic silencing of the 7 candidate proteins identified for functional validation did not yield stable 
knockdowns of target proteins 
Attempts to genetically silence the 7 candidate proteins of interest identified by LC-MS/MS failed to establish stable knockdowns of target proteins in the BT-20 cells to 
permit functional interrogation of their role in mediating the β6–adhesome. Cells were transfected with 20 nM siRNA for 72 hr using the INTERFERin© protocol (Polyplus). 
(S5.5 A) Cell morphology was reviewed by phase contrast microscopy prior to RNA harvesting, cDNA synthesis and (S5.5 B) qPCR analysis using SYBR® Green which 
highlighted off-target effects of siRNA moieties.  
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   LAP-engaged integrin ανβ6-dependent signalling mediated by ERK1/2 
 phosphorylation is EGFR-dependent in the BT-20 TNBC model; inferential 
 network analyses suggest Akt1 isoform predominance in Akt mediated  




6. introduction  
Allosteric regulation of integrin receptor activation and consequent integrin-
mediated signalling events has long been established. Indeed, integrin signalling 
and receptor conformation are virtually synonymous; with integrin receptor 
signalling capacity intrinsically linked to activation status (Humphries 1996, 
Humphries 2002, Shimaoka et al 2002, Humphries et al 2003, Humphries 2004, 
Shattil et al 2010, Campbell and Humphries 2011, Kim et al 2011b, Ye et al 2012). 
Steric availability of regulatory motifs enables direct physical interactions between 
integrins and other protein moieties requisite for lateral integrin clustering (avidity 
regulation), adhesion complex microdomain formation via recruitment and 
assembly of adaptor proteins (notably talin, vinculin, Fyn, FAK and the kindlins) 
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necessary for downstream signal induction and actin cytoskeleton association 
(Cluzel et al 2005, Askari et al 2009, Harburger and Calderwood 2009, Shattil et al 
2010, Margadant et al 2011, Roca-Cusachs et al 2013).  
 
 
The strict spatiotemporal control of integrin receptor class expression, ligand 
specificity, affinity, activation, endocytic trafficking and consequent signalling 
underpins solid tissue morphogenesis and homeostasis in health, wound healing 
and tissue repair (Gumbiner 1996, Mosesson et al 2008, Huttenlocher and Horwitz 
2011, Ivaska and Heino 2011, Margadant et al 2011, Arjonen et al 2012, Danen 
2013, Alanko et al 2015). Logically, aberrant integrin receptor expression and 
activation has already been implicated in the aetiopathology of a variety of fibrotic 
disorders (Margadant and Sonnenberg 2010, Khan and Marshall 2016) and solid 
tumours (Ahmed et al 2002b, Bates et al 2005, Elayadi et al 2007, Havaki et al 
2007, Hazelbag et al 2007, Yang et al 2012, Zhou et al 2014); including during 
breast tumourigenesis and disease progression (White and Muller 2007, Lambert 
et al 2012).  
 
 
Of growing clinical significance, integrin-mediated signalling events are now 
thought to modulate tumour cell pro-invasive behaviour and therapeutic 
responses, notably during acquisition of chemoresistance (Aoudjit and Vuori 
2012). Aberrant gross integrin receptor class expression as a poor prognostic 
factor in BrCa has been demonstrated for integrins: β1 (Lesniak et al 2009, Zhou et 
al 2014), β4 (Vieira et al 2014), ανβ3 (Havaki et al 2007) and ανβ6 (Allen et al 2014, 
Moore et al 2014). In addition, integrin receptor activation status has also been 




The protumourigenic effects of constitutive integrin β1 activation were reported by 
Lee et al (2013), who found that integrin β1 was constitutively active in prostate 
cancer cell lines of high metastatic potential (PC3, PC3-mm2) in comparison with 
those of low metastatic potential (LNCaP, C4-2B4). Using the inhibitory anti-β1 
monoclonal antibody 33B6 to ablate integrin β1 activation in vivo, the authors 
noted SCID mice systemically treated with 33B6 following intra-prostatic 
orthotopic injection with metastatic PC3-mm2 cells exhibited fewer distal lymph 
node metastases in comparison with SCID mice in the control IgG antibody 
treatment cohort.  
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To characterise the underlying prometastatic mechanism of integrin β1 activation 
observed in their prostate cancer model, Lee and colleagues (2013) established 
that shRNA silencing of integrin β1 in PC3-mm2 cells reduced FAK397 and Akt473 
phosphorylation, sensitising cells to anoikis as demonstrated by increased 
cleavage of the DNA damage repair protein, poly (ADP-ribose) polymerase 
(PARP). The authors concluded that integrin β1 activation is associated with 
increased FAK397 and Akt473 phosphorylation, generatng survival and mitogenic 
signals that circumvent anoikis and promote a prometastatic phenotype; findings 
that are concordant with Lesniak et al’s (2009) earlier proposed mechanism of 
integrin β1–driven trastuzumab resistance in BrCa. 
 
 
Similarly, Moore et al (2014) demonstrated a putative role for integrin ανβ6–
mediated trastuzumab insensitivity in HER-2 positive BrCa. The authors found that 
functional abrogation of integrin ανβ6 using the therapeutic antibody 264RAD 
(Oncology iMED, AstraZeneca UK) potentiated treatment efficacy of trastuzumab 
(Herceptin®, Genentech USA Inc) HER-2 blockade in an in vivo model of HER-2-
driven BrCa. Co-targeting of both HER-2 (trastuzumab) and integrin ανβ6 (264RAD) 
was seen to reduce both tumour growth and metastasis. Preliminary mechanistic 
dissection of this integrin ανβ6-HER-2 RTK cross talk revealed a reduction of total 
Akt2 in trastuzumab/264RAD dual-therapy tumour samples in comparison with 
trastuzumab monotherapy, suggesting integrin ανβ6–derived Akt2-signalling 
compensation of trastuzumab downstream effects; again, a mechanism similar to 
that proposed by Lesniak et al (2009) for integrin β1 within the context of 
trastuzumab therapy in MBC. Indeed, Janes and Watt (2004) had earlier described 
that integrin ανβ6 expression conferred a survival advantange over integrin ανβ5 
expression during malignant transformation of stratified squamous epithelia to 
squamous cell carcinoma. The authors attributed this integrin ανβ6–mediated 




Derailed endocytic regulation of integrin receptors (Mosesson et al 2008), integrin 
signalling within endosomes (Alanko et al 2015) and integrin-RTK crosstalk during 
intracellular trafficking (Soung et al 2010, Ivaska and Heino 2011) have all been 
implicated as pro-tumourigenic and pro-metastatic determinants in human 
malignancy; with demonstrable links to generation of anoikis-resistant signalling. 
Thus, exploration of integrin receptor activation status and endocytic dynamics is 
of growing research interest.  
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Integrin ανβ6 expression within the myoepithelial compartment has already been 
associated with risk of progression to invasive disease in human primary DCIS 
(Allen et al 2014). This finding, in conjunction with the demonstrable treatment 
benefit achieved with integrin ανβ6 functional blockade in tandem with 
trastuzumab administration in HER-2 driven BrCa (Moore et al 2014), implicate 
integrin ανβ6–mediated signalling during BrCa progression to metastatic 
disseminated disease which warrants further investigation.  
 
 
Furthermore, given the emerging significance of integrin-mediated signalling 
compensating the antiproliferative effects of established therapeutics (Lesniak et al 
2009, Aoudjit and Vuori 2012), integrin ανβ6–derived signals may also play a role in 
stromal remodelling (Marsh et al 2008) and the development of chemoresistance. 
However, current definitions of integrin ανβ6–mediated signalling events following 
ligand engagement, receptor activation, subsequent internalisation and 
intracellular trafficking are presently limited; although several intracellular proteins 
have been shown to directly bind the integrin β6-cytoplasmic domain to modulate 
integrin ανβ6–dependent invasive functions in cancer including HS-1 Associated 




Other binding partners acting in concert with integrin ανβ6 to mediate its pro-
invasive effects have also been described. Jones et al (2013) reported that 
ADAM10 was overexpressed in oral cancer and may modulate progression to 
invasive disease. Jones and colleagues (2013) concluded that ADAM10 is an 
important regulator of invasion and migration in malignant cells by an as yet 
undefined mechanism. The authors hypothesised that crosstalk between integrin 
ανβ6 and ADAM10 may promote MMP expression to permit stromal remodelling 
and degradation thus imparting an invasive and migratory phenotype.  
 
 
Therefore, in light of the established biological importance of integrin ανβ6 
expression and localisation during tumour cell migration and invasion, it is evident 
that characterisation of integrin ανβ6–mediated signalling events that drive 
acquisition of a pro-metastatic phenotype is duly warranted to determine its 
aetiopathological significance within the context of BrCa progression to 
disseminated disease. Greater understanding of the mechanisms by which the 
integrin ανβ6 facilitates cellular invasion may elucidate novel targets for therapeutic 
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intervention, either as new monotherapy strategies or to potentiate the efficacy of 






          overview  of  key  findings 
 
 
To characterise signalling-associated phosphorylation events inducted upon 
integrin ανβ6 receptor activation following cognate ligand engagement and 
subsequent internalisation, a phosphoproteomics strategy was developed. A LAP-
ligand internalisation assay targeting the integrin ανβ6 receptor was first developed 
to generate peptides for phosphoenrichment and LC-MS/MS interrogation. As 
previously demonstrated (Chapter V: Results Part III, Figure 5.2C), LAP ligand 
specifically engages the integrin ανβ6 in BT-20 TNBC cells and was therefore used 
to interrogate integrin ανβ6–dependent processes in the BT-20 cell line.  
 
 
Using human IgG (Fc’)-tagged ligands, proof of concept experiments performed 
using the VB6 cell line showed that LAP-Fc (a surrogate marker for active, ligand-
engaged integrin ανβ6) internalises from the plasmalemma over a 60 min 
timeframe reaching the perinuclear region within 30 min, but the integrin function 
blocking antibody 53A2 does not internalise (Figure 6.1.1A - D). An Fc-tagged 
transferrin ligand (Tf-Fc) was used as a control to validate internalisation assays 
(Figure 6.1.1E).    
 
 
Given the purpose of the ligand engagement and internalisation assay was to 
generate phosphopeptides for downstream phosphoproteomic identification of 
novel integrin ανβ6–dependent signalling events, a panel of integrin ανβ6 cognate 
ligands comprising the synthetic peptide A20FMDV2 (-TJ) alongside natural ECM 
ligands LAP (LAP) and fibronectin (Fn) were evaluated in tandem with the non-
integrin β6 ligands collagen I (Col I) and epidermal growth factor (EGF), for their 
utility to stimulate downstream phosphorylation events in the BT-20 cell line 
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Once validated, four replicate LAP-ligand engagement and internalisation assays 
using an unconjugated human recombinant LAP ligand were performed from 
which phospho-enriched peptides were generated for LC-MS/MS interrogation. 
Phosphoproteomic LC-MS/MS analysis identified 88 533 tandem mass spectra 
corresponding to 8 874 unique peptide ions; of which 6 491 were 
phosphopeptides containing 7 129 phosphorylation sites mapping to 2 073 
proteins identified (Figure 6.2). 
 
 
Inferential network analysis using a kinase substrate enrichment analysis (KSEA) 
method pioneered by Casado et al (2013a) was used to characterise kinase-
mediated signalling events inducted or downregulated at defined LAP-ligand 
internalisation timepoints (Figure 6.3). Five kinases (MAP3K8; MAPKAPK2; Nuak1; 
PDK1; TBK1) identified by KSEA as putative regulators of early (5’, t=5: MAP3K8; 
MAPKAPK2; PDK1; TBK1) and late (30’, t=30: Nuak1) integrin ανβ6–mediated 
signalling following LAP ligand engagement and internalisation were selected for 
additional investigation using commercially available small molecule inhibitors 
(SMI) of kinase activity (Supplemental Figure S6.2).  
 
 
KSEA indicated that MAP3K8/COT kinase activity was upregulated upon integrin 
ανβ6/LAP internalisation (Figure 6.4A). Review of KSEA results for known MAP3K8 
downstream effectors (ERK1/2, JNK and p38) also exhibited upregulation in 
activity (Figure 6.4B), further implicating upstream activity of MAP3K8. Preliminary 
investigations into the regulatory role of MAP3K8 (COT) in the BT-20 cell line 
suggested MAP3K8 inhibition using the commercial SMI TC-S 7006 (Tocris, R&D 
Systems) dampened ERK1/2 phosphorylation downstream of LAP ligand 
stimulation, but did not appear to modulate Akt1 phosphorylation motifs nor EGFR 
phosphorylation at Tyr1068 (Figure 6.4C).  
 
 
Curiously, MAP3K8 inhibition was seen to promote the active integrin ανβ6 
conformer (recognised by FCM evaluation of surface bound antibody 6.2E5) in the 
presence of canonical integrin activation methods using Mn2+ ions and cognate 
LAP ligand (Figure 6.4D and E) in the BT-20 TNBC cell line. A similar effect in 
response to LAP activation in the presence of TC-S 7006 was observed in the VB6 
cell line (Figure 6.4F). Using the A375 matched pair cell lines, expression of 
integrin β6 appeared to sensitise A375β6 cells to the anti-proliferative effects of 
MAP3K8 targeting using TC S-7006, in comparison with integrin β6 null A375puro 
cells.    
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KSEA results also indicated that downstream LAP-ligand induced integrin ανβ6–
mediated signalling events in the BT-20 TNBC cell line are driven by Akt1 
(p≤0.01**) (Figure 6.5.1) and ERK1/2 (Figure 6.5.2) phosphorylation; with ERK1 
phosphorylation heavily implicated in late (30’; t=30) integrin ανβ6–associated 
signalling events (p≤0.001***). Attempts to functionally interrogate the five kinases 
identified by KSEA were hindered by a lack of reliable antibodies to confirm siRNA 
knockdown (Supplemental Figure S6.3) or SMI ablation of activating 
phosphorylation motifs (Supplemental Figure S6.4).   
 
 
Several phosphopeptides mapping to EGFR phosphorylation residues were 
strongly enriched and directly identified by LC-MS/MS; implicating EGFR-
mediated signalling downstream of LAP-ligand integrin ανβ6-engagement and 
internalisation in the BT-20 cell line (Figure 6.5.3A).  
 
 
To further investigate the putative role of RTK crosstalk during integrin ανβ6 LAP-
ligand engagement, LAP-sitmulation assays were performed in the BT-20, SUM159 
and MDA-MB-468 TNBC cell lines in the presence of EGFR and/or c-MET blockade 
(Figure 6.5.3B and C). Results from these assays suggested that LAP-induced 
ERK1/2 phosphorylation is EGFR-dependent but independent of c-MET in the BT-
20 and SUM159 cell lines, but is unaffected in the MDA-MB-468 cell line bearing 
constitutively active ERK1/2. 
 
 
Preliminary investigations seeking to define LAP-internalisation kinetics and 
downstream signalling in the presence of EGFR and/or integrin ανβ6 blockade to 
investigate putative EGFR/integrin co-regulatory cross talk met with limited 
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Figure 6.1.1 (A & B) 
LAP-ligand stimulation experimental work up: Immunofluorescence microscopy validation 
of LAP ligand-stimulated internalisation kinetics in comparison with the integrin ανβ6 
function-blocking antibody clone 53A2 
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Figure 6.1.1 (C)  
LAP-ligand stimulation experimental work up: Immunofluorescence microscopy validation 
of LAP ligand-stimulated internalisation kinetics in comparison with the integrin ανβ6 













Figure 6.1.1 (D)  
LAP-ligand stimulation experimental work up: Immunofluorescence microscopy validation 
of LAP ligand-stimulated internalisation kinetics in comparison with the integrin ανβ6 
function-blocking antibody clone 53A2 
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Figure 6.1.1 (E)  
LAP-ligand stimulation experimental work up: Immunofluorescence microscopy validation 
of a human IgG (Fc’)-tagged transferrin control ligand-stimulated internalisation kinetics in 
the VB6 and BT-20 cell lines  
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Figure 6.1.1  
LAP-ligand stimulation experimental work up: Immunofluorescence microscopy validation 
of LAP ligand-stimulated internalisation kinetics in comparison with the integrin ανβ6 
function-blocking antibody clone 53A2 
 
To permit phosphoproteomic dissection of integrin ανβ6-mediated signalling inducted upon cognate 
LAP-ligand engagement, the upstream ligand-stimulation/internalisation assay was first validated by 
IMF. Cells were seeded onto 13 mm non-derivatised glass coverslips at 2 x104 cells per coverslip and 
left to adhere overnight ready for assay. Cells were serum-starved for 4 hours in low serum media (1% 
FBS), cell monolayers washed and treated with ligand or antibody for 10 min at 4°C prior to washing 
to remove unbound ligand. Complete media was added and cells returned to standard culture 
conditions to permit ligand internalisation. The surface abundance of a human IgG (Fc’)-tagged LAP 
ligand (LAP-Fc; Biogen Idec) or transferrin ligand (Tf-Fc; Hölzel Diagnostika) undergoing 
internalisation were first evaluated by non-permeabilised IMF. VB6 cells were live-labelled with either 
(6.1.1 A) LAP-Fc ligand (Biogen Idec) or (6.1.1 B) the integrin ανβ6–function blocking antibody clone 
53A2 (CR-UK) at concentrations of 5, 10 and 20 μg ml-1 to compare cell surface labelling efficacy and 
internalisation kinetics over a 30’ time period. At 0’ or 30’ internalisation timepoints cells were fixed 
with 4% (w/v) PFA (P6148, Sigma Aldrich) for 8’. LAP-Fc was labelled with a monoclonal mouse anti-
human (Fc’) antibody (10 μg ml-1, ab113636, AbCam) and detected with a tertiary AlexaFluor®488-
fluorophore conjugated anti-mouse IgG antibody (16 μg ml-1, A11029, InvitrogenTM). An anti-rat IgG 
AlexaFluor®488 antibody (16 μg ml-1, A11006, InvitrogenTM) was used to detect surface-bound 
antibody 53A2. Corrected total cell fluorescence (CTCF) was determined using ImageJ software to 
quantify cell surface fluorescence as a read out for abundance of surface-bound LAP-Fc ligand or 
antibody 53A2 to determine their respective internalisation kinetics. Five fields of view were evaluated 
for each condition and timepoint across 3 biological replicates (n=3) each comprising intra-assay 
technical triplicates. Mean CTCF values were plotted in GraphPad Prism with error bars showing s.d. 
Isotype matched negative controls were prepared (mouse IgG and rat IgG) along with an integrin ανβ6 
positive control antibody (620W7). Representative images are shown. (6.1.1 A) LAP-Fc predominated 
at the cell periphery or cell-cell junctions at the 0’ starting timepoint (white outline arrows). Surface 
abundance of LAP-Fc ligand visibly and markedly decreased over a 30’ time period, suggesting 
internalisation. No discernible difference in labelling efficacy was observed between the 
concentrations 5, 10 and 20 μg ml-1. (6.1.1 B) The antibody 53A2 localised at the peripheral edges of 
cells and cell-cell junctions (white outline arrows). A diffuse cell surface distribution was also observed 
(block white arrows). Surface abundance of antibody 53A2 appeared relatively unaltered across the 
30’ time period studied, with no discernible difference in labelling efficacy or internalisation kinetics 
across the different concentrations evaluated. (6.1.1 C) To confirm that the loss of fluorescence signal 
for LAP-Fc observed in (6.1.1 A), was attributable to ligand-stimulated internalisation and not physical 
dissociation, permeabilised IMF was performed to assess subcellular distribution of LAP-Fc ligand 
over a 30’ time period. Again, VB6 cells were used to compare concentrations of LAP-Fc ranging from 
0 - 20 μg ml-1. At 0’, LAP-Fc was seen to localise at the cell periphery and cell-cell junctions (white 
outline arrows), with a punctate cytoplasmic distribution (block white arrows) most notable at 5 and 20 
μg ml-1. By 30’, the cell periphery, cell-cell junction and more diffuse cytoplasmic LAP-Fc distributions 
were lost. Instead, LAP-Fc was observed in a vesicular, perinuclear pattern. (6.1.1 D) The subcellular 
distribution of LAP-Fc (5 μg ml-1) was next characterised by permeabilised IMF over a 60’ time period 
in comparison with antibody 53A2 to optimise time points for phosphoproteomic interrogation. The 
antibody 53A2 (10 μg ml-1) predominated at cell-cell junctions (block white arrows). This subcellular 
distribution pattern was unaltered across the 0’, 5’, 15’ 30’ and 60’ time points evaluated, suggesting 
that the function blocking antibody 53A2 remains bound to the integrin ανβ6 in a steady state and 
does not undergo receptor-engaged internalisation. In contrast, LAP-Fc underwent subcellular 
redistribution from the plasma lemma to the cytoplasm in a vesicular pattern (white outline arrows). By 
60’, LAP-Fc appeared completely downregulated from the cell surface and predominated in large 
vesicular perinuclear clusters. (6.1.1 E) Binding and internalisation of a Tf-Fc ligand (5 μg ml-1) were 
also evaluated (as described for LAP-Fc) for utility as a control ligand/receptor biological comparator. 
The Images were acquired on the ZEISS LSM710 equipped with ZEISS Zen image analysis software (all 
Carl Zeiss AG, DE). Images were prepared for presentation using Image J (National Institutes of 
Health). 
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Figure 6.1.2 (A & B)  
LAP-ligand stimulation experimental work up (validation of LAP-ligand-integrin ανβ6 direct association in the BT-20 cell line): Non-permeabilised 
immunofluorescence microscopy validation of LAP ligand-stimulated internalisation kinetics and confirmation of LAP-integrin ανβ6 direct protein-protein 
interaction during internalisation by co-immunoprecipitation of integrin ανβ6 using a human IgG (Fc’)-tagged LAP-ligand  
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Figure 6.1.2 (C & D)  
LAP-ligand stimulation experimental work up (validation of LAP-ligand-integrin ανβ6 direct association in the BT-20 cell line): Non-permeabilised 
immunofluorescence microscopy validation of transferrin (Tf) ligand-stimulated internalisation kinetics and confirmation of Tf-Transferrin Receptor 
Complex (Tf-RC) direct ligand-receptor protein-protein interaction during internalisation by co-immunoprecipitation of Tf-RC using a human IgG (Fc’)-
tagged Tf-ligand  
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Figure 6.1.2 (E)  
LAP-ligand stimulation experimental work up (validation of LAP-ligand-integrin ανβ6 direct association in the BT-20 cell line): Confirming reproducibility 
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Figure 6.1.2 
LAP-ligand stimulation experimental work up (validation of LAP-ligand-integrin ανβ6 direct 
association in the BT-20 cell line): Non-permeabilised immunofluorescence microscopy 
validation of LAP ligand-stimulated internalisation kinetics and confirmation of LAP-integrin 
ανβ6 direct protein-protein interaction during internalisation by co-immunoprecipitation of 
integrin ανβ6 using a human IgG (Fc’)-tagged LAP-ligand  
 
Following proof of concept that the integrin ανβ6 is the predominant LAP receptor and may be used to 
specifically interrogate ligand-engaged integrin ανβ6–mediated functions in the BT-20 TNBC cell line 
(see Chapter V: results part III), non-permeabilised immunofluorescence (IMF) was used to confirm 
that surface-bound LAP ligand is internalised over a 60 min time frame (6.1.2 A) in comparison with 
transferrin (Tf) control ligand (6.1.2 C). Additional co-immunoprecipitation (co-IP) validation 
experiments were performed to confirm direct LAP-integrin ανβ6 protein-protein interaction, 
demonstrating that LAP-ligand engages and remains directly associated with integrin ανβ6 during 
LAP-ligand internalisation (6.1.2 B), as verified against transferrin ligand (Tf)-transferrin receptor 
complex (Tf-RC) co-IP (6.1.2 D); reproducibility of co-IP was assessed (6.1.2 E). For non-permeabilised 
IMF, BT-20 cells were plated on 13 mm non-derivatised glass coverslips at 2 x 104 cells per coverslips 
and left to adhere overnight under standard culture conditions. Cell monolayers were washed (x3) in 
serum-free α-MEM equilibrated to 37°C prior to 4-hour serum starvation in low serum media (1% 
charcoal-stripped FBS/α-MEM) supplemented with 25 mM HEPES, prior to human IgG (Fc’)-tagged-
ligand pre-treatments using either (6.1.2 A) LAP-Fc (5μg ml-1, Biogen Idec) or (6.1.2 C) Tf-Fc (5μg ml-1, 
13656-W02H, Hölzel-Diagnostika GmbH) for 10 min at 4°C. Unbound ligand was removed by 
washing, complete media supplemented with 25 mM pre-equilibrated to 37°C was added and 
coverslips returned to standard culture conditions to permit ligand internalisation. At designated time-
points, coverslips were fixed (4% (v/v) paraformaldehyde; 8 min) ready for labelling with a mouse anti-
human IgG (Fc’) antibody (10 μg ml-1, ab113636, AbCam) to detect Fc-tagged ligands and detected 
with AlexaFluor®488-fluorophore conjugated anti-mouse IgG antibody (16 μg ml-1, A11029, 
InvitrogenTM). Nuclei were demonstrated with membrane permeant Hoechst 33342 (H3570, Life 
Technologies). Corrected total cell fluorescence (CTCF) was determined using ImageJ software to 
quantify cell surface fluorescence as a read out for abundance of surface-bound LAP-Fc or Tf-Fc ligand 
determine their respective internalisation kinetics. Five fields of view were evaluated for each 
condition and timepoint across 3 biological replicates (n=3) each comprising intra-assay technical 
triplicates. Mean CTCF values were plotted with error bars showing s.d. Both (6.1.2 A) LAP-Fc and 
(6.1.2 C) Tf-Fc ligands were seen to internalise over a 60 minute time-period, most rapidly in the first 
15 min. To confirm that integrin ανβ6 remains bound to LAP during the ligand internalisation observed 
by IMF, co-IP experiments were performed (6.1.2 B, D & E). BT-20 cells were seeded in 10 cm dishes 
at 5 x 106 cells per dish and left to adhere overnight, prior to ligand labelling and internalisation (as 
previously described). At designated time-points, lysates were harvested in IP lysis buffer (prepared in-
house). Lysates were tumbled overnight at 4°C with unconjugated protein G beads (101243, 
Invitrogen™) to co-IP Fc’-tagged ligand/cognate receptor complexes. Beads were washed by 
centrifugation in a series of stringency IP wash buffers (prepared in-house): first in a high salt buffer, 
then a high detergent buffer with final washing in a salt-free buffer prior to boiling (100°C; 5 min) 
beads in an equal volume of [2X] reducing SDS sample buffer (prepared in-house). Beads were 
pelleted by centrifugation and supernatants kept for validation by Western blot (WB). (6.1.2 B & E) 
Integrin ανβ6 was successfully IP’d using LAP-Fc at specified internalisation time-points, confirming 
direct association of LAP undergoing internalisation with the integrin ανβ6 receptor. Control IP 
experiments using Tf-Fc to isolate Tf-RC provided technical validation (6.1.2 D & E). IP samples were 
probed by WB for: integrin β6 (c-19, 0.2 μg ml-1, sc-6632, Santa Cruz BioTech); Tf-RC (0.2 μg ml-1, S); 
alongside the endocytic vesicle coating protein clathrin (1 μg ml-1, BD610500, BDT); the integrin-
associated protein talin (0.2 μg ml-1, sc-7534, SCBT) was probed to evaluate the presence of 
additional known integrin binding partners; GAPDH (0.1 μg ml-1, 2118L, CST) was used to assess 
purity and specificity of ligand/receptor complexes co-IP’d.  
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Figure 6.1.3 (A and B) 
Development and protein-level validation of a ligand-stimulated internalisation assay to investigate and define downstream signalling pathways inducted 































































Figure 6.1.3 (C and D) 
Development and protein-level validation of a ligand-stimulated internalisation assay to investigate and define downstream signalling pathways inducted 
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Figure 6.1.3 
Development and protein-level validation of a ligand-stimulated internalisation assay to 
investigate and define downstream signalling pathways inducted upon integrin ανβ6 
ligand-engagement and internalisation 
 
Following proof of concept that surface-bound LAP ligand is internalised over a 60 min time frame, 
additional proof of concept experiments were performed to validate that integrin ανβ6-mediated 
signalling could be dissected using LAP-ligand engagement of integrin ανβ6 in the BT-20 cell line.  
(6.1.3 A) The effect of a 4-hour serum starvation step (performed prior to ligand-engagement/ 
internalisation assay) upon downstream signalling, was reviewed by WB. BT-20 cells were seeded in 3 
cm dishes at 3 x 106 cells per dish and left to adhere overnight. Cell monolayers were washed (x3) in 
serum-free α-MEM equilibrated to 37°C prior to serum starvation in low serum media (1% FBS/α-
MEM) for serial time-points as indicated. On completion of serum starvation, lysates were manually 
harvested at designated time-points by scraping in NP-40 lysis buffer supplemented with protease 
and phosphatase inhibitors. Lysates were normalised and samples evaluated by WB (20 ng loading 
protein) for surface receptor moieties to evaluate stability of surface receptor pools during serum 
starvation: integrin β6 (c-19, 0.2 μg ml-1, sc-6632, Santa Cruz BioTech); transferrin receptor complex 
(Tf-RC) (0.2 μg ml-1, S); alongside the known integrin downstream signalling mediators pAkt (pSer473, 
2 μg ml-1, 4060S, CST), pERK1/2 (pThr202/204, 2 μg ml-1, 9101L, CST); together with their 
corresponding total protein Akt (1 μg ml-1, 9272S, CST) and ERK1/2 (1 μg ml-1, 9102L, CST). A loading 
control was also performed (Hsc-70, 0.2 μg ml-1, S). Two biological repeats were performed (n=2). 
Notably, pERK1/2 was upregulated in the 2 hours immediately post induction of serum starvation 
however, pERK levels were restored to baseline (0 time-point) by 4 hours in both biological repeats. 
This validated the use of a 4-hour serum starvation step in low serum media (1% FBS), confirming that 
pERK1/2 signalling is not aberrantly upregulated due to low serum conditions which would confound 
use of pERK1/2 as a readout for induction of downstream signalling in the LAP-ligand/integrin ανβ6 
stimulation and internalisation assay being developed. (6.1.3 B - D) Evaluation of ligand species to be 
used for ligand-induced stimulation and internalisation of integrin ανβ6 was performed comparing 
signalling motifs inducted by a natural integrin ligands (LAP) in comparison with a synthetic peptide 
(A20FMDV2-TJ) and random sequence negative control peptide (BioTJ-Ran) alongside another 
integrin ανβ6 cognate ligand (Fn). An integrin β1 ligand (Col I) and an RTK ligand (EGF) were also 
evaluated. In all experiments shown, BT-20 cells were seeded in 3 cm dishes at 3 x 106 cells per dish, 
left to adhere overnight prior to 4-hour serum starvation and exposed to ligand for 10 min at 4°C 
(A20FMDV2-TJ or BioTJ-Ran (a kind gift from Prof T Jackson) 100 nM; LAP (L3408, Sigma) – 0.5 μg ml-
1; Fn (F2006, Sigma) – 10 μg ml-1; Col I (354236, Corning® – 10 μg ml-1; EGF (E9644, Sigma) – 50 ng 
ml-1) pior to internalisation at 37°C in complete media for designated times (as indicated in WB figure 
labels), when lysates were manually harvested in NP-40 supplemented with protease and 
phosphatase inhibitors. Lysates were probed by WB (20 ng loading protein) using a pan-phospho-
tyrosine antibody (pTyr: 2 μg ml-1; ab10321, AbCam) to evaluate global changes in tyrosine 
phosphorylation residues. Samples were also probed for: pAkt and pERK1/2 (as previously 
described), and where available, pFAK (pTyr397, 2 μg ml-1, 3283S, CST). All blots were revealed using 
Amersham ECL Detection Kit (RPN2106, GE Healthcare) and manually developed on X-Ray film 









6.1   development of a LAP-ligand internalisation assay to characterise 
 integrin ανβ6–mediated signalling associated with receptor activation 
 upon cognate ligand engagement and internalisation  
 
To characterise integrin ανβ6-mediated signalling events following cognate ligand 
engagement, receptor activation and internalisation, a phosphoproteomics 
strategy was adopted. First, a LAP-ligand internalisation assay was developed in 
the VB6 cell line (Figure 6.1.1) and validated for use in the BT-20 cell line (Figure 
6.1.2). Lysates from LAP-internalisation assays performed in the BT-20 TNBC cell 
line would then be used to generate peptides for phosphoenrichment and LC-
MS/MS interrogation. Previous experiments had shown that integrin ανβ6 is the 
predominant LAP receptor in BT-20 cells (Chapter V: Results Part III, Figure 5.2C) 
and may be used to specifically target the integrin ανβ6 in this cell line, although 
the utility of other ligands was also evaluated (Figure 6.1.3).  
 
 
Internalisation kinetics of a human IgG (Fc’)-tagged LAP ligand (LAP-Fc) were 
characterised over a 30 min time-period by non-permeabilised surface IMF in the 
VB6 cell line (Figure 6.1.1A) and compared to internalisation kinetics of the 
integrin ανβ6 function blocking antibody 53A2 (Figure 6.1.1B). A range of ligand 
concentrations was evaluated to optimise the protocol in development.  
 
 
Prior to internalisation at the 0’ time point, LAP-Fc was seen to predominate at the 
plasmalemma, showing intense immunopositivity at cell-cell interfaces. A similar 
pattern was observed for 53A2 at 0’, although antibody 53A2 also exhibited some 
diffuse cell surface immunopositivity. Following 30’ internalisation, an almost total 
loss of surface fluorescence was observed LAP-Fc, suggesting 
internalisation/downregulation from the plasmalemma. In contrast, cell surface 
fluorescence for antibody 53A2 was retained.  
 
 
Quantification of corrected total cell fluorescence (CTCF) indicated no significant 
difference in labelling efficacy or internalisation kinetics between the 
concentrations of LAP-Fc ligand or antibody 53A2 used, validating the use of LAP-
Fc at 5 μg ml-1 in future experiments. Permeabilised IMF was performed to 
determine the subcellular distribution of LAP-Fc (Figure 6.1.1C) which showed that 
LAP-Fc redistributes from the plasmalemma at 0’ to the perinuclear region by 30’. 
These findings confirmed that loss of cell surface fluorescence observed in Figure 
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With the ability of LAP-Fc to internalise now confirmed, additional permeabilised 
IMF was performed to characterise its internalisation kinetics over a 60’ min time 
period, again in comparison with the integrin ανβ6 function blocking antibody 
53A2 (Figure 6.1.1D). Results demonstrated that at 5’ and 15’ internalisation, LAP-
Fc begins subcellular redistribution from the plasmalemma, exhibiting a vesicular 
like cytoplasmic distribution with occasional residual cell-cell membrane 
immunopositivity. By 30’ LAP-Fc predominates in the perinuclear region with 
occasional cytoplasmic immunopositivity, with total localisation at the perinuclear 
region by 60’ internalisation.    
 
 
To biologically validate internalisation assays against a canonical cell surface 
receptor/cognate ligand complex (Hopkins and Trowbridge 1983, Ponka and Lok 
1999, Vercauteren et al 2010), a human IgG (Fc’)-tagged transferrin ligand (Tf-Fc) 
was also evaluated for use as a biological control in both the VB6 and BT-20 cell 
lines (Figure 6.1.1E). Permeabilised IMF confirmed that Tf-Fc redistributes from the 
plasma lemma to the cytoplasm and perinuclear region by 30’ and 60’ min. 
 
 
Having established proof of concept in the integrin ανβ6 overexpressing VB6 cell 
line, LAP-ligand internalisation assays were next validated in the high endogenous 
integrin ανβ6 expressing BT-20 TNBC cell line, using Tf-Fc as a biological 
comparator (Figure 6.1.2). Non-permeabilised IMF confirmed internalisation of 
both LAP-Fc (Figure 6.1.2A) and Tf-Fc (Figure 6.1.2C) ligands over a 60’ time 
period; LAP-Fc appeared to be more rapidly downregulated from the plasma 
lemma between 0’ and 15’ minutes than Tf-Fc.  
 
 
A previous experiment (Chapter V: Results Part III, Figure 5.2C) had demonstrated 
by FCM that integrin ανβ6 functional abrogation using antibody 53A2 abolished 
LAP-Fc binding; confirming LAP ligand specificity for the integrin ανβ6 in the BT-20 
cell line and its utility to interrogate integrin ανβ6–mediated process in this 
particular TNBC model. However, more robust validation of the association 
between LAP and integrin ανβ6 during internalisation rather than at the cell surface 
at a lone time-point was deemed necessary.  
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Owing to technical failings, co-localisation of LAP-Fc/integrin ανβ6 complexes 
undergoing internalisation in BT-20 cells could not be demonstrated by IMF 
methods. However, results from co-immunopreciptation (co-IP) experiments 
originally intended to isolate LAP/integrin ανβ6 complexes undergoing 
internalisation for proteomic interrogation, were used to confirm the direct 
physical interaction between integrin ανβ6 and LAP at defined internalisation time 
points (Figure 6.1.2B and E) and were validated by successful co-IP of the 
transferrin receptor complex (Tf-RC) using Tf-Fc ligand in tandem control 
experiments (Figure 6.1.2D and E). The repeated, reproducible and successful co-
IP of integrin β6 using LAP-Fc in 3 biological replicate internalisation experiments 
using the BT-20 cell line (Figure 6.1.2D and E; Supplemental Figure S6.1A) was 
deemed to sufficient to validate the use of LAP ligand to interrogate the LAP-
engaged integrin ανβ6 receptor undergoing internalisation.  
 
 
Next, features of the internalisation protocol were validated including a serum 
starvation step (Figure 6.1.3A) and use of ligands to stimulate signalling-associated 
downstream phosphorylation events (Figure 6.1.3B – D). Serum starvation of BT-20 
cells in low serum (1% charcoal-stripped FBS) conditions was evaluated over 24 
hours to determine a suitable timescale to ablate basal phosphorylation of 
downstream signalling mediators prior to ligand treatment and internalisation 
assay (Figure 6.1.3A). Two biological replicates revealed that levels of pERK1/2 
were diminished after 4 hours, validating use of a preceding 4-hour serum 
starvation step prior to ligand-based stimulation and/or internalisation assays.  
 
 
The synthetic 20mer peptide A20FMDV2 (A20FMDV2-TJ) known to specifically 
engage the integrin ανβ6 was assessed alongside a random sequence negative 
(non-RGD-motif) control 20mer peptide (A20FMDV2-TJRan) to broadly 
characterise downstream signalling events inducted upon ligand engagement and 
internalisation at 15’ and 60’ timepoints by Western blotting using a pan-phospho-
tyrosine (p-Tyr) antibody (Figure 6.1.3B).  
 
 
Few notable differences in p-Tyr motifs were observed. Probing for known integrin 
receptor signalling mediators pERK1/2 and pSmad3 revealed similar downstream 
phosphorylation signatures for these proteins inducted by both the negative (non-
RGD-motif) peptide (A20FMDV2-TJRan) and the integrin ανβ6–specific peptide 
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(A20FMDV2-TJ); obviating the use of A20FMDV2 to define integrin ανβ6–mediated 
signalling by these methods.  
 
 
The ability of the integrin ανβ6 natural ligand LAP to stimulate downstream 
signalling in the BT-20 cell line following ligand engagement and internalisation 
was evaluated alongside the β1 integrin ligand collagen I (Col I) (Figure 6.1.3C), in 
addition to fibronectin (Fn) and the epidermal growth factor receptor (EGFR) RTK 
ligand epidermal growth factor (EGF) (Figure 6.1.3D).  
 
 
Collectively, these results (Figure 6.1.3) indicated that LAP induced FAK 
phosphorylation at 10’ and 60’ following internalisation and ERK1/2 
phosphorylation at 10’ following internalisation but Akt phosphorylation appeared 
unaltered; confirming that LAP ligand may be used to induce detectable changes 
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Figure 6.2  
Mass spectrometry sample validation and dataset key metrics overview for the 
phosphoproteomic characterisation of downstream signalling events inducted upon LAP 
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Figure 6.2  
Mass spectrometry sample validation and dataset key metrics overview for the 
phosphoproteomic characterisation of downstream signalling events inducted upon LAP 
ligand-stimulated activation and internalisation of the integrin ανβ6  
  
To characterise integrin ανβ6–mediated signalling inducted upon LAP-ligand engagement and 
subsequent internalisation, a LAP-ligand internalisation assay (development thereof shown previously) 
was performed using the BT-20 cell line to generate lysates for peptide preparation and LC-MS/MS 
interrogation; four biological replicates were performed (n=4). The TNBC BT-20 cell line was seeded 
in 10 cm dishes at 5 x 106 cells per dish in complete culture media and left to adhere overnight. Cell 
monolayers were washed and serum starved in low serum-media (1% charcoal-stripped FBS/α-MEM) 
supplemented with 25 mM HEPES for 4 hours prior to LAP ligand pre-treatment (0.5μg ml-1, 10 min, 
4°C). Monolayers were washed and the 30’, 15’ and 5’ time-point dishes replenished with complete 
media (15% charcoal-stripped FBS/α-MEM) supplemented with 25 mM HEPES before returning to 
standard culture conditions (8%CO2/37°C/humidified atmosphere) to permit ligand internalisation. 
The 0’ baseline time-point was not subject to ligand internalisation. At the designated time-points, 
dishes were buried in wet ice and monolayers washed by flooding in pre-chilled (4°C) TBS 
supplemented with 1 mM Na3VO4 and 0.5 mM NaF. Lysates were manually harvested by scraping in 
the presence of pre-chilled (4°C) phosphoproteomic lysis buffer comprising: 8 M urea/20 mM HEPES 
supplemented with 0.5 M NaF, 0.1 M Na3VO4, 1 M CH3H7Na2O6P (disodium β–glycerophosphate), 
0.25 M Na2H2P2O7 (disodium pyrophosphate); prior to sonication at 4°C (20% intensity for 3 x 10 s, 
SONICS® Vibra-Cell™ Ultrasonic Liquid Processor VCX750, Sonics & Materials Inc). A total of four 
biological replicates were performed across two experiments; each experiment comprised two 
biological replicates run in tandem. (6.2 A) Harvested lysates were validated by WB (25 ng loading 
protein) prior to peptide preparation and TiO2 enrichment. Samples were probed to determine 
pERK1/2 (pThr202/204, 2 μg ml-1, 9101L, CST) signature as a read out of downstream signalling 
induction. Total ERK1/2 (1 μg ml-1, 9102L, CST) and Hsc-70 (0.2 μg ml-1, sc-7298, Santa Cruz Bio Tech) 
were also probed. Blots were revealed using Amersham ECL Detection Kit (RPN2106, GE Healthcare) 
and manually developed on X-Ray film (BioMax XAR Film, 165-1454, Carestream Health Inc.), prior to 
scanning to digitise image (Epson Scanner). Following TiO2 enrichment, phosphopeptides were 
analysed by LC-MS/MS (LTQ Orbitrap™-Velos™ Hybrid FT mass spectrometer, Thermo Scientific). LC-
MS/MS analysis identified a total of 88 533 tandem mass spectra corresponding to 8 874 unique 
peptide ions; of these unique ions, 6 491 were phosphopeptides containing 7 129 phosphorylation 
sites. A total of 7 368, 5 505 and 3 683 unique peptides showed expectation scores <0.05, <0.01 and 
<0.001 respectively; collectively these peptides mapped to 2 073 identified proteins. (6.2 B) Summary 
histograms showing the number of statistically significant differences in peptide abundance, either 
increase (red) or decrease (blue), across each experimental time-point at p-value thresholds p<0.05*, 
p<0.01** and p<0.001*** with Benjamini-Hochberg correction for multiple testing (n=4). (6.2 C) Two 
dimensional (2D) principal component analysis (PCA) summarising data variance between time-points 
revealed the similarity between phosphopeptide profiles characterised for the 5’ (t=5), 15’ (t=15) and 
30’ (t=30) time-points, which show marked variation from phosphopeptides characterising the 0’ (t=0) 
baseline. Histograms and multivariate PCA plots were prepared in the R statistical programming 
environment (R 3.2.5, The R Foundation) with the kind assistance of Dr Edmund Wilkes (Centre for 















6.2  phosphoproteomic interrogation of LAP-ligand, integrin ανβ6–
 mediated signalling events inducted during ligand engagement and 
 subsequent internalisation in the BT-20 TNBC cell line  
 
 
Following successful development and validation of a LAP ligand-based 
internalisation assay (Figures 6.1.1 to 6.1.3), four biological replicate LAP-ligand 
internalisation experiments were performed using the BT-20 cell line to permit 
phosphoproteomic interrogation of phosphorylation signatures associated with 




Before peptide preparation and TiO2 phosphoenrichment, lysates from four 
biological replicate experiments were initially validated by WB (Figure 6.2A) to 
confirm changes in ERK1/2 phosphorylation signatures (pERK1T202/Y204/ERK2 
T185/Y187), as had been observed in previous LAP-ligand stimulation assays (Figure 
6.1.3). Prior to internalisation (0’; t=0), ERK1/2 was not discernibly phosphorylated. 
However, ERK1/2 phosphorylation was inducted by 5’ (t=5) post-internalisation 
and sustained throughout the 30 min internalisation time-course (Figure 6.2A); 
validating success of the assay to generate downstream changes in 
phosphorylation signatures for LC-MS/MS interrogation. 
 
 
Lysates were then used to generate peptides that were subsequently TiO2-
phosphoenriched and subject to LC-MS/MS analysis. Phosphoproteomic 
interrogation of the four replicate LAP-ligand internalisation experiments 
successfully identified 88 533 tandem mass spectra corresponding to 8 874 
unique peptide ions; of which, 6 491 were phosphopeptides containing 7 129 
phosphorylation sites collectively mapping to 2 073 identified proteins. Summary 
histograms (Figure 6.2B) showed the number of statistically significant differences 
in peptide abundance, either an increase (red) or decrease (blue), across each 
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Two dimensional (2D) principal component analysis (PCA) summarising dataset-
wide variance between internalisation time-points (Figure 6.2C) indicated broad 
similarity between phosphopeptide profiles characterising the 5’ (t=5), 15’ (t=15) 
and 30’ (t=30) time-points, which collectively showed marked variation from 
phosphopeptides characterising the 0’ (t=0) time-point.  
 
 
Thus, the greatest changes in the dataset are between the pre-internalisation (0’) 
and post-internalisation (5’, 15’, 30’) time-points. This broad dataset analysis would 
suggest that the biggest changes in phosphorylation signatures are associated 
with internalisation as a broad process as no significant shift in variance between 





6.3  kinase substrate enrichment analysis (KSEA) reveals putative 
 regulatory kinases and associated pathways governing integrin 
 ανβ6–mediated signalling events inducted during LAP-ligand 
 engagement and subsequent internalisation in the BT-20 TNBC cell 
 line  
 
The phosphoproteomic dataset was interrogated using the kinase substrate 
enrichment analysis (KSEA) computational method first developed by Casado et al 
(2013a) to infer kinase pathway activation from LC-MS/MS-based 
phosphoproteomic analysis of human acute myeloid leukaemia cells (AML). The 
KSEA model utilises a repository of 330 PhosphoSitePlus® (Cell Signalling 
Technology Inc) kinases and literature-curated kinase(s)/kinase inhibitor activity 
studies. Based upon direct identification of phosphopeptides within the LC-MS/MS 
dataset that are known substrates of the 330 specified kinase(s) species curated in 
the KSEA repository, this analytical approach permitted inference of specific kinase 
activity and associated signalling network modulation during integrin ανβ6 LAP-
engagement and internalisation in the BT-20 TNBC cell line (Figure 6.3.1). 
 
 
The KSEA inferential approach evaluated the activity of these 330-curated kinases 
within the LC-MS/MS dataset to identify putative regulatory kinases and their 
inferred activity in terms of log2-fold-ratio enrichment across LAP-internalisation 
time-points; the KSEA results are summarised in a heatmap (Figure 6.3.1A).  
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Figure 6.3.1 (A) 
Summary of kinase substrate enrichment analysis (KSEA): Heatmap summarising fold-
changes in kinase activity (z-score) during integrin ανβ6 LAP-ligand engagement and 
internalisation, inferred from analysis of respective kinase substrates identified within the 
LC-MS/MS dataset   
chapter VI: 








































Figure 6.3.1 (B) 
Summary of kinase substrate enrichment analysis (KSEA): Time-point stratification of 
maximal kinase activation events (z-score) inducted during integrin ανβ6 LAP-ligand 
engagement and internalisation, inferred from analysis of respective kinase substrates 
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Figure 6.3.1 (C) 
Summary of kinase substrate enrichment analysis (KSEA): Time-point stratification of kinase 
deactivation (signal decay) events (z-score) inducted during integrin ανβ6 LAP-ligand 
engagement and internalisation, inferred from analysis of respective kinase substrates 
identified within the LC-MS/MS dataset 
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Figure 6.3.1 (D) 
Summary of kinase substrate enrichment analysis (KSEA): k-means analysis plot indicating 
kinases identified for functional validation as putative regulators of changes in the 
phosphoproteome (signalling events) downstream of integrin ανβ6 LAP-ligand 
engagement and internalisation  
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Figure 6.3.1  
Summary of kinase substrate enrichment analysis (KSEA): Heatmap (A), time-point 
stratifications of kinase modulation (activation and deactivation) events (B & C) and k-
means analysis (D) of kinases inducted during integrin ανβ6 LAP-ligand engagement and 
internalisation, inferred from analysis of respective kinase substrates directly identified 
within the LC-MS/MS dataset 
 
Phosphopeptide data was interrogated using a kinase substrate enrichment analysis (KSEA) method 
developed by Casado et al (2013a) to infer kinase activity based upon identified phosphopeptides 
that are known to be substrates of specified kinase(s) moieties; permitting inference of signalling 
pathway activation, deactivation or neutrality in response to integrin ανβ6 LAP-ligand engagement and 
internalisation in the BT-20 TNBC model. (6.3.1 A) A summary heatmap of kinases and their activity 
(log2 fold-ratio enrichment) identified (based on their known substrate phosphopeptides identified 
within the LC-MS/MS dataset) was mapped (R 3.5.2, The R Foundation), highlighting which of the 330 
PhosphoSitePlus® (Cell Signalling Technology Inc) and literature-curated kinases entered in the KSEA 
model exhibited alteration in activity in response to time of LAP-ligand internalisation. KSEA results 
were then stratified to identify which kinases maximally deviated from t=0 at each time point to 
identify early (5’), mid (15’) and late (30’) signalling events in terms of (6.3.1 B) activation (positive 
deviation of z-score adjusted to t=0) or (6.3.1 C) decay (negative deviation of z-score adjusted to t=0) 
to characterise signalling pathways inducted downstream of LAP-ligand internalisation; where z=0 no 
deviation in kinase activity from t=0 is inferred, where z=2 a deviation of 2 s.d from t=0 is inferred for 
kinase activity. (6.3.1 D) Results summary from k-means score analysis highlighting kinases identified 
for functional validation, showing log2-fold enrichment versus –log10 of the corresponding adjusted p-
value for each kinase shown.  
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The KSEA results were used to infer specific kinase pathway activation and 
associated signalling network modulation inducted upon integrin ανβ6 LAP-ligand 
engagement and subsequent internalisation. The KSEA-algorithm-derived z-score 
denotes how many standard deviations (s.d) a component within the dataset 
deviates from the mean (!). Here, a z-score (adjusted against 0’, t=0) was used as a 
measure of alteration in kinase activity at each time-point in comparison with its 
baseline activity (taken as 0’, t=0).  
 
 
The z-score values were then plotted to more clearly distinguish kinases according 
to signalling activation (upregulation in kinase activity from baseline; Figure 
6.3.1B) or signalling decay (downregulation in kinase activity from baseline; Figure 
6.3.1C); and stratify their temporal relevance (in terms of maximal increase or 
decrease) as early (5’), middle (15’) or late (30’) signalling mediators. 
 
 
Based on these temporal plots and k-means analysis (Figure 6.3.1D), in 
conjunction with a literature review, five kinases were identified as putative 
mediators of signalling derived from integrin ανβ6–dependent LAP-ligand 
engagement and internalisation in the BT-20 TNBC model (Supplementary Figure 
S6.2). Four early mediators (5’, (t=5): MAP3K8; MAPKAPK2; PDK1; TBK1) and a late 
mediator (30’, (t=30): Nuak1) were selected for subsequent functional validation 
using siRNA and commercially available SMIs (Chapter II: Materials and Methods, 
Table 2.11), to explore their putative role in regulating integrin ανβ6–driven LAP-
ligand derived signalling associated with ligand engagement and internalisation.  
 
 
Following temporal analyses of kinase activity based on z-score log2-fold 
enrichment or depletion (Figure 3.3.1), the KSEA dataset was subject to supervised 
hierarchical clustering analysis to group kinases according to correlation with 
Gene Ontology (GO) Biological Pathway annotations (Spearman’s correlation: 
ρ≥0.8 correlation with GO Biological Pathway annotation terms). These analyses 
(Figure 6.3.2) were kindly devised and performed by Dr Mark R Morgan (University 
of Liverpool) to provide novel insights into biological pathways that may be 
regulated (enriched or depleted) by the β6-kinome during integrin ανβ6 LAP-
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Amongst the 330 literature- and PhosphoSitePlus®-curated kinases comprising 
KSEA analysis, a total of 10 clusters (assigned Ontology Clusters A – J) were 
mapped based on individual kinase correlation (ρ≥0.8) with GO Biological 
Pathway terms (Figure 6.3.2A). Networks were plotted for each internalisation 
time-point (Figures 6.3.2B to F) to map alterations in the β6-kinome during integrin 
ανβ6 LAP-engagement and internalisation in terms of ontological cluster to identify 
putative biological pathway regulation. 
 
 
Interestingly, the 5 kinases identified for further functional validation (Figure 
6.3.1D) were also validated as viable target kinases based on GO analyses. Within 
the most active (enriched) ontology clusters A – C: MAP3K8/COT, MAPKAPK2, 
TBK1 and PDK1 kinases were identified within cluster A and Nuak1 identified 
within cluster B; suggesting commonality between regulation of phenotypic 
outputs in terms of biological pathways regulated by these kinases.  
 
 
Global pathway analyses using the Kyoto Encyclopædia of Genes and Genomes 
(KEGG) database (Kanehisa Laboratories, GenomeNet) revealed enrichment for 
pathway annotations corresponding to: i) inositol phosphate metabolism, ii) 
endocytosis and iii) MAPK signalling; whilst depletion for terms relating to: i) 
autophagy, ii) cell cycle and iii) JAK/STAT signalling were associated with the β6-
kinome during integrin ανβ6 LAP-engagement and internalisation.  
 
 
Disappointingly, antibodies intended to validate siRNA knockdown of target 
protein kinase expression (Supplementary Figure S6.3) or to evaluate 
phosphorylation status to confirm SMI efficacy (Supplementary Figure S6.4), could 
not be reliably validated by WB to permit robust functional interrogation of the 5 
target kinases identified by KSEA (Figures 6.3.1 and 6.3.2). However, preliminary 
experiments targeting MAP3K8/COT kinase were performed as an exploratory 





















































































































































































































































































Figure 6.3.2 (A) 
Summary of supervised hierarchical cluster analyses grouping the 330 individual kinases 
within the KSEA repository into ontological clusters based on their shared GO Pathway 
Activity to infer network plasticity during integrin ανβ6 LAP-engagement and internalisation 
in the BT-20 TNBC model 
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Figure 6.3.2 (B) 
Network analysis with supervised ontological clustering (GO Pathway Analysis) to infer network plasticity in the β6-mediated kinome during integrin ανβ6 
LAP-engagement and internalisation in the BT-20 TNBC model: Mapping the baseline (0’) KSEA-inferred network  
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C 5’LAP internalisation































Figure 6.3.2 (C) 
Network analysis with supervised ontological clustering (GO Pathway Analysis) to infer network plasticity in the β6-mediated kinome during integrin ανβ6 
LAP-engagement and internalisation in the BT-20 TNBC model: Mapping the early (5’) KSEA-inferred network  
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15’D LAP internalisation






























Figure 6.3.2 (D) 
Network analysis with supervised ontological clustering (GO Pathway Analysis) to infer network plasticity in the β6-mediated kinome during integrin ανβ6 
LAP-engagement and internalisation in the BT-20 TNBC model: Mapping the intermediate (15’) KSEA-inferred network  
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30’E LAP internalisation






























Figure 6.3.2 (E) 
Network analysis with supervised ontological clustering (GO Pathway Analysis) to infer network plasticity in the β6-mediated kinome during integrin ανβ6 
LAP-engagement and internalisation in the BT-20 TNBC model: Mapping the late (30’) KSEA-inferred network  
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Figure 6.3.2 (F) 
Network analysis with supervised ontological clustering (GO Pathway Analysis) to infer 
network plasticity in the β6-mediated kinome during integrin ανβ6 LAP-engagement and 
internalisation in the BT-20 TNBC model: Key to clustered KSEA network maps indicating 
kinases by ontological cluster  
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Figure 6.3.2  
Network analyses with supervised ontological clustering to infer network plasticity in the 
β6-mediated kinome during integrin ανβ6 LAP-engagement and internalisation in the BT-20 
TNBC model  
 
Phosphopeptide data were first interrogated using a kinase substrate enrichment analysis (KSEA) 
method developed by Casado et al (2013a) to infer kinase activity based upon identified 
phosphopeptides that are known to be substrates of specified kinase(s) moieties as outlined in Figure 
6.3.1. Courtesy of Dr Mark R Morgan (Receptor Dynamics in Cancer Laboratory, University of 
Liverpool), the KSEA dataset was subject to Gene Ontology (GO) Biological Pathway Analysis to 
cluster kinases (Ontology Clusters A – J) according to correlation with GO annotations to assigned 
pathway activity (6.3.2 A) (minimum threshold for cluster analysis: Spearman’s rank correlation 
coefficient ρ≥0.8) and used to plot clustered kinase activity networks for each internalisation time 
point (6.3.2 B - E). (6.3.2 A) A summary heatmap of kinase activity clustered according GO Pathway 
Analysis with corresponding ontological kinase cluster activity plots showing mean average kinase 
activity (% of maximal activity) of kinases grouped within each cluster according to correlation with GO 
Pathway Analysis terms (Spearman’s rank correlation coefficient ρ≥0.8). Network maps highlighting 
kinase activity by ontology cluster (clusters A – J) were generated for (6.3.2 B) baseline activity 0’ (t=0) 
alongside each time point to review changes in the β6–mediated kinome at (C) 5’ (t=5), (6.3.2 D) 15’ 
(t=15), and (6.3.2 E) 30’ (t=30) during LAP internalisation. A summary key to identify network-mapped 
kinases within each cluster is provided (6.3.2 F). Cluster analysis and networks were generated using 
Cytoscape v3.1.1 with ClueGO v2.3.4 plug in (Bindea et al 2009) (Cytoscape Consortium, National 
Resource for Network Biology). Acknowledgements: Analyses presented in this figure were devised 
and performed by, and reproduced here with the kind permission of, Dr Mark R Morgan (Principal 
Investigator, Receptor Dynamics in Cancer Laboratory, University of Liverpool).  
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Figure 6.4 (A and B) 
KSEA identifies significant upregulation of (A) the kinase COT (MAP3K8) and (B) its downstream pathway effectors implicating MAP3K8 activity as a 
putative mediator of integrin ανβ6/LAP ligand-derived signalling in the BT-20 cell line  
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Figure 6.4 (C) 
Investigating the regulatory role of the kinase COT (MAP3K8) during signalling inducted 
upon integrin ανβ6 LAP ligand engagement and internalisation using the COT kinase 
inhibitor TC-S 7006 
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Figure 6.4 (D – G) 
Investigating the regulatory role of the kinase COT (MAP3K8) during signalling inducted 
upon integrin ανβ6 LAP ligand engagement and internalisation using the COT kinase 
inhibitor TC-S 7006: treatment with TC-S7006 potentiates integrin activation in response to 
canonical integrin activation methods using Mn2+ ions (D) and LAP ligand (E, F) 
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Figure 6.4 
Investigating the regulatory role of the kinase COT (MAP3K8) during signalling inducted 
upon integrin ανβ6 LAP ligand engagement and internalisation using the COT kinase 
inhibitor TC-S 7006 
 
Results from KSEA analysis identified kinases that may potentially mediate signalling inducted 
downstream of integrin ανβ6 LAP ligand-engagement and internalisation in the BT-20 TNBC model. 
(6.4 A) COT (MAP3K8) kinase was identified based on its known substrates identified from 
phosphopeptide data in terms of both substrate moiety and specific phosphorylation site. A summary 
heatmap of identified phosphopeptides is shown, indicating log2-fold enrichment and statistical 
significance of identified phosphopeptide. KSEA plot showing inferred COT activity (z score v. t = 0) 
based on statistically significant abundance of 10 known COT substrates (m=10) identified within the 
dataset (p≤0.05*, p≤0.01**, p≤0.001***) and (6.4 B) upregulation of its downstream pathway 
effectors ERK1/2, Jnk and p38. (6.4 C) Given the apparent significance of COT, kinase inhibition 
assays were performed to dissect its putative role in integrin ανβ6–mediated signalling. The COT 
(MAP3K8) inhibitor TC-S7006 (Tocris, R&D Systems) was used to target COT activity. BT-20 cells were 
serum starved for 4-hr in low serum media (1% charcoal-stripped FBS) prior to treatment with 1 μM 
TC-S7006 for 30 min under standard culture conditions (all in low serum media) prior to challenge 
with ligand spiked in at: LAP (0.5 μg ml-1, L3408, Sigma); EGF (50 ng ml-1, E9644, Sigma); HGF (50 ng 
ml-1, H9661, Sigma). Cells were stimulated for 10 min; ligand stimulation was quenched by flooding 
prior to harvesting lysates in NP-40 supplemented with protease and phosphatase inhibitors. Samples 
were probed by WB for: pEGFR (pTyr1068, 2234S, 2 μg ml-1, 9018S, CST); pAkt1 (pSer473, 2 μg ml-1, 
9018S, CST) and pERK1/2 (pThr202/204, 2 μg ml-1, 9101L, CST) alongside corresponding total 
proteins Akt1 (1 μg ml-1, 2938S, CST) and ERK1/2 (1 μg ml-1, 9102L, CST). A loading control was also 
performed (Hsc-70, 0.2 μg ml-1, sc-7298, Santa Cruz Bio Tech). WBs were developed using Amersham 
ECL Detection Kit (RPN2106, GE Healthcare) and visualised using the Amersham™ Imager 600 (GE 
Healthcare Life Sciences Ltd) digital imaging system. To determine the effect of COT inhibition on 
integrin ανβ6 activation and LAP-ligand binding, (6.4 D) canonical Mn2+ cation (n=4) and (6.4 E) 
ligand-induced (n=2) activation assays were performed in the presence of TC-S7006. In brief, BT-20 
(6.4 D, E) or VB6 cells (6.4 F) were treated in suspension with either vehicle (0.1% DMSO) or 1μM TC-
S7006 for 30 min in low serum media prior to assay. Cells were washed and treated for 10 minutes in 
the presence of vehicle or 1μM TC-S7006 with either: (6.4 D) 0.1% BSA, 20 mM EDTA or 1 mM Mn2+-
ions; or (6.4 E, F) 0.5 μg ml-1 LAP-Fc (Biogen Idec), prior to washing, antibody labelling and detection 
by flow cytometry. To determine cell surface integrin ανβ6 activation, cells were labelled for an 
activation sensitive integrin ανβ6 epitope (6.2E5, 5 μg ml-1, Biogen Idec) or an activation refractory 
integrin ανβ6 epitope (53A2, 5 μg ml-1, CR-UK). Successful cell surface binding of LAP-Fc was 
demonstrated using an anti-Fc antibody (ABM121, 5 μg ml-1, ab113636, AbCam) to detect the human 
IgG (Fc’) tag of the LAP-Fc ligand. Surface antibody levels were determined by flow cytometry (BD 
LSRFortessa™, BD Biosciences) in the presence of a cell viability dye (propidium iodide, 5 μg ml-1, 
Sigma Aldrich) to ensure gated events comprised live cells only. A significant difference in 6.2E5 
binding (active integrin ανβ6 conformer) was found in the presence of TC-S7006 in comparison with 
vehicle alone (paired t-test: p<0.05, p=0.0286). (6.4 G) A preliminary screen of the potential effect of 
COT inhibition on integrin ανβ6–dependent proliferation was performed using 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT, M5655, Sigma Aldrich) based assays in the 
A375puro (integrin β6 negative) and A375β6 (integrin β6 positive) cell lines in the presence of 0 - 
1000 nM COT SMI TC-S7006 (as previous) or 0 – 1000 nM MAPKAPK2 SMI MK II (EMD Millipore). Cells 
were seeded in 96 well plates at 3.6 x 104 cells per well in complete media and left to adhere 
overnight prior to 72 hour treatment with kinase inhibitors under standard culture conditions. On 
completion of treatment, cells were incubated with 0.2 mg ml-1 MTT (M2003, Sigma Aldrich) for 1 hr in 
the dark at 37°C, insoluble formazan-products were liberated in the presence of 100% DMSO before 
optical density (OD) readings were taken at 550 nm using the Infinite®F50 platereader (TECAN 
Trading AG). OD values were normalised against assay matrix only background readings and 
converted to %MTT activity values normalised against 100% MTT activity/cell survival using Microsoft 
Excel. Graphs were plotted using GraphPad Prism software following log10(x) data transformation and 
curve-fitting using the agonist-response (variable slope) analysis function.   
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6.4  MAP3K8 (COT) kinase inhibition appears to downregulate LAP-
 induced ERK1/2 phosphorylation and  modulates divalent Mn2+-
 cation and cognate LAP-ligand-induced integrin ανβ6 activation 
 
Based upon LC-MS/MS detection of 10 phosphopeptides (m=10) mapping to its 
known substrates, mitogen-activated protein kinase kinase kinase 8 (MAP3K8) was 
significantly identified by KSEA (Figure 6.4A) as a putative regulator of integrin 
ανβ6–mediated signalling associated with LAP ligand engagement and subsequent 
internalisation at 5’ (t=5; z-(score)=8.231; p<0.001***), 15’ (t=15; z-(score)=6.811; 
p<0.001***) and 30’ (t=30; z-(score)=4.014; p<0.001***).  
 
 
Furthermore, Gene Ontology (GO) Biological Pathway analysis of the inferential 
KSEA dataset revealed enrichment for MAPK Signalling annotations associated 
with integrin ανβ6 LAP engagement and internalisation. This was validated by 
National Cancer Institute (NCI) Ontological Pathway Analysis of phosphopeptides 
directly detected by LC-MS/MS which revealed enrichment for GO terms 
corresponding to the MAPK Cascade (GO (Process): 0000165P: MAPK Cascade 
and GO (Function): 0004707F: MAPK Activity). Therefore, interrogation of MAPK 




MAP3K8, also known as Cancer Osaka Thyroid (COT) or tumour progression locus 
2 (TPL2), is a member of the serine/threonine protein kinase family involved in 
ERK1/2, JNK, p38 and NF-κB signalling nodes (Lee et al 2015). Its expression has 
been implicated as an oncogenic factor in several cancers, including BrCa 
(Sourvinos et al 1999). Review of KSEA results for MAP3K8/COT downstream 
effector kinase activity revealed upregulation in mediators of MAP3K8 derived 
signalling (Figure 6.4B), further implicating MAP3K8 activity during integrin 
ανβ6/LAP internalisation-associated signalling events.  
 
 
A commercial MAP3K8/COT-targeting SMI (TC-S 7006, Tocris, R&D Systems) was 
used to functionally interrogate the role of MAP3K8/COT during integrin ανβ6–
mediated processes including: LAP-stimulated downstream signalling (Figure 
6.4C; n=2), integrin ανβ6 receptor activation using Mn2+ ions (Figure 6.4D; n=4) or 
LAP-ligand (Figure 6.4E; n=2) in the BT-20 cell line and VB6 cell line (Figure 6.4F; 
n=2). The effect of MAP3K8/COT inhibitor treatment on integrin ανβ6–dependent 
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proliferation/survival was briefly evaluated using a 1-(4,5-dimethylthiazol-2-yl)-3,5-
diphenylformazan (MTT)-based metabolic assay in the A375puro (integrin β6 null) 
and A375β6 (integrin β6 positive) matched pair human malignant melanoma (MM) 
cell lines (Figure 6.4F; n=1). 
 
 
To investigate the effects of MAP3K8/COT on integrin ανβ6–derived signalling 
downstream of LAP-ligand engagement, BT-20 cells were pre-treated (30’) with 1 
μM TC-S7006 (TC-S 7006) prior to stimulation (10’) with LAP, or the EGFR and c-
MET RTK cognate ligands EGF and HGF respectively (Figure 6.4C). Probing of 
lysates by WB revealed treatment with TC-S 7006 reduced LAP-induced ERK1/2 
phosphorylation and EGFR phosphorylation at Tyr1068 in comparison with vehicle 
(veh); the effect on LAP-mediated Akt1 phosphorylation at Ser473 was negligible. 
Treatment with TC-S 7006 elicited no discernible alteration in EGFR 
phosphorylation levels at Tyr1068 downstream of EGF stimulation.  
 
 
The effect of TC-S 7006 treatment on integrin ανβ6 extracellular “outside-in” 
receptor activation via divalent Mn2+ cation exposure (Figure 6.4D) and cognate 
LAP ligand engagement (Figure 6.4E) in the BT-20 cell line, and LAP ligand 
engagement in the VB6 cell line (Figure 6.4F) were evaluated by FCM using 
canonical integrin activation experiments as previously described (Chapter III: 
Results Part I, Figures 3.1.1 – 3.2.2).  
 
 
Curiously, the presence of 1 μM TC-S 7006 (TC-S 7006) potentiated BT-20 cell 
surface abundance of integrin ανβ6 in its active conformer (recognised by the 
conformation-sensitive antibody 6.2E5) upon exposure to 1 mM Mn2+ ions (Figure 
6.4D), which was found to be significant in comparison with vehicle (veh) alone 
(paired t-test; p<0.05, p=0.0286; n=4). Treatment with TC-S 7006 exhibited no 
significant alteration in cell surface abundance of total integrin ανβ6 (recognised by 
the conformer-insenstive antibody 53A2); eliciting only a marginal reduction in 
53A2 binding in comparison with vehicle (veh) alone.   
 
 
The presence of TC-S 7006 also appears to potentiate the integrin ανβ6 active 
conformer (demonstrated by antibody 6.2E5) following engagement with a human 
IgG (Fc’)-tagged LAP-ligand (Figure 6.4E). This finding was replicated in 
experiments using the VB6 cell line (Figure 6.4F), suggesting this result may be of 
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biological significance. However, only 2 biological replicate (n=2) experiments 
were performed in each cell line, obviating statistical analyses.  
 
 
Finally, the possible effects of MAP3K8/COT and MAPKAPK2 (another KSEA-
identified target kinase), on integrin ανβ6–dependent cell survival were evaluated 
by MTT-proliferation assay using the A375puro (integrin ανβ6 negative) and 
A375β6 (integrin ανβ6 positive) matched pair MM cell lines (Figure 6.4G). 
Preliminary, single experiments using a MAP3K8/COT inhibitor (TC-S 7006) and a 
MAPKAPK2 inhibitor (MK II) over a range of 0 – 1 μM suggest that proliferation of 
integrin ανβ6 expression may sensitise A375β6 MM cells to the anti-proliferative 
effects mediated by MAP3K8/COT and MAPKAPK2 inhibition, in comparison with 
integrin ανβ6 null A375puro MM cells.  
 
 
Although successful inhibition of MAP3K8/COT kinase activity could not be 
demonstrated, these preliminary findings in the presence of a MAP3K8 inhibitor 
(TC-S 7006) implicate this kinase in integrin ανβ6 receptor extracellular activation 
and downstream ligand-stimulated signalling; warranting further investigation.  
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6.5  integrin ανβ6–mediating signalling events downstream of LAP-ligand 
 engagement and internalisation are characterised by ERK1/2T202/204 
 and Akt1S473 phosphorylation; LAP-induced ERK1/2 activation is 
 pEGFRY1068-dependent  
 
KSEA results indicated Akt1S473 (Figure 6.5.1) and ERK1/2T202/204 (Figure 6.5.2) 
phosphorylation are inducted during integrin ανβ6 LAP-ligand engagement and 
internalisation, which was confirmed by WB. Direct identification of EGFR 
phosphopeptides implicated EGFR phosphorylation motifs as key mediators of 
LAP-induced integrin ανβ6 signalling (Figure 6.5.3A); functional validation using 
the anti-EGFR SMI gefitinib (Gef) (IRESSA®, AstraZeneca UK Ltd) and anti-cMET 
SMI PHA665752 (PHA) (Tocris, R&D Systems) revealed that ERK1/2 
phosphorylation downstream of LAP-ligand stimulation in the integrin ανβ6–
positive BT-20 and SUM159 TNBC cell lines is EGFR-dependent but independent 
of c-MET (Figure 6.5.3B and C). 
 
 
Activity of Akt isoforms during integrin ανβ6 LAP-ligand engagement and 
internalisation was evaluated by KSEA. Curiously, phosphopeptides mapping to 
Akt1 phosphorylation sites were not directly detected with significance or 
abundance (Figure 6.5.1A). However, based on the presence of 45 
phosphopeptides detected by LC-MS/MS (m=45) mapping to known Akt1 
substrates (Figure 6.5.1B), KSEA inferred that Akt1 activity is significantly and 
rapidly upregulated following integrin ανβ6 LAP-ligand engagement and 
internalisation reaching maximal activity at 15’ (t=5; z-(score)=3.027; p<0.01**).  
 
 
Conversely, KSEA indicated Akt2 and Akt3 isoforms were gradually 
downregulated during integrin ανβ6 LAP-ligand engagement and internalisation, 
reaching maximal signalling decay at 30’ post-internalisation (t=30; Akt2: z-
(score)=−1.125; Akt3: z-(score)=−0.796). To validate Akt1 activity inferred by 
KSEA, parental lysates used to prepare peptides for phosphoenrichment and LC-
MS/MS were analysis were probed for the Akt1 isoform phosphorylated at Ser473 
(p(S473)Akt1), total Akt1 (Akt1) and pan-Akt (all isoforms) phosphorylated at Ser473 































KSEA results suggests Akt isoform specific activation during signalling inducted upon integrin ανβ6 LAP ligand engagement and internalisation: Akt1 
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Figure 6.5.1 
KSEA results suggests Akt isoform specific activation during signalling inducted upon 
integrin ανβ6 LAP ligand engagement and internalisation: Akt1 kinase activity is 
upregulated, but Akt2 and Akt3 activity decreases upon LAP ligand engagement and 
internalisation 
 
Results from KSEA analysis identified putative Akt isoform specific signalling downstream of integrin 
ανβ6 LAP ligand-engagement and internalisation in the BT-20 TNBC model. (6.5.1 A) Akt1 
phosphorylation signatures directly identified from Akt1-derived phosphopeptide species detected by 
LC-MS/MS were not found to be significantly different in abundance compared to 0’ (t=0) baseline. 
(6.5.1 B) Akt1 kinase activity data generated from KSEA interrogation of 45 unique phosphopeptide 
species (m=45) directly detected that are known Akt1 substrates, indicate that Akt1 kinase activity 
increases significantly post integrin ανβ6 LAP-engagement and internalisation; reaching maximal 
activity at 15’ (t=15) compared to t=0 (baseline) (p<0.05*, p<0.01**). However, KSEA suggested that 
Akt2 and Akt3 kinase activity decreases over the 30 min time-scale studied for integrin ανβ6 LAP 
ligand-engagement and internalisation. (6.5.1 C) To confirm KSEA-inferred Akt isoform-specific 
activity, the original lysates used for peptide preparation for LC-MS/MS were probed for: Akt1 
phosphorylation at Ser473 (pAkt1S473: 2 μg ml-1, 9018S, CST), total Akt1 (Akt1: 2 μg ml-1, 2938S, CST) 
and pan-pAkt (pAktS473: 2 μg ml-1, 4060S, CST). A loading control was performed (Hsc-70: 0.2 μg ml-1, 
sc-7298, Santa Cruz Biotech). Blots were revealed using Amersham ECL Detection Kit (RPN2106, GE 
Healthcare) and visualised using the Amersham™ Imager 600 (GE Healthcare Life Sciences Ltd) digital 
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Concordant with KSEA, Akt1S473 phosphorylation was negligible (replicates i and ii) 
or absent (replicates iii and iv) at 0’ (t=0) but subsequently inducted from 5’ (t=5) 
post-internalisation; total Akt1 levels were constant across all timepoints (0’ − 30’). 
For all Akt isoforms evaluated using a pan-Akt antibody, phosphorylation at 




To robustly validate the inferred, putative Akt1 dominance in signalling 
downstream of integrin ανβ6 LAP-ligand engagement and internalisation, parental 
lysates require probing for Akt2 and Akt3 isoforms alongside their Ser473 
phosphorylation status to asses whether these Akt isoforms are indeed 
downregulated as indicated by KSEA.  
 
 
Within the LC-MS/MS dataset, phosphopeptides mapping to ERK1 (MAPK3: 
pT202/pY204 >6 log2-fold; pY204 >3 log2-fold) and ERK2 (MAPK1: pT185/pY187 >5 
log2-fold; pY187 >6 log2-fold) phosphorylation residues were directly identified 
(Figure 6.5.2A), exhibiting significant enrichment during integrin ανβ6 LAP-ligand 
internalisation 5’ (t=5) to 30’ (t=30) timepoints.   
 
 
Based on identification of 40 known ERK1 (MAPK3) (m=40) and 35 known ERK2 
(MAPK1) (m=35) substrates, KSEA evaluation of ERK activity (Figure 6.5.2B) 
inferred ERK1>ERK2 upregulation following integrin ανβ6–mediated LAP 
internalisation; ERK1 reaching maximal activity at 30’ (t=30; z-(score)=3.342; 
p<0.001***). Parental LC-MS/MS lysates were re-probed for phosphorylated and 
total ERK1/2 to validate these findings (Figure 6.5.2C). Induction of ERK1/2 
phosphorylation from 5’ (t=5) onwards was confirmed, demonstrating integrin 
ανβ6–mediated LAP-ligand induced signalling in the BT-20 TNBC cell line is 
characterised by ERK1>ERK2 activity.   
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Phosphopeptide data and KSEA results suggest ERK1/2 phosphorylation occurs early (t=5) and its downstream kinase activity significantly mediates late 
(t=30) signalling events during integrin ανβ6 LAP ligand engagement and internalisation 
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Figure 6.5.2 
Phosphopeptide data and KSEA results suggest ERK1/2 phosphorylation occurs early (t=5) 
and its downstream kinase activity significantly mediates late (t=30) signalling events 
during integrin ανβ6 LAP ligand engagement and internalisation 
 
Directly detected phosphopeptide species and results from KSEA analysis indicate the significance of 
ERK1/2 phosphorylation and kinase activity downstream of integrin ανβ6 LAP ligand-engagement and 
internalisation in the BT-20 TNBC model. (6.5.2 A) ERK1/2 phosphorylation signatures directly 
identified from ERK1 (MAPK3) and ERK2 (MAPK1)-derived phosphopeptide species detected by LC-
MS/MS were found to be significantly different in abundance compared to 0’ (t=0) baseline (p<0.01** 
and p<0.001***). ERK1/2 phosphorylation motifs were most significantly enriched at 5’ (t=5) at 
residues known to be associated with ERK1 (T202/Y204) and ERK2 (T185/Y187) activation. (6.5.2 B) 
ERK1 and ERK2 kinase activity exhibited markedly similar trends over time in terms of KSEA-modelled 
levels of kinase activity, based on the abundance of phosphopeptides detected that map to their 
known substrates (m=40 and m=35 respectively). ERK1/2 kinase activity increases significantly post 
integrin ανβ6 LAP-engagement and internalisation; reaching maximal activity at 30’ (t=30) compared 
to t=0 (baseline) (p<0.05* and p<0.001***). (6.5.2 C) To confirm ERK1/2 activity, the original lysates 
used for peptide preparation for LC-MS/MS were probed for pERK1/2 phosphorylation at 
Thr202/Tyr204 (pERK1T202/Y204/2T185/187: 2 μg ml-1, 9101L, CST) and total ERK1/2 (ERK1/2: 1 μg ml-1, 
9102L, CST). A loading control was performed (Hsc-70: 0.2 μg ml-1, sc-7298, Santa Cruz Biotech). 
Blots were revealed using Amersham ECL Detection Kit (RPN2106, GE Healthcare) and visualised 











In addition to induction of Akt1S473 and ERK1T202/Y204/ERK2T185/Y187 phosphorylation, 
significant changes in site-specific EGFR phosphorylation motifs downstream of 
integrin ανβ6 LAP-ligand engagement and internalisation were directly detected 
and identified by LC-MS/MS (Figure 6.5.3A). National Cancer Institute (NCI) 
Pathway Analysis of phosphopeptides detected by LC-MS/MS indicated the 
involvement of EGFR (ErbB1) Signalling during integrin ανβ6 LAP-engagement and 
internalisation (Figure 6.5.3A i). Early EGFR phosphorylation events appear to be 
directed at Thr693 (pEGFRT693: >3 log2-fold enrichment; p<0.05*; p=0.012) and 
Ser1042 (pEGFRS1042: >4 log2-fold enrichment p<0.05*; p=0.022), which showed 
significant increases in abundance at 5’ (t=5) (Figure 6.5.3A ii).  
 
 
Notably, EGFR underwent dephosphorylation at two motifs (Tyr1172 and Ser1104) 
which exhibited downregulation in abundance in comparison with 0’ (t=0) 
baseline; Tyr1172 showed significant downregulation at 15’ (pEGFRY1172: t=15; 
<−3 log2-fold enrichment; p<0.05*; p=0.022) and 30’ (t=30; <−3 log2-fold 
enrichment p<0.05*; p=0.028). Parental LC-MS/MS lysates were then probed by 
WB for EGFR phosphorylation at Tyr1086 (pEGFRY1086).  
 
 
Curiously, pEGFRY1086 appears to decrease across 5’ (t=5), 15’ (t=15) and 30’ (t=30) 
timepoints in comparison with baseline 0’ (t=0); suggesting EGFR undergoes 
dephosphorylation at Tyr1086 following integrin ανβ6 LAP-internalisation. 
Although the extent of the observed decrease in pEGFRY1086 detected by WB was 
variable across the four biological replicates, a general trend was observed, being 
most marked in replicates (ii) and (iii). 
 
 
To further investigate the putative EGFR regulation of signalling inducted 
downstream of integrin ανβ6 LAP-ligand engagement and internalisation, a kinase 
inhibition assay was combined with a ligand stimulation assay (Figure 6.5.3B). 
Using commercially available SMIs to target: EGFR (gefitinib/IRESSA® (Gef), 
AstraZeneca UK Ltd) and c-MET (PHA665752 (PHA), Tocris, R&D Systems) kinase 
activity either alone or in tandem, the BT-20 (Figure 6.5.3B), MDA-MB-468 and 
SUM159 (Figure 6.5.3C) TNBC cell lines were then challenged with LAP ligand to 
investigate the effects of RTK ablation on integrin ανβ6-mediated downstream 
signalling events.   
chapter VI: 


























































!" !# !$ !% !& !' !( !) * ) ( ' & % $ # "







0’ 5’ 15’ 30’ 0’ 5’ 15’ 30’








STAT3 seq: 710 - 729  + 2 Phospho (ST)         
PLCG1 pS1263   ** **   
EGFR pY1172   ** ** ** 
EGFR pY1172   ** *   
NCK1 pY105       * 




















MAPK1 pT185 pY187   *** *** *** 
MAPK3 pT202 pY204   *** *** *** 
EGFR seq: 1032 - 1052  + Phospho (ST)   ** ** ** 
MAPK1 pT185   *** *** *** 
EGFR pS1042 pS1045   * ** ** 
SOS1 seq: 1132 - 1142  + Phospho (ST)   *** *** *** 
EGFR pT693   *** * * 
EGFR pT693   *** * ** 
NCK1 seq: 83 - 103  + Phospho (ST)   *** *** *** 
MAPK1 pY187   *** *** *** 
MAPK3 pY204   *** *** *** 
EGFR pS1042   ** * ** 
NCK1 seq: 82 - 103  + Phospho (ST)   *** *** *** 
STAT3 pS727   *** *** *** 
STAT3 pS727   *** *** ** 
STAT1 pS727   * ** ** 
EGFR pS991     *   
EGFR pS1064         
EGFR seq: 987 - 999  + Phospho (ST)         
PTPN11 seq: 551 - 577  + Phospho (ST)   ** *   
EGFR pS1166         
PAK1 seq: 216 - 237  + Phospho (ST)       * 
GAB1 seq: 417 - 428  + Phospho (ST)     ** ** 
WASL seq: 421 - 434  + Phospho (ST)     *   
EGFR pS1166         
GAB1 seq: 417 - 428  + Phospho (ST)         
GAB1 seq: 273 - 301  + Phospho (ST)         
EGFR pS1064         
EGFR seq: 1000 - 1031  + Phospho (ST)         
PTPN6 seq: 555 - 570  + Phospho (ST)         
SRC pS17         
NCK1 seq: 146 - 178  + Phospho (ST)         
GAB1 pS266   *     
GAB1 pS454         
EGFR seq: 1069 - 1099  + Phospho (ST)         
PTPN1 pS378         
WASL pY256         
MAPK1 seq: 173 - 191  + Phospho (Y)         
MAPK1 seq: 173 - 191  + Phospho (ST)         
PTPN6 seq: 555 - 570  + Phospho (ST)         
EGFR seq: 1032 - 1052  + 2 Phospho (ST)         
GAB1 seq: 365 - 384  + Phospho (ST)         
PAK1 pS204         
EGFR seq: 987 - 999  + 2 Phospho (ST)         
SOS1 pS1064         
MAPK3 pT202 pY204         
GSN seq: 200 - 237  no mod         
GSN seq: 200 - 234  no mod         
STAT1 pS727         
TLN1 seq: 405 - 427  + Phospho (ST)         
PAK1 pS144   *     
PAK1 seq: 163 - 198  + Phospho (ST)         
PAK1 seq: 163 - 198  + Phospho (ST)         
SRC pS17         
STAT3 seq: 181 - 197  no mod         
TLN1 seq: 972 - 999  + Phospho (ST)         
TLN1 seq: 1097 - 1122  no mod         

















































Figure 6.5.3 (A) 
Duality of EGFR phosphorylation signatures characterise alteration in the BT-20 TNBC 
phosphoproteome during integrin ανβ6 LAP-ligand engagement and internalisation; 
significant upregulation of EGFR phosphorylation at Ser1042/1045 and Thr693 with 
concomitant significant downregulation of EGFR phosphorylation at Tyr1172 is observed 
during LAP internalisation  
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Figure 6.5.3 (B) 
Schematic overview of a combined kinase-inhibition, LAP-ligand stimulation assay to 
investigate the regulatory effects of EGFR and c-MET RTKs during LAP-mediated integrin 




































































































































































Figure 6.5.3 (C & D) 
LAP-induced ERK1/2 activation is EGFR-dependent but independent of c-Met in the BT-20 and SUM159 TNBC cell line models and is unaffected in the 
MDA-MB-468 cell line bearing constitutively active ERK1/2   
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Figure 6.5.3 
LAP-induced ERK1/2 activation is EGFR-dependent but independent of c-Met in the BT-20 
and SUM159 TNBC cell line models and is unaffected in the MDA-MB-468 cell line bearing 
constitutively active ERK1/2   
 
(6.5.3 A) NCI Pathway Analysis (i) highlighted EGFR (ErbB1) signalling pathway is active within the β6-
kinome during LAP internalisation. (ii) Phosphopeptide species mapping to EGFR phosphorylation 
sites were significantly enriched following LAP-ligand engagement and internalisation. Early (5’, t=5) 
EGFR phosphorylation events appear to be directed at Thr693 (p<0.05*; p=0.012) and Ser1042 
(p<0.05*; p=0.022). Notably, two EGFR phosphopeptides (pY1172 and pS1104) were downregulated 
in comparison with 0’ baseline (t=0); pY1172 showing significant downregulation at 15’ (t=15; 
p<0.05*; p=0.022) and 30’ (t=30; p<0.05*; p=0.028). P-values are adjusted for multiple-testing 
correction using the Benjamini-Hochberg procedure. (iii) Lysates used for phosphoproteomics were 
probed for phosphorylation of the EGFR receptor at Tyr1086 (pEGFRY1086: 2 μg ml-1, 2220S, CST) 
which demonstrated that following LAP ligand engagement and internalisation, phosphorylation at 
this residue appears to decay between 5’ and 30’ timepoints. A kinase inhibition/ligand stimulation 
assay (6.5.3 B) was used to investigate the role of RTK-integrin crosstalk in LAP-mediated signalling in 
the (6.5.3 C) BT-20 and (6.5.3 D) SUM159 and MDA-MB-468 cell lines, LAP-ligand stimulation assays 
were performed under EGFR and c-MET blockade conditions. Adherent cells were serum starved 
(1%FBS/α-MEM) for 4 hours prior to 30’ treatment under serum-free conditions with small molecule 
inhibitors to EGFR (gefitinib (Gef); 1 μM; AstraZeneca) or c-MET (PHA665752 (PHA); 1 μM; R & D 
Systems), or with a 10% DMSO vehicle (veh) control. At the end of inhibitor treatments, human 
recombinant LAP (0.5 μg ml-1, L3408, Sigma Aldrich) was spiked in to stimulate cells for 10’ in the 
presence of inhibitors. Upon completion, cell monolayers were washed and lysates harvested for 
Western blotting. Lysates were probed for EGFR phosphorylation at Tyr1068 (pEGFRY1068: 2 μg ml-1, 
2234S, CST); ERK1/2 phosphorylation at Thr202/204 (pERK1/2T202/204: 2 μg ml-1, 9101L, CST) and Akt 
phosphorylation at Ser473 (pAkt1S473: 2 μg ml-1, 9018S, CST). Loading controls are indicated (Hsc-70: 
0.2 μg ml-1, sc-7298, Santa Cruz Biotech). Blots were revealed using Amersham ECL Detection Kit 
(RPN2106, GE Healthcare) and visualised using the Amersham™ Imager 600 (GE Healthcare Life 
Sciences Ltd) digital imaging system. Acknowledgements: Replicate experiments (iii) and (iv) shown in 
(6.5.3 C) were performed by Mr Philip Adeniran (MSc student) and reproduced here with his kind 
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Results from four biological replicate kinase inhibition/LAP-stimulation assays 
(n=4) consistently showed that LAP ligand induction of ERK1/2 phosphorylation 
(pERK1T202/Y204/pERK2T185/Y187) is EGFR dependent, but independent of c-MET, in 
the BT-20 cell line (Figure 6.5.3C). Treatment with 1 μM gefitinib (Gef) was 
sufficient to abrogate ERK1/2 phosphorylation downstream of LAP ligand 
stimulation in comparison with vehicle (veh) control; treatment with 1 μM 
PHA665752 (PHA) did not abolish nor reduce induction of ERK1/2 
phosphorylation following LAP stimulation. Dual-targeting of EGFR/c-MET using a 
combination treatment (Gef+PHA) was also seen to ablate ERK1/2 
phosphorylation downstream of LAP ligand stimulation. 
 
 
A single experiment (n=1) was successfully probed for pan-Akt phosphorylation at 
Ser473 (pAktS473). This preliminary result showed that EGFR blockade (Gef) 
diminished but did not ablate pAktS473 levels following LAP stimulation in 
comparison with LAP-stimulated vehicle (veh) control; c-MET blockade (PHA) 
appeared to mediate little or no effect on downstream pAktS473 levels following 
LAP stimulation in comparison with LAP-stimulated vehicle (veh) control. As 
previously observed for ER1/2 phosphorylation, co-targeting of EGFR/c-MET using 
a combination treatment (Gef+PHA) was also seen to ablate Akt Ser473 
phosphorylation downstream of LAP ligand stimulation.  
 
 
To explore the broader, biological relevance of this putative integrin ανβ6/LAP-
inducted/EGFR-dependent-ERK1/2-phosphorylation signalling axis in the BT-20 
TNBC model, additional TNBC cell lines (SUM159 and MDA-MB-468) were briefly 
evaluated (n=1) (Figure 6.5.3D). As had been observed in the BT-20 cell line, EGFR 
functional blockade in the SUM159 cell line using 1 μM gefitinib (Gef) ablated 
downstream ERK1/2 phosphorylation (pERK1T202/Y204/pERK2T185/Y187) in 
comparison with LAP-stimulated vehicle (veh) control. 
 
 
However, LAP-induced ERK1/2 phosphorylation was unaffected by EGFR inhibition 
in the MDA-MB-468 cell line. Levels of ERK1/2 phosphorylation in cells treated with 
1 μM gefitinib (Gef) were comparable between ligand-naïve (unstimulated) and 
LAP-stimulated samples. The broadly consistent ERK1/2 phosphorylation levels 
across all ±kinase inhibition/±ligand stimulation conditions is concordant with the 
MDA-MB-468 constitutively active ERK status reported by Kovala and Poulin 
(2009).  
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In both the SUM159 and MDA-MB-468 cell lines, phosphorylation of Akt at Ser473 
(pAktS473) downstream of LAP-stimulation was diminished by both EGFR blockade 
alone (Gef) and by EGFR/c-MET co-targeting treatment (Gef+PHA), in comparison 
with LAP-stimulated vehicle (veh) control. Inhibition of c-MET alone (PHA) elicited 
no effect on LAP-induced pAktS473 levels in SUM159 and MDA-MB-468 cells. These 
results were concordant with pAktS473 downregulation in the presence of 1 μM 
gefitinib (Gef) observed in the BT-20 cell line (Figure 6.5.3C). 
 
 
Collectively, these preliminary investigations into the role of EGFR activity during 
integrin ανβ6–LAP engaged signalling (EGFR-integrin ανβ6 crosstalk) in TNBC, 
suggest that LAP-induced ERK1/2 phosphorylation (pERK1T202/Y204/pERK2T185/Y187) 
is EGFR-dependent, but independent of c-MET in TNBC cells (SUM159, BT-20); 
except in cells exhibiting constitutively active ERK1/2 (MDA-MB-468).  
 
 
Furthermore, LAP-mediated Akt phosphorylation (pAktS473) is EGFR blockade 
sensitive but insenstive to c-MET blockade in TNBC cells (BT-20, MDA-MB-468, 
SUM159). These results implicate integrin ανβ6 dependency on replete EGFR 
activity to modulate signalling downstream of LAP-ligand engagement, supporting 
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6.6 discussion  
 
In light of the emerging clinical significance of integrin-derived signalling following 
cognate ligand-induced activation, internalisation and trafficking as determinants 
of patient outcome (in terms of disease progression, therapeutic sensitivity and 
acquisition of chemoresistance), a LAP ligand-based internalisation assay targeting 
the integrin ανβ6 was successfully developed (Figures 6.1.1 to 6.1.3) to permit 
novel phosphoproteomic dissection (Figure 6.2) of integrin ανβ6-mediated 
signalling events downstream of LAP-ligand engagement and internalisation in the 
BT-20 TNBC model.   
 
 
The use of LAP ligand to interrogate integrin ανβ6–specific ligand-mediated 
processes in the BT-20 cell line was partly validated by abrogation of LAP 
engagement following cell surface integrin ανβ6 blockade with the inhibitory 
antibody clone 53A2 (Chapter V: Results Part III, Figure 5.2C). However, use of LAP 
to specifically bait the integrin ανβ6 to characterise receptor internalisation-
associated kinetics and signalling events required more robust validation of a 
direct physical association between LAP and integrin ανβ6 that is demonstrably 
sustained during intracellular trafficking. 
 
 
Attempts were made to demonstrate co-localisation of an Fc-tagged LAP ligand 
with the active integrin ανβ6 conformer (recognised by antibody clones 6.2E5 and 
6.2G2) by IMF, but these proved unsuccessful (Supplemental Figure S6.4). It was 
hypothesised that steric hindrance may limit availability of epitopes when post-
labelling adherent cells cultured in 2D in the presence of ligand; impeding 
successful antibody binding, especially if competing for epitopes proximal to the 
ligand-binding site. However, previous flow cytometry experiments (Chapter III: 
Results Part I, Figures 3.1.2 and 3.2.2) using antibodies 6.2E5 and 6.2G2 to label 
active, ligand-engaged integrin ανβ6 in the presence of ligands A20FMDV2-biotin 
and LAP-Fc were successful, negating the theory of steric hindrance impeding 
antibody binding for IMF analyses.  
 
 
Furthermore, as antibodies 6.2E5 and 6.2G2 bound in the presence of ligand 
(Chapter III: Results Part I, Figures 3.1.2 and 3.2.2), it was concluded that these 
antibodies are not ligand-mimetic; precluding the possibility of epitope binding 
site competitive inhibition preventing successful IMF dual labelling of integrin 
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ανβ6/LAP-Fc. Therefore, further optimisation of the IMF protocol is required to 
permit successful demonstration of integrin ανβ6/LAP colocalisation to generate a 
sufficient evidence base to use LAP ligand as a means of specifically targeting the 
integrin ανβ6 adhesion receptor. 
 
 
A set of co-IP experiments downstream of a LAP-Fc internalisation assay (originally 
designed to isolate integrin ανβ6/LAP complexes undergoing internalisation for 
proteomic interrogation), were revisited to address the question of integrin 
ανβ6/LAP specificity (Chapter II: Materials and Methods, Section 2.9). Results from 
three biological replicate IP experiments (n=3) demonstrated the integrin β6–
subunit was reproducibly immunoprecipitated using an Fc-tagged LAP ligand 
across all internalisation timepoints (Figure 6.1.2B and E; Supplementary Figure 
S6.1). This broadly confirmed the direct physical interaction between LAP and 
integrin ανβ6 is sustained during internalisation and intracellular trafficking.  
 
 
Ideally, lysates would have been probed for LAP to robustly demonstrate co-IP of 
integrin ανβ6/LAP; alongside evaluation of other integrin receptors reported to 
engage LAP to further validate integrin ανβ6 specificity for LAP in the BT-20 TNBC 
model used. However, for the purposes of the LC-MS/MS dataset presented 
subsequently (Figure 6.2), these co-IP experiments provided additional evidence 
for the utility of LAP to study integrin ανβ6–mediated processes within the BT-20 
cell line; but with caveats to prevent over- or misinterpretation of findings.  
  
 
Inferential KSEA evaluation of known kinase substrates detected by LC-MS/MS 
(Figures 6.3.1 and 6.3.2) permitted identification of five putative kinase moieties 
implicated in early (5’, (t=5): MAP3K8; MAPKAPK2; PDK1; TBK1) and late (30’, 
(t=30): Nuak1) signal activation and temporal pathway modulation during integrin 
ανβ6 LAP-engagement and internalisation (target kinases tabulated in 
Supplementary Figure S6.2). These candidate kinases were selected for functional 
validation using commercially available SMIs and siRNA to interrogate their role in 
integrin ανβ6–dependent signalling and phenotypic outputs (ligand engagement, 
invasion, migration, proliferation).  
 
 
Disappointingly, antibodies purchased to confirm siRNA silencing (Supplementary 
Figure S6.3) or phosphorylation status to determine SMI ablation of kinase activity 
(Supplementary Figure S6.4) were not successfully optimised nor validated within 
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the timescale of this project; limiting the robustness and reliability of subsequent 
experiments seeking to manipulate activity of the target kinases identified.   
 
 
Despite an inability to robustly validate kinase inhibition, exploratory investigations 
were tentatively conducted using a MAP3K8/COT-targeting SMI (TC-S7006) to 
gain additional (if rudimentary) insight into the role of this kinase during LAP-
induced integrin ανβ6-mediated activation and downstream signalling (Figure 6.4). 
In the absence of a working antibody to confirm inhibition of MAP3K8/COT activity 
and optimise treatment concentration, a concentration of 1 μM was chosen as a 
previous study had reported in vitro efficacy of a SMI targeting MAP3K8/COT at 
this concentration in human cytotoxic T lymphocytes (Chowdhury et al 2014).  
 
 
Another study dissecting MAP3K8 pathway activity in human MM had targeted V-
Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) and MAPK/ERK (MEK) 
kinases downstream of MAP3K8 using 1 μM BRAF and MEK SMIs to manipulate the 
MAP3K8 pathway (Johannessen et al 2010). It is acknowledged that cell line-
specific titration of inhibitor concentrations to determine optimal efficacy would be 
preferable. However, allowing for the caveats associated with insufficient validation 
procedures that restrict interpretation of results, several interesting observations 
were made regarding the effects of MAP3K8/COT inhibitor treatment on integrin 
ανβ6–associated processes in the BT-20 TNBC model.  
 
 
Notably, ERK1/2 phosphorylation downstream of LAP-ligand engagement was 
diminished in the presence of 1 μM TC-S7006 (TC-S 7006) in comparison with LAP-
stimulated vehicle (veh) control (Figure 6.4C); one of the two biological repeats (ii) 
showed near ablation of ERK1/2 phosphorylation downstream of LAP stimulation 
in comparison with corresponding LAP-stimulated vehicle (veh) control. 
Phosphorylation of ERK1/2 downstream of EGFR and c-MET stimulation (with their 
respective cognate ligands EGF and HGF) was unaffected by the presence of a 
MAP3K8/COT inihibitor (1 μM TC-S7006), suggesting specific sensitivity of integrin 
ανβ6–mediated signalling following MAP3K8 targeting using 1 μM TC-S 7006. 
 
 
Phosphorylation of Akt1 at Ser473 (pAkt1S473) downstream of integrin ανβ6–
directed LAP-stimulation is unaffected by the presence of a MAP3K8/COT inhibitor 
in comparison with corresponding LAP-stimulated vehicle (veh) control. 
Collectively, results from these preliminary signalling studies in the presence of the 
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MAP3K8/COT-targeting SMI TC-S 7006, implicate replete MAP3K8/COT kinase 
activity in LAP/integrin ανβ6-induced ERK1/2 phosphorylation; suggesting 
MAP3K8/COT may be a positive regulator of LAP ligand-induced, integrin ανβ6–
derived outside-in signal transduction that warrants more robust characterisation.   
 
 
Curiously, canonical integrin activation studies using divalent Mn2+ cations (n=4) 
(Figure 6.4D) or cognate ligand (n=2) (Figure 6.4E) in conjunction with 1 μM TC-S 
7006 treatment suggested the presence of a MAP3K8/COT inhibitor potentiated 
the active integrin ανβ6 conformer (detected by the active conformer-sensitive 
antibody clone 6.2E5) following exposure to both Mn2+ ions and LAP ligand; but 
did not alter detection of surface integrin ανβ6 using a conformation-independent 
antibody (clone 53A2). Interestingly, potentiation of LAP-ligand-induced integrin 
ανβ6 activation in the presence of TC-S 7006 was also observed in the VB6 cell line 




Although inhibition or ablation of MAP3K8/COT could not be demonstrated to 
validate kinase abrogation by TC-S 7006 treatment, the consistency of results 
indicating that the presence of a MAP3K8/COT inhibitor did not affect cell surface 
levels of total integrin ανβ6 (demonstrated with antibody clone 53A2), but 
specifically promoted adoption of the active conformation (demonstrated with 
antibody clone 6.2E5) in response to canonical extracellular activators, suggest 
that functionally replete MAP3K8/COT may be implicated in the negative 
regulation of integrin ανβ6 receptor activation.   
 
 
These intriguing and counterintuitive findings warrant further investigation to 
dissect the putative dichotomy of MAP3K8/COT activity during integrin ανβ6–
mediated signalling and extracellular activation revealed in these exploratory 
studies. The existence of a moiety eliciting pleiotropic effects on the integrin ανβ6 
receptor, acting as a positive regulator of signal transduction downstream of 
integrin ανβ6-activation (downstream signal agonist) but inhibitor of integrin ανβ6 
activation (receptor activation antagonist), is not entirely illogical.  
 
 
Ye et al (2017) described the pleiotropic effects of the polyphenol 
epigallocatechin gallate (EGCG) on integrin αIIbβ3 activation and EGFR signalling in 
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both a purified system and cell lines. The authors reported that EGCG inhibited 
talin-induced integrin αIIbβ3 activation but activates integrin in the absence of talin.  
 
 
Ye and colleagues (2017) attributed the pleiotropic effects of EGCG on integrin 
αIIbβ3 activation to toplogical modulation of the integrin β3-subunit transmembrane 
domain (TMD). EGCG decreased integrin β3 TMD embedding, which opposed 
talin-mediated integrin αIIbβ3 activation. In the absence of talin, the EGCG-induced 
decrease in integrin β3 TMD embedding disrupted the α–β subunit TMD 
interaction causing receptor activation. Furthermore, the authors described similar 
topological modulation of the EGFR TMD eliciting pleiotropic effects on receptor 
activation; EGCG was seen to activate EGFR in the absence of cognate EGF ligand, 
but inhibit EGF-induced activation. The authors concluded that EGCG exerted 
dichotomous transmembrane signalling effects through TMD topology 
modification.   
 
 
In addition, the pleiotropic effects of several kinases on adhesion-mediated 
signalling have been reported. Rho kinase (ROCK) signalling has been shown to 
promote either pro-apoptotic or pro-survival outcomes in a cell type and 
microenvironment context-specific manner (Street and Bryan 2011). Therefore, the 
notion that MAP3K8/kinase may elicit pleiotropic effects in response to upstream 
integrin rececptor activation is plausible.    
 
 
Indeed MAP3K8/COT has itself been ascribed the pleiotropic role of both tumour 
suppressor and oncogenic tumour promoter in a cancer-type specific manner; 
acting as tumour suppressor in intestinal and lung cancer (Gkirtzimanaki et al 
2013) but exerting pro-tumourigenic effects as an oncogene in several cancers 
including ovarian (Gruosso et al 2015) and BrCa (Lee et al 2015). MAP3K8/COT 
mRNA overexpression in breast tumour tissue in comparison with adjacent normal 
breast tissue was reported in 35 cases of primary human BrCa reviewed by 
Sourvinos et al (1999), implicating MAP3K8 expression in breast tumourigenesis. 
The oncogenic role of MAP3K8 in ovarian high-grade serous carcinoma (HGSC) 
was dissected by Gruosso et al (2015). Immunohistochemical evaluation of 
MAP3K8 expression in 139 HGSC cases demonstrated a significant association 
between MAP3K8 protein levels and poorer patient outcome in terms of disease 
progression and treatment response, leading the authors to propose that MAP3K8 
may prove a useful prognostic marker in HGSC.  
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Gruosso and colleagues (2015) also demonstrated that MAP3K8 activity imparted 
a pro-tumourigenic phenotype in SKOV3 and IGROV-1 human ovarian cancer cells 
in vitro, which was abrogated by treatment with a MAP3K8 SMI. Additional studies 
targeting activity of the MAP3K8 downstream effector MEK, indicated that MAP3K8 
expression predicts efficacy of the MEK inhibitor selumetinib (AZD6244, 
AstraZeneca) in vivo using human HGSC patient-derived xenografts. The authors 
concluded that MAP3K8 is a key oncogenic mediator during ovarian 
tumourigenesis and is a predictive marker for efficacy of novel MEK-inhibitor 
based therapeutics, such as selumetinib (currently in phase II clinical trial for low 
grade ovarion or peritoneal cancer: ClinicalTrials.gov ID NCT00551070).  
 
 
Disappointingly, since Sourvino et al’s (1999) first report of MAP3K8 as an 
oncogenic factor in BrCa, little research regarding MAP3K8 in breast 
tumourigenesis and disease progression has been published. Therefore, in light of 
the preliminary data presented here that strongly implicate induction of MAP3K8 
activity downstream of integrin ανβ6/LAP engagement and trafficking in the BT-20 
TNBC model, additional research focussed on the pro-tumourigenic role of 
MAP3K8 in BrCa is duly warranted.  
 
 
The use of an inferential computational model to interrogate the LC-MS/MS using 
KSEA was deemed appropriate to expedite analysis of relevant signal pathway 
modulation that would not be possible by manual data-mining of the >7 000 
phosphopeptides identified. Indeed, testament to its relevance and utility, the 
KSEA approach first described by Casado et al (2013a) has subsequently been 
developed into a web-based bioinformatics app tool by Wiredja et al (2017) to 
expedite meaningful user interrogation of phosphoproteomic datasets.  
 
 
Evaluation of the LC-MS/MS dataset by KSEA identified ERK1/2 and Akt 
phosphorylation as downstream mediators of LAP ligand/integrin ανβ6–derived 
signalling (Figure 6.5.1), concordant with established understanding of integrin-
mediated signalling within a broader context. The association between integrin-
mediated signalling and ERK1/2 phosphorylation has long been established for 
other integrin moieties (Moreno-Layseca and Streuli 2014) and logically, was 
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Ahmed et al (2002a) described a direct association between the integrin β6 
subunit cytodomain and ERK2 in the HT-29 colorectal carcinoma cell line, 
successfully co-immunoprecipitating ERK2 with integrin β6. The authors used 
20mer peptide fragments to mapping to the integrin cytodomain (amino acids 737 
– 788) to identify the putative ERK-binding sequence 749RSKAKWQTGTNPLYR763. 
Results presented here support the significance of ERK2, and more markedly 




Hyperactivation of phosphoinositide 3-kinase (PI3K)/Akt kinase signalling cascade 
has long been implicated in a variety of human pathologies, including malignant 
disease. Within the context of BrCa, active (phosphorylated) Akt has been 
associated with tamoxifen resistance (Kirkegaard et al 2005), HER2 amplification 
(Tokunaga et al 2006) and doxorubicin resistance (Knuefermann et al 2003). 
Current research highlights the emerging significance of Akt-isoform specific 
signalling modulating divergent functional outputs in cancer, including BrCa (Clark 
and Toker 2014); with high cytoplasmic Akt 2 reportedly associated with improved 




In their study revealing integrin ανβ6 inhibition with 264RAD potentiated 
trastuzumab efficacy in Her-2 driven BrCa, Moore et al (2014) reported 
downregulation of total Akt2 (active, phosphorylated Akt2 was not assessed) in 
trastuzumab/264RAD (HER-2/integrin inhibited) tumour samples in comparison 
with trastuzumab monotherapy. The authors implicated loss of Akt2 compensatory 
signals underlying integrin ανβ6/HER2 crosstalk that may drive the observed 
efficacy of dual-therapy in HER-2 positive BrCa.  
 
 
Curiously, KSEA evaluation of Akt isoform-specific activity within the LC-MS/MS 
dataset revealed significant induction of Akt1 isoform activity associated with LAP-
induced/integrin ανβ6–derived signalling during internalisation (Figure 6.5.2). The 
isoforms Akt2 and Akt3 were not significantly deactivated but showed a gradual 
declination in activity. Although this data does not fit with Moore et al’s (2014) 
proposed mechanism for HER-2 BrCa, this apparent Akt1 specificity may be a 
TNBC, or indeed BT-20 cell line-specific phenomenon that warrants validation in 
other TNBC models. Previous studies have highlighted the significance Akt1 
isoform specifically in BrCa. 
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Spears et al (2012) evaluated Akt isoform-specific phosphorylation at Thr308 
(pAktT308/Akt1/Akt2) in FFPE samples obtained from the Edinburgh Breast 
Conservation cohort of 1812 BrCa samples using a proximity ligation assay (PLA) 
to discriminate Akt1 versus Akt2 phosphorylation status. The authors determined 
that high levels of pAkt1 were associated with reduced distant recurrence-free 
survival (DRFS) and overall survival (OS). Notably, patients with high expression of 
pAkt1 isoform only exhibited significantly reduced DRFS; pAkt2 levels were not 
associated with differences in patient outcome. Spears and colleagues (2012) 
concluded that Akt1 activation may lead to poorer survival in BrCa patients.  
 
 
In light of the clinical signifiance of Akt1 phosphorylation demonstrated in Spear 
and colleagues’ (2012) study, the finding that Akt1 activity being specifically 
upregulated during integrin ανβ6 LAP-engagement and internalisation warrants 
further mechanistic dissection in additional TNBC models to validate whether Akt1 
is indeed a critical regulatory node in integrin ανβ6 –mediated signalling pathways. 
Evaluation of Akt1 activity within the broader context of BrCa tumourigenesis and 
disease progression would refine understanding of its temporal significance 
during BrCa natural history and relevance as a target for therapeutic intervention.  
 
 
Interestingly, several phosphopeptides mapping to specific EGFR phosphorylation 
motifs were significantly enriched, and one motif was significantly downregulated 
within the LC-MS/MS dataset. Early EGFR phosphorylation events appear to be 
directed at Thr693 (pEGFRT693) and Ser1042 (pEGFRS1042), which showed 
significant increases in abundance at 5’ (t=5). Notably, EGFR phosphorylation at 
Tyr1172 significantly decreased abundance at 15’ and 30’ in comparison with 
phosphorylation status at baseline (0’; t=0). This provided direct (as opposed to 
inferential, computational KSEA) evidence for integrin ανβ6–EGFR crosstalk during 
LAP engagement and internalisation in the BT-20 TNBC cell line.  
 
 
Based on pharmacokinetic data for gefitinib (IRESSA®, AstraZeneca) from Phase I 
clinical trials and U.S Food and Drug Administration (FDA) approved dosing of 250 
mg/day, Mukohara et al (2005) determined that 1 μM was the maximum 
achievable plasma concentration. Therefore, single-dose 1 μM gefitinib was used 
to target EGFR activity for in vitro assays seeking to dissect EGFR-integrin ανβ6 
crosstalk during LAP-engagement and internalisation that had been revealed by 
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the LC-MS/MS dataset. Integrin-EGFR crosstalk is not itself a novel concept. Moro 
et al (1998) first proposed a role for β1 and αν integrins during EGFR-derived 
mitogenic responses in human primary skin fibroblast and ECV304 endothelial 
cells adhering to immobilised fibronectin and collagen type I matrix proteins. 
Later, Moro et al (2002) demonstrated that β1- and ανβ3-integrin-mediated EGFR-
transactivation during mitosis was Src-kinase dependent.  
 
 
Of particular interest, Moro and colleagues (2002) determined that these β1- and 
ανβ3 integrin-mediated EGFR-transphosphorylation motifs were distinct from 
residues phosphorylated by classical EGFR activation inducted by EGF 
engagement. Integrins β1 and ανβ3 were shown to induce phosphorylation of 
EGFR at tyrosine residues Tyr845 (Y845), Tyr1068 (Y1068), Tyr1086 (Y1086) and 
Tyr1173 (Y1173), but not Tyr1148 (Y1148) – a significant EGFR phosphorylation site in 
response to EGF. The authors proposed a novel mechamism for integrin-EGFR 
crosstalk driven by formation of a EGFR-Src-integrin-p130CAS macromolecular 
complex that enabled EGFR transactivation. Finally, Moro and colleagues (2002) 
observed that integrin-mediated adhesion promoted increased cell surface EGFR 
expression, adding credence to the concept of co-operative reciprocity between 
integrin and EGFR receptors.  
 
 
Concordant with Moro et al’s (2002) description of integrin-mediated EGFR 
transactivation motifs, WB evaluation of single time-point LAP ligand stimulation 
assays demonstrated phosphorylation of EGFR at Tyr1068 (Y1068) in response to 
upstream LAP-ligand integrin ανβ6-stimulation that was diminished in the presence 
of gefitinib in the BT-20 TNBC cell line (Figure 6.5.3B). Curiously, evaluation of 
EGFR phosphorylation at Tyr1086 (Y1088) in the parental LC-MS/MS lysates 
revealed an apparent dephosphorylation of this residue during the LAP-
internalisation time-course (5’; t=5 to (30’; t=30) in comparison with baseline (0’; 
t=5). The phosphorylation status of other specific residues relating to integrin-
mediated EGFR transactivation described by Moro and colleagues (2002) was not 
evaluated by WB in parental LC-MS/MS lysates or LAP-stimulation assays owing to 
time and reagent constraints.  
 
 
However, of particular interest are the Thr693 (pEGFRT693) and Tyr1172 
(pEGFRT1172) EGFR phosphorylation motifs directly identified by LC-MS/MS, both 
of which are associated with altered EGFR-internalisation kinetics (PhosphoSite 
2017). Interestingly, Winograd-Katz and Levitzki (2006) identified that EGFR 
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Thr669 (equivalent to human EGFR Thr693) undergoes p38 kinase-mediated 
phosphorylation in response to cisplatin treatment. The authors generated a 
mutant EGFR in which Thr669 was mutated to an alanine residue, which was less 
sensitive to p38-mediated phosphorylation. Furthermore, the authors 
characterised a cisplatin-induced regulatory axis governing EGFR internalisation. 
Winograd-Katz and Livitzki (2006) concluded that EGFR is a p38 substrate and that 
cisplatin treatment induces EGFR internalisation, which is regulated by p38-
dependent EGFR phosphorylation at residue Thr669.  
 
 
Presciently, within the LC-MS/MS dataset presented here, both EGFR 
phosphorylation at Thr693 and its upstream regulatory kinase p38 were found to 
be significantly enriched during integrin ανβ6 LAP-engagement and internalisation.   
Therefore, it may be possible that in agreement with Winograd-Katz and Livitzki 
(2006), and extending upon Moro et al’s (2002) demonstration of αν–integrin-
induced EGFR transactivation, EGFR internalisation governed by p38-mediated 
Thr693 phosphorylation may be intrinsically linked with integrin ανβ6 ligand-
induced activation and internalisation in the BT-20 TNBC model.   
 
 
Furthermore, MAP3K8/COT (an upstream regulator of p38 kinase) was also found 
to be active within the LAP-induced integrin ανβ6-mediated kinome defined here 
by LC-MS/MS and KSEA. Therefore, a putative LAP-induced integrin ανβ6 derived 
signalling axis, involving MAP3K8/COT-p38-pEGFRT693 derailing receptor 
internalisation and associated signalling in a TNBC model assuredly warrants 




Maiello et al (2015) reported that co-targeting of EGFR and MEK1/2 (using a 
combination therapy of the respective SMIs gefitinib and selumetinib) elicited a 
synergistic inhibitory growth effect in a panel of TNBC cell lines in vitro. 
Furthermore, this anti-proliferative effect using EGFR/MEK dual-targeting reduced 
Akt-phosphorylation and nearly abolished ERK1/2 activation. The authors 
concluded that potential utility of this treatment strategy in TNBC be evaluated in a 
broader context to determine in vivo and clinical relevance. However, as warned 
by Duncan et al (2012), kinome reprogramming in response to MEK inhibition has 
already been reported in TNBC, and may swiftly drive chemoresistance. Therefore, 
detailed mechanistic dissection of any putative signalling axes to be 
therapeutically targeted is critical. 
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Preliminary experiments were designed to explore the regulatory role of EGFR 
activity on integrin ανβ6 internalisation using IMF internalisation (Supplementary 
Figure S6.5A), time course stimulation (Supplementary Figure S6.5B) and 3D-
physiomimetic mini-organotypic invasion assays (Supplementary Figure S6.5C) in 
the presence of inhibitory therapeutics gefitinib and/or 264RAD. These 
experiments were kindly performed by Mr Philip Adeniran (MSc student) and are 
included with his kind permission.  
 
 
Although these preliminary datasets are incomplete, lacking the requisite 
complement of controls and deconvolution of single agent versus multi-agent 
therapeutic effects, some interesting results indicate ongoing mechanistic 
dissection of EGFR/integrin ανβ6 reciprocity in terms of receptor dynamics, 
downstream signal modulation and invasive phenotypic output is warranted.  To 
define the pathological significance of integrin ανβ6/EGFR crosstalk inducting 
activity of downstream oncogenic factors already implicated in BrCa  
(MAP3K8/COT, p38, ERK1/2 and Akt1) would prove invaluable within the context 
of TNBC; a disease that disappointingly remains devoid of approved molecular 
targets and associated with poor outcome when conventional chemotherapy fails.   
 
 
Interestingly, several other proteins of interest were directly detected within the 
LC-MS/MS dataset, with phosphopeptides mapping to key phosphorylation motifs 
showing significant enrichment in the β6-kinome during integrin ανβ6 LAP-
engagement and internalisation (Supplementary Figure S6.6).  Nuclear Receptor 
Co-Repressor-1 (NCOR1) and -2 (NCOR2) showed enrichment within dataset, with 
NCOR1 phosphorylation at Ser70 showing significant enrichment (>2 log2-fold 
enrichment, p<0.01, p=0.0029 at maximal activity). Previous studies have shown 
that NCOR1 nonsense mutations and splice variants occur in BrCa (The Cancer 
Genome Atlas 2012); although an association was shown, a causal and/or 
functional link has not yet been established.   
 
 
In addition, phosphopeptides mapping to the two highly homologous α and β 
isoforms of glycogen synthase kinase-3 (GSK3A/B) were also enriched in the LAP-
induced β6-kinome (GSK3A: >3 log2-fold enrichment, p<0.01, p=0.0021; GSK3B: 
>2 log2-fold enrichment, p<0.05, p=0.017 at maximal activity). Reviewing the 
Edinburgh Breast Conservation Series, Quintayo et al (2012) found that high 
expression of GSK3B has been associated with distant recurrence-free survival 
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(DRFS). Subsequently, demonstrated that GSK3 inhibition using novel SMIs 
overcame chemoresistance in both in vitro and in vivo BrCa models, further 
implicating an oncogenic and progressive role for this kinase in BrCa. 
 
 
KEGG biological pathway analysis of the inferential KSEA dataset had revealed 
depletion of JAK/STAT signalling associated with the β6-kinome during LAP 
internalisation. Interestingly, phosphopeptides mapping to the signal transducer 
and activator of transcription-3 (STAT3) phosphorylated at Ser727 were 
significantly enriched within the LC-MS/MS dataset (STAT3: >2 log2-fold 
enrichment, p<0.001, p=0.0009 at maximal activity). This infers that pSTAT3S727 
may be a key downstream regulatory event following integrin ανβ6 LAP-ligand 
engagement and internalisation.  
 
 
In their comprehensive review of the role of STAT3 in human cancer, Xiong et al 
(2014) highlighted the significance of persistent STAT3 activation to drive multiple 
facets of incipient cancer biology including: immune evasion, proliferation and 
survival, malignant transformation and RTK cross-talk. Curiously, phosphorylation 
of STAT3 at Tyr705 (pSTAT3Y705) is critical for STAT3 function, but pSTAT3S727 has 
been shown to elicit both activation and inhibition of downstream transcription of 
STAT3 responsive genes. It has been shown that phosphorylation of STAT3 at 
Ser727 (as detected within this dataset) inhibits STAT3 phosphorylation at Tyr705 
and thus suppresses functional activation, inhibits dimerization, nuclear 
translocation and DNA binding (Chung et al 1997).  
 
 
Therefore, the significant upregulation of an inhibitory STAT3 phospho-motif 
(pSTAT3S727) is concordant with KSEA-based biological pathway analysis that 
suggested JAK-STAT signalling-associated KEGG annotations were depleted in 
the β6-kinome inducted during LAP internalisation. This putative STAT3 inhibition 
downstream of integrin ανβ6 ligand-engagement and activation warrants further 
investigation to ascertain the functional implications within the context of TNBC. 
 
 
Finally, phosphopeptides mapping to protein kinase C delta (δ) isoform (PKCδ) 
phosphorylation of Ser or Thr at residues 301 – 318 were also enriched in this 
dataset. Rybin et al (2009) have described phosphorylation at Ser302 and Ser304 
as novel sites of PKCδ autophosphorylation associated with activity. Therefore the 
PKCδ phosphophorylation motifs identified within the LC-MS/MS dataset may 
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implicate PKCδ activity within the β6-kinome. Overexpression of PKCδ has been 
shown to promote tumour progression in human ductal pancreatic cancer in vitro 
and in vivo (Mauro et al 2010) and to support BrCa cell survival in vitro via ERK1/2 
suppression (Lonne et al 2009). Therefore, further investigation into the role of 




Thus, further validation of mediators identified by LC-MS/MS data presented here 
as putative regulators of integrin ανβ6/LAP engagement and internalisation in 
TNBC is imperative to expedite the identification of novel molecular targets, be 
they receptors and/or signalling pathways, that can be validated for therapeutic 
intervention to improve TNBC patient outcomes and alleviate the personal and 





















Supplementary Information (Figure) S6.1 
Initial testing (A & B) and DTBP cross-link optimisation (C) of a LAP and transferrin Fc-
tagged ligand-based internalisation assay to co-IP cognate receptors (integrin ανβ6 and Tf-
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Supplementary Information (Figure) S6.1 
Initial testing (A & B) and DTBP cross-link optimisation (C) of a LAP and transferrin Fc-
tagged ligand-based internalisation assay to co-IP cognate receptors (integrin ανβ6 and Tf-
RC) undergoing internalisation  
 
Preliminary co-IP experiments performed in the BT-20 cell line to (A) compare utility of an Fc-tagged 
LAP ligand or anti-integrin ανβ6 antibody clone 53A2 to isolate the integrin ανβ6 receptor undergoing 
internalisation to identify novel trafficking partners by proteomics, in comparison with an Fc-tagged 
transferrin control ligand (B). Additional optimisation to stabilise internalised receptor complexes was 
performed (C) using the membrane permeant cross-linker DTBP. Experimental procedures for co-IP 
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Candidate/ 
UniProt ID Function 
Maxima 
Relevance in cancer (min) (z) (p) 






Oncogenic Ser/Thr protein kinase 
family. MAPK & JNK pathway 
agonist. Induces nuclear 
production of NF-κB (PhosphoSite 
2015a).  
5 8.2 *** 
Overexpression associated with resistance mechanisms to therapeutic BRAF inhibition 
[Vemurafenib] in metastatic melanoma (Johannessen et al 2010). 
RCC oncogene – siRNA silencing inhibited migration & proliferation of RCCs. miR-509-3p 
suppresses COT activity in RCC (Monsma et al 2015). COT phosphorylation of Pin1 
(peptidyl-prolyl cis/trans isomerase) promotes tumourigenesis & aggressiveness in BrCa 





Stress activated Ser/Thr kinase 
involved in CK production, 
endocytosis, cytoskeletal 
remodelling, cell migration & cell 
cycle control (PhosphoSite 2015b). 
5 4.1 *** 
MAPKAPK2 mediates resistance to H2O2 oxidative stress in human hepatobilliary cells. 
MAPKAPK2 inhibition induced caspase-3 & PARP cleavage, DNA breaks & cell death 
(Kim et al 2015).  
Mediates gemcitabine sensitivity/efficacy via MAPKAPK2/P38 signalling in PancCa cells 




Ser/Thr kinase involved in cell 
adhesion, proliferation, tumour 
progression, cell ploidy & 
senescence (PhosphoSite 2015c). 
30 2.5 ** 
May act as tumorigenic factor promoting invasion & metastasis under regulation & 
phosphorylation by Akt1. 
Nuak1 expression correlates with NSCLC TNM staging. Inihibition impaired migration & 
invasion in A549 cells. Nuak1 silencing suppressed expression of MMP-2 & MMP-9, & 
reduced lung mets in xenograft mouse model of NSCLC (Kopper et al 2014). miR-96 





Ser/Thr “master kinase” 
phosphorylating a subgroup of the 
AGC kinases (PhosphoSite 2015d). 
Substrates include: Akt 1/2/3, PKC, 
PKN, RSK, S6K (p70S6K) & SGK 
(Huang et al 2014). 
5 8.1 *** 
Constitutively active by transautophosphorylation? implicated in cancer.  
A novel & selective PDK1 inhibitor reduces BC cell invasion & tumour growth (C 
Raimondi AMUL poster session) 
PDK1 controls BC tumour growth in a kinase dependent but Akt-independent manner 




Associates with TRAF3 & TANK to 
phosphorylate IFN regulatory 
factors. Attenuates retroviral 
budding by phosphorylating 
ESCRT-I complex VPS37C subunit 
(PhosphoSite 2015e).  
5 3.6 *** 
TBK1 overexpression enhances tamoxifen resistance in BrCa (Armando Gagliardi et al 
2012). Loss of TBK1 impairs mitotic phosphorylation of PLK1 in TBK1-sensitive lung Ca 
cells. 
TBK1 interacts with & inhibits mTOR in prostate Ca regulating dormancy in the bone 
marrow (mets) niche. 
TBK1 addiction in NSCLC promotes direct activation of pro-survival Akt signals. 
Supplementary Information (Table) S6.2 
Summary of five candidate kinases identified by KSEA for functional validation as putative regulators of LAP-engaged integrin ανβ6-mediated signalling 
during internalisation (**p<0.01; ***=p<0.001; z = KSEA z-score) 
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Supplementary Information (Figure) S6.3 (A & B) 
Representative examples of antibody validation attempts using 20 nM siRNA to target kinases identified by KSEA   
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Supplementary Information (Figure) S6.3 (B) 
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Supplementary Information (Figure) S6.4 
Representative examples of antibody validation attempts to target kinases identified by KSEA : Probing the original LC-MS/MS lysates for pSer172TBK1 
and pThr334MAPK2 
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Supplementary Information (Figures) S6.3 and S6.4 
Representative examples of antibody validation attempts to target kinases identified by KSEA 
 
To functionally interrogate the five target kinases identified by KSEA to define their putative regulatory role 
during integrin ανβ6 LAP-engagement and internalisation, siRNA (ON-TARGET®Plus siRNA, Dharmacon, GE Life 
Sciences) and antibodies were purchased against (S6.3) total kinase protein and (S6.4) antibodies mapping to a 
phosphorylation specific kinase residue. (S6.3A) Following transfection (INTERFER-in transfection reagent kit, 
PolyPlus) BT-20 cells were subject to 72 hour culture in the presence of 20 nM siRNA to target kinases (as 
indicated). (S6.3B) Representative examples of WB to confirm siRNA silencing are shown. Four non-targeting 
siRNA controls were evaluated to trouble-shoot ongoing issues with off-target siCtrl effects that had lead to an 
upregulation of target gene expression when evaluates by qPCR. (S6.4) Parental lysates for LC-MS/MS were 
probed using the phosphorylation site-specific antibodies to target kinases (best representative images shown). 
Experimental procedures and WB protocol are as previously described.   
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Supplementary Information (Figure) S6.5 
Gefitinib inhibition of EGFR may modulate LAP-Fc internalisation and downstream LAP-ligand induced Akt phosphorylation at Ser473 in the BT-20 cell 
line whilst integrin β6 blockade with 264RAD circumvents downstream effects EGFR blockade to promote Akt pSer473 phosphorylation even in the 
presence of gefitinib 
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Supplementary Information (Figure) S6.5 (C) 
Dual therapy simultaneously targeting both integrin ανβ6 and EGFR using the inhibitory 
therapeutics antibody 264RAD and Gefitinib may abrogate cellular invasion in a 3D-
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Supplementary Information (Figure) S6.5 
Gefitinib inhibition of EGFR may modulate LAP-Fc internalisation and downstream LAP-
ligand induced Akt phosphorylation at Ser473 in the BT-20 cell line whilst integrin ανβ6 
blockade with 264RAD circumvents downstream effects EGFR blockade to promote Akt 
pSer473 phosphorylation even in the presence of gefitinib; co-targeting of integrin ανβ6 




To determine the effect of EGFR-integrin ανβ6 crosstalk during LAP-internalisation, a LAP-Fc 
internalisation assay was performed by confocal IMF in the presence of 1 μM gefitinib (Gef) (A), in 
conjunction with (B) a serum-free signalling time-course assay following LAP-stimulation in the 
presence of 1 μM gefitinib (Gef), 10 μg ml-1 264RAD (264RAD) or gefitinib+264RAD (Gef+264RAD) 
using the BT-20 cell line. (C) Preliminary experiments to evaluate integrin ανβ6 and EGFR on cellular 
invasion were performed using a 3D-miniorganotypic physiomimetic model.  (A) Attempts to co-label 
LAP-Fc ligand and the active integrin (demonstrated by antibody 6.2E5) to determine whether LAP 
and integrin co-localise throughout internalisation and trafficking were unsuccessful as only LAP-Fc 
was successfully demonstrated. Owing to limited availability of antibody 6.2E5, extensive optimisation 
of staining could not be undertaken. (B) A signalling study met with limited success, but warrants 
repeating to interrogate whether EGFR phosphorylation at Tyr1068 and Tyr1086 is differential and if 
these residues play distinct roles in integrin ανβ6–mediated LAP internalisation. (C) Physiomimetic 3D-
miniorganotypic models were prepared using BrCa cells alone (BT-20), normal breast fibroblasts 
alone (3137N) or an admixture of BrCa cells and normal breast fibroblasts (BT20+3137N). Cells were 
treated for 10 days with either veh+IgG control treatment (0.1% DMSO vehicle/human IgG(Fc’) or 
Gef+264RAD (1 μM gefitinib and 10 μg ml-1 264RAD) combination therapy. At the end of treatment, 
miniorganotypic gels were harvested, formalin fixed, paraffin embedded, sectioned at 4 μm and 
stained with haematoxylin and eosin (H&E). Treatment with gefitinib and 264RAD appeared to 
abrogate cellular invasion in comparison with combination control therapy. Images were acquired on 
the Axiophot. Acknowledgements: These experiments were designed and supervised by the author 
for Mr Philip Adeniran (MSc student), who kindly performed them during the tenure of his MSc project. 
The author prepared results figures for presentation; the data are reproduced here with Mr Adeniran’s 
kind permission.   
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GSK3A seq: 19 - 50 + phospho (ST) seq: 301 - 318 + phospho (ST)
seq: 301 - 318 + phospho (ST)
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7. future work and concluding remarks 
 
7.1 future work  
 
It is acknowledged that in order to exploit the full potential of this body of 
research, additional experimental work must be undertaken to more robustly 
validate and mechanistically dissect the exciting key findings presented here which 
attempt to determine the relevance of integrin ανβ6 activation status during breast 
tumourigenesis and disease progression.  
 
 
It is essential to complete the validation datasets for antibody clones 6.2E5 and 
6.2G2 to definitively establish their novel application as markers of integrin ανβ6 
activation status. Although it has been demonstrated that these antibodies 
recognise conformers induced by extracellular (“outside-in”) modes of activation, 
their ability to detect active integrin ανβ6 following intracellular (“inside-out”) 
activation and to distinguish signalling-replete receptors specifically was not 
proven herein.  
 
 
Genetic silencing or stable overexpression of known intracellular regulators of 
integrin activation and inhibition would permit validation of antibodies 6.2E5 and 
6.2G2 as markers of bidirectional integrin ανβ6 activation. The ability of antibodies 
6.2E5 and 6.2G2 to label the signalling replete, active integrin ανβ6 receptor 
subpopulation could be achieved by IMF co-localisation studies to demonstrate 




integrin activation, such as talin, vinculin, α-actinin and FAK, encompassing 
activation-specific phosphorylation residues such as pFAKY397.      
 
 
The significant and novel finding in the MCF10 isogenic model that the active 
integrin ανβ6 undergoes subcellular redistribution upon neoplastic transformation 
and malignant progression in the presence of a (relatively) stable pool of cell 
surface active integrin ανβ6, pressingly requires further investigation. Ideally 
intracellular trafficking routes should be elucidated using antibody co-labelling 
IMF strategies, similar to those employed by Arjonen et al (2012) for their 
dissection of active versus inactive integrin β1 trafficking in the MDA-MB-231 BrCa 
cell line.  
 
 
Demonstration of active integrin ανβ6 using antibodies 6.2E5 and/or 6.2G2, in 
conjunction with known endosomal compartment-specific markers, would identify 
which intracellular trafficking routes the active integrin ανβ6 is directed along 
during its internalisation and determine whether the active conformer is 
differentially targeted for lysosomal and/or proteosomal degradation or recycling 
to the membrane. Application of these methods in alternative models seeking to 
recapitulate the process of neoplastic transformation and malignant progression, 
in breast or other tissue, would permit evaluation of the broader aetiopathological 
significance of integrin ανβ6 activation status and spatial restriction during the 
natural history of malignant disease. 
 
 
It is acknowledged that extensive functional validation of candidates identified as 
novel, putative regulators of the integrin ανβ6–mediated adhesion environment (β6-
adhesome) and ligand engaged integrin ανβ6–mediated signalling networks (β6-
kinome) is requisite to establish a robust evidence base to reliably evaluate their 
role(s) in both the β6-adhesome and β6-kinome. Again, genetic manipulation 
strategies to silence or stably overexpress the candidate proteins of interest 
upstream of canonical functional and ligand-stimulation assays would permit 
extensive interrogation of the primacy of these putative regulators to elicit integrin 
ανβ6-mediated phenotypic outputs. The tumour suppressive, oncogenic or indeed 
pleiotropic roles of these regulators during tumourigenesis and disease 







7.2 concluding remarks 
 
The global burden of morbidity and mortality associated with BrCa (WHO 2014), 
coupled with BrCa remaining the most prevalent cancer in the UK (CR-UK 2016), 
collectively justify the ongoing need for research seeking to identify novel 
biomarkers that may be used for screening and prevention, and/or patient 
stratification for responsiveness to novel molecular therapeutics to improve BrCa 
patient outcomes. The groundswell of evidence demonstrating both the clinical 
relevance of integrin ανβ6 expression as a prognostic marker in BrCa, and 
experimental evidence highlighting the potential therapeutic benefits of integrin 
ανβ6 functional abrogation to reduce breast tumour growth and metastasis in vivo, 
vindicate research efforts (such as those presented in this thesis) aiming to dissect 
the functional role of integrin ανβ6 during the natural history of BrCa from 
neoplastic transformation and tumourigenesis through progression to invasive 
disease.   
 
 
Tumour cell expression of the epithelial-restricted integrin ανβ6 cellular adhesion 
receptor has long been associated with an invasive, pro-metastatic and more 
aggressive phenotype in both in vitro (Thomas et al 2001b, Nystrom et al 2006, 
Thomas et al 2006, Marsh et al 2008, Jones et al 2013) and in vivo (Van Aarsen et al 
2008, Eberlein et al 2013, Moore et al 2014) experimental cancer models. Studies 
utilising patient-derived samples revealed the clinical significance of tumoural 
integrin ανβ6 expression, demonstrating its expression is a poor prognostic 
indicator in a variety of human cancers, including colorectal (Bates et al 2005, Yang 
et al 2012), ovarian (Ahmed et al 2002b), cervical (Hazelbag et al 2007) and breast 
cancer (BrCa) (Saha et al 2010, Moore et al 2014), and is predictive of risk of 
progression from in situ to invasive disease within the context of ductal carcinoma 
in situ (DCIS) (Allen et al 2014). 
 
 
Thus, it is evident that the integrin ανβ6 receptor is functionally implicated in the 
process of breast tumourigenesis and disease progression, by mechanisms not yet 
exhaustively characterised nor unequivocally defined. Previous studies dissecting 
the protumourigenic effects of integrin adhesion receptors in human malignancy 
have revealed it is specifically the active integrin conformer that may drive integrin-
mediated oncogenic functions.  
 
 
Felding-Habermann et al (2001) first demonstrated that integrin ανβ3 in its active 




metastatic phenotype both in vitro and in vivo using the MDA-MB-231 BrCa model. 
Later, expression of the integrin β1 specifically in its active state was found to 
correlate with prostate cancer metastatic potential in vivo (Lee et al 2013).  Arjonen 
et al (2012) reported the differential endocytic trafficking kinetics of active versus 
inactive integrin β1 in the MDA-MB-231 BrCa model, suggesting distinct 
conformer-specific fates for β1 integrins. Indeed, derailed receptor internalisation 
and intracellular trafficking is an emerging cancer hallmark (Mosesson et al 2008). 
Therefore, perturbed endocytic regulation of integrin receptors and their 
consequent fate may ultimately be driven by receptor activation status and 
associated conformation.  
 
 
Interestingly, it has been demonstrated that integrin activation and associated 
signalling is not restricted to the plasma lemma but also occurs within the 
intracellular environment to drive cancer cell-associated phenotypic traits such as 
circumvention of anoikis, anchorage-independence and metastasis. Specifically, 
active integrin β1–derived signalling within endosomal compartments has been 
shown to suppress anoikis and promote metastasis in MDA-MB-231 BrCa cells 
(Alanko et al 2015). These findings further implicate an oncogenic role specifically 
attributable to active integrins, not only at the cell surface, but also during their 
intracellular trafficking. Mechanistic dissection of this concept warrants further 
investigation into other integrin receptor species implicated in breast 
tumourigenesis, such as the integrin ανβ6. 
 
 
Therefore, based on existing literature (using both experimental BrCa models and 
clinical data) that established: i) a defined oncogenic role for the active integrin β1 
receptor using in vitro BrCa models, ii) integrin ανβ6 expression imparts a more 
aggressive, pro-invasive phenotype in human cancer cells in vitro and in vivo and 
iii) the clinical prognostic significance of tumoural integrin ανβ6 that is predictive of 
risk of progression to invasive disease, it was deemed pertinent to undertake a 
body of work seeking to investigate the role of integrin ανβ6 activation status 
during the natural history of human BrCa using established in vitro models. 
 
 
Within the scope and purpose outlined at the beginning of this study, the research 
presented here has successfully addressed several of the original investigative 
aims seeking to characterise novel aspects of integrin ανβ6 activation status and 
associated signalling within the context of human BrCa. However, it is 




fulfilled, primarily owing to the financial and temporal constraints applicable to any 
programme of scientific enquiry and endeavour.   
 
 
In summary, a monoclonal antibody-based approach to study the active integrin 
ανβ6 conformer was validated in vitro (Chapter III, Results Part I). These antibodies 
(6.2E5 and 6.2G2) were then used to interrogate facets of integrin ανβ6 receptor 
activation status during breast tumourigenesis and disease progression using an 
established in vitro model (MCF-10 isogenic cell line series) recapitulating the 
natural history of BrCa from neoplastic transformation through to malignant 
progression to poorly differentiated disease (Chapter IV, Results Part II).  
 
 
Later, using the BT-20 model of triple negative BrCa (TNBC), investigations were 
designed, validated and executed to define a LAP-ligand engaged integrin ανβ6–
mediated 2-dimensional (2-DE) adhesion environment (β6–adhesome) (Chapter V, 
Results Part III) and characterise an integrin ανβ6-kinome (β6–kinome) associated 
with LAP-ligand engagement and internalisation to dissect novel aspects of 




Firstly, a means by which the conformationally distinct, signalling-replete, active 
subpopulation of integrin ανβ6 may be distinguished amongst the gross integrin 
ανβ6 receptor pool was successfully achieved through validation of two anti-
integrin ανβ6 monoclonal antibodies (6.2E5 and 6.2G2, Biogen Idec), first 
described by Weinreb et al (2004) as novel, non-function blocking integrin ανβ6–
specific antibodies. These antibodies had not been extensively evaluated 
previously for their ability to recognise a specific integrin ανβ6 conformer. 
Therefore, to robustly establish their ability to detect active integrin ανβ6 would 
permit salient interrogation of the aetiopathological role of integrin ανβ6 activation 
status in human disease, including BrCa.  
 
 
Based on preliminary flow cytometry (FCM) and enzyme-linked immunosorbent 
assay (ELISA) results, Dr Danielle DiCara and Dr Antonio Saha demonstrated 
differential binding kinetics of antibodies 6.2E5 and 6.2G2 in comparison with the 
established ligand-mimetic antibody 10D5 (details provided in Chapter III, Results 
Part I; Introduction). Having excluded antibody affinity as the underlying cause, it 




epitope thus justifying the in-depth validation and characterisation reported in this 
body of work. 
 
 
For the purposes of robust validation, the established integrin ανβ6 positive VB6 
cell line engineered in-house was predominantly used for antibody 
characterisation studies. Experiments to evaluate the utility of antibodies 6.2E5 
and 6.2G2 to recognise an active subpopulation of integrin ανβ6 (Chapter III, 
Results Part I) revealed that these antibodies each recognise conformation-
sensitive (activation-associated) epitopes. Binding of 6.2E5 and 6.2G2 was seen to 
significantly increase in the presence of Mn2+ ions (Figures 3.1.1 and 3.1.2) and 
cognate ligand (LAP or A20FMDV2) engagement (Figure 3.2.1 and 3.2.2). This 
provided evidence for their ability to recognise an activation-associated epitope 
that is induced by canonical integrin activation methods.  
 
 
Their ability to bind subsequent to integrin ανβ6 ligand-engagement suggested 
these antibodies are non-ligand mimetic and do not bind via the integrin α-β 
heterodimeric RGD cleft (as demonstrated by the established ligand-mimetic 
antibody 10D5, Figure 3.2.3.). These functional characterisations of cell surface 
binding kinetics lead to the conclusion that antibodies 6.2E5 and 6.2G2 each 
recognise an activation-associated epitope on the integrin ανβ6 that are also 




Excitingly, their utility to label active integrin ανβ6 to discriminate subcellular 
distributions of distinct integrin ανβ6 conformers using immunofluorescence (IMF) 
methods as demonstrated in cells adhering to ligand (Figures 3.3.1 and 3.3.2) and 
live-labelled cells (Figures 3.3.3), showcased the novel utility of antibodies 6.2E5 
and 6.2G2 to study the spatiotemporal distribution of active integrin ανβ6. 
Immunohistochemical (IHC) evaluation of antibodies 6.2E5 and 6.2G2 in matched 
formalin fixed paraffin-embedded (FFPE) and snap frozen primary patient-derived 
BrCa tissue samples (Figure 3.4.2) demonstrated their utility for detecting integrin 
ανβ6 in primary human tissue, but their ability to specifically discriminate the active 
integrin ανβ6 by IHC methods was not validated.  
 
 
Therefore, in terms of the first research aim, a means by which the primed or active 




6.2E5 and 6.2G2 was successfully validated; permitting their use to further 
investigate integrin ανβ6 activation status in BrCa using conformer-specific 
antibodies to label active versus inactive/total integrin ανβ6 receptor populations in 
a manner previously outlined by Humphries (2004) and employed experimentally 
by Felding-Habermann et al (2001), Arjonen et al (2012), Lee et al (2013) and 
Alanko et al (2015) for ανβ3 and β1 integrins.  
 
 
It was acknowledged that recognition of the conformation-dependent activation-
associated epitopes recognised respectively by antibodies 6.2E5 and 6.2G2 is 
sensitive to experimental procedures, thus conferring a critical caveat to their use. 
Therefore, any experimental procedures that may artificially reveal 6.2E5 and 
6.2G2 cognate epitopes in a manner that does not reflect the in vivo 




Therefore, when using these newly validated tools to interrogate integrin ανβ6 
activation status during breast tumourigenesis and disease progression using the 
MCF-10 in vitro model (Chapter IV, Results Part II), only FCM and IMF methods 
were employed as these had been validated for conservation of conformation-
dependent 6.2E5 and 6.2G2 cognate epitopes. Integrin ανβ6 subpopulations were 
characterised across the MCF-10 model using a panel of anti-integrin ανβ6 
antibodies comprising: conformer-specific (6.2E5, 6.2G2), non-conformer specific 
recognising all maturation states (620W7) and ligand mimetic (10D5) or non-
ligand mimetic (53A2) antibodies. 
 
 
Excitingly, FCM and IMF results (respectively evaluating cell surface integrin ανβ6 
expression and subcellular distribution) revealed that although cell surface 
expression of active integrin ανβ6 recognised by antibodies 6.2E5 and 6.2G2 
(relative to total integrin ανβ6 expression determined 10D5) was not significantly 
altered across the MCF-10 model (Figure 4.2), active integrin ανβ6 undergoes 
subcellular redistribution following neoplastic transformation (MCF10-AT and -
KCl.2 variants) and malignant progression (MCF10-CA1h and –CA1a variants) in 
comparison with the MCF-10A benign parental cell line (Figure 4.3).  
 
 
These results suggested derailed internalisation and trafficking kinetics of the 




expression) may be a critical event during oncogenic transformation of the breast. 
Disappointingly, experiments to define active versus inactive integrin ανβ6 
internalisation kinetics and trafficking routes within the MCF-10 model to 
characterise the nature of the observed, putative derailment associated with 
neoplastic transformation and malignant progression, could not be undertaken 
owing to restricted availability of antibodies 6.2E5 and 6.2G2.  
 
 
The critical caveat to meaningful comparisons between active versus inactive 
integrin ανβ6 internalisation and trafficking kinetics is identification of a suitable 
antibody to robustly demonstrate cell surface and intracellular total integrin ανβ6 
concomitantly. The function blocking antibodies 53A2 and 10D5 were used for 
surface labelling or static intracellular post-labelling of total integrin ανβ6 studies. 
However, using these antibodies to live-label cells for longitudinal studies of 
integrin ανβ6 receptor internalisation may not be suitable.  
 
 
The antibody 10D5 is ligand-mimetic so may evoke a ligand-induced, “pseudo”-
activated integrin ανβ6 response that may confound definition of strictly inactive 
integrin ανβ6 intracellular trafficking using this antibody. Furthermore, antibody 
53A2 was used to label integrin ανβ6 in subsequent IMF internalisation assays 
(using both live-labelling and post-labelling methods) and was found to remain 
bounded predominantly at the plasma lemma (Chapter VI, Results Part IV; Figures 
6.1 and 6.2). This may be due to low or absent internalisation of non-ligand 
engaged (inactive) integrin ανβ6, or may be a sequela of cell surface integrin ανβ6 
functional abrogation using the non-ligand-mimetic inhibitory antibody 53A2; 
again, potentially confounding comparisons between active and inactive integrin 
subpopulations.     
 
 
Therefore, an anti-integrin ανβ6 antibody to robustly label the inactive (or rather, 
non-activated) integrin ανβ6 conformer must first be identified and validated. A 
repository of anti-integrin antibodies generated in-house are fortuitously available 
(Desai 2011), so this is an achievable prospect. With validated antibodies to 
discriminate active and inactive integrin ανβ6 subpopulations in hand, IMF 
exploration of putative conformer-specific differential trafficking during breast 
tumourigenesis and disease progression (as implicated by findings using the 







Despite the utility of the MCF10 isogenic model to study the sequential neoplastic 
transformation of benign mammary epithelium, acquisition of invasive potential 
and progression to aggressive metastatic disease, several key limitations 
regarding the translatable clinical relevance of this model aiming to recapitulate 
the complexities of breast tumourigenesis in vitro. Firstly, the parental MCF-10A 
variant isolated from fibrocystic mammary epithelium and generated by 
spontaneous immortalisation in culture (Soule et al 1990, Dawson et al 1996) is not 
wholly representative of “normal” breast parenchyma; therefore, it has been 
astutely described as “non-malignant” for the purposes of this study. Secondly, the 
transformative event used to induce neoplastic transformation of the parental 
MCF-10A cell line was transfection with a plasmid vector (pHo6T1) containing the 
T24 bladder carninoma-derived Ha-ras oncogene (and aminoglycoside 
phosphotransferase gene to permit selection by geneticin antibiotic selection).  
 
 
Reviewing data archived in the Sanger Catalogue of Somatic Mutations in Cancer, 
Fernández-Medarde and Santos (2011) reported distribution and frequency of ras 
mutations in human BrCa as follows: H-ras: 1% (542); N-ras: 2% (330) and K-ras 4% 
(544) (where values represent the percentage of clinical samples analysed and 
numbers in parentheses indicated total number of clinical samples analysed). 
Therefore, although H-ras mutations do occur in a small proportion of human 
BrCas, the generation of the neoplastic MCF-10AT variant using a urinary bladder-
derived mutant H-ras may not be the best representative, most clinically relevant 
example of transformed breast epithelium.  
 
 
Given the noted limitations of the MCF-10 isogenic cell line series, any interesting 
findings arising within this model would need robust interrogation within more 
clinically relevant models for broader biological validation; or ideally, within the 
context of human primary BrCa-tumour derived patient samples, to extrapolate the 
aetiopathological and therapeutic pertinence of preliminary discoveries unearthed 
using the MCF-10 model. Although the directly translatable clinical relevance of 
the MCF-10 model to recapitulate breast tumourigenesis and disease progression 
in vitro may be limited, its utility as a basic model of the natural history of BrCa to 
broadly interrogate the functional biology of mechanisms associated with a 
transformative oncogenic event may be justified. Therefore, use of the MCF-10 
isogenic model (as utilised in this study) as a preliminary, exploratory tool is valid 
and revealed novel insights into the role of active integrin ανβ6 in BrCa that 




transformation and malignant progression; a finding that undoubtedly warrants 
further investigation.  
 
 
Given that acquisition of an invasive phenotype is associated with altered cellular 
adhesion repertoires, it was deemed pertinent to characterise an as yet undefined 
integrin ανβ6–mediated adhesion environment (β6 adhesome) during 2D-
engagement to cognate ECM ligands latency-associated peptide of transforming 
growth factor β1 (LAP), fibronectin (Fn) and collagen type I (Col I). Given the 
prescient need for identification of novel molecular targets for therapeutic 
intervention in TNBC and poor patient outcome when first-line chemotherapies 
fail, it was deemed appropriate to commence this portion of research within the 
context of TNBC using the BT-20 and MDA-MB-468 TNBC cell lines.  
 
 
The existence of an oncogenic integrin ανβ5/integrin ανβ6 switch conferring an 
anoikis-resistant survival advantage in oral squamous cell carcinoma (OSCC) cells 
that is mediated by integrin ανβ6 upregulation and downstream Akt activation, has 
been previously described (Janes and Watt 2004). These data suggest the 
acquisition of an integrin ανβ6–driven proteome may be a transformative event 
during carcinogenesis. Therefore, in kind collaboration with and under the 
supervision of Dr Mark R Morgan (Principal Investigator, Receptor Dynamics in 
Cancer Laboratory, Institute of Translational Medicine, University of Liverpool), 
experiments employing a 2D-enrichment (2D-E) strategy to isolate adhesion 
complexes for proteomic interrogation as described by Humphries et al (2009) 
and refined by Byron et al (2011), were undertaken to characterise global 
proteome changes inducted by specific ECM ligand engagement in TNBC cells 
(Chapter V, Results Part III).  
 
 
Having demonstrated integrin ανβ6 is the predominant cell surface LAP receptor in 
the BT-20 cell line (Figure 5.2), LAP ligand was used to specifically “bait” integrin 
ανβ6-mediated adhesions in 2D-E experiments. Comparison of adhesion 
complexes formed on LAP with those formed on Fn or Col I permitted 
identification of putative molecular mediators of an integrin ανβ6–mediated 
adhesion environment (β6 adhesome). Although integrin receptor switching was 
not observed as had been anticipated, four biological replicate experiments 
successfully and reproducibly yielded specific enrichment of integrin β6 in LAP-






Network mapping of proteins showing ≥2 log2-fold enrichment in LAP-mediated 
adhesions in the BT-20 cell line (Figure 5.4) permitted identification of 7 putative 
regulators of the β6 adhesome for functional validation based upon their unique 
enrichment to LAP in conjunction with a literature review: DMBT-1, MARCKS, 
MXRA5, SEPT6, SEPT9, MYH9 and MYH10. Disappointingly, endeavours to 
functionally interrogate these target proteins using siRNA methods were thwarted 
by technical limitations relating to qPCR and gene silencing methods that could 
not be optimised within the time frame of this study (Supplementary Figure S6.2). 
 
 
A single 2D-E experiment performed using MDA-MB-468 cells excitingly revealed 
unique and specific enrichment of EGFR in LAP-mediated adhesions in 
comparison with Fn-mediated adhesions. This finding tentatively suggests a 
relationship between the integrin ανβ6 and EGFR, concordant with previous studies 
that have reported integrin-EGFR crosstalk mediated by β1 and αν-integrins (Moro 
et al 1998, Moro et al 2002). Curiously, EGFR was not enriched in LAP-mediated 
adhesion complexes formed by BT-20 cells. Indeed, EGFR was not detected within 
the BT-20 2D-E/LC-MS/MS dataset. Therefore, further investigation into whether 




Finally, in efforts to characterise active, ECM ligand-engaged integrin ανβ6–derived 
signalling (β6–kinome) during internalisation, a LAP-ligand internalisation assay 
(Figure 6.1) coupled to downstream phosphoproteomics was employed using the 
BT-20 TNBC model to augment the 2D-E BT-20 dataset (Chapter VI, Results Part 
IV). Four biological replicate experiments were performed enabling LC-MS/MS 
identification of 88 533 tandem mass spectra corresponding to 8 874 unique 
peptide ions; of which 6 491 were phosphopeptides containing 7 129 
phosphorylation sites mapping to 2 073 proteins identified (Figure 6.2). 
 
 
Interrogation of the LC-MS/MS using inferential kinase substrate enrichment 
analysis (KSEA) permitted characterisation of changes in the BT-20 TNBC 
phosphoproteome during integrin ανβ6 LAP engagement and internalisation 
(Figure 6.3). This approach permitted identification of 5 putative kinase mediators 
of the β6–kinome for functional validation using commercially available small 






The KSEA dataset was also probed using Gene Ontology (GO) Biological Pathway 
analysis which revealed that GO Pathway annotation terms relating to: i) inositol 
phosphate metabolism, ii) endocytosis and iii) MAPK signalling are upregulated in 
the β6-kinome during integrin ανβ6 LAP-engagement and internalisation, whilst 
JAK/STAT signalling-related annotations are depleted. The phosphopeptide LC-
MS/MS dataset was interrogated using National Cancer Institute (NCI) Ontological 
Pathway annotations which also revealed enrichment of (GO) terms relating to 
MAPK signalling (GO (Process): GO0000165P: MAPK Cascade and GO (Function): 
0004707F: MAPK Activity), validating the primacy of MAPK signalling associated 
with integrin ανβ6 LAP engagement and internalisation inferred from KSEA.  
 
 
Preliminary interrogation of the role of MAP3K8/COT kinase as mediator of the β6-
kinome during LAP internalisation curiously suggested a dichotomous role for 
MAP3K8/COT (Figure 6.4). Targeting MAP3K8 function using the commercial SMI 
TC-S7006 appeared to diminish ERK1/2 phosphorylation downstream of LAP 
stimulation, but potentiated cell surface integrin ανβ6 activation in response to 
canonical stimulus with divalent Mn2+-ions and cognate LAP ligand.  
 
 
Disappointingly, functional abrogation of MAP3K8/COT activity in these 
exploratory experiments could not be confirmed owing to antibody and siRNA 
validation issues (Supplementary Figure S6.3 and S6.4). The putative duality of 
MAP3K8/COT activity during integrin ανβ6 LAP-engagement undoubtedly warrants 
further investigation to dissect whether this kinase elicits pleiotropic effects within 
the context of TNBC, and more broadly, during breast tumourigenesis and disease 
progression.    
 
 
Interrogation of the LAP-mediated β6-kinome revealed interesting signalling motifs 
that also warrant further investigation and broader biological validation beyond 
the single cell line (BT-20) used to generate the phosphoproteomics dataset. 
Activation of Akt1 (Figure 6.5.1) and ERK1/2 (Figure 6.5.2) downstream of integrin 
ανβ6 LAP-ligand engagement were significantly implicated as downstream 
effectors of the β6-kinome, concordant with previous findings (Kirk et al 2000, 
Ahmed et al 2002a, Janes and Watt 2004, Virtakoivu et al 2012), but novel with 






Of marked, potential clinical significance was the finding of a putative functional 
relationship between integrin ανβ6 LAP-stimulation and downstream EGFR 
phosphorylation (Figure 6.5.3). NCI Pathway Analysis revealed enrichment for 
terms associated with EGFR (ErbB1) Signalling within the LC-MS/MS dataset. 
Notably, phosphorylation of EGFR at Thr693 (also referred to in literature as 
Thr669) was significantly enriched during integrin ανβ6 LAP-engagement and 
internalisation. This particular motif (pEGFRT693) has been reported as critical for 
endocytic regulation of EGFR (Winograd-Katz and Levitzki 2006). Endocytic 
regulation of EGFR via Thr693 phosphorylation, together with previous reports of 
integrin-mediated EGFR transactivation (Moro et al 2002), undoubtedly warrant 
exhaustive functional interrogation to establish the possibility of co-regulatory 
cross-talk between integrin ανβ6 and EGFR during integrin ανβ6 ligand-induced 
activation and internalisation.  
 
 
LAP-ligand stimulation assays in the presence of the EGFR targeting SMI gefitinib 
were performed to dissect the possibility of integrin ανβ6–EGFR crosstalk in TNBC 
using the BT-20 (Figure 6.5.3C), MDA-MB-468 and SUM159 (Figure 6.5.3D) cell 
lines. Results from these in vitro functional screens revealed that downstream 
ERK1/2 phosphorylation inducted by integrin ανβ6 LAP-engagement is EGFR-
dependent in BT-20 and SUM159 TNBC cell lines, but not the MDA-MB-468 cell 
line harbouring constitutively active ERK1/2; whilst downstream Akt1 activation 
was diminished but not abolished following LAP stimulation in the presence of 
EGFR blockade. Collectively, these experiments provide further evidence for the 
exciting possibility of integrin ανβ6–EGFR crosstalk in TNBC that warrants additional 
interrogation.    
 
 
In summary, this body of work has managed to: 
 
i) validate a monoclonal antibody-based approach using antibody clones 6.2E5 
and 6.2G2 to discriminate the active subpopulation of integrin ανβ6 for use in 
future research seeking to characterise the aetiopathological significance of 
integrin ανβ6 activation status in human disease, including BrCa 
 
 
ii) demonstrate application of this newly validated antibody-based approach to 
characterise total cell surface expression and subcellular distribution of the active 
integrin ανβ6 subpopulation in the MCF-10 in vitro model of breast tumourigenesis 




stable, the active integrin undergoes ανβ6 subcellular redistribution during 
neoplastic transformation and malignant progression implicating derailed 
internalisation and intracellular trafficking as oncogenic factors 
 
 
iii) undertaken characterisation of an ECM-ligand engaged integrin ανβ6 –mediated 
adhesion environment to identify novel molecular mediators of the BT-20 TNBC 
β6-adhesome including: DMBT-1, MARCKS, MXRA5, SEPT6, SEPT9, MYH9 and 




iv) harness the power of phosphoproteomics to define the β6-kinome associated 
with integrin ανβ6 LAP-engagement and internalisation that is defined by induction 
of MAPK signalling, downstream ERK1/2 and Akt1 isoform activation which 
appears to be EGFR-dependent; inferential KSEA permitted identification of novel 
putative β6-kinome mediators including: MAP3K8/COT, MAPKAPK2, Nuak1, 
PDPK1 and TBK1  
 
 
Broadly, it is possible to hypothesise that it may not only be integrin ανβ6 activation 
status alone, but also its internalisation kinetics, intracellular trafficking routes and 
apparent EGFR-dependency that act in concert as oncogenic drivers during breast 
tumourigenesis and disease progression; a putative regulatory axis in BrCa that 
undoubtedly requires additional investigation. Indeed, each of the key findings 
presented here warrant further, more exhaustive functional interrogation and 
broader biological validation to establish their individual mechanistic and 
collective aetiopathological relevance within the context of breast tumourigenesis 
and disease progression. This would permit evaluation of the potential clinical 
significance of integrin ανβ6 activation status in BrCa that may be exploited to 
improve BrCa patient outcomes by refining treatment modalities that potentiate 
efficacy of existing regimens or prevent development of chemoresistance by co-
targeting the active integrin ανβ6 in conjunction with conventional therapeutics to 










ADEREM, A. 1992. The MARCKS brothers: a family of protein kinase C substrates. Cell, 71, 
713-6. 
AHMED, N., NIU, J., DORAHY, D. J., GU, X., ANDREWS, S., MELDRUM, C. J., SCOTT, R. J., 
BAKER, M. S., MACREADIE, I. G. & AGREZ, M. V. 2002a. Direct integrin alphavbeta6-
ERK binding: implications for tumour growth. Oncogene, 21, 1370-80. 
AHMED, N., RILEY, C., OLIVA, K., BARKER, G., QUINN, M. A. & RICE, G. E. 2004. Expression 
and localization of alphavbeta6 integrin in extraplacental fetal membranes: possible 
role in human parturition. Mol Hum Reprod, 10, 173-9. 
AHMED, N., RILEY, C., RICE, G. E., QUINN, M. A. & BAKER, M. S. 2002b. Alpha(v)beta(6) 
integrin-A marker for the malignant potential of epithelial ovarian cancer. J 
Histochem Cytochem, 50, 1371-80. 
AJEIAN, J. N., HORTON, E. R., ASTUDILLO, P., BYRON, A., ASKARI, J. A., MILLON-
FRÉMILLON, A., KNIGHT, D., KIMBER, S. J., HUMPHRIES, M. J. & HUMPHRIES, J. D. 
2016. Proteomic analysis of integrin- associated complexes from mesenchymal stem 
cells. Proteomics. Clinical Applications, 10, 51-57. 
AKAR, U., OZPOLAT, B., MEHTA, K., LOPEZ-BERESTEIN, G., ZHANG, D., UENO, N. T., 
HORTOBAGYI, G. N. & ARUN, B. 2010. Targeting p70S6K prevented lung metastasis 
in a breast cancer xenograft model. Mol Cancer Ther, 9, 1180-7. 
AL-HAZMI, N., THOMAS, G. J., SPEIGHT, P. M. & WHAWELL, S. A. 2007. The 120 kDa cell-
binding fragment of fibronectin up-regulates migration of alphavbeta6-expressing 
cells by increasing matrix metalloproteinase-2 and -9 secretion. Eur J Oral Sci, 115, 
454-8. 
ALANKO, J., MAI, A., JACQUEMET, G., SCHAUER, K., KAUKONEN, R., SAARI, M., GOUD, B. 
& IVASKA, J. 2015. Integrin endosomal signalling suppresses anoikis. Nat Cell Biol, 
17, 1412-21. 
ALLEN, J. L., COOKE, M. E. & ALLISTON, T. 2012. ECM stiffness primes the TGFbeta pathway 
to promote chondrocyte differentiation. Mol Biol Cell, 23, 3731-42. 
ALLEN, M. D., THOMAS, G. J., CLARK, S., DAWOUD, M. M., VALLATH, S., PAYNE, S. J., 
GOMM, J. J., DREGER, S. A., DICKINSON, S., EDWARDS, D. R., PENNINGTON, C. 
 
 379 
J., SESTAK, I., CUZICK, J., MARSHALL, J. F., HART, I. R. & JONES, J. L. 2014. Altered 
microenvironment promotes progression of preinvasive breast cancer: myoepithelial 
expression of alphavbeta6 integrin in DCIS identifies high-risk patients and predicts 
recurrence. Clin Cancer Res, 20, 344-57. 
ALLEN, M. D., VAZIRI, R., GREEN, M., CHELALA, C., BRENTNALL, A. R., DREGER, S., 
VALLATH, S., NITCH-SMITH, H., HAYWARD, J., CARPENTER, R., HOLLIDAY, D. L., 
WALKER, R. A., HART, I. R. & JONES, J. L. 2011. Clinical and functional significance of 
alpha9beta1 integrin expression in breast cancer: a novel cell-surface marker of the 
basal phenotype that promotes tumour cell invasion. J Pathol, 223, 646-58. 
ALMENDRO, V., KIM, H. J., CHENG, Y. K., GONEN, M., ITZKOVITZ, S., ARGANI, P., VAN 
OUDENAARDEN, A., SUKUMAR, S., MICHOR, F. & POLYAK, K. 2014. Genetic and 
phenotypic diversity in breast tumor metastases. Cancer Res, 74, 1338-48. 
ANDRE, F. & ZIELINSKI, C. C. 2012. Optimal strategies for the treatment of metastatic triple-
negative breast cancer with currently approved agents. Ann Oncol, 23 Suppl 6, vi46-
51. 
ANGELIS, D. & SPILIOTIS, E. T. 2016. Septin Mutations in Human Cancers. Front Cell Dev 
Biol, 4, 122. 
ANGELUCCI, C., MAULUCCI, G., LAMA, G., PROIETTI, G., COLABIANCHI, A., PAPI, M., 
MAIORANA, A., DE SPIRITO, M., MICERA, A., BALZAMINO, O. B., DI LEONE, A., 
MASETTI, R. & SICA, G. 2012. Epithelial-stromal interactions in human breast cancer: 
effects on adhesion, plasma membrane fluidity and migration speed and directness. 
PLoS One, 7, e50804. 
AOUDJIT, F. & VUORI, K. 2001. Integrin signaling inhibits paclitaxel-induced apoptosis in 
breast cancer cells. Oncogene, 20, 4995-5004. 
AOUDJIT, F. & VUORI, K. 2012. Integrin signaling in cancer cell survival and chemoresistance. 
Chemother Res Pract, 2012, 283181. 
ARJONEN, A., ALANKO, J., VELTEL, S. & IVASKA, J. 2012. Distinct recycling of active and 
inactive beta1 integrins. Traffic, 13, 610-25. 
ARJONEN, A., KAUKONEN, R. & IVASKA, J. 2011. Filopodia and adhesion in cancer cell 
motility. Cell Adhesion & Migration, 5, 421-430. 
ARJONEN, A., KAUKONEN, R., MATTILA, E., ROUHI, P., HOGNAS, G., SIHTO, H., MILLER, B. 
W., MORTON, J. P., BUCHER, E., TAIMEN, P., VIRTAKOIVU, R., CAO, Y., SANSOM, 
O. J., JOENSUU, H. & IVASKA, J. 2014. Mutant p53-associated myosin-X upregulation 
promotes breast cancer invasion and metastasis. J Clin Invest, 124, 1069-82. 
ARMANDO GAGLIARDI, P., DI BLASIO, L., ORSO, F., SEANO, G., SESSA, R., TAVERNA, D., 
BUSSOLINO, F. & PRIMO, L. 2012. 3-Phosphoinositide-Dependent Kinase 1 Controls 
 
 380 
Breast Tumor Growth in a Kinase-Dependent but Akt-Independent Manner. 
Neoplasia, 14, 719-IN19. 
ARNAOUT, M. A., GOODMAN, S. L. & XIONG, J. P. 2007. Structure and mechanics of 
integrin-based cell adhesion. Curr Opin Cell Biol, 19, 495-507. 
ARPINO, G., LAUCIRICA, R. & ELLEDGE, R. M. 2005. Premalignant and in situ breast disease: 
biology and clinical implications. Ann Intern Med, 143, 446-57. 
ASKARI, J. A., BUCKLEY, P. A., MOULD, A. P. & HUMPHRIES, M. J. 2009. Linking integrin 
conformation to function. J Cell Sci, 122, 165-70. 
ASPA. 1986. Animals (Scientific Procedures) Act 1986 [Online]. The National Archives. 
Available: http://www.legislation.gov.uk/ukpga/1986/14/contents [Accessed 15th 
October 2014]. 
ATCC. 2012a. Human skin cell lines; malignant melanoma: A375 (ATCC® CRL-1619™) 
[Online]. Available: http://www.atcc.org/Products/All/CRL-1619.aspx [Accessed 19th 
October 2012]. 
ATCC. 2012b. Human mammary gland; breast/epithelial cell lines: MCF-10A (ATCC® CRL-
10317™) [Online]. Available: http://www.atcc.org/Products/All/HTB-20.aspx 
[Accessed 25th May 2013]. 
ATCC. 2012c. Human mammary gland; breast/epithelial cell lines: MDA-MB-231 
(ATCC®HTB-26™) [Online]. Available: http://www.atcc.org/Products/All/HTB-26.aspx 
[Accessed 25th May 2013]. 
ATCC. 2012d. Mammary gland/breast; cell lines derived from metastatic site (pleural 
effusion): MDA-MB-468 (ATCC ® HTB-132™) [Online]. American Type Culture 
Collection Available: http://www.atcc.org/Products/All/HTB-132.aspx [Accessed 25th 
November 2012]. 
ATCC. 2013a. Human mammary gland/breast; epithelial cell lines: BT-20 (ATCC® HTB-19™) 
[Online]. Available: http://www.atcc.org/Products/All/HTB-19.aspx [Accessed 13th 
January 2013]. 
ATCC. 2013b. Human mammary gland; breast/duct cell lines: BT-474 (ATCC®HTB-20™) 
[Online]. Available: http://www.atcc.org/Products/All/HTB-20.aspx [Accessed 25th 
May 2013]. 
ATHERTON, P., STUTCHBURY, B., JETHWA, D. & BALLESTREM, C. 2016. Mechanosensitive 
components of integrin adhesions: Role of vinculin. Exp Cell Res, 343, 21-7. 
ATHERTON, P., STUTCHBURY, B., WANG, D. Y., JETHWA, D., TSANG, R., MEILER-
RODRIGUEZ, E., WANG, P., BATE, N., ZENT, R., BARSUKOV, I. L., GOULT, B. T., 
CRITCHLEY, D. R. & BALLESTREM, C. 2015. Vinculin controls talin engagement with 
 
 381 
the actomyosin machinery. Nat Commun, 6, 10038. 
AZARE, J., LESLIE, K., AL-AHMADIE, H., GERALD, W., WEINREB, P. H., VIOLETTE, S. M. & 
BROMBERG, J. 2007. Constitutively activated Stat3 induces tumorigenesis and 
enhances cell motility of prostate epithelial cells through integrin beta 6. Mol Cell 
Biol, 27, 4444-53. 
BAKER, B. M. & CHEN, C. S. 2012. Deconstructing the third dimension: how 3D culture 
microenvironments alter cellular cues. J Cell Sci, 125, 3015-24. 
BANERJEE, S., BUHRLAGE, S. J., HUANG, H. T., DENG, X., ZHOU, W., WANG, J., TRAYNOR, 
R., PRESCOTT, A. R., ALESSI, D. R. & GRAY, N. S. 2014. Characterization of WZ4003 
and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated 
NUAK kinases. Biochem J, 457, 215-25. 
BARNABAS, N. & COHEN, D. 2013. Phenotypic and Molecular Characterization of 
MCF10DCIS and SUM Breast Cancer Cell Lines. Int J Breast Cancer, 2013, 872743. 
BASOLO, F., ELLIOTT, J., TAIT, L., CHEN, X. Q., MALONEY, T., RUSSO, I. H., PAULEY, R., 
MOMIKI, S., CAAMANO, J., KLEIN-SZANTO, A. J. & ET AL. 1991. Transformation of 
human breast epithelial cells by c-Ha-ras oncogene. Mol Carcinog, 4, 25-35. 
BASS, J. J., WILKINSON, D. J., RANKIN, D., PHILLIPS, B. E., SZEWCZYK, N. J., SMITH, K. & 
ATHERTON, P. J. 2017. An overview of technical considerations for Western blotting 
applications to physiological research. Scand J Med Sci Sports, 27, 4-25. 
BATEMAN, A. C. & SHAW, E. C. 2013. Breast pathology. Surgery (Oxford), 31, 4-10. 
BATES, R. C., BELLOVIN, D. I., BROWN, C., MAYNARD, E., WU, B., KAWAKATSU, H., 
SHEPPARD, D., OETTGEN, P. & MERCURIO, A. M. 2005. Transcriptional activation of 
integrin beta6 during the epithelial-mesenchymal transition defines a novel 
prognostic indicator of aggressive colon carcinoma. J Clin Invest, 115, 339-47. 
BAZZONI, G., SHIH, D. T., BUCK, C. A. & HEMLER, M. E. 1995. Monoclonal antibody 9EG7 
defines a novel beta 1 integrin epitope induced by soluble ligand and manganese, 
but inhibited by calcium. J Biol Chem, 270, 25570-7. 
BEDNARCZYK, J. L., WYGANT, J. N., SZABO, M. C., MOLINARI-STOREY, L., RENZ, M., 
FONG, S. & MCINTYRE, B. W. 1993. Homotypic leukocyte aggregation triggered by 
a monoclonal antibody specific for a novel epitope expressed by the integrin beta 1 
subunit: conversion of nonresponsive cells by transfecting human integrin alpha 4 
subunit cDNA. J Cell Biochem, 51, 465-78. 
BEHRENS, J. 1993. The role of cell adhesion molecules in cancer invasion and metastasis. 
Breast Cancer Res Treat, 24, 175-84. 
BENDAS, G. & BORSIG, L. 2012. Cancer cell adhesion and metastasis: selectins, integrins, 
 
 382 
and the inhibitory potential of heparins. Int J Cell Biol, 2012, 676731. 
BERRYMAN, S., CLARK, S., MONAGHAN, P. & JACKSON, T. 2005. Early events in integrin 
alphavbeta6-mediated cell entry of foot-and-mouth disease virus. J Virol, 79, 8519-34. 
BERTOS, N. R. & PARK, M. 2011. Breast cancer - one term, many entities? J Clin Invest, 121, 
3789-96. 
BEZDENEZHNYKH, N., SEMESIUK, N., LYKHOVA, O., ZHYLCHUK, V. & KUDRYAVETS, Y. 
2014. Impact of stromal cell components of tumor microenvironment on epithelial-
mesenchymal transition in breast cancer cells. Exp Oncol, 36, 72-8. 
BHARADWAJ, M., STROHMEYER, N., COLO, G. P., HELENIUS, J., BEERENWINKEL, N., 
SCHILLER, H. B., FÄSSLER, R. & MÜLLER, D. J. 2017. αV-class integrins exert dual 
roles on α5β1 integrins to strengthen adhesion to fibronectin. Nature 
Communications, 8, 14348. 
BINDEA, G., MLECNIK, B., HACKL, H., CHAROENTONG, P., TOSOLINI, M., KIRILOVSKY, A., 
FRIDMAN, W.-H., PAGÈS, F., TRAJANOSKI, Z. & GALON, J. 2009. ClueGO: a 
Cytoscape plug-in to decipher functionally grouped gene ontology and pathway 
annotation networks. Bioinformatics, 25, 1091-1093. 
BLACKBURN, A. C., HILL, L. Z., ROBERTS, A. L., WANG, J., AUD, D., JUNG, J., NIKOLCHEVA, 
T., ALLARD, J., PELTZ, G., OTIS, C. N., CAO, Q. J., RICKETTS, R. S. J., NABER, S. P., 
MOLLENHAUER, J., POUSTKA, A., MALAMUD, D. & JERRY, D. J. 2007. Genetic 
Mapping in Mice Identifies DMBT1 as a Candidate Modifier of Mammary Tumors and 
Breast Cancer Risk. The American Journal of Pathology, 170, 2030-2041. 
BONNANS, C., CHOU, J. & WERB, Z. 2014. Remodelling the extracellular matrix in 
development and disease. Nat Rev Mol Cell Biol, 15, 786-801. 
BOUVARD, D., POUWELS, J., DE FRANCESCHI, N. & IVASKA, J. 2013. Integrin inactivators: 
balancing cellular functions in vitro and in vivo. Nat Rev Mol Cell Biol. 
BOYER, A. P., COLLIER, T. S., VIDAVSKY, I. & BOSE, R. 2013. Quantitative proteomics with 
siRNA screening identifies novel mechanisms of trastuzumab resistance in HER2 
amplified breast cancers. Mol Cell Proteomics, 12, 180-93. 
BRAIDOTTI, P., NUCIFORO, P. G., MOLLENHAUER, J., POUSTKA, A., PELLEGRINI, C., 
MORO, A., BULFAMANTE, G., COGGI, G., BOSARI, S. & PIETRA, G. G. 2004. DMBT1 
expression is down-regulated in breast cancer. BMC Cancer, 4, 46-46. 
BRAKEBUSCH, C. & FASSLER, R. 2003. The integrin-actin connection, an eternal love affair. 
Embo j, 22, 2324-33. 
BREITKREUTZ, D., BRAIMAN-WIKSMAN, L., DAUM, N., DENNING, M. F. & TENNENBAUM, 
T. 2007. Protein kinase C family: on the crossroads of cell signaling in skin and tumor 
 
 383 
epithelium. J Cancer Res Clin Oncol, 133, 793-808. 
BRETSCHER, M. S. 1989. Endocytosis and recycling of the fibronectin receptor in CHO cells. 
Embo j, 8, 1341-8. 
BREUSS, J. M., GALLO, J., DELISSER, H. M., KLIMANSKAYA, I. V., FOLKESSON, H. G., 
PITTET, J. F., NISHIMURA, S. L., ALDAPE, K., LANDERS, D. V., CARPENTER, W. & ET 
AL. 1995. Expression of the beta 6 integrin subunit in development, neoplasia and 
tissue repair suggests a role in epithelial remodeling. J Cell Sci, 108 ( Pt 6), 2241-51. 
BRITSCHGI, A., BILL, A., BRINKHAUS, H., ROTHWELL, C., CLAY, I., DUSS, S., REBHAN, M., 
RAMAN, P., GUY, C. T., WETZEL, K., GEORGE, E., POPA, M. O., LILLEY, S., 
CHOUDHURY, H., GOSLING, M., WANG, L., FITZGERALD, S., BORAWSKI, J., 
BAFFOE, J., LABOW, M., GAITHER, L. A. & BENTIRES-ALJ, M. 2013. Calcium-
activated chloride channel ANO1 promotes breast cancer progression by activating 
EGFR and CAMK signaling. Proc Natl Acad Sci U S A, 110, E1026-34. 
BROWN, M. C., CARY, L. A., JAMIESON, J. S., COOPER, J. A. & TURNER, C. E. 2005. Src and 
FAK kinases cooperate to phosphorylate paxillin kinase linker, stimulate its focal 
adhesion localization, and regulate cell spreading and protrusiveness. Mol Biol Cell, 
16, 4316-28. 
BROWNE, B. C., HOCHGRAFE, F., WU, J., MILLAR, E. K., BARRACLOUGH, J., STONE, A., 
MCCLOY, R. A., LEE, C. S., ROBERTS, C., ALI, N. A., BOULGHOURJIAN, A., 
SCHMICH, F., LINDING, R., FARROW, L., GEE, J. M., NICHOLSON, R. I., O'TOOLE, 
S. A., SUTHERLAND, R. L., MUSGROVE, E. A., BUTT, A. J. & DALY, R. J. 2013. Global 
characterization of signalling networks associated with tamoxifen resistance in breast 
cancer. Febs j, 280, 5237-57. 
BUCHHEIT, C. L., RAYAVARAPU, R. R. & SCHAFER, Z. T. 2012. The regulation of cancer cell 
death and metabolism by extracellular matrix attachment. Semin Cell Dev Biol, 23, 
402-11. 
BURGESS, A. 2015. Using ImageJ to Measure Cell Fluorescence [Online]. Sydney, AUS: The 
Cell Division Lab, The Kinghorn Cancer Centre. Available: 
https://celldivisionlab.com/2015/08/12/using-imagej-to-measure-cell-fluorescence/ 
[Accessed 17th March 2017]. 
BUSK, M., PYTELA, R. & SHEPPARD, D. 1992. Characterization of the integrin alpha v beta 6 
as a fibronectin-binding protein. J Biol Chem, 267, 5790-6. 
BUSSARD, K. M., MUTKUS, L., STUMPF, K., GOMEZ-MANZANO, C. & MARINI, F. C. 2016. 
Tumor-associated stromal cells as key contributors to the tumor microenvironment. 
Breast Cancer Res, 18, 84. 
BUTCHER, D. T., ALLISTON, T. & WEAVER, V. M. 2009. A tense situation: forcing tumour 
progression. Nat Rev Cancer, 9, 108-22. 
 
 384 
BYRON, A. 2011. Analyzing the anatomy of integrin adhesions. Sci Signal, 4, jc3. 
BYRON, A., ASKARI, J. A., HUMPHRIES, J. D., JACQUEMET, G., KOPER, E. J., WARWOOD, 
S., CHOI, C. K., STROUD, M. J., CHEN, C. S., KNIGHT, D. & HUMPHRIES, M. J. 2015. 
A proteomic approach reveals integrin activation state-dependent control of 
microtubule cortical targeting. Nat Commun, 6, 6135. 
BYRON, A. & FRAME, M. C. 2016. Adhesion protein networks reveal functions proximal and 
distal to cell-matrix contacts. Current Opinion in Cell Biology, 39, 93-100. 
BYRON, A., HUMPHRIES, J. D., ASKARI, J. A., CRAIG, S. E., MOULD, A. P. & HUMPHRIES, M. 
J. 2009. Anti-integrin monoclonal antibodies. J Cell Sci, 122, 4009-11. 
BYRON, A., HUMPHRIES, J. D., BASS, M. D., KNIGHT, D. & HUMPHRIES, M. J. 2011. 
Proteomic analysis of integrin adhesion complexes. Sci Signal, 4, pt2. 
BYRON, A., HUMPHRIES, J. D., CRAIG, S. E., KNIGHT, D. & HUMPHRIES, M. J. 2012. 
Proteomic analysis of alpha4beta1 integrin adhesion complexes reveals alpha-
subunit-dependent protein recruitment. Proteomics, 12, 2107-14. 
BYRON, A., HUMPHRIES, J. D. & HUMPHRIES, M. J. 2013. Defining the extracellular matrix 
using proteomics. Int J Exp Pathol, 94, 75-92. 
BYRON, A., RANDLES, M. J., HUMPHRIES, J. D., MIRONOV, A., HAMIDI, H., HARRIS, S., 
MATHIESON, P. W., SALEEM, M. A., SATCHELL, S. C., ZENT, R., HUMPHRIES, M. J. 
& LENNON, R. 2014. Glomerular cell cross-talk influences composition and assembly 
of extracellular matrix. J Am Soc Nephrol, 25, 953-66. 
CAL, S., FREIJE, J. M., LOPEZ, J. M., TAKADA, Y. & LOPEZ-OTIN, C. 2000. ADAM 23/MDC3, 
a human disintegrin that promotes cell adhesion via interaction with the alphavbeta3 
integrin through an RGD-independent mechanism. Mol Biol Cell, 11, 1457-69. 
CALDERWOOD, D. A., CAMPBELL, I. D. & CRITCHLEY, D. R. 2013. Talins and kindlins: 
partners in integrin-mediated adhesion. Nat Rev Mol Cell Biol, 14, 503-17. 
CALDERWOOD, D. A., FUJIOKA, Y., DE PEREDA, J. M., GARCIA-ALVAREZ, B., NAKAMOTO, 
T., MARGOLIS, B., MCGLADE, C. J., LIDDINGTON, R. C. & GINSBERG, M. H. 2003. 
Integrin beta cytoplasmic domain interactions with phosphotyrosine-binding 
domains: a structural prototype for diversity in integrin signaling. Proc Natl Acad Sci 
U S A, 100, 2272-7. 
CALVO, F. & SAHAI, E. 2011. Cell communication networks in cancer invasion. Curr Opin Cell 
Biol, 23, 621-9. 
CAMPBELL, I. D. & HUMPHRIES, M. J. 2011. Integrin structure, activation, and interactions. 
Cold Spring Harb Perspect Biol, 3. 
 
 385 
CANEL, M., SERRELS, A., FRAME, M. C. & BRUNTON, V. G. 2013. E-cadherin-integrin 
crosstalk in cancer invasion and metastasis. J Cell Sci, 126, 393-401. 
CAO, R., CHEN, J., ZHANG, X., ZHAI, Y., QING, X., XING, W., ZHANG, L., MALIK, Y. S., YU, H. 
& ZHU, X. 2014. Breast cancer: Crucial role of myosin X in aggressiveness and 
metastasis. Nat Rev Clin Oncol, 11, 441-441. 
CARAPUCA, E. F., GEMENETZIDIS, E., FEIG, C., BAPIRO, T. E., WILLIAMS, M. D., WILSON, A. 
S., DELVECCHIO, F. R., ARUMUGAM, P., GROSE, R. P., LEMOINE, N. R., RICHARDS, 
F. M. & KOCHER, H. M. 2016. Anti-stromal treatment together with chemotherapy 
targets multiple signalling pathways in pancreatic adenocarcinoma. J Pathol, 239, 
286-96. 
CARISEY, A., TSANG, R., GREINER, A. M., NIJENHUIS, N., HEATH, N., NAZGIEWICZ, A., 
KEMKEMER, R., DERBY, B., SPATZ, J. & BALLESTREM, C. 2013. Vinculin regulates the 
recruitment and release of core focal adhesion proteins in a force-dependent 
manner. Curr Biol, 23, 271-81. 
CARMAN, C. V. 2012. Integrin and Cell Adhesion Molecules: Methods and Protocols. In: 
SHIMAOKA, M. (ed.) Springer Protocols: Methods in Molecular Biology. New York: 
Harvard Press. 
CARPENTER, P. M., SIVADAS, P., HUA, S. S., XIAO, C., GUTIERREZ, A. B., NGO, T. & 
GERSHON, P. D. 2017. Migration of breast cancer cell lines in response to pulmonary 
laminin 332. Cancer Med, 6, 220-234. 
CASADO, P., RODRIGUEZ-PRADOS, J. C., COSULICH, S. C., GUICHARD, S., 
VANHAESEBROECK, B., JOEL, S. & CUTILLAS, P. R. 2013a. Kinase-substrate 
enrichment analysis provides insights into the heterogeneity of signaling pathway 
activation in leukemia cells. Sci Signal, 6, rs6. 
CASWELL, P. T., CHAN, M., LINDSAY, A. J., MCCAFFREY, M. W., BOETTIGER, D. & 
NORMAN, J. C. 2008. Rab-coupling protein coordinates recycling of alpha5beta1 
integrin and EGFR1 to promote cell migration in 3D microenvironments. J Cell Biol, 
183, 143-55. 
CASWELL, P. T. & NORMAN, J. C. 2006. Integrin trafficking and the control of cell migration. 
Traffic, 7, 14-21. 
CDC. 2016. Global Cancer Statistics: Numer of Cases, Deaths and Survivors [Online]. online: 
CDC. Available: http://www.cdc.gov/cancer/international/statistics.htm [Accessed 
12th September 2016]. 
CHAFFER, C. L. & WEINBERG, R. A. 2011. A perspective on cancer cell metastasis. Science, 
331, 1559-64. 
CHANGEDE, R. & SHEETZ, M. 2017. Integrin and cadherin clusters: A robust way to organize 
 
 386 
adhesions for cell mechanics. Bioessays, 39, 1-12. 
CHANGEDE, R., XU, X., MARGADANT, F. & SHEETZ, M. P. 2015. Nascent Integrin Adhesions 
Form on All Matrix Rigidities after Integrin Activation. Dev Cell, 35, 614-21. 
CHAVEZ, K. J., GARIMELLA, S. V. & LIPKOWITZ, S. 2010. Triple negative breast cancer cell 
lines: one tool in the search for better treatment of triple negative breast cancer. 
Breast Dis, 32, 35-48. 
CHEN, C. H., CHENG, C. T., YUAN, Y., ZHAI, J., ARIF, M., FONG, L. W., WU, R. & ANN, D. K. 
2015. Elevated MARCKS phosphorylation contributes to unresponsiveness of breast 
cancer to paclitaxel treatment. Oncotarget, 6, 15194-208. 
CHEN, J., SALAS, A. & SPRINGER, T. A. 2003. Bistable regulation of integrin adhesiveness by 
a bipolar metal ion cluster. Nat Struct Biol, 10, 995-1001. 
CHEN, P., LI, K., LIANG, Y., LI, L. & ZHU, X. 2013. High NUAK1 expression correlates with 
poor prognosis and involved in NSCLC cells migration and invasion. Exp Lung Res, 
39, 9-17. 
CHOWDHURY, F. Z., ESTRADA, L. D., MURRAY, S., FORMAN, J. & FARRAR, J. D. 2014. 
Pharmacological inhibition of TPL2/MAP3K8 blocks human cytotoxic T lymphocyte 
effector functions. PLoS One, 9, e92187. 
CHUNG, J., UCHIDA, E., GRAMMER, T. C. & BLENIS, J. 1997. STAT3 serine phosphorylation 
by ERK-dependent and -independent pathways negatively modulates its tyrosine 
phosphorylation. Mol Cell Biol, 17, 6508-16. 
CLARK, A. R. & TOKER, A. 2014. Signalling specificity in the Akt pathway in breast cancer. 
Biochem Soc Trans, 42, 1349-55. 
CLINE, M. S., SMOOT, M., CERAMI, E., KUCHINSKY, A., LANDYS, N., WORKMAN, C., 
CHRISTMAS, R., AVILA-CAMPILO, I., CREECH, M., GROSS, B., HANSPERS, K., 
ISSERLIN, R., KELLEY, R., KILLCOYNE, S., LOTIA, S., MAERE, S., MORRIS, J., ONO, 
K., PAVLOVIC, V., PICO, A. R., VAILAYA, A., WANG, P. L., ADLER, A., CONKLIN, B. R., 
HOOD, L., KUIPER, M., SANDER, C., SCHMULEVICH, I., SCHWIKOWSKI, B., 
WARNER, G. J., IDEKER, T. & BADER, G. D. 2007. Integration of biological networks 
and gene expression data using Cytoscape. Nat Protoc, 2, 2366-82. 
CLUZEL, C., SALTEL, F., LUSSI, J., PAULHE, F., IMHOF, B. A. & WEHRLE-HALLER, B. 2005. 
The mechanisms and dynamics of (alpha)v(beta)3 integrin clustering in living cells. J 
Cell Biol, 171, 383-92. 
COLEMAN, S. J., CHIONI, A. M., GHALLAB, M., ANDERSON, R. K., LEMOINE, N. R., 
KOCHER, H. M. & GROSE, R. P. 2014a. Nuclear translocation of FGFR1 and FGF2 in 




COLEMAN, S. J., WATT, J., ARUMUGAM, P., SOLAINI, L., CARAPUCA, E., GHALLAB, M., 
GROSE, R. P. & KOCHER, H. M. 2014b. Pancreatic cancer organotypics: High 
throughput, preclinical models for pharmacological agent evaluation. World J 
Gastroenterol, 20, 8471-81. 
CONNOLLY, D., YANG, Z., CASTALDI, M., SIMMONS, N., OKTAY, M. H., CONIGLIO, S., 
FAZZARI, M. J., VERDIER-PINARD, P. & MONTAGNA, C. 2011. Septin 9 isoform 
expression, localization and epigenetic changes during human and mouse breast 
cancer progression. Breast Cancer Res, 13, R76. 
CORGIAT, B. A., NORDMAN, J. C. & KABBANI, N. 2014. Chemical crosslinkers enhance 
detection of receptor interactomes. Front Pharmacol, 4, 171. 
CORNING®INC. 2016. Corning Matrigel®Matrix®: Overview [Online]. Available: 
https://www.corning.com/emea/en/products/life-
sciences/products/surfaces/matrigel-matrix.html [Accessed 30th March 2017]. 
COWLEY, M. J., PINESE, M., KASSAHN, K. S., WADDELL, N., PEARSON, J. V., GRIMMOND, 
S. M., BIANKIN, A. V., HAUTANIEMI, S. & WU, J. 2012. PINA v2.0: mining interactome 
modules. Nucleic Acids Res, 40, D862-5. 
CR-UK. 2014. Breast Cancer Risk Factors [Online]. Available: 
http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/breast/riskfactors/breast-cancer-risk-factors [Accessed 11th 
November 2014]. 
CR-UK. 2016. Breast Cancer Statistics [Online]. online: CR-UK. Available: 
http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-
cancer-type/breast-cancer/ [Accessed 12th September 2016]. 
CRAIG, D., GAO, M., SCHULTEN, K. & VOGEL, V. 2004. Structural insights into how the 
MIDAS ion stabilizes integrin binding to an RGD peptide under force. Structure, 12, 
2049-58. 
CRISCITIELLO, C., ESPOSITO, A. & CURIGLIANO, G. 2014. Tumor-stroma crosstalk: targeting 
stroma in breast cancer. Curr Opin Oncol, 26, 551-5. 
CRITCHLEY, D. R. 2009. Biochemical and structural properties of the integrin-associated 
cytoskeletal protein talin. Annu Rev Biophys, 38, 235-54. 
CROWE, D. L. & OHANNESSIAN, A. 2004. Recruitment of focal adhesion kinase and paxillin 
to beta1 integrin promotes cancer cell migration via mitogen activated protein kinase 
activation. BMC Cancer, 4, 18. 
CRT. 2013. Cell Lines: DX3 Melanoma [Online]. Available: 




CRUM, C., LESTER, S. & COTRAN, R. 2003. The female genital system and breast. Robbins 
Basic Pathology, 7, 679-717. 
CUMMINGS, M. C., SIMPSON, P. T., REID, L. E., JAYANTHAN, J., SKERMAN, J., SONG, S., 
MCCART REED, A. E., KUTASOVIC, J. R., MOREY, A. L., MARQUART, L., O'ROURKE, 
P. & LAKHANI, S. R. 2014. Metastatic progression of breast cancer: insights from 50 
years of autopsies. J Pathol, 232, 23-31. 
CUTILLAS, P. R. & VANHAESEBROECK, B. 2007. Quantitative profile of five murine core 
proteomes using label-free functional proteomics. Mol Cell Proteomics, 6, 1560-73. 
CUTTS, R. J., GUERRA-ASSUNCAO, J. A., GADALETA, E., DAYEM ULLAH, A. Z. & CHELALA, 
C. 2015. BCCTBbp: the Breast Cancer Campaign Tissue Bank bioinformatics portal. 
Nucleic Acids Res, 43, D831-6. 
CUZICK, J., SESTAK, I., PINDER, S. E., ELLIS, I. O., FORSYTH, S., BUNDRED, N. J., FORBES, J. 
F., BISHOP, H., FENTIMAN, I. S. & GEORGE, W. D. 2011. Effect of tamoxifen and 
radiotherapy in women with locally excised ductal carcinoma in situ: long-term results 
from the UK/ANZ DCIS trial. Lancet Oncol, 12, 21-9. 
DABBS, D. J. 2008. Immunohistochemical protocols: back to the future. Am J Clin Pathol, 129, 
355-6. 
DAI, X., XIANG, L., LI, T. & BAI, Z. 2016. Cancer Hallmarks, Biomarkers and Breast Cancer 
Molecular Subtypes. J Cancer, 7, 1281-94. 
DANEN, E. H. J. 2013. Integrins: An Overview of Structural and Functional Aspects. In: 
Madame Curie Bioscience Database [internet]. Austin (TX): Landes Bioscience. 
DAVIDENKO, N., SCHUSTER, C. F., BAX, D. V., FARNDALE, R. W., HAMAIA, S., BEST, S. M. & 
CAMERON, R. E. 2016. Evaluation of cell binding to collagen and gelatin: a study of 
the effect of 2D and 3D architecture and surface chemistry. Journal of Materials 
Science. Materials in Medicine, 27, 148. 
DAWSON, P. J., WOLMAN, S. R., TAIT, L., HEPPNER, G. H. & MILLER, F. R. 1996. MCF10AT: a 
model for the evolution of cancer from proliferative breast disease. Am J Pathol, 148, 
313-9. 
DAWSON, S. J., ROSENFELD, N. & CALDAS, C. 2013. Circulating tumor DNA to monitor 
metastatic breast cancer. N Engl J Med, 369, 93-4. 
DAY, E. S., OSBORN, L. & WHITTY, A. 2002. Effect of divalent cations on the affinity and 
selectivity of alpha4 integrins towards the integrin ligands vascular cell adhesion 
molecule-1 and mucosal addressin cell adhesion molecule-1: Ca2+ activation of 




DE HOOG, C. L., FOSTER, L. J. & MANN, M. 2004. RNA and RNA binding proteins 
participate in early stages of cell spreading through spreading initiation centers. Cell, 
117, 649-62. 
DE SERVI, B., HERMANI, A., MEDUNJANIN, S. & MAYER, D. 2005. Impact of PKCdelta on 
estrogen receptor localization and activity in breast cancer cells. Oncogene, 24, 4946-
55. 
DERYCKE, L., STOVE, C., VERCOUTTER-EDOUART, A. S., DE WEVER, O., DOLLE, L., 
COLPAERT, N., DEPYPERE, H., MICHALSKI, J. C. & BRACKE, M. 2011. The role of 
non-muscle myosin IIA in aggregation and invasion of human MCF-7 breast cancer 
cells. Int J Dev Biol, 55, 835-40. 
DESAI, A. 2011. The Ability of Rat Monoclonal Antibodies to Recognise Different 
Subpopulations of ανβ6. MSc Dissertation Queen Mary University of London. 
DESGROSELLIER, J. S. & CHERESH, D. A. 2010. Integrins in cancer: biological implications 
and therapeutic opportunities. Nat Rev Cancer, 10, 9-22. 
DIAZ, L. K., CRISTOFANILLI, M., ZHOU, X., WELCH, K. L., SMITH, T. L., YANG, Y., SNEIGE, N., 
SAHIN, A. A. & GILCREASE, M. Z. 2005. Beta4 integrin subunit gene expression 
correlates with tumor size and nuclear grade in early breast cancer. Mod Pathol, 18, 
1165-75. 
DICARA, D., RAPISARDA, C., SUTCLIFFE, J. L., VIOLETTE, S. M., WEINREB, P. H., HART, I. R., 
HOWARD, M. J. & MARSHALL, J. F. 2007. Structure-function analysis of Arg-Gly-Asp 
helix motifs in alpha v beta 6 integrin ligands. J Biol Chem, 282, 9657-65. 
DICARA, D. & SAHA, A. 2006. Screening cytoplasmic tail deficient recombinant integrin ανβ6 
variants derived from Weinacker et al (1994). Barts Cancer Institute. 
DIECI, M. V., ORVIETO, E., DOMINICI, M., CONTE, P. & GUARNERI, V. 2014. Rare breast 
cancer subtypes: histological, molecular, and clinical peculiarities. Oncologist, 19, 
805-13. 
DOBROVOLNY, P. L. & BESS, D. 2011. Optimized PCR-based Detection of Mycoplasma. 
Journal of Visualized Experiments : JoVE, 3057. 
DOMON, B. & AEBERSOLD, R. 2010. Options and considerations when selecting a 
quantitative proteomics strategy. Nat Biotechnol, 28, 710-21. 
DONG, X., HUDSON, N. E., LU, C. & SPRINGER, T. A. 2014. Structural determinants of 
integrin β-subunit specificity for latent TGF-β. Nature structural & molecular biology, 
21, 1091-1096. 
DOZYNKIEWICZ, M. A., JAMIESON, N. B., MACPHERSON, I., GRINDLAY, J., VAN DEN 
BERGHE, P. V., VON THUN, A., MORTON, J. P., GOURLEY, C., TIMPSON, P., 
 
 390 
NIXON, C., MCKAY, C. J., CARTER, R., STRACHAN, D., ANDERSON, K., SANSOM, 
O. J., CASWELL, P. T. & NORMAN, J. C. 2012. Rab25 and CLIC3 collaborate to 
promote integrin recycling from late endosomes/lysosomes and drive cancer 
progression. Dev Cell, 22, 131-45. 
DRANSFIELD, I., CABANAS, C., CRAIG, A. & HOGG, N. 1992. Divalent cation regulation of 
the function of the leukocyte integrin LFA-1. J Cell Biol, 116, 219-26. 
DRUGBANKV5.0. 2017. Gefitinib [Online]. Available: 
https://www.drugbank.ca/drugs/DB00317 [Accessed 22nd March 2017]. 
DU, J., ZU, Y., LI, J., DU, S., XU, Y., ZHANG, L., JIANG, L., WANG, Z., CHIEN, S. & YANG, C. 
2016. Extracellular matrix stiffness dictates Wnt expression through integrin pathway. 
6, 20395. 
DUFFY, M. J., MCGOWAN, P. M. & GALLAGHER, W. M. 2008. Cancer invasion and 
metastasis: changing views. J Pathol, 214, 283-93. 
DUNCAN, J. S., WHITTLE, M. C., NAKAMURA, K., ABELL, A. N., MIDLAND, A. A., 
ZAWISTOWSKI, J. S., JOHNSON, N. L., GRANGER, D. A., JORDAN, N. V., DARR, D. 
B., USARY, J., KUAN, P. F., SMALLEY, D. M., MAJOR, B., HE, X., HOADLEY, K. A., 
ZHOU, B., SHARPLESS, N. E., PEROU, C. M., KIM, W. Y., GOMEZ, S. M., CHEN, X., 
JIN, J., FRYE, S. V., EARP, H. S., GRAVES, L. M. & JOHNSON, G. L. 2012. Dynamic 
reprogramming of the kinome in response to targeted MEK inhibition in triple-
negative breast cancer. Cell, 149, 307-21. 
DUPERRET, E. K., DAHAL, A. & RIDKY, T. W. 2015. Focal-adhesion-independent integrin-αv 
regulation of FAK and c-Myc is necessary for 3D skin formation and tumor invasion. 
Journal of Cell Science, 128, 3997-4013. 
EBERLEIN, C., KENDREW, J., MCDAID, K., ALFRED, A., KANG, J. S., JACOBS, V. N., ROSS, S. 
J., ROONEY, C., SMITH, N. R., RINKENBERGER, J., CAO, A., CHURCHMAN, A., 
MARSHALL, J. F., WEIR, H. M., BEDIAN, V., BLAKEY, D. C., FOLTZ, I. N. & BARRY, S. 
T. 2013. A human monoclonal antibody 264RAD targeting alphavbeta6 integrin 
reduces tumour growth and metastasis, and modulates key biomarkers in vivo. 
Oncogene, 32, 4406-16. 
EBERLEIN, C., ROONEY, C., ROSS, S. J., FARREN, M., WEIR, H. M. & BARRY, S. T. 2015. E-
Cadherin and EpCAM expression by NSCLC tumour cells associate with normal 
fibroblast activation through a pathway initiated by integrin alphavbeta6 and 
maintained through TGFbeta signalling. Oncogene, 34, 704-16. 
EKE, I. & CORDES, N. 2015. Focal adhesion signaling and therapy resistance in cancer. Semin 
Cancer Biol, 31, 65-75. 
EKE, I., SCHNEIDER, L., FORSTER, C., ZIPS, D., KUNZ-SCHUGHART, L. A. & CORDES, N. 
2013a. EGFR/JIP-4/JNK2 signaling attenuates cetuximab-mediated radiosensitization 
 
 391 
of squamous cell carcinoma cells. Cancer Res, 73, 297-306. 
EKE, I., STORCH, K., KRAUSE, M. & CORDES, N. 2013b. Cetuximab attenuates its cytotoxic 
and radiosensitizing potential by inducing fibronectin biosynthesis. Cancer Res, 73, 
5869-79. 
ELAYADI, A. N., SAMLI, K. N., PRUDKIN, L., LIU, Y. H., BIAN, A., XIE, X. J., WISTUBA, II, 
ROTH, J. A., MCGUIRE, M. J. & BROWN, K. C. 2007. A peptide selected by 
biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for 
nonsmall cell lung cancer. Cancer Res, 67, 5889-95. 
ENGEBRAATEN, O., VOLLAN, H. K. & BORRESEN-DALE, A. L. 2013. Triple-negative breast 
cancer and the need for new therapeutic targets. Am J Pathol, 183, 1064-74. 
ERNSTER, V. L., BALLARD-BARBASH, R., BARLOW, W. E., ZHENG, Y., WEAVER, D. L., 
CUTTER, G., YANKASKAS, B. C., ROSENBERG, R., CARNEY, P. A., KERLIKOWSKE, K., 
TAPLIN, S. H., URBAN, N. & GELLER, B. M. 2002. Detection of ductal carcinoma in 
situ in women undergoing screening mammography. J Natl Cancer Inst, 94, 1546-54. 
EROLES, P., BOSCH, A., PEREZ-FIDALGO, J. A. & LLUCH, A. 2012. Molecular biology in 
breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev, 38, 698-
707. 
FAULL, R. J., WANG, J., LEAVESLEY, D. I., PUZON, W., RUSS, G. R., VESTWEBER, D. & 
TAKADA, Y. 1996. A novel activating anti-beta1 integrin monoclonal antibody binds 
to the cysteine-rich repeats in the beta1 chain. J Biol Chem, 271, 25099-106. 
FAZEKAS, D., KOLTAI, M., TUREI, D., MODOS, D., PALFY, M., DUL, Z., ZSAKAI, L., SZALAY-
BEKO, M., LENTI, K., FARKAS, I. J., VELLAI, T., CSERMELY, P. & KORCSMAROS, T. 
2013. SignaLink 2 - a signaling pathway resource with multi-layered regulatory 
networks. BMC Syst Biol, 7, 7. 
FELDING-HABERMANN, B. 2003. Integrin adhesion receptors in tumor metastasis. Clin Exp 
Metastasis, 20, 203-13. 
FELDING-HABERMANN, B., O'TOOLE, T. E., SMITH, J. W., FRANSVEA, E., RUGGERI, Z. M., 
GINSBERG, M. H., HUGHES, P. E., PAMPORI, N., SHATTIL, S. J., SAVEN, A. & 
MUELLER, B. M. 2001. Integrin activation controls metastasis in human breast cancer. 
Proc Natl Acad Sci U S A, 98, 1853-8. 
FIORE, M., FORLI, S. & MANETTI, F. 2015. Targeting Mitogen-Activated Protein Kinase-
Activated Protein Kinase 2 (MAPKAPK2, MK2): Medicinal Chemistry Efforts To Lead 
Small Molecule Inhibitors to Clinical Trials. Journal of Medicinal Chemistry. 
FOROZAN, F., VELDMAN, R., AMMERMAN, C. A., PARSA, N. Z., KALLIONIEMI, A., 
KALLIONIEMI, O. P. & ETHIER, S. P. 1999. Molecular cytogenetic analysis of 11 new 
breast cancer cell lines. Br J Cancer, 81, 1328-34. 
 
 392 
FREED, E., GAILIT, J., VAN DER GEER, P., RUOSLAHTI, E. & HUNTER, T. 1989. A novel 
integrin beta subunit is associated with the vitronectin receptor alpha subunit (alpha 
v) in a human osteosarcoma cell line and is a substrate for protein kinase C. Embo j, 
8, 2955-65. 
FRELINGER, A. L., 3RD, COHEN, I., PLOW, E. F., SMITH, M. A., ROBERTS, J., LAM, S. C. & 
GINSBERG, M. H. 1990. Selective inhibition of integrin function by antibodies specific 
for ligand-occupied receptor conformers. J Biol Chem, 265, 6346-52. 
FROELING, F. E., MIRZA, T. A., FEAKINS, R. M., SEEDHAR, A., ELIA, G., HART, I. R. & 
KOCHER, H. M. 2009. Organotypic culture model of pancreatic cancer demonstrates 
that stromal cells modulate E-cadherin, beta-catenin, and Ezrin expression in tumor 
cells. Am J Pathol, 175, 636-48. 
GARCIA-ALVAREZ, B., DE PEREDA, J. M., CALDERWOOD, D. A., ULMER, T. S., CRITCHLEY, 
D., CAMPBELL, I. D., GINSBERG, M. H. & LIDDINGTON, R. C. 2003. Structural 
determinants of integrin recognition by talin. Mol Cell, 11, 49-58. 
GILAD, R., MEIR, K., STEIN, I., GERMAN, L., PIKARSKY, E. & MABJEESH, N. J. 2015. High 
SEPT9_i1 protein expression is associated with high-grade prostate cancers. PLoS 
One, 10, e0124251. 
GINSBERG, M. H., FRELINGER, A. L., LAM, S. C., FORSYTH, J., MCMILLAN, R., PLOW, E. F. & 
SHATTIL, S. J. 1990. Analysis of platelet aggregation disorders based on flow 
cytometric analysis of membrane glycoprotein IIb-IIIa with conformation-specific 
monoclonal antibodies. Blood, 76, 2017-23. 
GKIRTZIMANAKI, K., GKOUSKOU, K. K., OLEKSIEWICZ, U., NIKOLAIDIS, G., VYRLA, D., 
LIONTOS, M., PELEKANOU, V., KANELLIS, D. C., EVANGELOU, K., 
STATHOPOULOS, E. N., FIELD, J. K., TSICHLIS, P. N., GORGOULIS, V., LILOGLOU, 
T. & ELIOPOULOS, A. G. 2013. TPL2 kinase is a suppressor of lung carcinogenesis. 
Proc Natl Acad Sci U S A, 110, E1470-9. 
GOMM, J. J., BROWNE, P. J., COOPE, R. C., LIU, Q. Y., BULUWELA, L. & COOMBES, R. C. 
1995. Isolation of pure populations of epithelial and myoepithelial cells from the 
normal human mammary gland using immunomagnetic separation with Dynabeads. 
Anal Biochem, 226, 91-9. 
GONCALVES, R., WARNER, W. A., LUO, J. & ELLIS, M. J. 2014. New concepts in breast 
cancer genomics and genetics. Breast Cancer Res, 16, 460. 
GRUOSSO, T., GARNIER, C., ABELANET, S., KIEFFER, Y., LEMESRE, V., BELLANGER, D., 
BIECHE, I., MARANGONI, E., SASTRE-GARAU, X., MIEULET, V. & MECHTA-
GRIGORIOU, F. 2015. MAP3K8/TPL-2/COT is a potential predictive marker for MEK 
inhibitor treatment in high-grade serous ovarian carcinomas. Nat Commun, 6, 8583. 
GUADAMILLAS, M. C., CEREZO, A. & DEL POZO, M. A. 2011. Overcoming anoikis--pathways 
 
 393 
to anchorage-independent growth in cancer. J Cell Sci, 124, 3189-97. 
GUDJONSSON, T., ADRIANCE, M. C., STERNLICHT, M. D., PETERSEN, O. W. & BISSELL, M. 
J. 2005. Myoepithelial cells: their origin and function in breast morphogenesis and 
neoplasia. J Mammary Gland Biol Neoplasia, 10, 261-72. 
GUMBINER, B. M. 1996. Cell adhesion: the molecular basis of tissue architecture and 
morphogenesis. Cell, 84, 345-57. 
GUO, W. & GIANCOTTI, F. G. 2004. Integrin signalling during tumour progression. Nat Rev 
Mol Cell Biol, 5, 816-26. 
HAHM, K., LUKASHEV, M. E., LUO, Y., YANG, W. J., DOLINSKI, B. M., WEINREB, P. H., 
SIMON, K. J., CHUN WANG, L., LEONE, D. R., LOBB, R. R., MCCRANN, D. J., 
ALLAIRE, N. E., HORAN, G. S., FOGO, A., KALLURI, R., SHIELD, C. F., SHEPPARD, D., 
GARDNER, H. A. & VIOLETTE, S. M. 2007. αvβ6 Integrin Regulates Renal Fibrosis and 
Inflammation in Alport Mouse. The American Journal of Pathology, 170, 110-125. 
HAHM, K., LUKASHEV, M. E., LUO, Y., YANG, W. J., DOLINSKI, B. M., WEINREB, P. H., 
SIMON, K. J., CHUN WANG, L., LEONE, D. R., LOBB, R. R., MCCRANN, D. J., 
ALLAIRE, N. E., HORAN, G. S., FOGO, A., KALLURI, R., SHIELD, C. F., 3RD, 
SHEPPARD, D., GARDNER, H. A. & VIOLETTE, S. M. 2007. Alphav beta6 integrin 
regulates renal fibrosis and inflammation in Alport mouse. Am J Pathol, 170, 110-25. 
HALE, J. S., LI, M. & LATHIA, J. D. 2012. The malignant social network: cell-cell adhesion and 
communication in cancer stem cells. Cell Adh Migr, 6, 346-55. 
HAMIDI, H., PIETILA, M. & IVASKA, J. 2016. The complexity of integrins in cancer and new 
scopes for therapeutic targeting. Br J Cancer, 115, 1017-1023. 
HAMILL, K. J., KLIGYS, K., HOPKINSON, S. B. & JONES, J. C. R. 2009. Laminin deposition in 
the extracellular matrix: a complex picture emerges. Journal of Cell Science, 122, 
4409-4417. 
HAMMER, A., RIDER, L., OLADIMEJI, P., COOK, L., LI, Q., MATTINGLY, R. R. & DIAKONOVA, 
M. 2013. Tyrosyl phosphorylated PAK1 regulates breast cancer cell motility in 
response to prolactin through filamin A. Mol Endocrinol, 27, 455-65. 
HANAHAN, D. & WEINBERG, R. A. 2000. The hallmarks of cancer. Cell, 100, 57-70. 
HANAHAN, D. & WEINBERG, R. A. 2011. Hallmarks of cancer: the next generation. Cell, 144, 
646-74. 




HAUSNER, S. H., DICARA, D., MARIK, J., MARSHALL, J. F. & SUTCLIFFE, J. L. 2007. Use of a 
peptide derived from foot-and-mouth disease virus for the noninvasive imaging of 
human cancer: generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in 
vivo imaging of integrin alphavbeta6 expression with positron emission tomography. 
Cancer Res, 67, 7833-40. 
HAVAKI, S., KOULOUKOUSSA, M., AMAWI, K., DROSOS, Y., ARVANITIS, L. D., GOUTAS, N., 
VLACHODIMITROPOULOS, D., VASSILAROS, S. D., KATSANTONI, E. Z., 
VOLOUDAKIS-BALTATZIS, I., ALEPOROU-MARINOU, V., KITTAS, C. & MARINOS, E. 
2007. Altered expression pattern of integrin alphavbeta3 correlates with actin 
cytoskeleton in primary cultures of human breast cancer. Cancer Cell Int, 7, 16. 
HAZELBAG, S., KENTER, G. G., GORTER, A., DREEF, E. J., KOOPMAN, L. A., VIOLETTE, S. 
M., WEINREB, P. H. & FLEUREN, G. J. 2007. Overexpression of the alpha v beta 6 
integrin in cervical squamous cell carcinoma is a prognostic factor for decreased 
survival. J Pathol, 212, 316-24. 
HEINO, J. 2000. The collagen receptor integrins have distinct ligand recognition and 
signaling functions. Matrix Biol, 19, 319-23. 
HEPPNER, G. H., MILLER, F. R. & SHEKHAR, P. M. 2000. Nontransgenic models of breast 
cancer. Breast Cancer Res, 2, 331-4. 
HEROLD, C. I. & ANDERS, C. K. 2013. New targets for triple-negative breast cancer. 
Oncology (Williston Park), 27, 846-54. 
HERZENBERG, L. A., PARKS, D., SAHAF, B., PEREZ, O., ROEDERER, M. & HERZENBERG, L. 
A. 2002. The history and future of the fluorescence activated cell sorter and flow 
cytometry: a view from Stanford. Clin Chem, 48, 1819-27. 
HIRATA, H., TATSUMI, H., LIM, C. T. & SOKABE, M. 2014. Force-dependent vinculin binding 
to talin in live cells: a crucial step in anchoring the actin cytoskeleton to focal 
adhesions. Am J Physiol Cell Physiol, 306, C607-20. 
HO-BOULDOIRES, T. H., CLAPERON, A., MERGEY, M., WENDUM, D., DESBOIS-MOUTHON, 
C., TAHRAOUI, S., FARTOUX, L., CHETTOUH, H., MERABTENE, F., SCATTON, O., 
GAESTEL, M., PRAZ, F., HOUSSET, C. & FOUASSIER, L. 2015. Mitogen-activated 
protein kinase-activated protein kinase 2 mediates resistance to hydrogen peroxide-
induced oxidative stress in human hepatobiliary cancer cells. Free Radic Biol Med. 
HOLLESTELLE, A., ELSTRODT, F., NAGEL, J. H., KALLEMEIJN, W. W. & SCHUTTE, M. 2007. 
Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer 
cell lines. Mol Cancer Res, 5, 195-201. 
HONG, B., LI, H., ZHANG, M., XU, J., LU, Y., ZHENG, Y., QIAN, J., CHANG, J. T., YANG, J. & 
YI, Q. 2015. p38 MAPK inhibits breast cancer metastasis through regulation of stromal 
expansion. Int J Cancer, 136, 34-43. 
 
 395 
HOOD, J. D. & CHERESH, D. A. 2002. Role of integrins in cell invasion and migration. Nat Rev 
Cancer, 2, 91-100. 
HOOPMANN, M. R., MERRIHEW, G. E., VON HALLER, P. D. & MACCOSS, M. J. 2009. Post 
analysis data acquisition for the iterative MS/MS sampling of proteomics mixtures. J 
Proteome Res, 8, 1870-5. 
HOPKINS, C. R. & TROWBRIDGE, I. S. 1983. Internalization and processing of transferrin and 
the transferrin receptor in human carcinoma A431 cells. J Cell Biol, 97, 508-21. 
HSIAO, Y. H., CHOU, M. C., FOWLER, C., MASON, J. T. & MAN, Y. G. 2010. Breast cancer 
heterogeneity: mechanisms, proofs, and implications. J Cancer, 1, 6-13. 
HTA. 2004. Human Tissue Act [Online]. Available: 
http://www.legislation.gov.uk/ukpga/2004/30/contents [Accessed 15th October 
2014]. 
HU, M., YAO, J., CARROLL, D. K., WEREMOWICZ, S., CHEN, H., CARRASCO, D., 
RICHARDSON, A., VIOLETTE, S., NIKOLSKAYA, T., NIKOLSKY, Y., BAUERLEIN, E. L., 
HAHN, W. C., GELMAN, R. S., ALLRED, C., BISSELL, M. J., SCHNITT, S. & POLYAK, K. 
2008. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell, 13, 
394-406. 
HUANG, X., LV, W., ZHANG, J. H. & LU, D. L. 2014. miR96 functions as a tumor suppressor 
gene by targeting NUAK1 in pancreatic cancer. Int J Mol Med, 34, 1599-605. 
HUGHES, P. E., DIAZ-GONZALEZ, F., LEONG, L., WU, C., MCDONALD, J. A., SHATTIL, S. J. 
& GINSBERG, M. H. 1996. Breaking the integrin hinge. A defined structural constraint 
regulates integrin signaling. J Biol Chem, 271, 6571-4. 
HUMPHRIES, J. D., BYRON, A., BASS, M. D., CRAIG, S. E., PINNEY, J. W., KNIGHT, D. & 
HUMPHRIES, M. J. 2009. Proteomic analysis of integrin-associated complexes 
identifies RCC2 as a dual regulator of Rac1 and Arf6. Sci Signal, 2, ra51. 
HUMPHRIES, J. D., WANG, P., STREULI, C., GEIGER, B., HUMPHRIES, M. J. & BALLESTREM, 
C. 2007. Vinculin controls focal adhesion formation by direct interactions with talin 
and actin. The Journal of Cell Biology, 179, 1043-1057. 
HUMPHRIES, M. J. 1996. Integrin activation: the link between ligand binding and signal 
transduction. Curr Opin Cell Biol, 8, 632-40. 
HUMPHRIES, M. J. 2002. Insights into integrin-ligand binding and activation from the first 
crystal structure. Arthritis Res, 4 Suppl 3, S69-78. 
HUMPHRIES, M. J. 2004. Monoclonal antibodies as probes of integrin priming and activation. 
Biochem Soc Trans, 32, 407-11. 
 
 396 
HUMPHRIES, M. J., MCEWAN, P. A., BARTON, S. J., BUCKLEY, P. A., BELLA, J. & MOULD, A. 
P. 2003. Integrin structure: heady advances in ligand binding, but activation still 
makes the knees wobble. Trends Biochem Sci, 28, 313-20. 
HUMPHRIES, M. J., SYMONDS, E. J. & MOULD, A. P. 2003. Mapping functional residues onto 
integrin crystal structures. Curr Opin Struct Biol, 13, 236-43. 
HURST, D. R. & WELCH, D. R. 2011. Metastasis suppressor genes at the interface between the 
environment and tumor cell growth. Int Rev Cell Mol Biol, 286, 107-80. 
HUTTENLOCHER, A. & HORWITZ, A. R. 2011. Integrins in cell migration. Cold Spring Harb 
Perspect Biol, 3, a005074. 
HYNES, R. O. 2002. Integrins: bidirectional, allosteric signaling machines. Cell, 110, 673-87. 
HYNES, R. O. & NABA, A. 2012. Overview of the matrisome--an inventory of extracellular 
matrix constituents and functions. Cold Spring Harb Perspect Biol, 4, a004903. 
IMPOLA, U., UITTO, V. J., HIETANEN, J., HAKKINEN, L., ZHANG, L., LARJAVA, H., ISAKA, K. 
& SAARIALHO-KERE, U. 2004. Differential expression of matrilysin-1 (MMP-7), 92 kD 
gelatinase (MMP-9), and metalloelastase (MMP-12) in oral verrucous and squamous 
cell cancer. J Pathol, 202, 14-22. 
INGTHORSSON, S., SIGURDSSON, V., FRIDRIKSDOTTIR, A., JR., JONASSON, J. G., 
KJARTANSSON, J., MAGNUSSON, M. K. & GUDJONSSON, T. 2010. Endothelial 
cells stimulate growth of normal and cancerous breast epithelial cells in 3D culture. 
BMC Res Notes, 3, 184. 
IORIO, V., TROUGHTON, L. D. & HAMILL, K. J. 2015. Laminins: Roles and Utility in Wound 
Repair. Advances in Wound Care, 4, 250-263. 
ISKRATSCH, T., YU, C. H., MATHUR, A., LIU, S., STEVENIN, V., DWYER, J., HONE, J., EHLER, 
E. & SHEETZ, M. 2013. FHOD1 is needed for directed forces and adhesion 
maturation during cell spreading and migration. Dev Cell, 27, 545-59. 
IVASKA, J. & HEINO, J. 2010. Interplay between cell adhesion and growth factor receptors: 
from the plasma membrane to the endosomes. Cell Tissue Res, 339, 111-20. 
IVASKA, J. & HEINO, J. 2011. Cooperation between integrins and growth factor receptors in 
signaling and endocytosis. Annu Rev Cell Dev Biol, 27, 291-320. 
JACKSON, T., SHEPPARD, D., DENYER, M., BLAKEMORE, W. & KING, A. M. 2000. The 
epithelial integrin alphavbeta6 is a receptor for foot-and-mouth disease virus. J Virol, 
74, 4949-56. 
JACQUEMET, G., MORGAN, M. R., BYRON, A., HUMPHRIES, J. D., CHOI, C. K., CHEN, C. S., 
 
 397 
CASWELL, P. T. & HUMPHRIES, M. J. 2013. Rac1 is deactivated at integrin activation 
sites through an IQGAP1-filamin-A-RacGAP1 pathway. J Cell Sci, 126, 4121-35. 
JANES, S. M. & WATT, F. M. 2004. Switch from αvβ5 to αvβ6 integrin expression protects 
squamous cell carcinomas from anoikis. The Journal of Cell Biology, 166, 419-431. 
JEMAL, A., BRAY, F., CENTER, M. M., FERLAY, J., WARD, E. & FORMAN, D. 2011. Global 
cancer statistics. CA Cancer J Clin, 61, 69-90. 
JIANG, X., SHA, X., XIN, H., XU, X., GU, J., XIA, W., CHEN, S., XIE, Y., CHEN, L., CHEN, Y. & 
FANG, X. 2013. Integrin-facilitated transcytosis for enhanced penetration of advanced 
gliomas by poly(trimethylene carbonate)-based nanoparticles encapsulating 
paclitaxel. Biomaterials, 34, 2969-79. 
JIN, H. & VARNER, J. 2004. Integrins: roles in cancer development and as treatment targets. 
Br J Cancer, 90, 561-5. 
JOHANNESSEN, C. M., BOEHM, J. S., KIM, S. Y., THOMAS, S. R., WARDWELL, L., 
JOHNSON, L. A., EMERY, C. M., STRANSKY, N., COGDILL, A. P., BARRETINA, J., 
CAPONIGRO, G., HIERONYMUS, H., MURRAY, R. R., SALEHI-ASHTIANI, K., HILL, D. 
E., VIDAL, M., ZHAO, J. J., YANG, X., ALKAN, O., KIM, S., HARRIS, J. L., WILSON, C. 
J., MYER, V. E., FINAN, P. M., ROOT, D. E., ROBERTS, T. M., GOLUB, T., FLAHERTY, 
K. T., DUMMER, R., WEBER, B. L., SELLERS, W. R., SCHLEGEL, R., WARGO, J. A., 
HAHN, W. C. & GARRAWAY, L. A. 2010. COT drives resistance to RAF inhibition 
through MAP kinase pathway reactivation. Nature, 468, 968-72. 
JOKINEN, J., DADU, E., NYKVIST, P., KAPYLA, J., WHITE, D. J., IVASKA, J., VEHVILAINEN, P., 
REUNANEN, H., LARJAVA, H., HAKKINEN, L. & HEINO, J. 2004. Integrin-mediated 
cell adhesion to type I collagen fibrils. J Biol Chem, 279, 31956-63. 
JONES, A. V., LAMBERT, D. W., SPEIGHT, P. M. & WHAWELL, S. A. 2013. ADAM 10 is over 
expressed in oral squamous cell carcinoma and contributes to invasive behaviour 
through a functional association with alphavbeta6 integrin. FEBS Lett, 587, 3529-34. 
KADABA, R., BIRKE, H., WANG, J., HOOPER, S., ANDL, C. D., DI MAGGIO, F., SOYLU, E., 
GHALLAB, M., BOR, D., FROELING, F. E., BHATTACHARYA, S., RUSTGI, A. K., 
SAHAI, E., CHELALA, C., SASIENI, P. & KOCHER, H. M. 2013. Imbalance of 
desmoplastic stromal cell numbers drives aggressive cancer processes. J Pathol, 230, 
107-17. 
KADOTA, M., YANG, H., GOMEZ, B., SATO, M. & CLIFFORD RJ, E. A. 2010. Delineating 
Genetic Alterations for Tumor Progression in the MCF10A Series of Breast Cancer 
Cell Lines. PLOS ONE, 5. 
KAMATA, T., PUZON, W. & TAKADA, Y. 1994. Identification of putative ligand binding sites 




KANCHANAWONG, P., SHTENGEL, G., PASAPERA, A. M., RAMKO, E. B., DAVIDSON, M. 
W., HESS, H. F. & WATERMAN, C. M. 2010. Nanoscale architecture of integrin-based 
cell adhesions. Nature, 468, 580-584. 
KANE, L. P., MOLLENAUER, M. N., XU, Z., TURCK, C. W. & WEISS, A. 2002. Akt-dependent 
phosphorylation specifically regulates Cot induction of NF-kappa B-dependent 
transcription. Mol Cell Biol, 22, 5962-74. 
KAO, J., SALARI, K., BOCANEGRA, M., CHOI, Y. L., GIRARD, L., GANDHI, J., KWEI, K. A., 
HERNANDEZ-BOUSSARD, T., WANG, P., GAZDAR, A. F., MINNA, J. D. & POLLACK, 
J. R. 2009. Molecular profiling of breast cancer cell lines defines relevant tumor 
models and provides a resource for cancer gene discovery. PLoS One, 4, e6146. 
KAPP, T. G., RECHENMACHER, F., NEUBAUER, S., MALTSEV, O. V., CAVALCANTI-ADAM, E. 
A., ZARKA, R., REUNING, U., NOTNI, J., WESTER, H. J., MAS-MORUNO, C., SPATZ, 
J., GEIGER, B. & KESSLER, H. 2017. A Comprehensive Evaluation of the Activity and 
Selectivity Profile of Ligands for RGD-binding Integrins. Sci Rep, 7, 39805. 
KATONO, K., SATO, Y., JIANG, S. X., KOBAYASHI, M., NAGASHIO, R., RYUGE, S., FUKUDA, 
E., GOSHIMA, N., SATOH, Y., SAEGUSA, M. & MASUDA, N. 2015. Prognostic 
significance of MYH9 expression in resected non-small cell lung cancer. PLoS One, 
10, e0121460. 
KENNY, P. A., LEE, G. Y., MYERS, C. A., NEVE, R. M., SEMEIKS, J. R., SPELLMAN, P. T., 
LORENZ, K., LEE, E. H., BARCELLOS-HOFF, M. H., PETERSEN, O. W., GRAY, J. W. & 
BISSELL, M. J. 2007. The morphologies of breast cancer cell lines in three-
dimensional assays correlate with their profiles of gene expression. Mol Oncol, 1, 84-
96. 
KHAN, Z. & MARSHALL, J. F. 2016. The role of integrins in TGFbeta activation in the tumour 
stroma. Cell Tissue Res, 365, 657-73. 
KIBBEY, M. C. 1994. Maintenance of the EHS sarcoma and Matrigel preparation. Journal of 
tissue culture methods, 16, 227-230. 
KIM, B. G., GAO, M.-Q., CHOI, Y. P., KANG, S., PARK, H. R., KANG, K. S. & CHO, N. H. 2012. 
Invasive breast cancer induces laminin-332 upregulation and integrin β4 
neoexpression in myofibroblasts to confer an anoikis-resistant phenotype during 
tissue remodeling. Breast Cancer Research : BCR, 14, R88-R88. 
KIM, C., YE, F. & GINSBERG, M. H. 2011b. Regulation of integrin activation. Annu Rev Cell 
Dev Biol, 27, 321-45. 
KIM, C., YE, F., HU, X. & GINSBERG, M. H. 2012. Talin activates integrins by altering the 
topology of the beta transmembrane domain. J Cell Biol, 197, 605-11. 
KIM, G., KHANAL, P., KIM, J. Y., YUN, H. J., LIM, S. C., SHIM, J. H. & CHOI, H. S. 2015. COT 
 
 399 
phosphorylates prolyl-isomerase Pin1 to promote tumorigenesis in breast cancer. 
Mol Carcinog, 54, 440-8. 
KIM, S. H., TURNBULL, J. & GUIMOND, S. 2011a. Extracellular matrix and cell signalling: the 
dynamic cooperation of integrin, proteoglycan and growth factor receptor. J 
Endocrinol, 209, 139-51. 
KIRK, R. I., SANDERSON, M. R. & LEREA, K. M. 2000. Threonine phosphorylation of the beta 3 
integrin cytoplasmic tail, at a site recognized by PDK1 and Akt/PKB in vitro, regulates 
Shc binding. J Biol Chem, 275, 30901-6. 
KIRKEGAARD, T., WITTON, C. J., MCGLYNN, L. M., TOVEY, S. M., DUNNE, B., LYON, A. & 
BARTLETT, J. M. 2005. AKT activation predicts outcome in breast cancer patients 
treated with tamoxifen. J Pathol, 207, 139-46. 
KITO, K. & ITO, T. 2008. Mass spectrometry-based approaches toward absolute quantitative 
proteomics. Curr Genomics, 9, 263-74. 
KNUEFERMANN, C., LU, Y., LIU, B., JIN, W., LIANG, K., WU, L., SCHMIDT, M., MILLS, G. B., 
MENDELSOHN, J. & FAN, Z. 2003. HER2/PI-3K/Akt activation leads to a multidrug 
resistance in human breast adenocarcinoma cells. Oncogene, 22, 3205-12. 
KOGELBERG, H., TOLNER, B., THOMAS, G. J., DI CARA, D., MINOGUE, S., RAMESH, B., 
SODHA, S., MARSH, D., LOWDELL, M. W., MEYER, T., BEGENT, R. H. J., HART, I., 
MARSHALL, J. F. & CHESTER, K. 2008. Engineering a Single Chain Fv Antibody to 
αvβ6 Integrin using the Specificity-Determining Loop of a Foot-and-Mouth Disease 
Virus. Journal of molecular biology, 382, 385-401. 
KOPPER, F., BINKOWSKI, A. M., BIERWIRTH, C. & DOBBELSTEIN, M. 2014. The MAPK-
activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells. 
Cell Cycle, 13, 884-9. 
KOVALA, T. & POULIN, J. 2009. ERK Inhibition by SU1498 Alters Expression of Bcl-2 Family 
Proteins in Breast Cancer Cells. The FASEB Journal, 23, 526.18. 
KURIEN, B. T. & SCOFIELD, R. H. 2006. Western blotting. Methods, 38, 283-293. 
LAKHANI, S. R., ELLIS, I. O., SCHNITT, S. J., TAN, P. H. & VAN DE VIJVER, M. J. 2012. WHO 
Classification of Tumours of the Breast USA, IACR / WHO. 
LAKHTAKIA, R. & CHINOY, R. F. 2014. A Brief History of Breast Cancer: Part II - Evolution of 
surgical pathology. Sultan Qaboos Univ Med J, 14, e319-22. 
LAMBERT, A. W., OZTURK, S. & THIAGALINGAM, S. 2012. Integrin Signaling in Mammary 
Epithelial Cells and Breast Cancer. ISRN Oncology, 2012, 493283. 
 
 400 
LARJAVA, H., KOIVISTO, L., HEINO, J. & HAKKINEN, L. 2014. Integrins in periodontal 
disease. Exp Cell Res, 325, 104-10. 
LARSEN, M. J., THOMASSEN, M., GERDES, A. M. & KRUSE, T. A. 2014. Hereditary breast 
cancer: clinical, pathological and molecular characteristics. Breast Cancer (Auckl), 8, 
145-55. 
LASFARGUES, E. Y., COUTINHO, W. G. & REDFIELD, E. S. 1978. Isolation of two human 
tumor epithelial cell lines from solid breast carcinomas. J Natl Cancer Inst, 61, 967-78. 
LASFARGUES, E. Y. & OZZELLO, L. 1958. Cultivation of human breast carcinomas. J Natl 
Cancer Inst, 21, 1131-47. 
LAUBY-SECRETAN, B., SCOCCIANTI, C., LOOMIS, D., GROSSE, Y., BIANCHINI, F. & STRAIF, 
K. 2016. Body Fatness and Cancer--Viewpoint of the IARC Working Group. N Engl J 
Med, 375, 794-8. 
LAWRENCE, R. T., PEREZ, E. M., HERNANDEZ, D., MILLER, C. P., HAAS, K. M., IRIE, H. Y., 
LEE, S. I., BLAU, C. A. & VILLEN, J. 2015. The proteomic landscape of triple-negative 
breast cancer. Cell Rep, 11, 630-44. 
LEE, H. W., CHOI, H. Y., JOO, K. M. & NAM, D. H. 2015. Tumor progression locus 2 (Tpl2) 
kinase as a novel therapeutic target for cancer: double-sided effects of Tpl2 on 
cancer. Int J Mol Sci, 16, 4471-91. 
LEE, Y. C., JIN, J. K., CHENG, C. J., HUANG, C. F., SONG, J. H., HUANG, M., BROWN, W. S., 
ZHANG, S., YU-LEE, L. Y., YEH, E. T., MCINTYRE, B. W., LOGOTHETIS, C. J., 
GALLICK, G. E. & LIN, S. H. 2013. Targeting constitutively activated beta1 integrins 
inhibits prostate cancer metastasis. Mol Cancer Res, 11, 405-17. 
LEGATE, K. R. & FASSLER, R. 2009. Mechanisms that regulate adaptor binding to beta-
integrin cytoplasmic tails. J Cell Sci, 122, 187-98. 
LEITINGER, B. 2011. Transmembrane collagen receptors. Annu Rev Cell Dev Biol, 27, 265-90. 
LEITINGER, B., MCDOWALL, A., STANLEY, P. & HOGG, N. 2000. The regulation of integrin 
function by Ca2+. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 
1498, 91-98. 
LENNON, R., BYRON, A., HUMPHRIES, J. D., RANDLES, M. J., CARISEY, A., MURPHY, S., 
KNIGHT, D., BRENCHLEY, P. E., ZENT, R. & HUMPHRIES, M. J. 2014. Global analysis 
reveals the complexity of the human glomerular extracellular matrix. J Am Soc 
Nephrol, 25, 939-51. 
LEONOUDAKIS, D., HUANG, G., AKHAVAN, A., FATA, J. E., SINGH, M., GRAY, J. W. & 
MUSCHLER, J. L. 2014. Endocytic trafficking of laminin is controlled by dystroglycan 
and is disrupted in cancers. J Cell Sci, 127, 4894-903. 
 
 401 
LEREA, K. M., CORDERO, K. P., SAKARIASSEN, K. S., KIRK, R. I. & FRIED, V. A. 1999. 
Phosphorylation sites in the integrin beta3 cytoplasmic domain in intact platelets. J 
Biol Chem, 274, 1914-9. 
LESNIAK, D., XU, Y., DESCHENES, J., LAI, R., THOMS, J., MURRAY, D., GOSH, S., MACKEY, 
J. R., SABRI, S. & ABDULKARIM, B. 2009. Beta1-integrin circumvents the 
antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-
positive breast cancer. Cancer Res, 69, 8620-8. 
LESURF, R., AURE, M. R., MORK, H. H., VITELLI, V., LUNDGREN, S., BORRESEN-DALE, A. L., 
KRISTENSEN, V., WARNBERG, F., HALLETT, M. & SORLIE, T. 2016. Molecular 
Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive 
Breast Cancer. Cell Rep, 16, 1166-79. 
LEY, K., RIVERA-NIEVES, J., SANDBORN, W. J. & SHATTIL, S. 2016. Integrin-based 
therapeutics: biological basis, clinical use and new drugs. Nat Rev Drug Discov, 15, 
173-83. 
LGC©STANDARDS 2011. Cell Line Authentication Report (Ref: 710081047). 
LI, N. F., GEMENETZIDIS, E., MARSHALL, F. J., DAVIES, D., YU, Y., FRESE, K., FROELING, F. 
E., WOOLF, A. K., FEAKINS, R. M., NAITO, Y., IACOBUZIO-DONAHUE, C., 
TUVESON, D. A., HART, I. R. & KOCHER, H. M. 2013. RhoC interacts with integrin 
alpha5beta1 and enhances its trafficking in migrating pancreatic carcinoma cells. 
PLoS One, 8, e81575. 
LI, Y., MELNIKOV, A. A., LEVENSON, V., GUERRA, E., SIMEONE, P., ALBERTI, S. & DENG, Y. 
2015. A seven-gene CpG-island methylation panel predicts breast cancer 
progression. BMC Cancer, 15, 417. 
LI, Y.-R. & YANG, W.-X. 2016. Myosins as fundamental components during tumorigenesis: 
diverse and indispensable. Oncotarget, 7, 46785-46812. 
LIDDINGTON, R. C. & GINSBERG, M. H. 2002. Integrin activation takes shape. J Cell Biol, 
158, 833-9. 
LIU, H., SADYGOV, R. G. & YATES, J. R., 3RD 2004. A model for random sampling and 
estimation of relative protein abundance in shotgun proteomics. Anal Chem, 76, 
4193-201. 
LIU, R., ZHANG, Z., LANG, Y., TANG, Z., PENG, Z., CAI, X., FU, X., FANG, W. & LI, L. 2017. 
High-level expression of MYH9 predicts poor prognosis in patients with colon cancer. 
Int J Clin Exp Pathol, 10, 5498-5505. 
LONNE, G. K., MASOUMI, K. C., LENNARTSSON, J. & LARSSON, C. 2009. Protein kinase 
Cdelta supports survival of MDA-MB-231 breast cancer cells by suppressing the 
ERK1/2 pathway. J Biol Chem, 284, 33456-65. 
 
 402 
LU, P., WEAVER, V. M. & WERB, Z. 2012. The extracellular matrix: a dynamic niche in cancer 
progression. J Cell Biol, 196, 395-406. 
LU, S., SIMIN, K., KHAN, A. & MERCURIO, A. M. 2008. Analysis of integrin beta4 expression in 
human breast cancer: association with basal-like tumors and prognostic significance. 
Clin Cancer Res, 14, 1050-8. 
LUCIANO, B. S., HSU, S., CHANNAVAJHALA, P. L., LIN, L. L. & CUOZZO, J. W. 2004. 
Phosphorylation of threonine 290 in the activation loop of Tpl2/Cot is necessary but 
not sufficient for kinase activity. J Biol Chem, 279, 52117-23. 
LUO, B. H., CARMAN, C. V. & SPRINGER, T. A. 2007. Structural basis of integrin regulation 
and signaling. Annu Rev Immunol, 25, 619-47. 
MADAMANCHI, A., ZIJLSTRA, A. & ZUTTER, M. M. 2014. Flipping the switch: integrin 
switching provides metastatic competence. Sci Signal, 7, pe9. 
MAHMOOD, T. & YANG, P. C. 2012. Western blot: technique, theory, and trouble shooting. 
N Am J Med Sci, 4, 429-34. 
MAIELLO, M. R., AMELIA, D., BEVILACQUA, S., GALLO, M., NORMANNO, N. & DE LUCA, A. 
2015. EGFR and MEK Blockade in Triple Negative Breast Cancer Cells. J Cell 
Biochem. 
MAKKI, J. 2015. Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance. 
Clinical Medicine Insights. Pathology, 8, 23-31. 
MALLER, O., MARTINSON, H. & SCHEDIN, P. 2010. Extracellular matrix composition reveals 
complex and dynamic stromal-epithelial interactions in the mammary gland. J 
Mammary Gland Biol Neoplasia, 15, 301-18. 
MAN, Y. K., DICARA, D., CHAN, N., VESSILLIER, S., MATHER, S. J., ROWE, M. L., HOWARD, 
M. J., MARSHALL, J. F. & NISSIM, A. 2013. Structural guided scaffold phage display 
libraries as a source of bio-therapeutics. PLoS One, 8, e70452. 
MANAI, M., THOMASSIN-PIANA, J., GAMOUDI, A., FINETTI, P., LOPEZ, M., EGHOZZI, R., 
AYADI, S., LAMINE, O. B., MANAI, M., RAHAL, K., CHARAFE-JAUFFRET, E., 
JACQUEMIER, J., VIENS, P., BIRNBAUM, D., BOUSSEN, H., CHAFFANET, M. & 
BERTUCCI, F. 2017. MARCKS protein overexpression in inflammatory breast cancer. 
Oncotarget, 8, 6246-6257. 
MARGADANT, C., MONSUUR, H. N., NORMAN, J. C. & SONNENBERG, A. 2011. 
Mechanisms of integrin activation and trafficking. Curr Opin Cell Biol, 23, 607-14. 
MARGADANT, C. & SONNENBERG, A. 2010. Integrin-TGF-beta crosstalk in fibrosis, cancer 
and wound healing. EMBO Rep, 11, 97-105. 
 
 403 
MARSH, D., DICKINSON, S., NEILL, G. W., MARSHALL, J. F., HART, I. R. & THOMAS, G. J. 
2008. alpha vbeta 6 Integrin promotes the invasion of morphoeic basal cell carcinoma 
through stromal modulation. Cancer Res, 68, 3295-303. 
MAURO, L. V., GROSSONI, V. C., URTREGER, A. J., YANG, C., COLOMBO, L. L., MORANDI, 
A., PALLOTTA, M. G., KAZANIETZ, M. G., BAL DE KIER JOFFE, E. D. & PURICELLI, L. 
L. 2010. PKC Delta (PKCdelta) promotes tumoral progression of human ductal 
pancreatic cancer. Pancreas, 39, e31-41. 
MCALISTER, D. 1879. The Law of the Geometric Mean. Proc. R. Soc. Lond., 29, 367 - 376. 
MCCLOY, R. A., ROGERS, S., CALDON, C. E., LORCA, T., CASTRO, A. & BURGESS, A. 2014. 
Partial inhibition of Cdk1 in G 2 phase overrides the SAC and decouples mitotic 
events. Cell Cycle, 13, 1400-12. 
MELAN, M. A. 1995. Overview of Cell Fixation and Permeabilization. In: JAVOIS, L. C. (ed.) 
Immunocytochemical Methods and Protocols. Totowa, NJ: Humana Press. 
MICHISHITA, M., VIDEM, V. & ARNAOUT, M. A. 1993. A novel divalent cation-binding site in 
the A domain of the beta 2 integrin CR3 (CD11b/CD18) is essential for ligand 
binding. Cell, 72, 857-67. 
MILLARD, M., ODDE, S. & NEAMATI, N. 2011. Integrin targeted therapeutics. Theranostics, 1, 
154-88. 
MILLER, F. R., SANTNER, S. J., TAIT, L. & DAWSON, P. J. 2000. MCF10DCIS.com xenograft 
model of human comedo ductal carcinoma in situ. J Natl Cancer Inst, 92, 1185-6. 
MILLER, L. 2010. ImageJ Gel Analysis [Online]. Available: 
http://www.lukemiller.org/ImageJ_gel_analysis.pdf [Accessed 17th March 2017 2017]. 
MOLITOR, T. P. & TRAKTMAN, P. 2013. Molecular genetic analysis of VRK1 in mammary 
epithelial cells: depletion slows proliferation in vitro and tumor growth and metastasis 
in vivo. Oncogenesis, 2, e48. 
MOLLENHAUER, J., HELMKE, B., MULLER, H., KOLLENDER, G., KREBS, I., WIEMANN, S., 
HOLMSKOV, U., MADSEN, J., OTTO, H. F. & POUSTKA, A. 2002. An integrative 
model on the role of DMBT1 in epithelial cancer. Cancer Detect Prev, 26, 266-74. 
MOLLENHAUER, J., HELMKE, B., MULLER, H., KOLLENDER, G., LYER, S., DIEDRICHS, L., 
HOLMSKOV, U., LIGTENBERG, T., HERBERTZ, S., KREBS, I., WIEMANN, S., 
MADSEN, J., BIKKER, F., SCHMITT, L., OTTO, H. F. & POUSTKA, A. 2002. Sequential 
changes of the DMBT1 expression and location in normal lung tissue and lung 
carcinomas. Genes Chromosomes Cancer, 35, 164-9. 
MONAGHAN, P., GOLD, S., SIMPSON, J., ZHANG, Z., WEINREB, P. H., VIOLETTE, S. M., 
ALEXANDERSEN, S. & JACKSON, T. 2005. The alpha(v)beta6 integrin receptor for 
 
 404 
Foot-and-mouth disease virus is expressed constitutively on the epithelial cells 
targeted in cattle. J Gen Virol, 86, 2769-80. 
MONSMA, D. J., CHERBA, D. M., EUGSTER, E. E., DYLEWSKI, D. L., DAVIDSON, P. T., 
PETERSON, C. A., BORGMAN, A. S., WINN, M. E., DYKEMA, K. J., WEBB, C. P., 
MACKEIGAN, J. P., DUESBERY, N. S., NICKOLOFF, B. J. & MONKS, N. R. 2015. 
Melanoma patient derived xenografts acquire distinct Vemurafenib resistance 
mechanisms. Am J Cancer Res, 5, 1507-18. 
MONTANEZ, E., USSAR, S., SCHIFFERER, M., BOSL, M., ZENT, R., MOSER, M. & FASSLER, R. 
2008. Kindlin-2 controls bidirectional signaling of integrins. Genes Dev, 22, 1325-30. 
MOORE, K. M., THOMAS, G. J., DUFFY, S. W., WARWICK, J., GABE, R., CHOU, P., ELLIS, I. 
O., GREEN, A. R., HAIDER, S., BROUILETTE, K., SAHA, A., VALLATH, S., BOWEN, R., 
CHELALA, C., ECCLES, D., TAPPER, W. J., THOMPSON, A. M., QUINLAN, P., 
JORDAN, L., GILLETT, C., BRENTNALL, A., VIOLETTE, S., WEINREB, P. H., 
KENDREW, J., BARRY, S. T., HART, I. R., JONES, J. L. & MARSHALL, J. F. 2014. 
Therapeutic targeting of integrin alphavbeta6 in breast cancer. J Natl Cancer Inst, 
106. 
MORENO-LAYSECA, P. & STREULI, C. H. 2014. Signalling pathways linking integrins with cell 
cycle progression. Matrix Biol, 34, 144-53. 
MORGAN, M. R., HAMIDI, H., BASS, M. D., WARWOOD, S., BALLESTREM, C. & HUMPHRIES, 
M. J. 2013. Syndecan-4 phosphorylation is a control point for integrin recycling. Dev 
Cell, 24, 472-85. 
MORGAN, M. R., JAZAYERI, M., RAMSAY, A. G., THOMAS, G. J., BOULANGER, M. J., HART, 
I. R. & MARSHALL, J. F. 2011. Psoriasin (S100A7) associates with integrin beta6 
subunit and is required for alphavbeta6-dependent carcinoma cell invasion. 
Oncogene, 30, 1422-35. 
MORGAN, M. R., THOMAS, G. J., RUSSELL, A., HART, I. R. & MARSHALL, J. F. 2004. The 
integrin cytoplasmic-tail motif EKQKVDLSTDC is sufficient to promote tumor cell 
invasion mediated by matrix metalloproteinase (MMP)-2 or MMP-9. J Biol Chem, 279, 
26533-9. 
MORO, L., DOLCE, L., CABODI, S., BERGATTO, E., BOERI ERBA, E., SMERIGLIO, M., 
TURCO, E., RETTA, S. F., GIUFFRIDA, M. G., VENTURINO, M., GODOVAC-
ZIMMERMANN, J., CONTI, A., SCHAEFER, E., BEGUINOT, L., TACCHETTI, C., 
GAGGINI, P., SILENGO, L., TARONE, G. & DEFILIPPI, P. 2002. Integrin-induced 
epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and 
leads to phosphorylation of specific EGF receptor tyrosines. J Biol Chem, 277, 9405-
14. 
MORO, L., VENTURINO, M., BOZZO, C., SILENGO, L., ALTRUDA, F., BEGUINOT, L., 
TARONE, G. & DEFILIPPI, P. 1998. Integrins induce activation of EGF receptor: role in 
MAP kinase induction and adhesion-dependent cell survival. Embo j, 17, 6622-32. 
 
 405 
MOSESSON, Y., MILLS, G. B. & YARDEN, Y. 2008. Derailed endocytosis: an emerging feature 
of cancer. Nat Rev Cancer, 8, 835-50. 
MOULD, A. P., AKIYAMA, S. K. & HUMPHRIES, M. J. 1996. The inhibitory anti-beta1 integrin 
monoclonal antibody 13 recognizes an epitope that is attenuated by ligand 
occupancy. Evidence for allosteric inhibition of integrin function. J Biol Chem, 271, 
20365-74. 
MOULD, A. P., GARRATT, A. N., ASKARI, J. A., AKIYAMA, S. K. & HUMPHRIES, M. J. 1995a. 
Identification of a novel anti-integrin monoclonal antibody that recognises a ligand-
induced binding site epitope on the beta 1 subunit. FEBS Lett, 363, 118-22. 
MOULD, A. P., GARRATT, A. N., ASKARI, J. A., AKIYAMA, S. K. & HUMPHRIES, M. J. 1995b. 
Regulation of integrin alpha 5 beta 1 function by anti-integrin antibodies and divalent 
cations. Biochem Soc Trans, 23, 395S. 
MU, Z., YANG, Z., YU, D., ZHAO, Z. & MUNGER, J. S. 2008. TGFbeta1 and TGFbeta3 are 
partially redundant effectors in brain vascular morphogenesis. Mech Dev, 125, 508-16. 
MUKOHARA, T., ENGELMAN, J. A., HANNA, N. H., YEAP, B. Y., KOBAYASHI, S., LINDEMAN, 
N., HALMOS, B., PEARLBERG, J., TSUCHIHASHI, Z., CANTLEY, L. C., TENEN, D. G., 
JOHNSON, B. E. & JANNE, P. A. 2005. Differential effects of gefitinib and cetuximab 
on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J 
Natl Cancer Inst, 97, 1185-94. 
MULLER, H., HU, J., POPP, R., SCHMIDT, M. H., MULLER-DECKER, K., MOLLENHAUER, J., 
FISSLTHALER, B., EBLE, J. A. & FLEMING, I. 2012. Deleted in malignant brain tumors 
1 is present in the vascular extracellular matrix and promotes angiogenesis. 
Arterioscler Thromb Vasc Biol, 32, 442-8. 
MULLER, P. A., CASWELL, P. T., DOYLE, B., IWANICKI, M. P., TAN, E. H., KARIM, S., 
LUKASHCHUK, N., GILLESPIE, D. A., LUDWIG, R. L., GOSSELIN, P., CROMER, A., 
BRUGGE, J. S., SANSOM, O. J., NORMAN, J. C. & VOUSDEN, K. H. 2009. Mutant 
p53 drives invasion by promoting integrin recycling. Cell, 139, 1327-41. 
MUNGER, J. S., HUANG, X., KAWAKATSU, H., GRIFFITHS, M. J., DALTON, S. L., WU, J., 
PITTET, J. F., KAMINSKI, N., GARAT, C., MATTHAY, M. A., RIFKIN, D. B. & 
SHEPPARD, D. 1999. The integrin alpha v beta 6 binds and activates latent TGF beta 
1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell, 96, 319-28. 
MUNGER, J. S. & SHEPPARD, D. 2011. Cross talk among TGF-beta signaling pathways, 
integrins, and the extracellular matrix. Cold Spring Harb Perspect Biol, 3, a005017. 
NABA, A., CLAUSER, K. R., HOERSCH, S., LIU, H., CARR, S. A. & HYNES, R. O. 2012a. The 
matrisome: in silico definition and in vivo characterization by proteomics of normal 
and tumor extracellular matrices. Mol Cell Proteomics, 11, M111 014647. 
 
 406 
NABA, A., HOERSCH, S. & HYNES, R. O. 2012b. Towards definition of an ECM parts list: an 
advance on GO categories. Matrix Biol, 31, 371-2. 
NAGEL, W., ZEITLMANN, L., SCHILCHER, P., GEIGER, C., KOLANUS, J. & KOLANUS, W. 
1998. Phosphoinositide 3-OH kinase activates the beta2 integrin adhesion pathway 
and induces membrane recruitment of cytohesin-1. J Biol Chem, 273, 14853-61. 
NAKAGAWA, H., NUOVO, G. J., ZERVOS, E. E., MARTIN, E. W., JR., SALOVAARA, R., 
AALTONEN, L. A. & DE LA CHAPELLE, A. 2001. Age-related hypermethylation of the 
5' region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable 
colorectal cancer development. Cancer Res, 61, 6991-5. 
NICE. 2009a. Clinical Guideline [CG80]: Early and locally advanced breast cancer: diagnosis 
and treatment [Online]. Available: https://www.nice.org.uk/guidance/cg80 [Accessed 
21st July 2017]. 
NICE. 2009b. Clinical Guideline [CG81] Advanced breast cancer: diagnosis and treatment 
[Online].  [Accessed 21st July 2017]. 
NICE. 2011. NICE Quality Standard 12: Breast Cancer Quality Standard [Online]. Available: 
http://www.nice.org.uk/guidance/qs12/resources/guidance-breast-cancer-quality-
standard-pdf [Accessed 11th November 2014]. 
NURDEN, A. T. 2006. Glanzmann thrombasthenia. Orphanet Journal of Rare Diseases, 1, 10-
10. 
NYSTROM, M. L., MCCULLOCH, D., WEINREB, P. H., VIOLETTE, S. M., SPEIGHT, P. M., 
MARSHALL, J. F., HART, I. R. & THOMAS, G. J. 2006. Cyclooxygenase-2 inhibition 
suppresses alphavbeta6 integrin-dependent oral squamous carcinoma invasion. 
Cancer Res, 66, 10833-42. 
ORLOWSKI, A., KUKKURAINEN, S., POYRY, A., RISSANEN, S., VATTULAINEN, I., HYTONEN, 
V. P. & ROG, T. 2015. PIP2 and Talin Join Forces to Activate Integrin. J Phys Chem B, 
119, 12381-9. 
OSKARSSON, T. 2013. Extracellular matrix components in breast cancer progression and 
metastasis. Breast, 22 Suppl 2, S66-72. 
OUDERKIRK, J. L. & KRENDEL, M. 2014. Non-muscle myosins in tumor progression, cancer 
cell invasion and metastasis. Cytoskeleton (Hoboken, N.J.), 71, 447-463. 
OUDIN, M. J., JONAS, O., KOSCIUK, T., BROYE, L. C., GUIDO, B. C., WYCKOFF, J., 
RIQUELME, D., LAMAR, J. M., ASOKAN, S. B., WHITTAKER, C., MA, D., LANGER, R., 
CIMA, M. J., WISINSKI, K. B., HYNES, R. O., LAUFFENBURGER, D. A., KEELY, P. J., 
BEAR, J. E. & GERTLER, F. B. 2016. Tumor Cell-Driven Extracellular Matrix 




PARKIN, D. M. 2011. 9. Cancers attributable to inadequate physical exercise in the UK in 
2010. Br J Cancer, 105 Suppl 2, S38-41. 
PARKIN, D. M. & BOYD, L. 2011. 8. Cancers attributable to overweight and obesity in the UK 
in 2010. Br J Cancer, 105 Suppl 2, S34-7. 
PARVANI, J. G., GALLIHER-BECKLEY, A. J., SCHIEMANN, B. J. & SCHIEMANN, W. P. 2013. 
Targeted inactivation of beta1 integrin induces beta3 integrin switching, which drives 
breast cancer metastasis by TGF-beta. Mol Biol Cell, 24, 3449-59. 
PASZEK, M. J., DUFORT, C. C., ROSSIER, O., BAINER, R., MOUW, J. K., GODULA, K., 
HUDAK, J. E., LAKINS, J. N., WIJEKOON, A. C., CASSEREAU, L., RUBASHKIN, M. G., 
MAGBANUA, M. J., THORN, K. S., DAVIDSON, M. W., RUGO, H. S., PARK, J. W., 
HAMMER, D. A., GIANNONE, G., BERTOZZI, C. R. & WEAVER, V. M. 2014. The 
cancer glycocalyx mechanically primes integrin-mediated growth and survival. 
Nature, 511, 319-25. 
PATEL, V. J., THALASSINOS, K., SLADE, S. E., CONNOLLY, J. B., CROMBIE, A., MURRELL, J. 
C. & SCRIVENS, J. H. 2009. A comparison of labeling and label-free mass 
spectrometry-based proteomics approaches. J Proteome Res, 8, 3752-9. 
PAUL, N. R. 2014. Proteomic and phosphoproteomic analysis of signalling by adhesion and 
growth factor receptors in mammary epithelial cells. PhD Doctoral Thesis, University 
of Manchester. 
PEARCE, L. R., KOMANDER, D. & ALESSI, D. R. 2010. The nuts and bolts of AGC protein 
kinases. Nat Rev Mol Cell Biol, 11, 9-22. 
PEGORARO, S., ROS, G., CIANI, Y., SGARRA, R., PIAZZA, S. & MANFIOLETTI, G. 2015. A 
novel HMGA1-CCNE2-YAP axis regulates breast cancer aggressiveness. Oncotarget, 
6, 19087-101. 
PEROU, C. M., SORLIE, T., EISEN, M. B., VAN DE RIJN, M., JEFFREY, S. S., REES, C. A., 
POLLACK, J. R., ROSS, D. T., JOHNSEN, H., AKSLEN, L. A., FLUGE, O., 
PERGAMENSCHIKOV, A., WILLIAMS, C., ZHU, S. X., LONNING, P. E., BORRESEN-
DALE, A. L., BROWN, P. O. & BOTSTEIN, D. 2000. Molecular portraits of human 
breast tumours. Nature, 406, 747-52. 
PESHO, M. M., BLEDZKA, K., MICHALEC, L., CIERNIEWSKI, C. S. & PLOW, E. F. 2006. The 
specificity and function of the metal-binding sites in the integrin beta3 A-domain. J 
Biol Chem, 281, 23034-41. 
PETITCLERC, E., STROMBLAD, S., VON SCHALSCHA, T. L., MITJANS, F., PIULATS, J., 
MONTGOMERY, A. M., CHERESH, D. A. & BROOKS, P. C. 1999. Integrin 
alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor 
cell survival. Cancer Res, 59, 2724-30. 
 
 408 
PHOSPHOSITE. 2015a. Cot (human) [Online]. Available: 
http://www.phosphosite.org/proteinAction.do?id=711&showAllSites=true [Accessed 
9th December 2015]. 
PHOSPHOSITE. 2015b. MAPKAPK2 (human) [Online]. Available: 
http://www.phosphosite.org/proteinAction.do?id=716 [Accessed 9th December 
2015]. 
PHOSPHOSITE. 2015c. Nuak1 (human) [Online]. Available: 
http://www.phosphosite.org/proteinAction.do?id=802&showAllSites=true [Accessed 
9th December 2015]. 
PHOSPHOSITE. 2015d. PDK1 (human) [Online]. Available: 
http://www.phosphosite.org/proteinAction.do?id=635&showAllSites=true [Accessed 
9th December 2015]. 
PHOSPHOSITE. 2015e. TBK1 (human) [Online]. Available: 
http://www.phosphosite.org/proteinAction.do?id=825&showAllSites=true [Accessed 
9th December 2015]. 
PHOSPHOSITE. 2017. EGFR (human) [Online].  [Accessed 30th August 2017 2017]. 
PICKUP, M. W., MOUW, J. K. & WEAVER, V. M. 2014. The extracellular matrix modulates the 
hallmarks of cancer. EMBO Rep, 15, 1243-53. 
PLACE, A. E., JIN HUH, S. & POLYAK, K. 2011. The microenvironment in breast cancer 
progression: biology and implications for treatment. Breast Cancer Res, 13, 227. 
POLYAK, K. 2011. Heterogeneity in breast cancer. J Clin Invest, 121, 3786-8. 
POLYAK, K. 2014. Tumor heterogeneity confounds and illuminates: a case for Darwinian 
tumor evolution. Nat Med, 20, 344-6. 
PONKA, P. & LOK, C. N. 1999. The transferrin receptor: role in health and disease. Int J 
Biochem Cell Biol, 31, 1111-37. 
PORTE, J. & JENKINS, G. 2014. Assessment of the effect of potential antifibrotic compounds 
on total and alphaVbeta6 integrin-mediated TGF-beta activation. Pharmacol Res 
Perspect, 2, e00030. 
POUS, C., KLIPFEL, L. & BAILLET, A. 2016. Cancer-Related Functions and Subcellular 
Localizations of Septins. Front Cell Dev Biol, 4, 126. 
POUWELS, J., NEVO, J., PELLINEN, T., YLANNE, J. & IVASKA, J. 2012. Negative regulators of 
integrin activity. J Cell Sci. England. 
 
 409 
POVEDA, J., SANZ, A. B., FERNANDEZ-FERNANDEZ, B., CARRASCO, S., RUIZ-ORTEGA, M., 
CANNATA-ORTIZ, P., ORTIZ, A. & SANCHEZ-NINO, M. D. 2017. MXRA5 is a TGF-
beta1-regulated human protein with anti-inflammatory and anti-fibrotic properties. J 
Cell Mol Med, 21, 154-164. 
PRAT, A., KARGINOVA, O., PARKER, J. S., FAN, C., HE, X., BIXBY, L., HARRELL, J. C., 
ROMAN, E., ADAMO, B., TROESTER, M. & PEROU, C. M. 2013. Characterization of 
cell lines derived from breast cancers and normal mammary tissues for the study of 
the intrinsic molecular subtypes. Breast Cancer Res Treat, 142, 237-55. 
QU, Y., HAN, B., YU, Y., YAO, W., BOSE, S., KARLAN, B. Y., GIULIANO, A. E. & CUI, X. 2015. 
Evaluation of MCF10A as a Reliable Model for Normal Human Mammary Epithelial 
Cells. PLoS One, 10, e0131285. 
QUAIL, D. F. & JOYCE, J. A. 2013. Microenvironmental regulation of tumor progression and 
metastasis. Nat Med, 19, 1423-37. 
QUINTAYO, M. A., MUNRO, A. F., THOMAS, J., KUNKLER, I. H., JACK, W., KERR, G. R., 
DIXON, J. M., CHETTY, U. & BARTLETT, J. M. S. 2012. GSK3β and cyclin D1 
expression predicts outcome in early breast cancer patients. Breast Cancer Research 
and Treatment, 136, 161-168. 
RAAB-WESTPHAL, S., MARSHALL, J. F. & GOODMAN, S. L. 2017. Integrins as therapeutic 
targets: successes and cancers. Cancers, 9. 
RAINERO, E., CASWELL, P. T., MULLER, P. A. J., GRINDLAY, J., MCCAFFREY, M. W., ZHANG, 
Q., WAKELAM, M. J. O., VOUSDEN, K. H., GRAZIANI, A. & NORMAN, J. C. 2012. 
Diacylglycerol kinase α controls RCP-dependent integrin trafficking to promote 
invasive migration. The Journal of Cell Biology, 196, 277-295. 
RAINERO, E., VAN DEN BERGHE, P. V. E. & NORMAN, J. C. 2013. In: YARDEN, Y. & TARCIC, 
G. (eds.) Vesicle Trafficking in Cancer. Springer. 
RAMSAY, A. G., KEPPLER, M. D., JAZAYERI, M., THOMAS, G. J., PARSONS, M., VIOLETTE, 
S., WEINREB, P., HART, I. R. & MARSHALL, J. F. 2007. HS1-associated protein X-1 
regulates carcinoma cell migration and invasion via clathrin-mediated endocytosis of 
integrin alphavbeta6. Cancer Res, 67, 5275-84. 
RANTALA, J. K., POUWELS, J., PELLINEN, T., VELTEL, S., LAASOLA, P., MATTILA, E., 
POTTER, C. S., DUFFY, T., SUNDBERG, J. P., KALLIONIEMI, O., ASKARI, J. A., 
HUMPHRIES, M. J., PARSONS, M., SALMI, M. & IVASKA, J. 2011. SHARPIN is an 
endogenous inhibitor of beta1-integrin activation. Nat Cell Biol, 13, 1315-24. 
RAPISARDA, V., BORGHESAN, M., MIGUELA, V., ENCHEVA, V., SNIJDERS, A. P., LUJAMBIO, 
A. & O’LOGHLEN, A. 2017. Integrin Beta 3 Regulates Cellular Senescence by 
Activating the TGF-β Pathway. Cell Reports, 18, 2480-2493. 
 
 410 
RASHID, S. T., HUMPHRIES, J. D., BYRON, A., DHAR, A., ASKARI, J. A., SELLEY, J. N., 
KNIGHT, D., GOLDIN, R. D., THURSZ, M. & HUMPHRIES, M. J. 2012. Proteomic 
analysis of extracellular matrix from the hepatic stellate cell line LX-2 identifies CYR61 
and Wnt-5a as novel constituents of fibrotic liver. J Proteome Res, 11, 4052-64. 
REDDY, K. B., GASCARD, P., PRICE, M. G., NEGRESCU, E. V. & FOX, J. E. 1998. Identification 
of an interaction between the m-band protein skelemin and beta-integrin subunits. 
Colocalization of a skelemin-like protein with beta1- and beta3-integrins in non-
muscle cells. J Biol Chem, 273, 35039-47. 
REDDY, K. B., SMITH, D. M. & PLOW, E. F. 2008. Analysis of Fyn function in hemostasis and 
alphaIIbbeta3-integrin signaling. J Cell Sci, 121, 1641-8. 
REID, P. A. & WATTS, C. 1990. Cycling of cell-surface MHC glycoproteins through 
primaquine-sensitive intracellular compartments. Nature, 346, 655-7. 
RESZKA, A. A., HAYASHI, Y. & HORWITZ, A. F. 1992. Identification of amino acid sequences 
in the integrin beta 1 cytoplasmic domain implicated in cytoskeletal association. J 
Cell Biol, 117, 1321-30. 
REYES, C. D., PETRIE, T. A. & GARCIA, A. J. 2008. Mixed extracellular matrix ligands 
synergistically modulate integrin adhesion and signaling. J Cell Physiol, 217, 450-8. 
REYNOLDS, A. R., HART, I. R., WATSON, A. R., WELTI, J. C., SILVA, R. G., ROBINSON, S. D., 
DA VIOLANTE, G., GOURLAOUEN, M., SALIH, M., JONES, M. C., JONES, D. T., 
SAUNDERS, G., KOSTOUROU, V., PERRON-SIERRA, F., NORMAN, J. C., TUCKER, G. 
C. & HODIVALA-DILKE, K. M. 2009. Stimulation of tumor growth and angiogenesis by 
low concentrations of RGD-mimetic integrin inhibitors. Nat Med, 15, 392-400. 
RICH, T. A., WOODSON, A. H., LITTON, J. & ARUN, B. 2014. Hereditary breast cancer 
syndromes and genetic testing. J Surg Oncol. 
RIVAS, G. A. & GONZALEZ-RODRIGUEZ, J. 1991. Calcium binding to human platelet integrin 
GPIIb/IIIa and to its constituent glycoproteins. Effects of lipids and temperature. 
Biochem J, 276 ( Pt 1), 35-40. 
ROBERTS, M., BARRY, S., WOODS, A., VAN DER SLUIJS, P. & NORMAN, J. 2001. PDGF-
regulated rab4-dependent recycling of alphavbeta3 integrin from early endosomes is 
necessary for cell adhesion and spreading. Curr Biol, 11, 1392-402. 
ROBERTSON, J. 2014. Phosphoproteomic analysis of adhesion of receptor signalling. PhD 
Doctoral Thesis, University of Manchester. 
ROBERTSON, J., JACQUEMET, G., BYRON, A., JONES, M. C., WARWOOD, S., SELLEY, J. N., 
KNIGHT, D., HUMPHRIES, J. D. & HUMPHRIES, M. J. 2015. Defining the phospho-
adhesome through the phosphoproteomic analysis of integrin signalling. Nat 
Commun, 6, 6265. 
 
 411 
ROCA-CUSACHS, P., DEL RIO, A., PUKLIN-FAUCHER, E., GAUTHIER, N. C., BIAIS, N. & 
SHEETZ, M. P. 2013. Integrin-dependent force transmission to the extracellular matrix 
by alpha-actinin triggers adhesion maturation. Proc Natl Acad Sci U S A, 110, E1361-
70. 
RODLER, E., KORDE, L. & GRALOW, J. 2010. Current treatment options in triple negative 
breast cancer. Breast Dis, 32, 99-122. 
RYBIN, V. O., GUO, J., HARLETON, E., FEINMARK, S. J. & STEINBERG, S. F. 2009. Regulatory 
autophosphorylation sites on protein kinase C-delta at threonine-141 and threonine-
295. Biochemistry, 48, 4642-51. 
SAHA, A., ELLISON, D., THOMAS, G. J., VALLATH, S., MATHER, S. J., HART, I. R. & 
MARSHALL, J. F. 2010. High-resolution in vivo imaging of breast cancer by targeting 
the pro-invasive integrin alphavbeta6. J Pathol, 222, 52-63. 
SAHAI, E. 2005. Mechanisms of cancer cell invasion. Curr Opin Genet Dev, 15, 87-96. 
SAITO, R., SMOOT, M. E., ONO, K., RUSCHEINSKI, J., WANG, P. L., LOTIA, S., PICO, A. R., 
BADER, G. D. & IDEKER, T. 2012. A travel guide to Cytoscape plugins. Nat Methods, 
9, 1069-76. 
SAKAMOTO, H., BROEKELMANN, T., CHERESH, D. A., RAMIREZ, F., ROSENBLOOM, J. & 
MECHAM, R. P. 1996. Cell-type specific recognition of RGD- and non-RGD-
containing cell binding domains in fibrillin-1. J Biol Chem, 271, 4916-22. 
SALZANO, M., VAZQUEZ-CEDEIRA, M., SANZ-GARCIA, M., VALBUENA, A., BLANCO, S., 
FERNANDEZ, I. F. & LAZO, P. A. 2014. Vaccinia-related kinase 1 (VRK1) confers 
resistance to DNA-damaging agents in human breast cancer by affecting DNA 
damage response. Oncotarget, 5, 1770-8. 
SAN SEBASTIAN, E., MERCERO, J. M., STOTE, R. H., DEJAEGERE, A., COSSIO, F. P. & 
LOPEZ, X. 2006. On the affinity regulation of the metal-ion-dependent adhesion sites 
in integrins. J Am Chem Soc, 128, 3554-63. 
SANDIN, M., TELEMAN, J., MALMSTROM, J. & LEVANDER, F. 2014. Data processing 
methods and quality control strategies for label-free LC-MS protein quantification. 
Biochim Biophys Acta, 1844, 29-41. 
SANEYASU, T., AKHTAR, R. & SAKAI, T. 2016. Molecular Cues Guiding Matrix Stiffness in 
Liver Fibrosis. BioMed Research International, 2016, 2646212. 
SANTNER, S. J., DAWSON, P. J., TAIT, L., SOULE, H. D., ELIASON, J., MOHAMED, A. N., 
WOLMAN, S. R., HEPPNER, G. H. & MILLER, F. R. 2001. Malignant MCF10CA1 cell 
lines derived from premalignant human breast epithelial MCF10AT cells. Breast 
Cancer Res Treat, 65, 101-10. 
 
 412 
SCHALLER, M. D., OTEY, C. A., HILDEBRAND, J. D. & PARSONS, J. T. 1995. Focal adhesion 
kinase and paxillin bind to peptides mimicking beta integrin cytoplasmic domains. J 
Cell Biol, 130, 1181-7. 
SCHEDIN, P. & ELIAS, A. 2004. Multistep tumorigenesis and the microenvironment. Breast 
Cancer Res, 6, 93-101. 
SCHEDIN, P. & KEELY, P. J. 2011. Mammary gland ECM remodeling, stiffness, and 
mechanosignaling in normal development and tumor progression. Cold Spring Harb 
Perspect Biol, 3, a003228. 
SCHEID, M. P., PARSONS, M. & WOODGETT, J. R. 2005. Phosphoinositide-Dependent 
Phosphorylation of PDK1 Regulates Nuclear Translocation. Molecular and Cellular 
Biology, 25, 2347-2363. 
SCHMIDT, E. V. 2002. Genes involved in breast cancer progression: analysis of global 
changes in gene expression or retroviral tagging? Am J Pathol, 161, 1973-7. 
SCHNITT, S. J. 2010. Classification and prognosis of invasive breast cancer: from morphology 
to molecular taxonomy. Mod Pathol, 23 Suppl 2, S60-4. 
SCOTT, M., MCCLUGGAGE, W. G., HILLAN, K. J., HALL, P. A. & RUSSELL, S. E. 2006. Altered 
patterns of transcription of the septin gene, SEPT9, in ovarian tumorigenesis. Int J 
Cancer, 118, 1325-9. 
SERRELS, B., SANDILANDS, E., SERRELS, A., BAILLIE, G., HOUSLAY, M. D., BRUNTON, V. G., 
CANEL, M., MACHESKY, L. M., ANDERSON, K. I. & FRAME, M. C. 2010. A complex 
between FAK, RACK1, and PDE4D5 controls spreading initiation and cancer cell 
polarity. Curr Biol, 20, 1086-92. 
SHANNON, P., MARKIEL, A., OZIER, O., BALIGA, N. S., WANG, J. T., RAMAGE, D., AMIN, 
N., SCHWIKOWSKI, B. & IDEKER, T. 2003. Cytoscape: a software environment for 
integrated models of biomolecular interaction networks. Genome Res, 13, 2498-504. 
SHATTIL, S. J., KIM, C. & GINSBERG, M. H. 2010. The final steps of integrin activation: the 
end game. Nat Rev Mol Cell Biol, 11, 288-300. 
SHEPPARD, D. 2015. Epithelial-mesenchymal interactions in fibrosis and repair. Transforming 
growth factor-beta activation by epithelial cells and fibroblasts. Ann Am Thorac Soc, 
12 Suppl 1, S21-3. 
SHEVCHENKO, A., WILM, M., VORM, O., JENSEN, O. N., PODTELEJNIKOV, A. V., 
NEUBAUER, G., SHEVCHENKO, A., MORTENSEN, P. & MANN, M. 1996. A strategy 
for identifying gel-separated proteins in sequence databases by MS alone. Biochem 
Soc Trans, 24, 893-6. 
SHI, S. R., LIU, C., POOTRAKUL, L., TANG, L., YOUNG, A., CHEN, R., COTE, R. J. & TAYLOR, 
 
 413 
C. R. 2008. Evaluation of the value of frozen tissue section used as "gold standard" 
for immunohistochemistry. Am J Clin Pathol, 129, 358-66. 
SHI, S. R., SHI, Y. & TAYLOR, C. R. 2011. Antigen retrieval immunohistochemistry: review and 
future prospects in research and diagnosis over two decades. J Histochem 
Cytochem, 59, 13-32. 
SHIMAOKA, M. & SPRINGER, T. A. 2003. Therapeutic antagonists and conformational 
regulation of integrin function. Nat Rev Drug Discov, 2, 703-16. 
SHIMAOKA, M., TAKAGI, J. & SPRINGER, T. A. 2002. Conformational regulation of integrin 
structure and function. Annu Rev Biophys Biomol Struct, 31, 485-516. 
SINN, H.-P. & KREIPE, H. 2013. A Brief Overview of the WHO Classification of Breast Tumors, 
4th Edition, Focusing on Issues and Updates from the 3rd Edition. Breast Care, 8, 
149-154. 
SIPOS, B., HAHN, D., CARCELLER, A., PIULATS, J., HEDDERICH, J., KALTHOFF, H., 
GOODMAN, S. L., KOSMAHL, M. & KLOPPEL, G. 2004. Immunohistochemical 
screening for beta6-integrin subunit expression in adenocarcinomas using a novel 
monoclonal antibody reveals strong up-regulation in pancreatic ductal 
adenocarcinomas in vivo and in vitro. Histopathology, 45, 226-36. 
SLOAN, E. K., POULIOT, N., STANLEY, K. L., CHIA, J., MOSELEY, J. M., HARDS, D. K. & 
ANDERSON, R. L. 2006. Tumor-specific expression of alphavbeta3 integrin promotes 
spontaneous metastasis of breast cancer to bone. Breast Cancer Res, 8, R20. 
SMITH, J. W., PIOTROWICZ, R. S. & MATHIS, D. 1994. A mechanism for divalent cation 
regulation of beta 3-integrins. J Biol Chem, 269, 960-7. 
SMOOT, M. E., ONO, K., RUSCHEINSKI, J., WANG, P. L. & IDEKER, T. 2011. Cytoscape 2.8: 
new features for data integration and network visualization. Bioinformatics, 27, 431-2. 
SMYTH, G. K. 2004. Linear models and empirical bayes methods for assessing differential 
expression in microarray experiments. Stat Appl Genet Mol Biol, 3, Article3. 
SORLIE, T. 2009. Introducing molecular subtyping of breast cancer into the clinic? J Clin 
Oncol, 27, 1153-4. 
SORLIE, T., PEROU, C. M., TIBSHIRANI, R., AAS, T., GEISLER, S., JOHNSEN, H., HASTIE, T., 
EISEN, M. B., VAN DE RIJN, M., JEFFREY, S. S., THORSEN, T., QUIST, H., MATESE, J. 
C., BROWN, P. O., BOTSTEIN, D., LONNING, P. E. & BORRESEN-DALE, A. L. 2001. 
Gene expression patterns of breast carcinomas distinguish tumor subclasses with 
clinical implications. Proc Natl Acad Sci U S A, 98, 10869-74. 
SOTERIOU, D., ISKENDER, B., BYRON, A., HUMPHRIES, J. D., BORG-BARTOLO, S., 
HADDOCK, M. C., BAXTER, M. A., KNIGHT, D., HUMPHRIES, M. J. & KIMBER, S. J. 
 
 414 
2013. Comparative proteomic analysis of supportive and unsupportive extracellular 
matrix substrates for human embryonic stem cell maintenance. J Biol Chem, 288, 
18716-31. 
SOULE, H. D., MALONEY, T. M., WOLMAN, S. R., PETERSON, W. D., JR., BRENZ, R., 
MCGRATH, C. M., RUSSO, J., PAULEY, R. J., JONES, R. F. & BROOKS, S. C. 1990. 
Isolation and characterization of a spontaneously immortalized human breast 
epithelial cell line, MCF-10. Cancer Res, 50, 6075-86. 
SOUNG, Y. H., CLIFFORD, J. L. & CHUNG, J. 2010. Crosstalk between integrin and receptor 
tyrosine kinase signaling in breast carcinoma progression. BMB Rep, 43, 311-8. 
SOURVINOS, G., TSATSANIS, C. & SPANDIDOS, D. A. 1999. Overexpression of the Tpl-2/Cot 
oncogene in human breast cancer. Oncogene, 18, 4968-73. 
SPANDIDOS, A., WANG, X., WANG, H. & SEED, B. 2010. PrimerBank: a resource of human 
and mouse PCR primer pairs for gene expression detection and quantification. 
Nucleic Acids Res, 38, D792-9. 
SPEARS, M., CUNNINGHAM, C. A., TAYLOR, K. J., MALLON, E. A., THOMAS, J. S., KERR, G. 
R., JACK, W. J., KUNKLER, I. H., CAMERON, D. A., CHETTY, U. & BARTLETT, J. M. 
2012. Proximity ligation assays for isoform-specific Akt activation in breast cancer 
identify activated Akt1 as a driver of progression. J Pathol, 227, 481-9. 
SRICHAI, M. B. & ZENT, R. 2010. In: ZENT, R. & POZZI, A. (eds.) Cell-Extracellular Matrix 
Interactions in Cancer. Springer. 
STAUNTON, D. E. 2006. Targeting Integrin Structure and Function in Disease. Advances in 
Immunology, 91, 111–157. 
STAWOWY, P., MARGETA, C., BLASCHKE, F., LINDSCHAU, C., SPENCER-HANSCH, C., 
LEITGES, M., BIAGINI, G., FLECK, E. & GRAF, K. 2005. Protein kinase C epsilon 
mediates angiotensin II-induced activation of beta1-integrins in cardiac fibroblasts. 
Cardiovasc Res, 67, 50-9. 
STEVENS, A. & LOWE, J. S. 2005. Human histology, Spain, Elsevier Mosby. 
STEWART, R. L. & O'CONNOR, K. L. 2015. Clinical significance of the integrin alpha6beta4 in 
human malignancies. Lab Invest, 95, 976-86. 
STRATFORD, A. L., REIPAS, K., HU, K., FOTOVATI, A., BROUGH, R., FRANKUM, J., TAKHAR, 
M., WATSON, P., ASHWORTH, A., LORD, C. J., LASHAM, A., PRINT, C. G. & DUNN, 
S. E. 2012. Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by 
inactivating Y-box binding protein-1 in triple-negative breast cancers. Stem Cells, 30, 
1338-48. 
STREET, C. A. & BRYAN, B. A. 2011. Rho Kinase Proteins—Pleiotropic Modulators of Cell 
 
 415 
Survival and Apoptosis. Anticancer research, 31, 3645-3657. 
STRICKLAND, L. B., DAWSON, P. J., SANTNER, S. J. & MILLER, F. R. 2000. Progression of 
premalignant MCF10AT generates heterogeneous malignant variants with 
characteristic histologic types and immunohistochemical markers. Breast Cancer Res 
Treat, 64, 235-40. 
SU, Z., CHEN, D., ZHANG, E., LI, Y., YU, Z., SHI, M., JIANG, Z., NI, L., YANG, S., GUI, Y., YE, J. 
& LAI, Y. 2015. MicroRNA-509-3p inhibits cancer cell proliferation and migration by 
targeting the mitogen-activated protein kinase kinase kinase 8 oncogene in renal cell 
carcinoma. Mol Med Rep, 12, 1535-43. 
SUBBIAH, I. M. & GONZALEZ-ANGULO, A. M. 2014. Advances and future directions in the 
targeting of HER2-positive breast cancer: implications for the future. Curr Treat 
Options Oncol, 15, 41-54. 
SUN, X., GAO, L., CHIEN, H. Y., LI, W. C. & ZHAO, J. 2013. The regulation and function of the 
NUAK family. J Mol Endocrinol, 51, R15-22. 
SUN, Z., GUO, S. S. & FÄSSLER, R. 2016. Integrin-mediated mechanotransduction. The 
Journal of Cell Biology. 
SUZUKI, A., LU, J., KUSAKAI, G., KISHIMOTO, A., OGURA, T. & ESUMI, H. 2004. ARK5 is a 
tumor invasion-associated factor downstream of Akt signaling. Mol Cell Biol, 24, 
3526-35. 
SUZUKI, A., OGURA, T. & ESUMI, H. 2006. NDR2 acts as the upstream kinase of ARK5 during 
insulin-like growth factor-1 signaling. J Biol Chem, 281, 13915-21. 
TAHERIAN, A., LI, X., LIU, Y. & HAAS, T. A. 2011. Differences in integrin expression and 
signaling within human breast cancer cells. BMC Cancer, 11, 293. 
TAKADA, Y. & PUZON, W. 1993. Identification of a regulatory region of integrin beta 1 
subunit using activating and inhibiting antibodies. J Biol Chem, 268, 17597-601. 
TAKAGI, J., KAMATA, T., MEREDITH, J., PUZON-MCLAUGHLIN, W. & TAKADA, Y. 1997. 
Changing ligand specificities of alphavbeta1 and alphavbeta3 integrins by swapping 
a short diverse sequence of the beta subunit. J Biol Chem, 272, 19794-800. 
TAM, S. H., SASSOLI, P. M., JORDAN, R. E. & NAKADA, M. T. 1998. Abciximab (ReoPro, 
chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of 
glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation, 98, 1085-91. 
TAN, K. H., SIMONELLA, L., WEE, H. L., ROELLIN, A., LIM, Y. W., LIM, W. Y., CHIA, K. S., 
HARTMAN, M. & COOK, A. R. 2013. Quantifying the natural history of breast cancer. 
Br J Cancer, 109, 2035-43. 
 
 416 
TANG, B., VU, M., BOOKER, T., SANTNER, S. J., MILLER, F. R., ANVER, M. R. & WAKEFIELD, 
L. M. 2003. TGF-beta switches from tumor suppressor to prometastatic factor in a 
model of breast cancer progression. J Clin Invest, 112, 1116-24. 
TATLER, A. L. & JENKINS, G. 2012. TGF-beta activation and lung fibrosis. Proc Am Thorac 
Soc, 9, 130-6. 
TAYLOR, M. A., PARVANI, J. G. & SCHIEMANN, W. P. 2010. The pathophysiology of 
epithelial-mesenchymal transition induced by transforming growth factor-beta in 
normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia, 
15, 169-90. 
TAYLOR, S. C., BERKELMAN, T., YADAV, G. & HAMMOND, M. 2013. A defined methodology 
for reliable quantification of Western blot data. Mol Biotechnol, 55, 217-26. 
TCHATCHOU, S., RIEDEL, A., LYER, S., SCHMUTZHARD, J., STROBEL-FREIDEKIND, O., 
GRONERT-SUM, S., MIETAG, C., D'AMATO, M., SCHLEHE, B., HEMMINKI, K., 
SUTTER, C., DITSCH, N., BLACKBURN, A., HILL, L. Z., JERRY, D. J., BUGERT, P., 
WEBER, B. H., NIEDERACHER, D., ARNOLD, N., VARON-MATEEVA, R., 
WAPPENSCHMIDT, B., SCHMUTZLER, R. K., ENGEL, C., MEINDL, A., BARTRAM, C. 
R., MOLLENHAUER, J. & BURWINKEL, B. 2010. Identification of a DMBT1 
polymorphism associated with increased breast cancer risk and decreased promoter 
activity. Hum Mutat, 31, 60-6. 
TECKCHANDANI, A., MULKEARNS, E. E., RANDOLPH, T. W., TOIDA, N. & COOPER, J. A. 
2012. The clathrin adaptor Dab2 recruits EH domain scaffold proteins to regulate 
integrin beta1 endocytosis. Mol Biol Cell, 23, 2905-16. 
TERRANOVA, V. P., RAO, C. N., KALEBIC, T., MARGULIES, I. M. & LIOTTA, L. A. 1983. 
Laminin receptor on human breast carcinoma cells. Proc Natl Acad Sci U S A, 80, 444-
8. 
THE CANCER GENOME ATLAS, N. 2012. Comprehensive molecular portraits of human 
breast tumors. Nature, 490, 61-70. 
THOMAS, G. J., HART, I. R., SPEIGHT, P. M. & MARSHALL, J. F. 2002. Binding of TGF-beta1 
latency-associated peptide (LAP) to alpha(v)beta6 integrin modulates behaviour of 
squamous carcinoma cells. Br J Cancer, 87, 859-67. 
THOMAS, G. J., LEWIS, M. P., HART, I. R., MARSHALL, J. F. & SPEIGHT, P. M. 2001a. 
AlphaVbeta6 integrin promotes invasion of squamous carcinoma cells through up-
regulation of matrix metalloproteinase-9. Int J Cancer, 92, 641-50. 
THOMAS, G. J., LEWIS, M. P., WHAWELL, S. A., RUSSELL, A., SHEPPARD, D., HART, I. R., 
SPEIGHT, P. M. & MARSHALL, J. F. 2001b. Expression of the alphavbeta6 integrin 




THOMAS, G. J., NYSTROM, M. L. & MARSHALL, J. F. 2006. Alphavbeta6 integrin in wound 
healing and cancer of the oral cavity. J Oral Pathol Med, 35, 1-10. 
TIWARI, S., ASKARI, J. A., HUMPHRIES, M. J. & BULLEID, N. J. 2011. Divalent cations regulate 
the folding and activation status of integrins during their intracellular trafficking. J 
Cell Sci, 124, 1672-80. 
TOKUNAGA, E., KIMURA, Y., OKI, E., UEDA, N., FUTATSUGI, M., MASHINO, K., 
YAMAMOTO, M., IKEBE, M., KAKEJI, Y., BABA, H. & MAEHARA, Y. 2006. Akt is 
frequently activated in HER2/neu-positive breast cancers and associated with poor 
prognosis among hormone-treated patients. Int J Cancer, 118, 284-9. 
TOWBIN, H., STAEHELIN, T. & GORDON, J. 1979. Electrophoretic transfer of proteins from 
polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc 
Natl Acad Sci U S A, 76, 4350-4. 
TRUONG, H. H., XIONG, J., GHOTRA, V. P., NIRMALA, E., HAAZEN, L., LE DEVEDEC, S. E., 
BALCIOGLU, H. E., HE, S., SNAAR-JAGALSKA, B. E., VREUGDENHIL, E., MEERMAN, 
J. H., VAN DE WATER, B. & DANEN, E. H. 2014. beta1 integrin inhibition elicits a 
prometastatic switch through the TGFbeta-miR-200-ZEB network in E-cadherin-
positive triple-negative breast cancer. Sci Signal, 7, ra15. 
TSAI, H. C. & BAYLIN, S. B. 2011. Cancer epigenetics: linking basic biology to clinical 
medicine. Cell Res, 21, 502-17. 
UNIPROTCONSORTIUM. 2017. Homo sapiens (Human) [Online]. Available: 
http://www.uniprot.org/taxonomy/9606. 
VALDRAMIDOU, D., HUMPHRIES, M. J. & MOULD, A. P. 2008. Distinct roles of beta1 metal 
ion-dependent adhesion site (MIDAS), adjacent to MIDAS (ADMIDAS), and ligand-
associated metal-binding site (LIMBS) cation-binding sites in ligand recognition by 
integrin alpha2beta1. J Biol Chem, 283, 32704-14. 
VAN 'T VEER, L. J., DAI, H., VAN DE VIJVER, M. J., HE, Y. D., HART, A. A. M., MAO, M., 
PETERSE, H. L., VAN DER KOOY, K., MARTON, M. J., WITTEVEEN, A. T., 
SCHREIBER, G. J., KERKHOVEN, R. M., ROBERTS, C., LINSLEY, P. S., BERNARDS, R. 
& FRIEND, S. H. 2002. Gene expression profiling predicts clinical outcome of breast 
cancer. Nature, 415, 530-536. 
VAN AARSEN, L. A., LEONE, D. R., HO, S., DOLINSKI, B. M., MCCOON, P. E., LEPAGE, D. J., 
KELLY, R., HEANEY, G., RAYHORN, P., REID, C., SIMON, K. J., HORAN, G. S., TAO, 
N., GARDNER, H. A., SKELLY, M. M., GOWN, A. M., THOMAS, G. J., WEINREB, P. H., 
FAWELL, S. E. & VIOLETTE, S. M. 2008. Antibody-mediated blockade of integrin 
alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-
beta-regulated mechanism. Cancer Res, 68, 561-70. 
VAN WEERT AW, G. H., GROOTHUIS B, STOORVOGEL W. 2000. Primaquine interferes with 
 
 418 
membrane recycling from endosomes to the plasma membrane through a direct 
interaction with endosomes which does not involve neutralisation of endosomal pH 
nor osmotic swelling of endosomes. European Journal of Cell Biology, 79, 394–399. 
VAN'T VEER, L. J. & WEIGELT, B. 2003. Road map to metastasis. Nat Med, 9, 999-1000. 
VARZAVAND, A., HACKER, W., MA, D., GIBSON-CORLEY, K., HAWAYEK, M., TAYH, O. J., 
BROWN, J. A., HENRY, M. D. & STIPP, C. S. 2016. α3β1 Integrin Suppresses Prostate 
Cancer Metastasis via Regulation of the Hippo Pathway. Cancer Research, 76, 6577-
6587. 
VAZQUEZ RODRIGUEZ, G., ABRAHAMSSON, A., JENSEN, L. D. & DABROSIN, C. 2017. 
Estradiol Promotes Breast Cancer Cell Migration via Recruitment and Activation of 
Neutrophils. Cancer Immunol Res, 5, 234-247. 
VEISEH, O., KIEVIT, F. M., ELLENBOGEN, R. G. & ZHANG, M. 2011. Cancer cell invasion: 
treatment and monitoring opportunities in nanomedicine. Adv Drug Deliv Rev, 63, 
582-96. 
VERBISCK, N. V., COSTA, E. T., COSTA, F. F., CAVALHER, F. P., COSTA, M. D., MURAS, A., 
PAIXAO, V. A., MOURA, R., GRANATO, M. F., IERARDI, D. F., MACHADO, T., MELO, 
F., RIBEIRO, K. B., CUNHA, I. W., LIMA, V. C., MACIEL MDO, S., CARVALHO, A. L., 
SOARES, F. F., ZANATA, S., SOGAYAR, M. C., CHAMMAS, R. & CAMARGO, A. A. 
2009. ADAM23 negatively modulates alpha(v)beta(3) integrin activation during 
metastasis. Cancer Res, 69, 5546-52. 
VERCAUTEREN, D., VANDENBROUCKE, R. E., JONES, A. T., REJMAN, J., DEMEESTER, J., 
DE SMEDT, S. C., SANDERS, N. N. & BRAECKMANS, K. 2010. The use of inhibitors to 
study endocytic pathways of gene carriers: optimization and pitfalls. Mol Ther, 18, 
561-9. 
VIALE, G. 2012. The current state of breast cancer classification. Ann Oncol, 23 Suppl 10, 
x207-10. 
VIEIRA, A. F., RIBEIRO, A. S., DIONÍSIO, M. R., SOUSA, B., NOBRE, A. R., ALBERGARIA, A., 
SANTIAGO-GÓMEZ, A., MENDES, N., GERHARD, R., SCHMITT, F., CLARKE, R. B. & 
PAREDES, J. 2014. P-cadherin signals through the laminin receptor α6β4 integrin to 
induce stem cell and invasive properties in basal-like breast cancer cells. Oncotarget, 
5, 679-692. 
VINAYAGAM, A., ZIRIN, J., ROESEL, C., HU, Y., YILMAZEL, B., SAMSONOVA, A. A., 
NEUMULLER, R. A., MOHR, S. E. & PERRIMON, N. 2014. Integrating protein-protein 
interaction networks with phenotypes reveals signs of interactions. Nat Methods, 11, 
94-9. 
VIRTAKOIVU, R., PELLINEN, T., RANTALA, J. K., PERALA, M. & IVASKA, J. 2012. Distinct roles 
of AKT isoforms in regulating beta1-integrin activity, migration, and invasion in 
 
 419 
prostate cancer. Mol Biol Cell, 23, 3357-69. 
VUONG, D., SIMPSON, P. T., GREEN, B., CUMMINGS, M. C. & LAKHANI, S. R. 2014. 
Molecular classification of breast cancer. Virchows Arch, 465, 1-14. 
WANG, G. H., YAO, L., XU, H. W., TANG, W. T., FU, J. H., HU, X. F., CUI, L. & XU, X. M. 2013. 
Identification of MXRA5 as a novel biomarker in colorectal cancer. Oncol Lett, 5, 544-
548. 
WANG, T. N., ALBO, D. & TUSZYNSKI, G. P. 2002. Fibroblasts promote breast cancer cell 
invasion by upregulating tumor matrix metalloproteinase-9 production. Surgery, 132, 
220-5. 
WCRF. 2017. Breast Cancer: Continuous Update Project Report [Online]. Available: 
http://www.wcrf.org/int/research-we-fund/continuous-update-project-findings-
reports/breast-cancer [Accessed 21st July 2017]. 
WEHRLE-HALLER, B. & IMHOF, B. A. 2003. Integrin-dependent pathologies. J Pathol, 200, 
481-7. 
WEI, C., CAO, Y., YANG, X., ZHENG, Z., GUAN, K., WANG, Q., TAI, Y., ZHANG, Y., MA, S., 
CAO, Y., GE, X., XU, C., LI, J., YAN, H., LING, Y., SONG, T., ZHU, L., ZHANG, B., XU, 
Q., HU, C., BIAN, X. W., HE, X. & ZHONG, H. 2014. Elevated expression of TANK-
binding kinase 1 enhances tamoxifen resistance in breast cancer. Proc Natl Acad Sci 
U S A, 111, E601-10. 
WEINACKER, A., CHEN, A., AGREZ, M., CONE, R. I., NISHIMURA, S., WAYNER, E., PYTELA, 
R. & SHEPPARD, D. 1994. Role of the integrin alpha v beta 6 in cell attachment to 
fibronectin. Heterologous expression of intact and secreted forms of the receptor. J 
Biol Chem, 269, 6940-8. 
WEINREB, P. H., SIMON, K. J., RAYHORN, P., YANG, W. J., LEONE, D. R., DOLINSKI, B. M., 
PEARSE, B. R., YOKOTA, Y., KAWAKATSU, H., ATAKILIT, A., SHEPPARD, D. & 
VIOLETTE, S. M. 2004. Function-blocking integrin alphavbeta6 monoclonal 
antibodies: distinct ligand-mimetic and nonligand-mimetic classes. J Biol Chem, 279, 
17875-87. 
WELF, E. S., NAIK, U. P. & OGUNNAIKE, B. A. 2012. A spatial model for integrin clustering as 
a result of feedback between integrin activation and integrin binding. Biophys J, 103, 
1379-89. 
WHITE, D. E. & MULLER, W. J. 2007. Multifaceted roles of integrins in breast cancer 
metastasis. J Mammary Gland Biol Neoplasia, 12, 135-42. 
WHITE, J. M. 2003. ADAMs: modulators of cell-cell and cell-matrix interactions. Curr Opin 
Cell Biol, 15, 598-606. 
 
 420 
WHO. 2014. Breast Cancer: prevention and control [Online]. online. Available: 
http://www.who.int/cancer/detection/breastcancer/en/ [Accessed 7th November 
2014]. 
WINOGRAD-KATZ, S. E. & LEVITZKI, A. 2006. Cisplatin induces PKB/Akt activation and 
p38(MAPK) phosphorylation of the EGF receptor. Oncogene, 25, 7381-90. 
WIPFF, P. J., RIFKIN, D. B., MEISTER, J. J. & HINZ, B. 2007. Myofibroblast contraction 
activates latent TGF-beta1 from the extracellular matrix. J Cell Biol, 179, 1311-23. 
WIREDJA, D. D., KOYUTURK, M. & CHANCE, M. R. 2017. The KSEA App: a web-based tool 
for kinase activity inference from quantitative phosphoproteomics. Bioinformatics. 
WIXLER, V., GEERTS, D., LAPLANTINE, E., WESTHOFF, D., SMYTH, N., AUMAILLEY, M., 
SONNENBERG, A. & PAULSSON, M. 2000. The LIM-only protein DRAL/FHL2 binds to 
the cytoplasmic domain of several alpha and beta integrin chains and is recruited to 
adhesion complexes. J Biol Chem, 275, 33669-78. 
WOLFENSON, H., LAVELIN, I. & GEIGER, B. 2013. Dynamic regulation of the structure and 
functions of integrin adhesions. Dev Cell, 24, 447-58. 
WONG, J. W. & CAGNEY, G. 2010. An overview of label-free quantitation methods in 
proteomics by mass spectrometry. Methods Mol Biol, 604, 273-83. 
WU, J., VALLENIUS, T., OVASKA, K., WESTERMARCK, J., MAKELA, T. P. & HAUTANIEMI, S. 
2009. Integrated network analysis platform for protein-protein interactions. Nat 
Methods, 6, 75-7. 
WU, Y., ZHANG, D. & KANG, S. 2013. Physical activity and risk of breast cancer: a meta-
analysis of prospective studies. Breast Cancer Res Treat, 137, 869-82. 
XIE, C., SHIMAOKA, M., XIAO, T., SCHWAB, P., KLICKSTEIN, L. B. & SPRINGER, T. A. 2004. 
The integrin alpha-subunit leg extends at a Ca2+-dependent epitope in the 
thigh/genu interface upon activation. Proc Natl Acad Sci U S A, 101, 15422-7. 
XIONG, A., YANG, Z., SHEN, Y., ZHOU, J. & SHEN, Q. 2014. Transcription Factor STAT3 as a 
Novel Molecular Target for Cancer Prevention. Cancers, 6, 926-957. 
XIONG, J., BALCIOGLU, H. E. & DANEN, E. H. 2013. Integrin signaling in control of tumor 
growth and progression. Int J Biochem Cell Biol, 45, 1012-1015. 
YANG, S. B., DU, Y., WU, B. Y., XU, S. P., WEN, J. B., ZHU, M., CAI, C. H. & YANG, P. C. 2012. 
Integrin alphavbeta6 promotes tumor tolerance in colorectal cancer. Cancer Immunol 
Immunother, 61, 335-42. 




YE, F., KIM, S.-J. & KIM, C. 2014. Intermolecular Transmembrane Domain Interactions 
Activate Integrin αIIbβ3. The Journal of Biological Chemistry, 289, 18507-18513. 
YE, F., YANG, C., KIM, J., MACNEVIN, C. J., HAHN, K. M., PARK, D., GINSBERG, M. H. & 
KIM, C. 2017. Epigallocatechin gallate has pleiotropic effects on transmembrane 
signaling by altering the embedding of transmembrane domains. J Biol Chem, 292, 
9858-9864. 
YEH, Y. T., HUR, S. S., CHANG, J., WANG, K. C., CHIU, J. J., LI, Y. S. & CHIEN, S. 2012. Matrix 
stiffness regulates endothelial cell proliferation through septin 9. PLoS One, 7, 
e46889. 
YOUNG, L., SUNG, J., STACEY, G. & MASTERS, J. R. 2010. Detection of Mycoplasma in cell 
cultures. Nat Protoc, 5, 929-34. 
YU, C. H., LUO, W. & SHEETZ, M. P. 2012. Spatial-temporal reorganization of activated 
integrins. Cell Adh Migr, 6, 280-4. 
ZAGORSKA, A., DEAK, M., CAMPBELL, D. G., BANERJEE, S., HIRANO, M., AIZAWA, S., 
PRESCOTT, A. R. & ALESSI, D. R. 2010. New roles for the LKB1-NUAK pathway in 
controlling myosin phosphatase complexes and cell adhesion. Sci Signal, 3, ra25. 
ZAIDEL-BAR, R., ITZKOVITZ, S., MA'AYAN, A., IYENGAR, R. & GEIGER, B. 2007. Functional 
atlas of the integrin adhesome. Nat Cell Biol, 9, 858-67. 
ZANTEK, N. D., WALKER-DANIELS, J., STEWART, J., HANSEN, R. K., ROBINSON, D., MIAO, 
H., WANG, B., KUNG, H. J., BISSELL, M. J. & KINCH, M. S. 2001. MCF-10A-NeoST: a 
new cell system for studying cell-ECM and cell-cell interactions in breast cancer. Clin 
Cancer Res, 7, 3640-8. 
ZARZYNSKA, J. M. 2014. Two faces of TGF-beta1 in breast cancer. Mediators Inflamm, 2014, 
141747. 
ZHANG, J., TIAN, X. J., ZHANG, H., TENG, Y., LI, R., BAI, F., ELANKUMARAN, S. & XING, J. 
2014. TGF-beta-induced epithelial-to-mesenchymal transition proceeds through 
stepwise activation of multiple feedback loops. Sci Signal, 7, ra91. 
ZHANG, K. & CHEN, J. 2012. The regulation of integrin function by divalent cations. Cell Adh 
Migr, 6, 20-9. 
ZHONG, X. & RESCORLA, F. J. 2012. Cell surface adhesion molecules and adhesion-initiated 
signaling: understanding of anoikis resistance mechanisms and therapeutic 
opportunities. Cell Signal, 24, 393-401. 
 
 422 
ZHOU, B., GIBSON-CORLEY, K. N., HERNDON, M. E., SUN, Y., GUSTAFSON-WAGNER, E., 
TEOH-FITZGERALD, M., DOMANN, F. E., HENRY, M. D. & STIPP, C. S. 2014. Integrin 
α3β1 Can Function to Promote Spontaneous Metastasis and Lung Colonization of 
Invasive Breast Carcinoma. Molecular cancer research : MCR, 12, 143-154. 
ZHOU, W., FAN, M. Y., WEI, Y. X., HUANG, S., CHEN, J. Y. & LIU, P. 2016. The expression of 
MYH9 in osteosarcoma and its effect on the migration and invasion abilities of tumor 
cell. Asian Pac J Trop Med, 9, 597-600. 
ZHU, J., LUO, B. H., XIAO, T., ZHANG, C., NISHIDA, N. & SPRINGER, T. A. 2008. Structure of 
a complete integrin ectodomain in a physiologic resting state and activation and 
deactivation by applied forces. Mol Cell, 32, 849-61. 
ZIEGLER, W. H., GINGRAS, A. R., CRITCHLEY, D. R. & EMSLEY, J. 2008. Integrin connections 
to the cytoskeleton through talin and vinculin. Biochem Soc Trans, 36, 235-9. 
ZUTTER, M. M., SANTORO, S. A., STAATZ, W. D. & TSUNG, Y. L. 1995. Re-expression of the 
alpha 2 beta 1 integrin abrogates the malignant phenotype of breast carcinoma cells. 
Proc Natl Acad Sci U S A, 92, 7411-5. 
 
